---
document_datetime: 2023-09-21 21:06:28
document_pages: 174
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/polivy-h-c-004870-ii-0012-epar-assessment-report-variation_en.pdf
document_name: polivy-h-c-004870-ii-0012-epar-assessment-report-variation_en.pdf
version: success
processing_time: 315.8423572
conversion_datetime: 2025-12-31 01:08:31.193832
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 March 2022 EMA/287823/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Polivy

International non-proprietary name: polatuzumab vedotin

Procedure No. EMEA/H/C/004870/II/0012

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 8                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................8 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................9                                                 |
| 2. Scientific discussion..............................................................................                     | 10                                                                                                        |
| 2.1. Introduction                                                                                                          | ...................................................................................................... 10 |
| 2.1.1. Problem statement                                                                                                   | .......................................................................................... 10             |
| 2.1.2. About the product ...........................................................................................       | 11                                                                                                        |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                  | advice...... 12                                                                                           |
| 2.1.4. General comments on compliance with                                                                                 | GCP........................................................ 12                                            |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Introduction                                                                                                        | ................................................................................................... 12    |
| 2.2.2. Ecotoxicity/environmental risk assessment.........................................................                  | 12                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 13     |
| 2.3.1. Introduction                                                                                                        | ................................................................................................... 13    |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 13           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 39                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 40          |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 48                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 49                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 49     |
| 2.4.1. Dose response study                                                                                                 | ....................................................................................... 49                |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 56  |
| 2.4.3. Discussion on clinical efficacy..........................................................................           | 103                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy                                                                                | .................................................................. 107                                    |
| 2.5. Clinical safety                                                                                                       | .................................................................................................. 107    |
| 2.5.1. Discussion on clinical safety............................................................................           | 156                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 162                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 162   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 163                 |
| 2.7. Update of the Product information......................................................................               | 166                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 166                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 167                                                                                                       |
| 3.1. Therapeutic Context                                                                                                   | ......................................................................................... 167             |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 167                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 167                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 167                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 168                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 168                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 169                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 169                                                               |
| 3.6. Effects Table....................................................................................................     | 169                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 171                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 171                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 171                            |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ......................................... 171

3.8. Conclusions  ..................................................................................................... 172

4. Recommendations  ............................................................................... 172

5. EPAR changes ..................................................................................... 173

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Description                                                 |
|----------------|-------------------------------------------------------------|
| ABC            | Activated B-cell type                                       |
| ADA            | Anti-drug antibodies                                        |
| ADC            | antibody-drug conjugate                                     |
| AE             | Adverse event                                               |
| AEGT           | Adverse event grouped terms                                 |
| AEPI           | Adverse event of particular interest                        |
| AESI           | AEs of special interest                                     |
| ALT            | Alanine aminotransferase                                    |
| AST            | Aspartate Aminotransferase                                  |
| BAR            | Bioanalytical report                                        |
| BICR           | Blinded independent central review                          |
| BLD            | Belowlimit of detection                                     |
| BOR            | Best observed response                                      |
| BSA            | Body surface area                                           |
| CCI            | Commercially confidential information                       |
| CCOD           | Clinical cutoff date                                        |
| CCP            | Confirmatory cut point                                      |
| CDR            | Complementarity determining region                          |
| CHOP           | cyclophosphamide, doxorubicin, vincristine, and prednisone  |
| CHP            | cyclophosphamide, doxorubicin, and prednisone               |
| CIOMS          | Council for International Organizations of Medical Sciences |
| CL             | Confidence limits                                           |
| CLL            | Chronic lymphocytic leukemia                                |
| CMH            | Cochran-Mantel-Haenszel                                     |
| CMR            | Complete Metabolic Response                                 |
| CNS            | Central nervous system                                      |
| COA            | Clinical outcome assessments                                |
| cOO            | Cell-of-origin                                              |
| CR             | Complete Response                                           |
| CRF            | Case report form                                            |
| CSR            | Clinical Study Report                                       |
| CT             | Computed tomography                                         |
| ctDNA          | Circulating tumor DNA                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IRB    | Institutional Review Boards                                        |
|--------|--------------------------------------------------------------------|
| IRC    | Independent Review Committee                                       |
| IRF    | Independent Review Facility                                        |
| IRR    | Infusion-related reactions                                         |
| ITT    | Intent-to-treat                                                    |
| IxRS   | interactive voice or Web-based response system                     |
| LDH    | Lactate dehydrogenase                                              |
| LLOQ   | Lower limit of quantitation                                        |
| LoPO   | List of planned outputs                                            |
| LST    | Lymphoma Subtyping                                                 |
| LTR    | less than reportable                                               |
| LymS   | Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale |
| MedDRA | Medical dictionary of regulatory activities                        |
| MMAE   | mono-methyl auristatin E                                           |
| MQC    | Minimum quantifiable concentration                                 |
| MRI    | Magnetic resonance imaging                                         |
| MUGA   | Multiple-gated acquisition                                         |
| NALT   | New anti-lymphoma therapy                                          |
| NCI    | National Cancer Institute                                          |
| ND     | Not done                                                           |
| NHL    | Non-Hodgkin lymphoma                                               |
| NMR    | No metabolic response                                              |
| NOS    | Not otherwise specified                                            |
| OBD    | Oncology Biomarker Development                                     |
| ORR    | Objective response rate                                            |
| OS     | Overall survival                                                   |
| PCL    | Protocol Clarification Letter                                      |
| PCR    | Polymerase chain reaction                                          |
| PD     | Progression Disease                                                |
| PDMS   | Protocol Deviation Management System                               |
| PET    | Positron emission tomography                                       |
| PFS    | Progression-free survival                                          |
| PK     | Pharmacokinetic                                                    |
| PMD    | Progressive metabolic disease                                      |
| PMR    | Partial metabolic response                                         |
| PN     | Peripheral neuropathy                                              |
| PO     | Orally                                                             |

<div style=\"page-break-after: always\"></div>

| pola   | polatuzumab vedotin               |
|--------|-----------------------------------|
| PPD    | Protected patient data            |
| PR     | Partial response                  |
| PRO    | Patient-reported outcomes         |
| PT     | Preferred term                    |
| PV     | Pharmacovigilance                 |
| QoL    | Quality of life                   |
| RBC    | Red blood cell                    |
| RDI    | Relative Dose Intensity           |
| RMST   | Restricted mean survival time     |
| RNA    | Ribonucleic acid                  |
| SAE    | Serious adverse events            |
| SCP    | Summary of Clinical Pharmacology  |
| SD     | Standard deviation                |
| SE     | Safety-evaluable                  |
| SMQ    | Standardized MedDRA queries       |
| SoC    | Standard of care                  |
| SOC    | System Organ Class                |
| THL    | Triple-hit lymphoma               |
| TLS    | Tumor lysis syndrome              |
| TTD    | Time to deterioration             |
| ULN    | Upper limit of normal             |
| VHP    | Voluntary Harmonization Procedure |
| WBC    | White blood cell                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 5 November 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of the indication to include: Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) based on the efficacy and safety data from the Pivotal Phase III Study GO39942 (POLARIX). This submission fulfills SOB003 thus supporting the switch from CMA to full MA. Annexes I, II, IIIB are revised. The RMP is also updated.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Polivy, was designated as an orphan medicinal product EU/3/18/2013 on 16 April 2018. Polivy was designated as an orphan medicinal product in the following indication: Treatment of diffuse large B-cell lymphoma.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Polivy as an orphan medicinal product in the approved indication. The outcome of the COMP review can be found here &lt;insert link &gt;.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision EMA/PDCO/818664/2017 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products. Assessment of these claims is appended.

## Protocol assistance

The MAH received Protocol Assistance from the CHMP on 18 May 2017 (EMEA/H/SA/2809/3/2017/II). The Protocol Assistance pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                                                               | Actual dates     |
|-----------------------------------------------------------------------------------------|------------------|
| Submission date                                                                         | 5 November 2021  |
| Start of procedure:                                                                     | 27 November 2021 |
| CHMP Co-Rapporteur Assessment Report                                                    | 26 January 2022  |
| CHMP Rapporteur Assessment Report                                                       | 26 January 2022  |
| PRAC Rapporteur Assessment Report                                                       | 27 January 2022  |
| PRAC members comments                                                                   | 2 February 2022  |
| CHMP Co-Rapporteur Critique                                                             | 3 February 2022  |
| PRAC Outcome                                                                            | 10 February 2022 |
| CHMP members comments                                                                   | 14 February 2022 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                    | 17 February 2022 |
| Request for supplementary information (RSI)                                             | 24 February 2022 |
| CHMP Rapporteur Assessment Report                                                       | 09 March 2022    |
| PRAC Rapporteur Assessment Report                                                       | 10 March 2022    |
| PRAC members comments                                                                   | 14 March 2022    |
| CHMP members comments                                                                   | 14 March 2022    |
| Updated PRAC Rapporteur Assessment Report                                               | 17 March 2022    |
| Updated CHMP Rapporteur Assessment Report                                               | 17 March 2022    |
| CHMP opinion:                                                                           | 24 March 2022    |
| The CHMP adopted a report on similarity of Polivy with Minjuvi, Yescarta and Kymriah on | 24 March 2022    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Polatuzumab  vedotin  in  the  initial  MA  application  was  approved  in  combination  with  rituximab  and bendamustin for treatment of relapsed/refractory (R/R) DLBCL. The present application is an extension of indication for first line treatment of DLBCL in combination with Rituximab, cyclophosphamide, doxorubicine, prednisone.

## Epidemiology

DLBCL is the most common histologic subtype of non-Hodgkin's lymphoma (NHL), accounting for 30% of NHL cases (Armitage and Weisenburger 1998) and 80% of aggressive lymphomas. In 2020, 544,352 new NHL cases worldwide were estimated with over 163,000 patients estimated to be diagnosed with DLBCL (Global Cancer Observatory 2020). While DLBCL is mostly frequently diagnosed between ages of 65 and 74 years (with median age of 65 years at diagnosis [SEER]), it can also occur in the younger population, including children and young adults.

## Biologic features, Aetiology and pathogenesis

DLBCL is a heterogeneous disease with a number of histologic, proteomic and molecular subsets with distinctive prognostic profiles, including cell of origin (activated Bcell-like [ABC], germinal center B-cell-like [GCB]), elevated protein expression of MYC and BCL2 seen in double-expressing lymphoma [DEL]), and gene rearrangements in MYC and BCL2 and/or BCL6 (double or triple-hit lymphoma [DHL/THL]) (Schmitz et al 2018; Scott et al 2015; Lenz et al 2008; Johnson et al 2009; Johnson et al 2012).

For  the  vast  majority  of  patients,  the  etiology  of  DLBCL  is  unknown.  Hereditary  and  acquired immunodeficiencies, occupational exposures, and pharmacological immunosuppression in the setting of transplantation or treatment of autoimmune diseases have been identified as factors thought to potentially confer increased risk of developing DLBCL.

## Clinical presentation, diagnosis and stage/prognosis

Initially, DLBCL may be asymptomatic, but it may also be associated with constitutional symptoms such as fever, recurrent night sweats, weight loss, and/or local effects of lymph node enlargement, as well as those of bone marrow failure (Armitage and Weisenburger 1998). These disease symptoms, along with treatmentrelated side effects, often lead to impairments in aspects of health-related quality of life (HRQoL) including physical functioning and fatigue (Tholstrup et al 2011). Without treatment, DLBCL is fatal with a median survival of approximately 6 months (Armitage and Weisenburger 1998).

<div style=\"page-break-after: always\"></div>

Although the biologic features of DLBCL are evaluated in clinical practice and clinical research, they do not clearly guide the choice of therapy, as no definitive studies have demonstrated superiority to R-CHOP in biomarker-selected populations. While molecular features help to define higher and lower risk subtypes, clinical  features  are  also  integrated  into  risk  assessment  and  estimating  prognosis.  The  International Prognostic Index (IPI) for aggressive NHL identifies five patient factors obtained at diagnosis used to stratify prognosis and overall survival (OS). The IPI factors reflect clinical features, each representing one point, and are a combination of patient characteristics (age &gt;60, ECOG PS &gt;2) and disease-related findings (Ann Arbor Stage III or IV, elevated LDH, and extranodal involvement in more than one site).

## Management

The standard of care therapy for DLBCL involves frontline multi-agent chemotherapy with complementary mechanisms of action combined with immunotherapy. Up to 8 cycles of R-CHOP given in 21-day intervals (R-CHOP-21), or R-CHOP-like chemotherapy is considered to be the standard of care therapy for patients with previously untreated DLBCL. Analyses suggest that 6 cycles is not inferior to 8 cycles (Wästerlid et al 2018; Sehn et al 2018).

Since the introduction of R-CHOP there has been limited advancement in treatment options for previously untreated DLBCL patients for over 20 years as the majority of randomized studies in previously untreated DLBCL have failed to show a benefit. While R-CHOP may cure approximately 60% of patients with previously untreated DLBCL (Sehn and Salles 2021), alternative strategies have so far been unable to demonstrate meaningful benefit over R-CHOP. These include: increased dose density with R-CHOP given at 14 day intervals (Delarue et al 2013; Cunningham et al. 2013); dose intensification with dose-adjusted etoposide plus prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R), Bartlett et al 2019.

Thus there is a rationale for introducing novel therapeutic agents that can build upon R-CHOP and improve outcomes in patients with previously untreated DLBCL by preventing or delaying relapse.

## 2.1.2. About the product

Polatuzumab vedotin (pola) is an antibody-drug conjugate (ADC) that contains a humanized immunoglobulin  G1  anti-CD79b  monoclonal  antibody  (MCDS4409A)  and  a  potent  anti-mitotic  agent, monomethyl  auristatin  E  (MMAE).  Pola  binds  CD79b,  a  surface  antigen  restricted  to  B-cells  that  is ubiquitously  expressed  across  a  majority  of  mature  B-cell  malignancies  including  diffuse  large  B-cell lymphoma (DLBCL). MMAE is a potent analog of dolastatin 10 that exerts its cytotoxicity by binding to microtubules and inhibiting microtubule polymerization, inhibiting cell division, inducing apoptosis. Upon binding  to  the  CD79b,  pola  is  rapidly  internalized  to  enable  targeted  delivery  of  MMAE.  This  allows microtubule inhibition with greater potency and without additional toxicity.

In the EU, the initial MAA (procedure EMEA/H/C/004870/0000) for polatuzumab vedotin was granted Conditional Marketing Authorization (CMA) on 16 January 2020 for Polivy in combination with BR for the treatment of adult patients with relapsed/refractory DLBCL who are not candidates for haematopoietic stem cell transplant. The initial MAA for Polivy was based on data from one pivotal study GO29365, performed in a small number of patients and as comprehensive data on the product in the proposed indication were not available, the CHMP was of the view that a full marketing authorisation could not be

<div style=\"page-break-after: always\"></div>

granted. Instead, a conditional marketing authorisation was proposed by the CHMP during the assessment, after having consulted the applicant.

The product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a life-threatening disease and is designated as an orphan medicinal product. In order to further confirm the safety and efficacy of polatuzumab vedotin in DLBCL the MAH will provide  Study GO39942, a randomized, double-blind, placebocontrolled trial that evaluates  polatuzumab  vedotin  in  combination  with  R-CHP  (rituximab,  cyclophosphamide,  doxorubicin, prednisone) versus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The MAH received in the 2017 scientific advice (SA) (EMA/CHMP/SAWP/301908/2017) and was encouraged to increase the sample size to achieve higher power, particularly for the analysis of OS. Indeed, there was a concern that the lack of power may lead to immature OS results. However, the expected number of OS events at study termination was smaller in the study protocol than in the SA (estimated as 178 in protocol vs 209 in the SA request), leading to a smaller anticipated power of 52% (vs 62% in SA).

## 2.1.4. General comments on compliance with GCP

The MAH states that all studies included in this application were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The appropriate Ethics Committees and Institutional Review Boards reviewed and approved all studies. The studies also took guidelines into consideration regarding statistical principles (ICH E9), and EMA and FDA guidelines on clinical trial endpoints for the approval of cancer drugs (CPMP/EWP/205/95 Rev. 3 and the FDA Guidance to Industry, May 2007).

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.2. Ecotoxicity/environmental risk assessment

No new data have been submitted in this application which was considered acceptable by the CHMP. As the original ERA included in the initial MAA was performed on the basis of a theoretical use of the product in the broad indication, a submission of an updated ERA on a potential increase in environmental exposure further to this extension of indication was not needed.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Protocol No.                | Locationof Synopsis Location of Report                                  | Objective(s) of the Study                                             | Study Design and Type of Control                                       | Test Product(s); Dosage regimen; Route of Admin.                                                                                                                                                                       | Numberof Subjects                                                                                                                                                                    | Numberof Subjects                                           | Healthy Subjects or of Diagnosis ofPatients                                                                                          | Duration Treatment                                                                                                             | Study Status; Type of Report          |
|-----------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| GO39942 (POLARIX) [pivotal] | 5.3.5.1 Primary CSR 1106275, Synopsis Report Primary CSR Report 1106275 | Efficacy, safety, PK, biomarker, immuno- genicity, PRO, health status | Phase Ill, multicenter, randomized, placebo- double- blind, controlled | Arm A: pola 1.8 mg/kg + 6 cycles followed by R-CHP +vincristine placebo q21 days x rituximab Arm B: R-CHOP + pola placebo q 21 days x 6cyclesfollowed by rituximab Rituximab375mg/m2                                   | Arm A: pola 1.8 mg/kg + 6 cycles followed by R-CHP +vincristine placebo q21 days x rituximab Arm B: R-CHOP + pola placebo q 21 days x 6cyclesfollowed by rituximab Rituximab375mg/m2 | Total1L DLBCL=879* Pola+ Arm A: R-CHP=440 Arm B: R-CHOP=439 | Previously untreated patients with positive DLBCL CD20-                                                                              | 6 cycles of pola+R- intervals R-CHOP at 21-day CHP or received Both arms two additional cycles (cycles 7 and 8)of single agent | Study ongoing Primary CSR report      |
| GO29044 [supportive]        | 5.3.5.2 Final CSR Report 1109685, Synopsis Final CSR Report 1109685     | Phase Ib: MTD of pola + R/G- CHP safety, efficacy Phase Il:           | Phase Ib/ll, open-label, multicenter, single arm (pola + R/G- CHP)     | Doseescalation: pola 1.0-1.8 mg/kg + R-CHP q 21 days x6-8cycles pola 1.4-1.8 mg/kg + G-CHP q 21 days x 6-8 cycles Expansion: pola 1.8 mg/kg + R-CHP q21 days x 6-8 cycles pola 1.8 mg/kg + G-CHP q 21 days x6-8 cycles | Totaln=84 Non-DLBCL =8 1LDLBCL +expansion) = 75b (dose-escalation Pola +R-CHP=50 Dose- escalation= 10 Dose- expansion=40 Pola + G-CHP = 25 Dose- escalation = 8 Dose-                | expansion=17                                                | Dose escalation: newly diagnosed or R/R therapy) B-NHL of systemic (≤1 prior line Expansion: Previously untreated DLBCL with IPI 2-5 | 6or8 pola+ cycles of R/G-CHP at 21-day intervals                                                                               | Study completed Final CSR Full report |

acMMAE = antibody-conjugated monomethyl auristatin E; ADA = anti-drug antibody; B-NHL=B-cellnon-Hodgkin's lymphoma; DLBCL=diffuse large B-cell lymphoma;G=obinutuzumab;IPl=Intemational PrognosticIndex;IV=intravenous(ly);MMAE=monomethyl auristatin E;PK=pharmacokinetic;Pola=polatuzumab vedotin;popPK=populationPK;PRO=patientreportedoutcomes;R=rituximab;R-CHP=rituximab,cyclophosphamide,doxorubicin,prednisone;R-CHOP= rituximab,cyclophosphamide,doxorubicin,vincristine,prednisone;R/R=relapsed orrefractory.

a The China extension cohort includes Chinese patients enrolled after the global study phase closed to enrollment and those patients are not included in the pivotal

75DLBCLpatient,66patients were treated withpola1.8mg/kg and9 treated at doses&lt;1.8mg/kg.

population analyses.The 121 Chinesepatients enrolled in theChina extension cohort followed the same study design as the global study. bSafety and efficacy evaluable population in 1L DLBCL patients (n =75).A total of 82 patients were safety evaluable, as n= 7 were other NHL histologies.Ofthe

## 2.3.2. Pharmacokinetics

Polatuzumab vedotin clinical pharmacology has been described in the initial MA application where it was approved in combination with rituximab and bendamustin for treatment of relapsed/refractory (R/R)

<div style=\"page-break-after: always\"></div>

DLBCL. The present application aims to characterize polatuzumab vedotin PK as a first line treatment for DLBCL in combination with Rituximab, cyclophosphamide, doxorubicine, prednisone.

The clinical PK has been investigated in two clinical studies. Study GO29044 was a phase 1/2 study with dose escalation phase followed by a dose expansion phase in patients with B-cell non-Hodgkin's lymphoma (NHL), including DLBCL previously untreated patients. This was the main study with frequent sampling to allow insight in polatuzumab vedotin PK, including the antibody- conjugated MMAE (acMMAE), the total antibody, and the unconjugated MMAE. The second study, a phase 3 study GO29042, was conducted in previously untreated DLBCL patients with sparse PK sampling for polatuzumab vedotin PK characterisation. These PK data were analysed in a pop PK model. The population PK model used was the model submitted in the initial application, so called 'legacy model'. The additional PK data were analysed by external validation using the latter data based on the legacy popPK model.

Bioanalytical methods: There have been no updates to the polatuzumab vedotin assay method (i.e., no additional studies conducted) since the initial MA procedure. It included the measurement of three key analytes (conjugate evaluated as antibody-conjugated monomethyl auristatin E [acMMAE], total antibody, and unconjugated MMAE) to assess the overall pharmacokinetics of polatuzumab vedotin. The acMMAE, total antibody, and unconjugated MMAE were quantitated by immunoaffinity HPLC MS/MS in human plasma, ELISA in human serum and LC/MS/MS in human plasma respectively. These three bioanalytical methods were used in the presented clinical studies: study GO29044 and GO39942 (POLARIX).

Immunogenicity: There have been no updates to the anti-polatuzumab vedotin antibody assay method (i.e., no additional studies conducted) since the initial MA procedure.

The potential for pola to induce an undesirable immune response was assessed in the available data from POLARIX and supportive Study GO29044. The ADA analysis strategy is based on a tiered approach designed to detect and characterize ADA responses to polatuzumab vedotin (as well as obinutuzumab in study GO29044).

Patient samples were screened to detect all antibody responses toward polatuzumab vedotin (and obinutuzumab in study GO29044). Samples that screened positive were analyzed in a confirmatory assay to assess the specificity of the positive response. Titers were determined for confirmed ADA positive samples. In study GO39942 (POLARIX), further characterization was assessed by competitive binding with the antibody component of pola to characterize whether the ADA responses were primarily to the antibody portion, the linker-drug regions, or neo-epitopes of the ADC.

ICDCBA 106 validation report describes the validation process of the qualitative assay designed to detect neutralizing antibodies against polatuzumab vedotin. Neutralizing antibodies are measured in human serum through the assessment of caspase 3/7 activity in Human Burkitt lymphoma B cells (BJAB), an Epstein-Barr virus (EBV) negative B lymphoma cell line transfected.

The method validation is summarized in the following Table 1 .

<div style=\"page-break-after: always\"></div>

Table 1 Bioanalytical method validation summary: NAb to polatuzumab vedotin in human serum

<!-- image -->

| Species/Matrix:                                                                      | Human serm                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Matrix Population:                                                                   | Non-Hodgkin's Lymphoma (NHL)                                                                                                                                                                                                                                                                                                      |
| Analysis Method:                                                                     | Luminescence                                                                                                                                                                                                                                                                                                                      |
| Data Capture of RLU:                                                                 | Biotek Cytation 5 Multi-Mode Plate Reader                                                                                                                                                                                                                                                                                         |
| Additional Data Analysis and Caleulations:                                           | Microsoft* Excel Office 365, Gen 5 Version 2.09, and PPD Assist LIMS Version 6                                                                                                                                                                                                                                                    |
| Normalization Control (NC):                                                          | PNHS + polatuzumab vedotin (100 ng/mL) + cells                                                                                                                                                                                                                                                                                    |
| Maximun Control (Max):                                                               | PNHS + polatuzumab vedotin (40.0 μg/mL) + cells                                                                                                                                                                                                                                                                                   |
| Minimum Control (Min):                                                               | PNHS + assay medium + cells                                                                                                                                                                                                                                                                                                       |
| Positive Controls (PC):PNHS +polatuzumab vedotin (100 ng/mL) + anti-DCDS4501S +cells |                                                                                                                                                                                                                                                                                                                                   |
| Sample Volume (μL):                                                                  | 20.0 μL aliquot for screening                                                                                                                                                                                                                                                                                                     |
| Sample Storage Temperature!                                                          | -80 °℃                                                                                                                                                                                                                                                                                                                            |
| NC/LPC 2 Ratio:                                                                      | 1.09 to 1.89 (determined at the end of validation)                                                                                                                                                                                                                                                                                |
| Max/Min:                                                                             | 3.34 to 7.32 (determined at the end of validation)                                                                                                                                                                                                                                                                                |
| CPF:                                                                                 | 0.911                                                                                                                                                                                                                                                                                                                             |
| PC Plate-Specific Cut Point:                                                         | Plate Mean NC x CPF, 0.911                                                                                                                                                                                                                                                                                                        |
| Assay Cut Point:                                                                     | Plate Mean NC x CPF                                                                                                                                                                                                                                                                                                               |
| Relative Assay Sensitivity: MatrixInterference/ Selectivity: screened negative.      | 650 ng/mL Unspiked: Acceptable, as ten out of ten individual donors with NHL                                                                                                                                                                                                                                                      |
| Relative Drug Tolerance:                                                             | LPC 2: Acceptable, as ten out of ten individual donors with NHL screened positive. LPC 1: Neuhralizing antibodies can be detected in PNHS samples in the presence of up to 14.6 μg/mL excess polatuzumab vedotin (analyzed for informational pwposes only). LPC 2: Neuhralizing antibodies can be detected in PNHS samples in the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Intra-Assay Precision Across PCst                                       |                                                                         | NC                                                                                                                                                                                                                                                                   | NC                                                                                                                                                                                                                                                                   | LPC 1*                                                                                                                                                                                                                                                               | LPC 1*                                                                                                                                                                                                                                                               | LPC 2*                                                                                                                                                                                                                                                               | HPC                                                                                                                                                                                                                                                                  | HPC                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intra-Assay Precision Across PCst                                       | Conc. (ng/mL)                                                           | 0                                                                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                                                    | 1000                                                                                                                                                                                                                                                                 | 1000                                                                                                                                                                                                                                                                 | 1617                                                                                                                                                                                                                                                                 | 5000                                                                                                                                                                                                                                                                 | 5000                                                                                                                                                                                                                                                                 |
| Intra-Assay Precision Across PCst                                       | Intra-Assay (%CV)                                                       | 1.94                                                                                                                                                                                                                                                                 | 1.94                                                                                                                                                                                                                                                                 | 3.30                                                                                                                                                                                                                                                                 | 3.30                                                                                                                                                                                                                                                                 | 5.73                                                                                                                                                                                                                                                                 | 2.70                                                                                                                                                                                                                                                                 | 2.70                                                                                                                                                                                                                                                                 |
| Inter-Assay Precision Across PCst                                       |                                                                         | NC LPC 1*                                                                                                                                                                                                                                                            | NC LPC 1*                                                                                                                                                                                                                                                            | LPC 2* HPC                                                                                                                                                                                                                                                           | LPC 2* HPC                                                                                                                                                                                                                                                           | NC/LPC 2                                                                                                                                                                                                                                                             | NC/HPC MaxMin                                                                                                                                                                                                                                                        | NC/HPC MaxMin                                                                                                                                                                                                                                                        |
| Inter-Assay Precision Across PCst                                       | Conc. (ng/mL)                                                           | 0                                                                                                                                                                                                                                                                    | 1000                                                                                                                                                                                                                                                                 | 1617                                                                                                                                                                                                                                                                 | 5000                                                                                                                                                                                                                                                                 | N/A                                                                                                                                                                                                                                                                  | N/A                                                                                                                                                                                                                                                                  | N/A                                                                                                                                                                                                                                                                  |
| Inter-Assay Precision Across PCst                                       | Inter-Assay (%CV)                                                       | 21.3                                                                                                                                                                                                                                                                 | 22.1                                                                                                                                                                                                                                                                 | 24.2                                                                                                                                                                                                                                                                 | 25.9                                                                                                                                                                                                                                                                 | 11.7                                                                                                                                                                                                                                                                 | 21.7                                                                                                                                                                                                                                                                 | 16.0                                                                                                                                                                                                                                                                 |
| Robustness/Ruggedness:                                                  | Robustness/Ruggedness:                                                  | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              | The minimum and maximum times for conhol sample incubation, control/sample/cell incubation, and substrate incubation were evaluated alongwith two different insthuments. Data for all assay controls met the acceptance                                              |
| Freeze/Thaw Stability:                                                  | Freeze/Thaw Stability:                                                  | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           | Demonstrated for eleven cycles thawed at room temperature.                                                                                                                                                                                                           |
| Thawed Matrix Stability:                                                | Thawed Matrix Stability:                                                | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              | Demonshrated for 24 hours at room temperature and 24 hows at 2 to 8 °C.                                                                                                                                                                                              |
| Cross Reactivity/Interference- Atezolizumab:                            | Cross Reactivity/Interference- Atezolizumab:                            | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 1000 μg/mL atezolizumab. No cross-reactivity was observed in samples without NAb in the presence of 1000 μg/mL atezolizumab.                                   |
| Cross Reactivity/Interference- Mosunetuzumab:                           | Cross Reactivity/Interference- Mosunetuzumab:                           | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 5.00 μg/mL mosumetuzumab. No cross-reactivity was observed in samples without NAb in the presence of 5.00 μg/mL mosumetuzumab.                                 |
| Cross Reactivity/Interference - Tocilizumab:                            | Cross Reactivity/Interference - Tocilizumab:                            | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 200 μg/mL tocilizumab. No cross-reactivity was observed in samples without NAb                                                                                 |
| Cross Reactivity/Interference- Rituximab:                               | Cross Reactivity/Interference- Rituximab:                               | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. | in the presence of 200 μg/mL tocilizumab. No interference was observed at the LPC 2 (l6l7 ng/mL) and HPC (5000 ng/mL) levels in the presence of 600 μg/mL rituximab. No cross-reactivity was observed in samples without NAb in the presence of 600 μg/mL rihuximab. |
| Cross Reactivity/Interference - Obinutuzumab:                           | Cross Reactivity/Interference - Obinutuzumab:                           | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       | No interference was observed at the LPC 2 (1617 ng/mL) and HPC (5000 ng/mL) levels in the presence of 800ug/mLobinutuzumab. No cross-reactivity was observed in samples without NAb in the presence of 800 μg/mL obinutuzumab.                                       |
| Cross Reactivity/Interference - Hemolysis:                              | Cross Reactivity/Interference - Hemolysis:                              | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of > 5% hemolyzed PNHS mahix. No cross-reactivity was observed in samples without NAb in the presence of > 5% hemolyzed PNHS matix.                               |
| Cross Reactivity/Interference- Lipemia:                                 | Cross Reactivity/Interference- Lipemia:                                 | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  | No interference was observed at the LPC 2 (l617 ng/mL) and HPC (5000 ng/mL) levels in the presence of >300 mg/dL tiglycerides. No cross-reactivity was observed in samples without NAb in the presence of > 300 mg/dL tiglycenides.                                  |
| Prozone Effect:                                                         | Prozone Effect:                                                         | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      | No prozone (hook) effect was observed at concenhations up to 100 μg/mL amti-DCDS4501S antibody.                                                                                                                                                                      |
| Stability of Sera-Mfag Streptavidin Coated Maguetic Particles in BA003: | Stability of Sera-Mfag Streptavidin Coated Maguetic Particles in BA003: | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            | Sera-Mag Streptavidin-Coated Magnetic Particles in BA003 were stable for up to two weeks.                                                                                                                                                                            |

## Study GO29044

ADAs were assessed at pre-infusion of Cycles 1, 2, and 4, at treatment completion/early termination, and at the 3 month follow-up visit.

The relative sensitivities of the polatuzumab vedotin ADA screening assay were estimated to be 60.1 ng/mL using an anti-CD79b antibody complementarity determining region monoclonal antibody (positive control) and 1141 ng/mL using an anti-auristatin monoclonal antibody diluted in normal human serum. The screening assay was optimized to tolerate drug interference. In the presence of 20 µg/mL of polatuzumab vedotin, two levels of the positive control sample (90 and 500 ng/mL) tested positive.

<div style=\"page-break-after: always\"></div>

The prevalence of ADA at baseline was calculated by dividing the total number of patients in all study groups that tested positive for ADA at baseline by the total number of patients with a valid ADA test result at baseline.

The incidence of ADAs post-baseline in each study group was calculated by dividing the number of patients that developed treatment-induced ADAs (i.e., patients with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result) plus the number of patients that had treatment-enhanced ADAs (i.e. the ADA response had increased 0.6 titer units from baseline) in the study by the total number of patients with valid post-baseline results in that study group during the study period.

The overall treatment emergent ADA response rate in all polatuzumab vedotin and obinutuzumab treatment groups was 0.0%, because there were no observed ADA responses at either baseline or postbaseline timepoints.

False-negative ADA response results are unlikely regarding polatuzumab vedotin, as levels of circulating ADC were below levels expected to interfere in the assay based on the drug tolerance profile of the assay.

Table 2 Incidence of Anti-Drug Antibodies to Polatuzumab Vedotin in Study GO29044

|                                          | R-CHP+POV 1.8 mg/kg (N=1)   | G-CHP+POV 1.4 mg/kg (N=6)   | G-CHP+POV 1.8 mg/kg (N=6)   | EXPR-CHP+POV 1.8 mg/kg (c≤=N)   | EXPG-CHP+POV 1.8 mg/kg (N=17)   | AlI Polatuzumab Vedotin Treated Patients (N=63)   |
|------------------------------------------|-----------------------------|-----------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------------------------|
| BaselinePrevalenceofADAs                 |                             |                             |                             |                                 |                                 |                                                   |
| Baselineevaluablepatients                |                             | 9                           | 6                           | 30                              | 17                              | 60                                                |
| Patientswith apositivesampleatbaseline   | 0                           | 0                           | 0                           | 0                               | 0                               | 0                                                 |
| Patientswithnopositivesamplesat baseline |                             | 9                           | 6                           | 30                              | 17                              | 60                                                |
| Post-BaselineIncidenceofADAs             |                             |                             |                             |                                 |                                 |                                                   |
| Post-baselineevaluablepatients           |                             | 6                           | 6                           | 33                              | 17                              | 63                                                |
| PatientsPositiveforADA                   | 0                           | 0                           | 0                           | 0                               | 0                               | 0                                                 |
| PatientsnegativeforADA                   |                             | 9                           | 6                           | 33                              | 17                              | 63                                                |
| Treatment unaffected                     | 0                           | 0                           | 0                           | 0                               | 0                               | 0                                                 |

## Study GO39942 (POLARIX)

ADAs were assessed at pre-infusion of Cycles 1 and 4, at treatment completion/early termination, and at the 3 month follow-up visit.

The ADA screening and confirmatory assays were optimized to tolerate drug interference and were able to detect 100 ng/mL of the positive control sample in the presence of 50 µg/mL of pola. Pola total antibody concentrations were determined for each ADA sample. Out of a total of 1125 ADA samples that were measured for pola total antibody, 1124 samples had levels less than 50 µg/mL. Pola total antibody concentrations ranged from &lt;0.05 µg/mL to 77.6 µg/mL with a median concentration of 1.3 µg/mL. Therefore, there is a low likelihood of false-negative ADA results.

The biological background signal can vary between the samples used to determine the cut points during assay validation and the patient population being analyzed. Therefore, in-study screening cut point factor (sCPF), confirmatory cut point (CCP), and titer offset were assessed using individual POLARIX baseline samples and compared to those determined during assay validation.

The sCPF, using 307 individuals and targeting a 5% untreated positive rate, was 0.854 with CI90% of 0.816 to 0.897. The validation sCPF (1.16) was outside the limits of the in-study sCPF; therefore, the instudy sCPF was implemented. The CCP, using 100 individuals and targeting a 1% untreated positive rate, was 40.3% with CI90% of 37.7% to 43.3%. Although the validation CCP (38%) was within the CI90%, it was decided to use the in-study cut points for both the sCPF and CCP for consistency. The in-study titer offset was also implemented. The titer offset value (0.0626) was based on 4 times the standard deviation of the assay signal from 307 individual baseline samples.

<div style=\"page-break-after: always\"></div>

Using the in-study titer offset, the relative sensitivity of the screening assay was estimated to be 27.8 ng/mL. Using the CCP of 40.3%, relative sensitivity of the confirmatory assay was estimated to be 20.7 ng/mL. Both the screening and confirmatory assays were able to detect 100 ng/mL of the surrogate positive control in the presence of 50 µg/mL of pola.

For all patients, the baseline prevalence of ADAs was 2.4% (20 of 849 ADA evaluable patients). Postbaseline, ADAs were detected in 6 of 427 (1.4%) ADA evaluable patients treated with pola (Table 3). All 6 ADA-positive patients had treatment-induced responses. Out of the 6 patients with treatment-induced ADA, 0 patients had a transient response but all had persistent responses. The 8 patients from the pola+R-CHP treatment arm who tested positive for ADA at baseline were treatment-unaffected (ADA response was similar to, or lower than, that at baseline).

Table 3 Incidence of Anti-Drug Antibodies to Pola in POLARIX

|                                               | Arm A Pola+R-CHP (N=433)   | Arm B R-CHOP (N=425)   | AllPatients (N=858)   |
|-----------------------------------------------|----------------------------|------------------------|-----------------------|
| BaselinePrevalenceofADAs                      |                            |                        |                       |
| Baselineevaluablepatients                     | 424                        | 425                    | 849                   |
| Patients with a positive sample at baseline   | 8 (1.9%)                   | 12 (2.8%)              | 20 (2.4%)             |
| Patients with no positive samples at baseline | 416                        | 413                    | 829                   |
| Post-BaselineIncidence of ADAs                |                            |                        |                       |
| Post-baseline evaluablepatients               | 427                        |                        |                       |
| Patients Positive for ADA                     | 6 (1.4%)                   |                        |                       |
| Treatment-Induced                             | 6                          |                        |                       |
| Treatment-Enhanced                            | 0                          |                        |                       |
| Patients negative for ADA                     | 421                        |                        |                       |
| Treatment unaffected                          | 8                          |                        |                       |

Domain specificity assay indicated through competitive binding that the antibody responses were directed primarily against the linker, drug, or neo-epitopes. Furthermore, all 6 patients with treatment-induced ADA were negative for NAb.

No significant difference in pola PK exposure for acMMAE, total antibody, and unconjugated MMAE was observed between ADA positive and ADA-negative patients. Individual pola PK exposure for acMMAE, total antibody, and unconjugated MMAE for 6 ADA positive patients were within the range of ADA negative patients.

## Absorption

The drug product is administered intravenously.

## Distribution

Already characterized in initial MAA

## Elimination

Already characterized in initial MAA

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Already characterized in initial MAA

## Pharmacokinetics in target population

Polatuzumab vedotin PK was characterized in Polivy initial application were the drug conjugate acMMAE, the unconjugated drug MMAE, and total antibody PK was characterized. Although the initial application target patients with relapsed/refractory DLBCL patients, clinical study GO29044 PK results also included DLBCL treatment naïve patients. The PK results, based on NCA analysis were presented in the initial application which included 1 st  line DLBCL PK data collected with the cut-off date of 29/12/2017. Polatuzumab vedotin PK in first line DLBCL treatment is thus considered characterised from the initial application. The PK results are reminded below in GO29044 study results.

Study GO29044 was an open-label, dose-escalation Phase Ib/II study with escalating dose phase of polatuzumab vedotin (1.0 mg/kg up to 2.4 mg/kg) in combination with a standard regimen of R-CHP or G-CHP in patients with B-cell NHL. An expansion phase was added which included newly diagnosed DLBCL patients receiving 1.8 mg/kg of polatuzumab vedotin with either R-CHP or G-CHP. PK parameters were estimated based on NCA analysis using Phoenix WinNonlin version 6.4.0.768 (Pharsight,Inc., Mountain View, CA). The estimated parameters were presented in the following table.

At cycle 1, following 1.8 mg/kg administered intravenously, acMMAE half-life is estimated to 5 days with a volume of distribution of 96.5 mL/kg (Vss). Cmax was estimated to 532 (±163) ng/mL and AUCinf to 1870 (±527) ng/mL*day. The unconjugated drug MMAE reached peak concentration of 2.60 ng/mL within 5.90 days ranging from 2.87 days to 6.99 days. The variability was low to moderate for acMMAE with CV% on Cmax of 30.6% and AUCinf of 28.1%; whereas, as expected, the variability on the unconjugated drug was moderate with CV% on Cmax of 39.2%, and AUClast of 46.9%. Overall based on cycle 1, polatuzumab vedotin PK in R/R NHL and newly diagnosed DLBCL appears to be comparable.

Table 4 Study GO29044: Mean (SD) summary of Cycle 1 PK parameters of polatuzumab vedotin in patients with B-NHL or DLBCL: dose escalation and expansion cohorts following 1.8 mg/kg Potuzumab vedotin co-administered with R-CHP or G-CHP in dose escalation and expansion cohort

| Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   | Conjugate (evaluated as acMMAE)   |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Dose (mg)                         | Treatment                         | Histology Phase                   |                                   | No. of patients                   | Cmax (ng/mL)                      | AUCinf (ng/mL)*day                | t1/2 (day)                        | Vss (mL/kg)                       | CL (mL/kg/day)                    |
| 1.8                               | R- CHP+Pola                       | B-NHL                             | ESC                               | 6                                 | 781 (72.6)                        | 2600 (413)                        | 4.79 (0.675)                      | 57.7 (7.95)                       | 12.8 (2.05)                       |
| 1.8                               | G- CHP+Pola                       | B-NHL                             | ESC                               | 6                                 | 557 (114)                         | 1850 (491)                        | 4.89 (0.526)                      | 87.5 (19.3)                       | 18.7 (5.30)                       |
| 1.8                               | R- CHP+Pola                       | DLBCL                             | EXP                               | 36                                | 532 (163)                         | 1870 (527) b                      | 5.03 (0.621) b                    | 96.5 (34.1) b                     | 18.9 (5.27) b                     |
| 1.8                               | G- CHP+Pola                       | DLBCL                             | EXP                               | 17                                | 530 (138)                         | 1940 (482) c                      | 5.50 (0.795) c                    | 99.3 (27.4) c                     | 17.7 (3.83) c                     |
| UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  | UnconjugatedMMAE                  |
| Dose (mg)                         | Treatment                         | Histology                         | Phase                             | No. of patients                   | No. of patients                   | C max (ng/mL)                     | AUClast (ng/mL)*day               | AUClast (ng/mL)*day               | Tmax (day)                        |
| 1.8                               | R- CHP+Pola                       | B-NHL                             | ESC                               | 6                                 | 6                                 | 2.18 (0.653)                      | 21.4 (11.1)                       | 21.4 (11.1)                       | 5.98 (5.87-                       |

11 9)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|   1.8 | G- CHP+Pola   | B-NHL   | ESC   |   6 | 3.48 (1.89)   | 27.0 (16.2) e   | 5.85 (0.0900-             |
|-------|---------------|---------|-------|-----|---------------|-----------------|---------------------------|
|   1.8 | R- CHP+Pola   | DLBCL   | EXP   |  35 | 2.60 (1.02)   | 24.5 (11.5) f   | 5.90 (2.87-               |
|   1.8 | G- CHP+Pola   | DLBCL   | EXP   |  14 | 2.88 (2.05)   | 23.9 (15.3) g   | 6 99) 5.35 (0.0900- 6.02) |

ac= antibody-conjugated; AUCinf = area under the concentration-time curve extrapolating to infinity; AUClast = area under the concentration-time curve from time zero to time of last measureable concentration; CHP=cyclophosphamide, dosorubicin, prednisone; CL = clearance; Cmax = peak serum/plasma concentration; DLBCL= diffuse large B-cell lymphoma; FL= follicular lymphoma; G=obinutuzumab; MMAE=monomethyl auristatin E; NHL=non-Hodgkin's lymphoma; R= rituximab; t1/2 = terminal half-life; tmax= time to reach maximum concentration; Vss = volume of distribution atsteady state.  a n=2,  b n=28,  c n=11,  d n=1,  e n=5,  f n=27,  g n=10,

To further characterize polatuzumab vedotin PK, mainly acMMAE concentration and the unconjugated MMAE, pop PK approach (Pop PK report 1111192) was used to characterize PK in subpopulation and for exposure-response analyses purposes. Previous popPK model (PopPK Report 1090510) included treatment naïve DLBCL patients (study GO29044) developed in the initial application and should be applicable to characterize polatuzumab vedotin PK in this population. External validation was consequently performed using PK data from study GO39942 (POLARIX) in which only patients with treatment naïve patients with DLBCL administered intravenously 1.8 mg/kg Q3W pola for 6 cycles concomitant with R-CHP regimen (Pop PK report 1111192). This previously developed integrated acMMAE-MMAE model (Model 201) was re-run with all parameters fixed using the data of Study GO39942 as external evaluation of the formerly established population PK model, further refered to model 301.

Cross-study comparison of pola PK in R/R DLBCL and 1L DLBCL patients showed the observed acMMAE, total Ab and unconjugated MMAE concentrations at C1D1 and C1D4 pre-dose and/or post-dose at 1.8 mg/kg ,the PK of pola related analytes were found to be overall similar (Table 6).

Table 5 Observed Mean Pola PK Concentration Comparisons Across Three studies

<!-- image -->

|                           |                       |                                    |                                           |                                                                    | Ratio            | Ratio            |
|---------------------------|-----------------------|------------------------------------|-------------------------------------------|--------------------------------------------------------------------|------------------|------------------|
| Analyte                   | Visit                 | POLARIX Previously Untreated DLBCL | G029365 (Combined Arm G and H)* R/R DLBCL | G029044 R-CHP+Pola 1.8 mg/kg expansion Previously Untreated DLBCL* | POLARIX/ G029365 | POLARIX/ G029044 |
| acMMAE (ng/mL)            | C1D1 30-min post dose | 603; N=362                         | 653; N=102                                | 532; N=36                                                          | 0.923            | 1.13             |
|                           | C4D1 pre-dose         | 18.2; N=402                        | 23.2; N=61                                | 20.6; N=36                                                         | 0.784            | 0.883            |
|                           | C4D1 post-dose        | 657; N=360                         | 659; N=60                                 | 561; N=36                                                          | 0.997            | 1.17             |
| Total antibody (μg/mL)    | C1D1 30-min post dose | 36.1; N=395                        | 33.9;N=103                                | 32.2; N=36                                                         | 1.06             | 1.12             |
| Total antibody (μg/mL)    | C4D1 pre-dose         | 5.44; N=407                        | 5.41; N=63                                | 5.90; N=36                                                         | 1.01             | 0.922            |
| Total antibody (μg/mL)    | C4D1 post-dose        | 44.4; N=398                        | 39.2; N=61                                | 38.1; N=35                                                         | 1.13             | 1.17             |
| unconjuagted MMAE (ng/mL) | C1D130-minpostdose    | 0.424; N=403                       | 0.590;N=103                               | 0.509; N=36                                                        | 0.719            | 0.833            |
| unconjuagted MMAE (ng/mL) | C4D1 pre-dose         | 0.144; N=406                       | 0.186; N=61                               | 0.133; N=36                                                        | 0.774            | 1.08             |
| unconjuagted MMAE (ng/mL) | C4D1post-dose         | 0.222; N=398                       | 0.256; N=60                               | 0.235; N=36                                                        | 0.867            | 0.945            |

ac=antibodyconjugated;DLBCL=diffuselargeB-cell lymphoma;MMAE=monomethyl auristatinE;PK=pharmacokinetic;R-CHP=rituximabplus cyclophosphamide, doxorubicin, and prednisone; R/R=relapsed or refractory.

*Polatuzumabvedotin1.8mg/kgIVonDay2of Cycle1,thenDay1ofeachsubsequentcycle

POLARIX/GO39942:APhaseIll,multicenter,randomized,double-blind,placebo-controlledtrialcomparingtheefficacyandsafetyofpolatuzumab vedotinincombinationwithrituximabandCHP(R-CHP)versusrituximabandCHOP(R-CHOP)inpreviouslyuntreatedpatientswithdiffuse largeB-celllymphoma.

GO29365: A Phase Ib/ll, multicenter, open-label study evaluating the safety, tolerability, and anti-tumor activity of polatuzumab vedotin in combinationwithrituximaborobinutuzumabplusbendamustineinpatientswithR/RfollicularlymphomaorR/RdiffuselargeBcelllymphoma. GO29044:APhaseIb/llmulticenter,open-label,dose-escalationstudyevaluatingthesafety,tolerabilityandanti-tumoractivityofpolatuzumab vedotin (DcDS4501A) in combination with rituximab or obinutuzumab, cyclophosphamide, doxorubicin, and prednisone in patients with B cell non-Hodakin'sIvmphoma.

<div style=\"page-break-after: always\"></div>

## Pop PK model (Pop PK report 1111192)

## Methods

Dataset: study GO39942

Study GO39942 (POLARIX , Table 1, Figure 1) is an ongoing Phase III, multicenter, randomized, doubleblind, placebo-controlled, trial comparing the efficacy and safety of pola plus R-CHP versus R-CHOP in previously untreated CD20-positive DLBCL. In the treatment arm, Pola 1.8 mg/kg, placebo for vincristine, rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, and doxorubicin 50 mg/m2 IV each are given on Day 1 and prednisone 100 mg/day orally (PO) is given on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m2 IV is given as monotherapy in Cycles 7 and 8.

All patients who had at least one quantifiable acMMAE or unconjugated MMAE concentration value by the pharmacokinetic samples analysis data cut-off date (03/16/2021) were included in the analysis.

DLBCL=diffuse large B-cell lymphoma; ECOG PS=Eastern Cooperative Oncology Group Performance Status; IPl=lnternational Prognostic Index; Q21D=every 21 days; R=randomization; R-CHOP=rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP=rituximab plus cyclophosphamide, doxorubicin, and prednisone.

Figure 1 Study GO39942 overall design

<!-- image -->

A total of 429 patients from Study GO39942 (POLARIX) contributed to 1122 acMMAE and 1175 unconjugated MMAE concentration values that were used in the external evaluation of the formerly established population PK model.

At Cycle 1 Day 1 pre-dose, only a serum PK sample for total antibody was taken, while at Cycle 1 Day 1 30-minutes post-dose as well as Cycle 4 Day 1 pre-dose and 30 minutes post-dose, PK samples were taken for measuring all the three pola analytes: total antibody (serum, measured by ELISA minimal quantifiable concentration 50 ng/mL), antibody-conjugated Monomethyl Auristatin E (AacMMAE, plasma measured by immunoaffinity HPLCMS/MS LLOQ 0.359 ng/mL) and unconjugated MMAE (MMAE plasma, measured by LCMS/MS 0.0359 ng/mL). In addition, PK samples were taken at treatment completion or early treatment termination visit for the three analytes and at 3 month post-treatment follow-up visit for for the total antibody only. Summaries of plasma acMMAE, and unconjugated MMAE are presented respectively in Table 6 and Table 7.

<div style=\"page-break-after: always\"></div>

Table 6 Summary table of plasma acMMAE concentration (ng/mL) by visit

| Treatment Arm Study Visit   | Sample Time Point    |   Number of Samples In the Analysis Including LTRs |   Number Of LTRs | Mean (SD) CV% Mean   |      |   Median | Range (Minimum - Maximum)   |   Geometric Mean |   CV% Geometric Mean |
|-----------------------------|----------------------|----------------------------------------------------|------------------|----------------------|------|----------|-----------------------------|------------------|----------------------|
| Cycle 1 Day 1               | 30 minutes Post-Dose |                                                362 |                0 | 603 (153)            | 25.3 |    594   | 16.6-1230                   |            576   |                 38.1 |
| Cycle 4 Day 1               | Pre-Dose             |                                                402 |                0 | 18.2 (12.0)          | 65.7 |     17.1 | 1.09-218                    |             16.5 |                 46.8 |
| Cycle 4 Day 1               | 30 minutes Post-Dose |                                                360 |                0 | 657 (175)            | 26.6 |    648   | 286-2520                    |            639   |                 23.8 |

acMMAE = antibody-conjugate Monomethyl Auristatin E; CV = coefficient of variation; LTR = less than reportable; SD = standard deviation

CV = coefficient of variation ; LTR=less than reportable; NE = Not Estimable; NR = Not Reportable; PK = pharmacokinetic; SD = standard deviation

Note: Number of LTRs = number of LTR concentration results, which are imputed as below.

Note: For post-dose pola samples if the sample is LTR, the value are replaced with 1/2(LLOQ=0.359 ng/mL) for calculating the summary statistics. If one-third or fewer values were LTR, then all summary statistics are reported, otherwise, only the n, median, minimum and maximum are reported.

## Source:t\\_pkc\\_polaac

Table 7 Summary of plasma unconjugated MMAE concentration (ng/mL) by visit

| Treatment Arm Study Visit   | Sample Time Point    |   Number of Samples in the analysis including LTRs |   Number of LTRs | Mean (SD)     |   CV% Mean |   Median | Range (Minimum- Maximum)   |   Geometric Mean |   CV% Geometric Mean |
|-----------------------------|----------------------|----------------------------------------------------|------------------|---------------|------------|----------|----------------------------|------------------|----------------------|
| Cycle 1 Day 130 minutes     | Post-Dose            |                                                403 |               12 | 0.424 (0.335) |       79   |    0.353 | 0.0180-3.07                |            0.327 |                 93.4 |
| Cycle 4 Day 1               | Pre-Dose             |                                                406 |               19 | 0.144 (0.116) |       80.4 |    0.112 | 0.0180-1.06                |            0.111 |                 85   |
| Cycle 4 Day 1               | 30 minutes Post-Dose |                                                398 |                2 | 0.222 (0.142) |       64   |    0.189 | 0.0180-1.37                |            0.189 |                 63.3 |

CV = coefficient of variation ; LTR=less than reportable; MMAE; Monomethyl Auristatin E; PK = pharmacokinetic; SD = standard deviation

Note: LTRs = number of LTR concentration results, which are imputed as below.

Note: For post-dose pola samples if the sample is LTR, the value are replaced with 1/2(LLoQ=0.0359 ng/mL) for calculating the summary statistics. lf one-third or fewer values were LTR, then all summary statistics are reported, otherwise, only the n, median, minimum and maximum are reported.

## Source:t\\_pkc\\_polafree

Anti-drug antibodies to pola were detected in serum samples using a validated bridging enzyme-linked immunosorbent assay. The screening and confirmatory ADA assays were able to detect 100 ng/mL of a surrogate anti-pola antibody in the presence of 50 μg/mL of pola. All patients who had at least one quantifiable acMMAE or unconjugated MMAE concentration value by the pharmacokinetic samples analysis data cut-off date 16.03.2021 were included in the analysis.

## Covariate definition

Baseline creatinine clearance (BCRCL) was calculated based on the widely used Cockcroft-Gault formula.

Renal function category was defined based on creatinine Clearance values, and hepatic function was based on The National Cancer Institute Organ Dysfunction Working Group Classification of Hepatic Dysfunction classification.

Summaries of the covariates from the study population are presented in Table 8 for continuous covariates and in Table 9 for categorical covariates

<div style=\"page-break-after: always\"></div>

Table 8 Summary of continuous covariates of study POLARIX

| Covariate   | Description                       | Mean (SD)    | Median [Range]   |
|-------------|-----------------------------------|--------------|------------------|
| BAGE        | Age (years)                       | 62.9 (11.4)  | 65 [19-80]       |
| BWT         | Weight (kg)                       | 75.9 (20)    | 74.4 [38.4-228]  |
| BBSA        | Body Surface Area (m^)            | 1.86 (0.266) | 1.85 [1.28-3.4]  |
| BBMI        | Body Mass Index(kg/m^)            | 26.7 (6)     | 26.2 [16.4-68.1] |
| BLBWT       | Lean Body Weight (kg)             | 53.5 (10.7)  | 51.9 [31.5-87.5] |
| BHT         | Height (cm)                       | 168 (10.2)   | 168 [144-200]    |
| BALBUM      | Albumin (g/L)                     | 36.8 (6.14)  | 37 [17.1-54.2]   |
| BTPROT      | Total Protein (g/L)               | 66.6 (8.09)  | 67.3 [39.4-85]   |
| BALP        | Alkaline Phosphatase (u/L)        | 122 (139)    | 87 [1.52-1960]   |
| BALT        | Alanine Amino-transferase (u/L)   | 26.7 (21.2)  | 21 [0.3-149]     |
| BAST        | Aspartate Amino-transferase (u/L) | 28.6 (23.9)  | 23 [0.35-288]    |
| BBILI       | Bilirubin (umol/L)                | 9.69 (7.09)  | 8 [1.71-79]      |
| HGB         | Hemoglobin (g/L)                  | 121 (19)     | 123 [65-170]     |
| BLDH        | Lactate Dehydrogenase (u/L)       | 425 (422)    | 297 [4.2-4820]   |
| BSCR        | Serum Creatinine (umol/L)         | 75.1 (22.5)  | 71 [35-200]      |
| BCRCL       | Creatinine Clearance (ml/min)     | 94.8 (38)    | 88.1 [29.3-441]  |
| BBCC        | Absolute B Cell Count (10%L)      | 263 (1100)   | 90.5 [0-19100]   |
| Log BBCC    | Log of BBCC (10°/L)               | 4.41 (1.42)  | 4.51 [0-9.86]    |
| BTMBD       | Tumor SPD (mm2)                   | 7420 (12900) | 4690[96-227000]  |

Source: ContCovMean.csv, ContCovMedian.csv (DLBCL\\_BLA\\_Report.R)

<div style=\"page-break-after: always\"></div>

Table 9 Summary of categorical covariates of study POLARIX

| Covariate                              | Level                     | Number(Percent)        |
|----------------------------------------|---------------------------|------------------------|
| Race                                   | White                     | 228 (53.1%)            |
| (RACE)                                 | Asian                     | 84 (19.6%)             |
| Race                                   | Unknown or Other          | 117 (27.3%)            |
| Gender (SEX)                           | Female                    | 196 (45.7%)            |
| Gender (SEX)                           | Male                      | 233 (54.3%)            |
| Region                                 | West. Europe              | 159 (37.1%)            |
| Region                                 | Eeast. Europe             | 46 (10.7%)             |
| Region                                 | South and Central America | 6 (1.4%)               |
| Region                                 | North America             | 117 (27.3%)            |
| Region                                 | Asia                      | 80 (18.6%)             |
|                                        | Pacific                   | 21 (4.9%)              |
| ECOGPerfomance Status (BECOG)          | 0                         | 169 (39.4%)            |
| ECOGPerfomance Status (BECOG)          | 1                         | 196 (45.7%)            |
| ECOGPerfomance Status (BECOG)          | 2                         | 64 (14.9%)             |
| Bulky Disease (BBULKY)                 | Absent                    | 242 (56.4%)            |
| Bulky Disease (BBULKY)                 | Present                   | 187 (43.6%)            |
| Computed Hepatic Impaiment (HEPA)      | Missing                   | 2 (0.5%)               |
| Computed Hepatic Impaiment (HEPA)      | Normal                    | 338 (78.8%)            |
| Computed Hepatic Impaiment (HEPA)      | Mild                      | 79 (18.4%)             |
| Computed Hepatic Impaiment (HEPA)      | Moderate                  | 9 (2.1%)               |
| Computed Hepatic Impaiment (HEPA)      | Severe                    | 1 (0.2%)               |
| Renal Impaimment (RENAL)               | Missing                   | 3 (0.7%)               |
| Renal Impaimment (RENAL)               | Normal                    | 171 (39.9%)            |
| Renal Impaimment (RENAL)               | Mild                      | 200 (46.6%)            |
| Renal Impaimment (RENAL)               | Moderate                  | 54 (12.6%)             |
|                                        | Severe                    | 1 (0.2%)               |
| ADA Status                             | Missing                   | 7 (1.6%)               |
| ADA Status                             | Present                   | 6 (1.4%)               |
| (ATAP)                                 | Absent ABC                | 416 (97%) 99 (23.1%)   |
| DLBCL Subgroup (ABCGCB)                | GCB                       | 180 (42%)              |
| DLBCL Subgroup (ABCGCB)                | Unclassified              | 44 (10.3%)             |
| DLBCL Subgroup (ABCGCB)                | Unknown                   | 106 (24.7%)            |
| Number of Risk Factors for IPI (BIPIN) | 1                         | 1 (0.2%)               |
| Number of Risk Factors for IPI (BIPIN) | 2                         | 159 (37.1%)            |
| Number of Risk Factors for IPI (BIPIN) | 3                         | 170 (39.6%)            |
| Number of Risk Factors for IPI (BIPIN) | 4                         | 75 (17.5%)             |
| NHL Subtype                            | 5 DLBCL NOS,ABC,GCB       | 24 (5.6%) 363 (84.6%)  |
| NHL Subtype                            | HGBL,NOS,DHLTHL           | 42 (9.8%)              |
| (NHL)                                  |                           |                        |
| (NHL)                                  | Other Large B-cell        | 24 (5.6%)              |
| LDH level (LDH)                        | >ULN                      | 283 (66%)              |
| LDH level (LDH)                        | ≤ULN missing              | 143 (33.3%) 3 (0.7%)   |
|                                        | DEL                       | 135 (31.5%)            |
| Double Expressor by IHC (DEL)          |                           |                        |
| Double Expressor by IHC (DEL)          | No DEL Unknown            | 220 (51.3%) 74 (17.2%) |
|                                        | Level                     | Number (Percent)       |
| Covariate                              |                           |                        |
|                                        | 1                         | 2 (0.5%)               |
| AnnArbor Stage at Study Entry          | 2 3                       | 43 (10%) 120 (28%)     |

Source file: CatCov.csv (DLBCL\\_BLA\\_Report.R)

<div style=\"page-break-after: always\"></div>

## Structural model

The previously developed PK model of pola in patients with NHL (Model 201) was a complex fourcompartment model that consisted of the acMMAE model and the unconjugated MMAE model. The unconjugated MMAE model had parallel linear and Michaelis-Menten elimination and time-dependent relative conversion fraction from acMMAE to unconjugated MMAE (Figure 2). Model 201 parameters estimates are reported in Table 9.

## Figure 2 Schematic Representation of Structural acMMAE-MMAE Model (Report 1111192)

CLns = CLine&lt;(1+CLinF.EMAx T5/(T5Y+t')): acMMAE non-specific clearance (t in months); CL,=CLr-exp(-Kdes-t) (t in hours); CLinr: acMMAE non-specific linear clearance at time of infinity; Q:acMMAEinter-compartmentclearance;V,:acMMAE centralvolume;V2:acMMAEperipheral volume; Vmax: maximum acMMAE Michaelis-Menten elimination rate; Km: Michaelis-Menten constant of acMMAE elimination.

FRACns: acMMAE-unconjugated MMAE conversion fraction for non-specific elimination; FRACct: ratio of acMMAE-unconjugated MMAE conversion fractions for CL: and CLns elimination pathways; FRACmm: ratio of acMMAE-unconjugated MMAE conversion fractions for MM and CLns elimination pathways; CLmMAe: unconjugated MMAE apparent clearance; QmmAe: unconjugated MMAE apparent inter-compartment clearance; VmmAe: unconjugated MMAE apparent central volume; V2.MMAe: unconjugated MMAE peripheral volume; Vmax.MMAe: maximum unconjugated MMAE Michaelis-Menten elimination rate; Kss: Michaelis-Menten constant of unconjugated MMAE elimination.

<!-- image -->

This previously developed integrated acMMAE-MMAE model (Model 201) was re-run with all parameters fixed (Table 9) using the data of Study GO39942 as Model 301. The initial model (model 201) parameters were initially estimated from 4 studies: Studies DCS4968g in B-NHL patients, studies GO27834, GO29365 in R/R DLBCL and R/R FL patients (excluding Arm G and Arm H),, and study GO29044 in DLBCL 1st line patients. Covariates were investigated and the retained significant covariates were bodyweight, gender, race (Asian vs non-Asian) treatment naïve, combination therapy effect, B-cell count effect, tumor SPD, prior treatment, threshold B-cells hepatic impairment, ECOG score=0, albumin.

<div style=\"page-break-after: always\"></div>

Table 10 Estimates of Structural Fixed-Effect Parameters from previous model, Integrated Model 201

| Parameter                    | Parameter                    | Parameter                                           | Description                                            | Value                        | RSE%                         | 95%CI                        |
|------------------------------|------------------------------|-----------------------------------------------------|--------------------------------------------------------|------------------------------|------------------------------|------------------------------|
| acMMAE parameters            | acMMAE parameters            | acMMAE parameters                                   | acMMAE parameters                                      | acMMAE parameters            | acMMAE parameters            | acMMAE parameters            |
| Kdes (1/hr)                  | 01                           | rate constant of CLt decrease                       | rate constant of CLt decrease                          | 0.0046                       | 7.95                         | 0.00389- 0.00532             |
| CLT (L/hr)                   | θ2                           | initial time-dependent CL                           | initial time-dependent CL                              | 0.00623                      | 19.6                         | 0.00383- 0.00862             |
| CLine (L/hr)                 | 03                           | non-specific linear clearance after repeated dosing | non-specific linear clearance after repeated dosing    | 0.0344                       | 3.6                          | 0.032-0.0368                 |
| V, (L)                       | 04                           | central volume                                      | central volume                                         | 3.15                         | 1.58                         | 3.05-3.25                    |
| V2 (L)                       | 05                           | peripheral volume                                   | peripheral volume                                      | 3.98                         | 2.92                         | 3.75 - 4.2                   |
| Q (L/hr)                     | 08                           | inter-compartment rate                              | inter-compartment rate                                 | 010145                       | 2.53                         | 0.0138-0.0153                |
| Vmax (ng/mL/hr)              | 07                           | maximum MM elimination                              | maximum MM elimination                                 | 0.0203                       | 14.3                         | 0.0146-0.026                 |
| Km (ng/mL)                   | 08                           | MM constant                                         | MM constant                                            | 0.604                        | 36.2                         | 0.175 - 1.03                 |
| CLINF.MAX                    | 0g                           | maximum effect of time on CLns                      | maximum effect of time on CLns                         | 0.223                        | 8.6                          | 0.185 -0.261                 |
| T5o (month)                  | θ10                          | time of the half-effect of CLINF MAX                | time of the half-effect of CLINF MAX                   | 3.53                         | 6.77                         | 3.07 - 4                     |
| Y                            | θ11                          | Sigmoidicity of CLns(t) function                    | Sigmoidicity of CLns(t) function                       | 2.27                         | 12.5                         | 1.71 - 2.82                  |
| Unconjugated MMAE parameters | Unconjugated MMAE parameters | Unconjugated MMAE parameters                        | Unconjugated MMAE parameters                           | Unconjugated MMAE parameters | Unconjugated MMAE parameters | Unconjugated MMAE parameters |
| VMMAE( (L) 012               | VMMAE( (L) 012               | VMMAE( (L) 012                                      | unconjugated MMAE apparent central volume              | 82.2                         | 8.15                         | 69.1 - 95.4                  |
| CLmMAe (L/hr) θ13            | CLmMAe (L/hr) θ13            | CLmMAe (L/hr) θ13                                   | unconjugated MMAE apparent clearance                   | 1.89                         | 8.14                         | 1.59 -2.2                    |
| QMMAe (L/hr) θ14             | QMMAe (L/hr) θ14             | QMMAe (L/hr) θ14                                    | unconjugated MMAE apparent inter-compartment clearance | 36.3                         | 12.3                         | 27.5 - 45.1                  |
| V2.MMA= (L) θ15              | V2.MMA= (L) θ15              | V2.MMA= (L) θ15                                     | unconjugated MMAE apparent peripheral volume           | 200                          | 6.13                         | 176 -224                     |
| VMAX.MMAE θ16 (ng/mL/hr)     | VMAX.MMAE θ16 (ng/mL/hr)     | VMAX.MMAE θ16 (ng/mL/hr)                            | maximum MM elimination                                 | 0.0307                       | 9.17                         | 0.0252- 0.0362               |
| Kss (ng/mL) θ17              | Kss (ng/mL) θ17              | Kss (ng/mL) θ17                                     | MM constant                                            | 0.581                        | 10.5                         | 0.461 -0.701                 |
| FRACcLT θ18                  | FRACcLT θ18                  | FRACcLT θ18                                         | factor for relative conversion fraction of CL:pathway  | 3.70                         | 3.11                         | 3.48-3.93                    |
| FRACMM θ19                   | FRACMM θ19                   | FRACMM θ19                                          | factor for relative conversion fraction of MM pathway  | 2.72                         | 9.45                         | 2.21-3.22                    |
| ALPH θ20 (1/month)           | ALPH θ20 (1/month)           | ALPH θ20 (1/month)                                  | rate constant of FRACt decrease                        | 0.167                        | 38.5                         | 0.0411-0.293                 |
| FRACT θ21                    | FRACT θ21                    | FRACT θ21                                           | initial time-dependent part of FRAC                    | 0.139                        | 21.0                         | 0.0816 -0.196                |

SE:Standard Error; PE:ParameterEstimate;RSE%:Relative Standard Error=100-SE/PE;95%Cl:95% confidence interval

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Parameter                                           | Parameter                                           | Description                                         | Value                                               | RSE%                                                | 95% CI                                              |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Effects on acMMAE Model Parameters                  | Effects on acMMAE Model Parameters                  | Effects on acMMAE Model Parameters                  | Effects on acMMAE Model Parameters                  | Effects on acMMAE Model Parameters                  | Effects on acMMAE Model Parameters                  |
| CLINF. WT                                           | θ22                                                 | Weight effect on CLINF                              | 0.73                                                | 8.18                                                | 0.613-0.848                                         |
| V1.wT; V2.wT; QwT                                   | θ23                                                 | Weight effect on V, V2 and Q                        | 0.50                                                | 6.24                                                | 0.439 -0.561                                        |
| V1. males                                           | θ24                                                 | Male vs. female effect on V,                        | 1.20                                                | 1.83                                                | 1.16 - 1.24                                         |
| V1. ASIAN                                           | θ25                                                 | Asian race effect on V                              | 0.929                                               | 4.18                                                | 0.852 - 1                                           |
| V1. NAIVE                                           | θ26                                                 | Treatment-naive effect on V,                        | 1.2                                                 | 1.96                                                | 1.16 - 1.25                                         |
| CLINF.SEX                                           | θ27                                                 | Gender effect on CLINF                              | 1.1                                                 | 2.66                                                | 1.04 - 1.15                                         |
| CLINF, ALBUM                                        | 828                                                 | Albumin effect on CLINF                             | -0.247                                              | 36.3                                                | -0.423--0.0712                                      |
| CLINF. RTX,Ob                                       | θ29                                                 | Combination therapy effect on CLINF                 | 0.844                                               | 2.95                                                | 0.795-0.892                                         |
| CLINF. B-cells                                      | θ30                                                 | B-cell count effect on CLINF                        | 0.0212                                              | 17.9                                                | 0.0138-0.0286                                       |
| CLINF.TMBD                                          | θ31                                                 | Tumor SPD effect on CLINF                           | 0.0521                                              | 27.4                                                | 0.0241 -0.0801                                      |
| Kdes,NAIVE                                          | θ32                                                 | Prior treatment effect on Kdes                      | 3.38                                                | 12.7                                                | 2.54 -4.22                                          |
| KDES.RTX,Ob                                         | θ33                                                 | Combination therapy effect on Kdes                  | 0.932                                               | 11.2                                                | 0.727 - 1.14                                        |
| CLT,NAIVE                                           | θ34                                                 | Treatment-naive effect on CLT                       | 3.53                                                | 34.7                                                | 1.13 -5.93                                          |
| CLT.TMBD                                            | 035                                                 | Tumor SPD of 50% effect on CLL                      | 1150                                                | 46.0                                                | 114-2190                                            |
| CLT.Threshold                                       | θ36                                                 | Threshold of B-cells on CLT                         | 121                                                 | 46.0                                                | 11.9 -229                                           |
| CLT.B-cells                                         | θ37                                                 | B-cell count effect on CLT                          | 0.578                                               | 24.6                                                | 0.3-0.856                                           |
| Effects on acMMAE-MMAE relative conversion fraction | Effects on acMMAE-MMAE relative conversion fraction | Effects on acMMAE-MMAE relative conversion fraction | Effects on acMMAE-MMAE relative conversion fraction | Effects on acMMAE-MMAE relative conversion fraction | Effects on acMMAE-MMAE relative conversion fraction |
| FRACWT                                              | 038                                                 | Weight effect on FRAC                               | -0.467                                              | 23.1                                                | -0.679 - -0.256                                     |
| FRACSEX                                             | 039                                                 | Gender effect on FRAC                               | 0.911                                               | 4.72                                                | 0.827-0.995                                         |
| FRACNAIVE                                           | 040                                                 | Treatment-naive effect on FRAC                      | 0.756                                               | 5.95                                                | 0.668 - 0.844                                       |
| FRACRTX.Ob                                          | θ41                                                 | Combination therapy effect on FRAC                  | 0.709                                               | 5.54                                                | 0.632-0.786                                         |
| FRACHEPA                                            | 042                                                 | Hepatic Impairment on FRAC                          | 1.19                                                | 5.58                                                | 1.06 - 1.32                                         |
| FRACECOG                                            | 043                                                 | ECOG (=0) effect on FRAC                            | 0.905                                               | 4.34                                                | 0.828-0.982                                         |
| FRACALB                                             | 044                                                 | Albumin effect on FRAC                              | -0.613                                              | 23.2                                                | -0.892--0.334                                       |

Missing data and BLQs

<div style=\"page-break-after: always\"></div>

Missing continuous covariates were imputed by the median value of the covariate. There were no continuous covariates with more than 15% of missing values. Missing categorical covariates were not imputed and were identified as a separate \"Missing\" category. The imputation flags (1 or 0) were provided for the continuous covariates and for the categorical covariates that were derived from continuous covariates.

AcMMAE or unconjugated MMAE post-dose observation below the limit of quantification (BLQ) were excluded from the analysis (commented out in the analysis data file). It was not deemed necessary to apply a likelihood-based method for handling the BQL data.

## Softwares

The population PK analysis was conducted via nonlinear mixed-effects modeling with the NONMEM software, Version 7.5.0 (ICON Development Solutions) [9]. The first-order conditional estimation method with interaction (FOCEI) was used for all NONMEM model runs.

## Model validation

This model was then externally validated with study GO39942 (POLARIX) based on

- -diagnostic plots (DV vs PRED, IPRED; CWRED vs TIME, nominal time, TAD and PRED; CWRES distribution; ETA distributions, …),
- -shrinkage of the random effect distribution
- -VPC
- -NPDE
- -Conditional VPCs

## Model application

## Simulation modalities

Model application included comparison of individual PK parameters and exposure measures. Simulations were utilized to compute individual exposures using the final population PK model. In the simulation procedure, individual values of random effects and individual values of covariates were used. The resulting exposures were used to compare exposures between groups of patients.

Individual empirical Bayes estimates of acMMAE PK parameters were used to estimate Cycle 6 terminal half-life (t1/2,term) of the linear part of the acMMAE PK model according to the equations of the twocompartment linear model, considering that the MM elimination only plays a minor role in the total clearance. The equations for estimating t1/2,term are listed below:

<!-- image -->

Simulations using individual parameter estimates were used to characterize changes in exposures with time from Cycle 1 to Cycle 6 (following six 1.8 mg/kg Q3W doses) and further to Cycle 30 in order to estimate time to steady state.

## Impact of Key Variables on Pola PK Exposure Measures

To support key label claims and filing questions, simulations from the final model were conducted to assess the impact of covariates on model projected acMMAE and unconjugated MMAE exposure. The

<div style=\"page-break-after: always\"></div>

proposed pola dosing regimen is 1.8 mg/kg Q3W for up to six cycles. Thus, a maximum (and the closest to steady-state) acMMAE exposure is expected to be observed at Cycle 6. The exposure at cycle 6 (AUC and Cmax), further called the steady state exposure, was used for all comparisons. While Ctrough was also computed, it was deemed irrelevant for safety and efficacy, and was not used for comparisons.

Individual exposure parameters were computed for all patients following simulated 1.8 mg/kg doses Q3W for 6 cycles.

The following covariate categories were compared: body weight ( ≥ 100 kg. vs. &lt; 100 kg), sex (males vs. females), age ( ≥ 65 vs. &lt;65 years old), race (Asian vs. non-Asian), country (Asia country vs. non-Asian country; Asian country vs. Western country; Asian countries vs. rest of the world except Asian and Western countries; Taiwan vs. not Taiwan; South Korea vs. not South Korea), hepatic impairment (mild, or moderate vs. normal), renal impairment (mild, moderate, or severe vs. normal), ECOG performance status (1 versus 0 and 2 versus 1), disease characteristics (bulky vs. not bulky; Ann Arbor stage at study entry 3-4-5 vs. 1-2; baseline IPI score 3 vs. 1-2 and 4-5 vs. 1-2; DLBCL subgroup GCB vs. ABC; NHL subtypes; Double Expressor by IHC DEL vs. not DEL, baseline LDH levels (above ULN vs. below ULN), ADA status (ADA positive versus negative).

## Results

Comparison of the random effects of PK parameters shrinkage estimated from the initial model, model 201, and the present model based on study GO39942 PK results are presented in Table 10.

Bias was noticeable in the distribution of the random effects on the acMMAE to MMAE conversion fraction (η7), and the random effects on the residual error (η10 and η11). Shrinkage values are low (&lt;30%) for inter-individual random effect on time-independent clearance (η2), central volume (η3), and acMMAE to MMAE conversion fraction (η7). Shrinkage of the random effect on time -dependent clearance (η1) was moderate (43.5%). For all other parameters, shrinkage of the random effects exceeded 50%. High shrinkage of the random effects is likely related to the sparse sampling.

Low shrinkage values (27.7% and 22.6% respectively) of the random effects on acMMAE timeindependent clearance (η2) and central volume (η3) indicate that computation of the individual Cycle 6 acMMAE AUC and Cmax values is not shrinking toward the population mean and can be used for the exposure-response analysis.

Although shrinkage of the random effects on unconjugated MMAE model parameters is high, unconjugated MMAE exposure is mostly defined by the FRAC parameter, unconjugated MMAE central volume (for unconjugated MMAE Cmax value), and by the ratio of CLMMAE/FRAC (for unconjugated MMAE AUC value). Shrinkage of the FRAC parameter is low (19.3%), and unconjugated MMAE central volume does not have the random effect. The expected value of CLMMAE/FRAC variance is the sum of CLMMAE and FRAC variances estimated by the model (equal to 0.212) while the observed variance of the ratio is the variance of the difference η8 -η7 (equal to 0.161). Due to the hi gh correlation of the random effects on CLMMAE and FRAC, the resulting shrinkage of the ratio of CLMMAE/FRAC is low (13.0%). Thus, unconjugated MMAE AUC and Cmax values are not shrinking toward the population mean and can be used for the exposure response analysis.

<div style=\"page-break-after: always\"></div>

Table 11 Shrinkage of Variance Parameters, Integrated Model 301

<!-- image -->

| Parameter         | Parameter   | Description                          |   Value | Shrinkage of Model 201   | Shrinkage of Model 301   |
|-------------------|-------------|--------------------------------------|---------|--------------------------|--------------------------|
| WcLt              | Ω11         | Random effect on CL                  |  1.89   | 17.4%                    | 43.5%                    |
|                   | Oz2         | Random effect on CLINF               |  0.0376 | 8.1%                     | 27.7%                    |
|                   | Q33         | Random effect on V4                  |  0.0151 | 11.8%                    | 22.6%                    |
| w²v2              | 044         | Random effect on V2                  |  0.107  | 21.6%                    | 74.6%                    |
| w'a               | Qs5         | Random effect on Q                   |  0.0538 | 30.6%                    | 79.8%                    |
| wWvMAx            |             | Random effect on VMAx                |  0.462  | 33.4%                    | 66.6%                    |
|                   |             | Random effect on conversion fraction |  0.0972 | 11.1%                    | 19.3%                    |
| WcLMMAE           |             | Randomi effect on CLuMAE             |  0.115  | 21.5%                    | 51.4%                    |
|                   |             | Random effect on V2,MMAE             |  0.0422 | 48.5%                    | 83.8%                    |
|                   | Q10,10      | Random effect On OacMMAE             |  0.0521 | %1'7-                    | 63.2%                    |
| R WgacMMAE WgMMAE | Q11,10      | OScMMAE-OMMAE Correlation            |  0.038  |                          |                          |
| OMMAE             | Q11,11      | Random effect on OMMAE               |  0.0427 | 0.1%                     | 65.3%                    |
| SCMMAE            | E1          | for acMMAE Residual error            |  0.0254 | 9.2%                     | 26.8%                    |
| MMAE              | En          | Residual error for unconjugated MMAE |  0.0726 | 6.4%                     | 43.6%                    |

The diagnostic plots are presented in Figure 4 for ac MMAE, and Figure 5 for unconjugated MMAE. The NPDE, and VPCs plots for both acMMAE, and unconjugated MMAE are presented in Figure 6, and Figure 7 respectively. The visual predictive check plots show an acceptable agreement between the simulated and observed acMMAE data. The visual predictive check plots for unconjugated MMAE show acceptable agreement between the simulated and observed data for the 10th percentile and the median, while the model over-estimated 90th percentile of observed data, especially at the first sampling point two hours after the first dose. A higher than observed variability of time-dependent acMMAE clearance estimated by the legacy model and higher than observed residual variability may explain the difference. The model was developed on a more diverse data set leading to higher than observed variability of predicted unconjugated MMAE concentrations following the first dose. As steady-state is approached (e.g., Cycle 4 Day 1 post-dose samples at nominal time of 1513 hours after the fisrt dose), differences of observed and simulated unconjugated MMAE concentrations are much smaller. A total of 96%, 60%, and 13% on NPDE values were above 10th, 50th, and 90th percentiles of the expected acMMAE NPDE distribution. A total of 93%, 44%, and 4% on NPDE values were above 10th, 50th, and 90th percentiles of the expected unconjugated MMAE NPDE distribution.

<div style=\"page-break-after: always\"></div>

Figure 3 Goodness-of-Fit for Integrated Model 301: acMMAE

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 Goodness- of-Fit for Integrated Model 301: unconjugated MMAE

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5 NPDE plots for integrated model 301. Circles correspond to NPDE of observations in the distribution of 500 simulated values. Lines at y=0 correspond to median, and dashed lines show the 10th and 90th percentiles. Percentages of points below 10th percentile and above 50th and 90th percentiles are reported. Red lines show the lowess trend lines.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## acMMAE

<!-- image -->

## Unconjugated MMAE

Figure 6 Visual Predictive Check for Integrated Model 301: Semi-log Scale Points are observed concentrations. The lines show median (red), and the 10th and 90 th  percentiles (blue) of observed concentrations. The shaded regions show the 80% confidence intervals on the respective predicted percentiles obtained by simulations. The simulated values were computed from 500 trials with dosing, sampling, and the covariate values of the analysis dataset. Nominal time point of 1513 hours was shifted for better visibility

<!-- image -->

## Model application

## acMMAE PK properties

- The median (2.5th-97.5th percentiles) terminal half-life of acMMAE in patients included in the analysis (estimated based on the values of the linear clearance at Cycle 6) was 11.8 (10.0-13.2) days.
- The acMMAE AUC and Ctrough increased mildly with repeated Q3W dosing, due to the decrease of acMMAE clearance with time. Based on the population PK simulations of exposures for each cycle up to 6 cycles of 1.8 mg/kg Q3W dose, the acMMAE Cycle 3 AUC and Ctrough (i.e., Cycle 4 day 1 pre-dose) were approximately 1.3 and 1.8 fold of the values at Cycle 1 AUC and Ctrough (i.e.,

<div style=\"page-break-after: always\"></div>

Cycle 2 day 1 predose); the Cycle 6 values were approximately 1.4 and 2.2 fold of the values at Cycle 1. There were no apparent increase in Cmax values.

- Based on the population PK model simulation, the Cycle 3 acMMAE AUC, Cmax and Ctrough (i.e., Cycle 4 day 1 pre-dose) values were 92%, 99% and 82% of Cycle 6 AUC, Cmax and Ctrough (Cycle 6 day 21) values, which were the maximum acMMAE exposures for the proposed dosing regimen of up to 6 cycles of treatment. In turn, Cycle 6 acMMAE AUC, Cmax and Ctrough values are 90%, 99% and 80% of the model estimated steady-state AUC, Cmax and Ctrough values (represented by the simulated value for the exposure during hypothetical Cycle 30 after repeated Q3W dosing, at which time the CLNS approximated CLINF).

Unconjugated MMAE PK properties

- An integrated acMMAE-MMAE population PK model well described PK of unconjugated MMAE. Unconjugated MMAE demonstrated formation rate limited kinetics. Unconjugated MMAE exposures decreased after repeated dosing of pola, which is empirically fitted by a reduction of relative fraction of formation of unconjugated MMAE from acMMAE (FRAC) with time.
- Unconjugated MMAE AUC and Cmax decreased, potentially due to decrease of acMMAE clearance and decrease of relative fraction of formation of MMAE from acMMAE (FRAC) with time. Based on the population PK simulations of exposures for each cycle up to 6 cycles of 1.8 mg/kg Q3W dose, AUC and Cmax values were the highest in Cycle 1 after which they declined. The unconjugated MMAE AUC and Cmax at Cycle 3 are approximately 66% and 55% of the values at Cycle 1; the Cycle 6 values are approximately 64% and 51% of the values at Cycle 1. The Ctrough values are low (&lt;0.5 ng/mL).

## Special populations

Simulation of Cycle 6 exposures (AUC, Cmax) based on individual empirical Bayes estimates of PK parameters were performed. Heavy patients (body weight &gt;= 100 kg) had mildly higher acMMAE exposures (14% for AUC, 18% for Cmax) and higher unconjugated MMAE exposures (54% for AUC and 48% for Cmax). Age, sex, race (Asian versus non-Asian), region (Asian country versus non-Asian country), renal function impairment (mild or moderate impairment), ECOG performace status, disease characteristics (bulky disease, Ann Arbor stage; IPI score, DLBCL subgroup, Double Expressor by IHC, LDH) were not associated with clinically relevant difference of acMMAE and unconjugated MMAE exposures.

Patients with mild hepatic impairment had similar acMMAE exposures to patients with normal hepatic function but moderately higher unconjugated MMAE exposures (46% higher for AUC and 35% for Cmax).

## Pharmacokinetic interaction studies

Polatuzumab was evaluated as a potential victim and perpetrator of a PK drug-drug interaction with rituximab (R)/obinutuzumab (G)-CHP (GO29044 study). Prednisone was not assessed in this analysis given the wide therapeutic window of steroids and low risk for pola as a perpetrator of a PK DDI for prednisone.

Study GO29044 is a phase Ib/II, multicenter, open-label, and dose-escalation study (NCT01992653). Patients with B-NHL received six or eight cycles of pola 1.0-1.8 mg/kg + R/GCHP (21-day cycles; R/GCHP was given as per the standard regimen). Patients were given either six or eight cycles of treatment based on the discretion of the investigator in accordance with local institutional practice.

<div style=\"page-break-after: always\"></div>

## Evaluation of the potential interaction of CHP as a perpetrator of a DDI with polatuzumab vedotin PK

Polatuzumab was assessed as a DDI 'victim' of CHP by comparing pola exposure with data from previous studies as a comparator, which included Study GO27834 where pola was administered with rituximab/obinutuzumab in the absence of CHP. Patients in Study GO27834 followed the same pola PK sampling scheme in comparison to GO29044 study.

Exposure comparisons included Cycle 1 Cmax and AUC of each polatuzumab vedotin analyte (acMMAE, total antibody, and unconjugated MMAE). The results are presented in both Table 11 &amp; Table 12. The latter is taken from Shemesh et al. (2020) and provides data on variability as 90% confidence intervals associated with central values. Although taken from the same studies, the results presented in Table 11 &amp; Table 12 are not based on the same number of patients.

Table 12 Comparison of mean (SD) PK parameters of polatuzumab vedotin (1.8 mg/kg) when given in combination with R/G-CHP in the expansion arm to historical data (Study GO27834)

<!-- image -->

| Analyte           | Parameter         | G029044 (Pola+R-CHP) DLBCL (N-36)   | G027834 (Pola+R) FL (N = 20)   | G029044/G027834 Comparative Ratio (9%6)   |
|-------------------|-------------------|-------------------------------------|--------------------------------|-------------------------------------------|
| acMMAE            | Cmax(ng/mL)       | 532 (163)                           | 787 (113) *                    | 32.4% lower                               |
|                   | AUC, (ng'day/mL)  | 1870 (527)                          | 2600 (630) *                   | 28.1% lower                               |
| Total Antibody    | Cm. (ug/mL)       | 32.2 (7.48)                         | 42.2 (7.92)*                   | 23.7% lower                               |
|                   | AUC, (μg*daylmL)  | 186 (52.9) *                        | 258 (84.1)*                    | 27.9% lower                               |
| Unconjugated MMAE | Cmax (ng/mL)      | 2.60 (1.02) *                       | 2.02 (1.34)                    | 28.7% greater                             |
| Unconjugated MMAE | AUC..(ng*day/mL)  | 24.5 (11.5)                         | 17.7 (9.39)                    | 38.4% greater                             |
| Analyte           | Parameter         | G029044 (Pola+G-CHP) DLBCL (N=17)   | G027834 (Pola+G) DLBCL (N=40)  | G029044IG027834 Comparative Ratio (%)     |
| acMMAE            | Cm.x(ng/mL)       | 530 (138)                           | 711 (155)                      | 25.5% lower                               |
|                   | AUC (ng*day/mL)   | 1940 (482)                          | 2440 (665)*                    | 20.5% lower                               |
| Total Antibody    | C. (ug/mL)        | 39.1 (12.0)                         | 35.0 (9.89)                    | 11.7% greater                             |
|                   | AUCn (μg*day/mL)  | 215 (45.9)*                         | 218 (89.1)                     | 1.4% lower                                |
| Unconjugated MMAE | Cmax (ng/mL)      | 2.88 (2.05)                         | 3.62 (3.73)                    | 20.4% lower                               |
| Unconjugated MMAE | AUC.n (ng*day/mL) | 23.9 (15.3)                         | 27.9 (21.3)                    | 14.3% lower                               |

DLBCL = diffuse large b-celllymphoma; G-CHP+Pola=pola with obinutuzumab, cyclophosphamide doxorubicin, and prednisone; Pola=polatuzumab vedotin; Comparative Ratio=exposure within GO29044 divided by exposure within Go27834 stratified by treatment and subtype and expressed as a percent. l=No'6=N'/=N'9I=N'9Z=N'L=Nr'=N'2Z=N'9=N6'/1=N '6Z=Na'61=Nb'5L=Nb'8Z=Na'/1=Ne PN=10.

Source: t\\_pkpt\\_polaMmaeEXP; t\\_pkpt\\_polaTabEXP; t\\_pkpt\\_polaFreeEXP; Primary GO27834 CSR, Report No.1081108

<div style=\"page-break-after: always\"></div>

Table 13 Assessment of CHP as a perpetrator of a PK DDI with 1.8 mg/kg of pola as a victim based on C1 non-compartmental analysis results (Shemesh et al., 2020)

| Analyte           | Parameter                     | N     | G029044 (pola+R-CHP) DLBCL   | N     | G027834 (pola+R) FL                | GMR (90% C1)                          |
|-------------------|-------------------------------|-------|------------------------------|-------|------------------------------------|---------------------------------------|
| acMMAE            | Cma (ng/mL) AUCnr (ng day/mL) | 36 28 | 503 (36.4) 1800 (28.5)       | 17 15 | 780 (14.4) 2530 (25.9)             | 0.646 (0.5760.724) 0.711 (0.6160.820) |
| Unconjugaled MMAE | Cma (ng/mL) AUCa (ng day/mL)  | 35 27 | 2.43 (37.9) 22.6 (40.4)      | 20 20 | 1.75 (54.3) 15.8 (50.1)            | 1.39 (1.11-1.73) 1.43 (1.15-1.78)     |
| Analyte           | Parameter                     | N     | G029044 (pola+G-CHP) DLBCL   | N     | G027834 (pola+G) DLBCL             | GMR (90% CI)                          |
| acMMAE            | Cmx (ng/mL) AUCnr (ng day/mL) | 17 11 | 513 (26.6) 1890 (23.7)       | 33 26 | 694 (22.7) 2350 (28.4) 2.68 (81.1) | 0.739 (0.6510.839) 0.805 (0.6910.938) |
| Unconjugated MMAE | Cmx (ng/mL) AUCa (ng day/mL)  | 14 10 | 2.44 (60.0) 20.4 (62.8)      | 40 40 | 22.5 (70.7)                        | 0.911 (0.664-1.25) 0.907 (0.629-1.31) |

All values are geometric mean (% geo CV), except for GMR

acMMAE antibody-conjugated MMAE, AUC, area under the concentration-time curve from 0 to infinity, AUC,, area under the concentration- time curve from O until the last measurable time point, CHP cyclophosphamide, doxorubicin, and prednisone, Cl confidence interval, Cae maximum concentration, CV coefficient of variation, DLBCL. diffuse large B-cell lymphoma, FL follicular lymphoma, G obinutwzumab, G-CHP obinutuzumab, cyclophosphamide, doxorubicin, and prednisone, GMR geometric mean ratio, MMAE monomethyl auristatin E, PK pharmacokinetic,pola polatuzumab vedotin,R rituximab, R-CHP rituximab, cyclophosphamide, doxorubicin, and prednisone

For exposure assessments of pola + R-CHP compared with pola combined with rituximab (without CHP), a direct comparison in patients of the same B-NHL type was not possible. However, given DLBCL and FL patients have generally similar PK for pola, a cross-study comparison of available data was conducted.

In both arms, Cycle 1 PK differences were within the PK variability of each analyte and could also be attributed to differences in patient characteristics (especially in the case of histological non-similarity). Furthermore, given the acceptable safety profiles of all treatment arms, the applicant considers that the observed PK differences were not considered as clinically meaningful after the first 1.8-mg/kg dose of pola + R/G-CHP vs. pola + R/G.

The applicant concludes that polatuzumab was not a victim of a drug-drug interaction with CHP.

## PK of rituximab in combination with polatuzumab vedotin and CHP

To evaluate pola and CHP as 'perpetrators' for DDIs with rituximab, data were compared with those for rituximab exposure from historical studies, e.g. study BO22334 (NCT01200758).

According to the applicant, the mean serum concentrations of rituximab approximating steady-state conditions, (Cycle 4 pre-dose) in DLBCL patients within Study GO29044: 70.2 (23.5) µg/mL (N = 22) were generally comparable to those seen in Study BO22334 (R + CHOP): 66.2 (30.5) µg/mL (N = 197) in the absence of polatuzumab vedotin, and were also comparable to Study GO27834 (pola + R): 82.0 (29.4) µg/mL (N = 18) in the absence of CHP at the same time point, in similar patient populations. In conclusion, the applicant states that no significant impact of the combination on rituximab PK was observed either due to the administration of polatuzumab vedotin or CHP, based on the cross-study comparison of rituximab exposure.

Shemesh et al. (2020) presents mean rituximab serum C4 pre-dose concentration comparison between study GO29044 and study BO22334 (Table 13). Differences observed with cross-study comparison of rituximab exposure are within the variability of rituximab observed in study BO22334 (up to 111%). The authors drawn a similar conclusion to the applicant, i.e. no significant impact of the combination on rituximab PK was observed either due to the administration of polatuzumab vedotin or CHP.

<div style=\"page-break-after: always\"></div>

Table 14 Assessment of 1.8 mg/kg of pola as a perpetrator of a PK drug-drug interaction with rituximab as a victim based on descriptive statistics of exposure comparisons (Shemesh et al., 2020)

| DDIvictim         | Tx    | Parameter   |   n | BO22334 R-CHOP   | GO29044 Pola+R-CHP   | GMR (90% CI)     |
|-------------------|-------|-------------|-----|------------------|----------------------|------------------|
| Rituximab (μg/mL) | R-CHP | C4 pre-dose | 189 | 45.0 (111)       | 66.3 (36.2)          | 1.47 (1.26-1.72) |

## PK of obinutuzumab in combination with polatuzumab vedotin and CHP

To evaluate pola and CHP as 'perpetrators' for DDIs with obinutuzumab, data were compared with those for obinutuzumab exposure from historical studies, e.g. study BO21003 (NCT00576758).

First, matching obinutuzumab dosing regimens for patients with DLBCL in Study GO29044 up to cycle 2 in patients with B-NHL in Study BO21003 allowed for a cross-study comparison of pola + G-CHP to singleagent obinutuzumab therapy based on cycle 2 pre-dose &amp; cycle 1 mean Cmax concentrations. Therefore, comparison of Cycle 1 obinutuzumab Cmax and Cycle 2 pre-dose concentrations in patients with DLBCL in Study GO29044 receiving (pola + G-CHP) versus Study BO21003 (G) were evaluated.

In the study GO29044 body report, the applicant states that ' small numerical inter study differences in Cycle 2 pre-dose obinutuzumab PK between Study GO29044 and Study BO21003 were seen ' without further details. In the other hand, it is specified that the cycle 1 mean Cmax for DLBCL patients receiving pola + G-CHP in Study GO29044 was approximately 20% higher than the mean Cmax within NHL patients in Study BO21003 receiving G-monotherapy.

Furthermore, comparisons of serum obinutuzumab Cmax in Cycles 1 and 4 and pre-dose in Cycles 2 and 4 show generally comparable PK between the pola + G-CHP regimen in Study GO29044 and the pola + G regimen in Study GO27834 with mean maximal differences across all observations of less than 20% observed.

According to the applicant, the addition of CHP to the pola + G regimen does not appear to substantially impact obinutuzumab PK.

Shemesh et al. (2020) presents mean obinutuzumab serum C2 pre-dose concentration comparison between study GO29044 and study BO21003 (Table 14). The observed difference in GMR values was well within the variability of obinutuzumab (60% CV in Study BO21003), and may reflect variability in body weight, gender, and tumor burden due to differences in patient populations between the studies (e.g., DLBCL in GO29044 vs. R/R indolent B-cell NHL in BO21003).

Table 15 Assessment of 1.8 mg/kg of pola as a perpetrator of a PK drug-drug interaction with obinutuzumab as a victim based on descriptive statistics of exposure comparisons (Shemesh et al., 2020)

| DDIvictim            | Tx    | Parameter   |   n | BO21003 G   |   n | GO29044 Pola+G-CHP   | GMR (90% CI)        |
|----------------------|-------|-------------|-----|-------------|-----|----------------------|---------------------|
| Obinutuzumab (μg/mL) | G-CHP | C2 pre-dose |  74 | 378 (60.5)  |  15 | 266 (71.0)           | 0.703 (0.517-0.955) |

## PK of cyclophosphamide in combination with rituximab (or obinutuzumab), polatuzumab vedotin, doxorubicin and prednisone

Polatuzumab was assessed as a 'perpetrator' of DDIs with cyclophosphamide by comparing cyclophosphamide between cycle 1, day 1 (prior to first pola dose on cycle 1, day 2) and cycle 3, day 1 (after pola dosing). Plasma PK concentrations of cyclophosphamide were evaluated at the end of infusion and at 3 and 23 hours after the first dose and after Cycle 3 in patients with DLBCL receiving 1.8 mg/kg of pola + R/G-CHP in the Phase II expansion portion of the study.

Comparisons of Cycle 1 exposures of cyclophosphamide (prior to polatuzumab vedotin administration) were similar to those in Cycle 3 (after polatuzumab vedotin administration). Cyclophosphamide was

<div style=\"page-break-after: always\"></div>

administered on Day 1 of Cycle 1, with polatuzumab vedotin administered on Day 2 of Cycle 1; while on Day 1 of Cycle 3 both analytes were administered on Day 1. These results suggest that polatuzumab vedotin does not have a clinically relevant impact on the pharmacokinetics of cyclophosphamide when given in combination.

Shemesh et al. (2020) presents geometric mean C1D1 and C3D1 cyclophosphamide plasma 23h concentrations (Table 15).

Table 16 Assessment of 1.8 mg/kg of pola as a perpetrator of a PK drug-drug interaction with cyclophosphamide as a victim based on descriptive statistics of exposure comparisons (Shemesh et al., 2020)

| DDIvictim                | Tx    | Parameter   |   N | GO29044(C1D1) Beforepola dosing   |   N | GO29044(C3D1) Afterpoladosing   | GMR (90% CI)       |
|--------------------------|-------|-------------|-----|-----------------------------------|-----|---------------------------------|--------------------|
| Cyclophosphamide (μg/mL) | R-CHP | C23h        |  25 | 2.64 (56.2)                       |  19 | 2.67 (74.8)                     | 1.01(0.737-1.38)   |
|                          | G-CHP |             |  14 | 3.00 (52.4)                       |  14 | 2.83 (50.1)                     | 0.943 (0.691-1.29) |

C23h

## PK of doxorubicin in combination with rituximab (or obinutuzumab), polatuzumab vedotin, cyclophosphamide and prednisone

Polatuzumab was assessed as a 'perpetrator' of DDIs with doxorubicin by comparing doxorubicin exposure between cycle 1, day 1 (prior to first pola dose on cycle 1, day 2) and cycle 3, day 1 (after pola dosing). Plasma PK concentrations of doxorubicin were evaluated at 2 and 24 hours after the end of infusion after the first dose and after Cycle 3 in patients with DLBCL receiving 1.8 mg/kg of pola + R/GCHP in the Phase II expansion portion of the study.

Comparisons of Cycle 1 exposures of doxorubicin (prior to polatuzumab vedotin administration) were similar to those in Cycle 3 (after polatuzumab vedotin administration). Doxorubicin was administered on Day 1 of Cycle 1, with polatuzumab vedotin administered on Day 2 of Cycle 1; while on Day 1 of Cycle 3 both analytes were administered on Day 1. These results suggest that polatuzumab vedotin does not have a clinically relevant impact on the pharmacokinetics of doxorubicin when given in combination.

Shemesh et al. (2020) presents geometric mean C1D1 and C3D1 doxorubicin plasma 24h concentrations (Table 16).

Table 17 Assessment of 1.8 mg/kg of pola as a perpetrator of a PK drug-drug interaction with doxorubicin as a victim based on descriptive statistics of exposure comparisons (Shemesh et al., 2020)

| DDIvictim           | Tx    | Parameter   |   N | G029044(C1D1) Beforepola dosing   |   N | GO29044(C3D1) After pola dosing   | GMR (90% CI)       |
|---------------------|-------|-------------|-----|-----------------------------------|-----|-----------------------------------|--------------------|
| Doxorubicin (ng/mL) | R-CHP | C24h        |  25 | 8.79 (29.1)                       |  20 | 8.43 (25.8)                       | 0.959 (0.838-1.10) |
|                     | G-CHP |             |  12 | 9.44 (60.6)                       |  14 | 8.94 (21.3)                       | 0.947 (0.701-1.28) |

C24h

## 2.3.3. Pharmacodynamics

## Mechanism of action

Polatuzumab vedotin (pola) is an antibody-drug conjugate (ADC) that contains a humanized immunoglobulin G1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE). Pola binds CD79b, a surface antigen restricted to B-cells that is ubiquitously expressed across a majority of mature B-cell malignancies including diffuse large B-cell lymphoma (DLBCL). MMAE is a potent analog of dolastatin 10 that exerts its cytotoxicity by binding to microtubules and inhibiting microtubule polymerization, inhibiting cell division, inducing apoptosis. Upon binding to the CD79b, pola is rapidly internalized to enable targeted delivery of MMAE. This allows microtubule inhibition with greater potency and without additional toxicity.

<div style=\"page-break-after: always\"></div>

## Primary and secondary pharmacology

No additional pharmacology data has been provided by the MAH in this procedure.

## 2.3.4. PK/PD modelling

Based on study GO39942 POLARIX, , exposure response analyses following dose of 1.8 mg/kg Q3W of up to 6 cycles given in combination with R-CHP, were conducted to assess

- -efficacy based on (Progression Free Survival) PFS, Event-Free Survival (EFSeff), Overall Survival (OS), and Complete response at end of treatment by FDG-PET as determined by blinded independent central review (CREOT)
- -safety based on  Grade ≥ 3 Neutrop enia, Peripheral Neuropathy, Infections and Infestations; Anemia; Thrombocytopenia; AST increase (by lab); ALT increase (by lab); Bilirubin increase (by lab); Hepatic toxicity; Hyperglycemia; Cardiac Arrhythmia.

## Methods

Pop PK model developed for polatuzumab vedotin was validated in patients newly diagnosed DLBCL in report 1111192. This model was subsequently used to simulate individual exposure for exposureresponse analysis. The individual PK parameters estimated using the final population PK model and the relevant PK covariates for each subject were used to simulate individual concentration-time course following pola Q3W administration for a total of 6 cycles to compute individual exposure values in Cycle 6. Nominal (1.8 mg/kg) dose was used for each patient in the simulation. AUC and Cmax values of acMMAE and unconjugated MMAE in Cycle 6 were used as exposure measures for the exposure-response analyses as described in Table 17. AUC and Cmax were defined as AUC and Cmax over 21 day in Cycle 6 using nominal dose specified by the cohort assignment.

For some of the analyses (described in the following sections), categories of exposure (where patients were divided into 2 or 3 groups of equal size based on exposure) were evaluated in addition to continuous exposure measures.

Dataset:

Study GO39942 POLARIX; results were used in the exposure-response relationship.

## Mathematical modeling

For safety and efficacy the modeling approach used, and the PK parameter used for exposure analyses are presented below:

<div style=\"page-break-after: always\"></div>

Table 18 Model used for exposure response analyses

<!-- image -->

| Analysis Type      | Analyte                   | Exposure Measures   | Base Models*                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|---------------------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exposure- safety   | acMMAE unconjug ated MMAE | AUC Cmax AUC Cmax   | Logistic regression models of AE probability versus exposure for each type of AEs with more that 5% frequency rate. KM plots and Cox proportional hazard models for time to the first dose modification due to AE. Summaries of dose intensity of pola, rituximab doxorubicin, cyclophosphamide, and prednisone byl tertiles of pola exposure; linear regression and box plots. |
| Exposure- efficacy | acMMAE                    | AUC                 | Logistic regression models of CREoT probability versus exposure. KM plots ² and Cox proportional hazard models of PFS, EFSeff, and OS versus exposure.                                                                                                                                                                                                                          |

1: AUC was defined as AUC over 21-day in Cycle 6 (AUC=AUCcyces). Cmax was defined as Cmax over 21-day in Cycle 6 (Cmax=Cmaxcydes);

2: The R-CHoP control arm was included as a reference in the Kaplan Meier analysis of the survival endpoints;

3: Covaniate analyses were perfomed for significant exposure-safety and exposure-efficacy relationships using AUC of acMMAE or unconjugated MMAE as exposure measure.

## Exposure - Safety response

Endpoints with less than 5% incidence rate were excluded from the analysis. For each AE type, linear logistic regression models were implemented to assess the relationship between the probability of AE occurrence and pola exposure for acMMAE and unconjugated MMAE. The p-value as provided by the glm() function was used to evaluate whether or not the tested exposure metric was significant in the model at the significance level of α = 0.05. If a significant increase for probability of an AE with increasing exposure was detected, a covariate analysis was conducted using the relevant covariates described belowCovariates were added linearly in the logit scale:

logit(p) = a0+a1∙COV + b0∙exposure. (Eq.1)

To define the confidence interval for the model predicted probabilities, 1000 bootstrap samples were drawn with replacement from the analysis population, and the logistic regression models were fitted to each of these samples. For each value of exposure, 90% confidence intervals were defined as the 5th and 95th percentiles of the model predicted probabilities among 1000 bootstrap data sets. Distributions for time of the first AE occurrence were plotted and summarized to assess the acute or chronic feature of each AE.

The data sets for the exposure-safety analysis also included the following dose intensity related endpoints: occurrence status for the dose modification of pola due to AE (1 or 0), time for the first dose modification of pola due to AE (or censoring time if no event), dose intensity for pola, rituximab, doxorubicin, cyclophosphamide, and prednisone.

The dose modifications included reduction, delay, or discontinuation. The probability of dose modification due to AE was investigated using the logistic regression analysis, as described above. The time to first modification due to AE was investigated using the time-to-event analysis.

Dose intensity (%) accounted for dose delay and dose reduction. It was computed based on the actual doses administered to each patient up to the end-of-treatment assessment relative to the planned dose. The early discontinuation was not accounted in the dose intensity calculation. Only dose delays were allowed for rituximab. The impact of exposure on dose intensity of pola, rituximab, doxorubicin, cyclophosphamide, and prednisone was investigated by the linear regression, lowess regression, and by

<div style=\"page-break-after: always\"></div>

comparison of distributions of intensity values between categories of exposure (tertiles) using box plots. Summary statistics (mean, standard deviation [SD], median, range, geometric mean [Geomean], coefficient of variation [CV]) stratified by categories of exposure were also provided. P-values of the linear regression models were used to assess significance of the exposure-dose intensity relationships at the significance level of α = 0.05.

## Exposure - efficacy response

The logistic regression analysis (as described in Section 4.3.4) was implemented to assess the relationship of the probability of complete response with exposure. The covariate analysis was performed (using the covariates listed in Section 4.3.1) if a significant effect of exposure was detected at 0.05 level, using the strategy described in Section 4.3.4.

Two analyses were performed for each survival measure. In the first analysis, Kaplan- Meier plots were performed to compare the survival probability over time for patients with low and high exposure (categorized by the median value of acMMAE AUC) and also for patients in the control arm (R-CHOP). In the second analysis, the exposuresurvival relationships were described by semi-parametric Cox proportional hazards (CPH) models. The control arm was not used in these models.

The CPH relationships between exposure (acMMAE AUC) and EFSeff, PFS, or OS were first characterized using base models that described the marginal effect of exposure on survival without consideration of covariates. The hazard functions were expressed as:

<!-- image -->

where λ0(t) is the baseline hazard function and is a vector of predictor variables (covariates). For the base model, the vector of predictor variables consisted of a continuous exposure variable (acMMAE AUC). The parameters of vector were estimated by maximum partial-likelihood.

The P-value as provided by coxph() function was used for significance evaluation of exposure coefficients at the significance le vel of α = 0.05. Covariates were added linearly in the log hazard scale.

## Covariate testing

## Covariate selection.

The forward addition and backward elimination procedure was implemented for covariate screening. A significance level of α = 0.01 (the objective function change of 6.64 points for one parameter) was used for forward addition procedure while backward elimination steps used α = 0.001 significance level (the objective function change of 10.83 points for one parameter). The exposure was always kept in the model during the backward elimination steps.

## The following covariates were tested

- Demographics: body weight, sex, age, race, region;
- Baseline Laboratory Measurements: lactate dehydrogenase (LDH), serum albumin, B-cell (CD19) count, neutrophil-to-lymphocyte ratio (NLR), neutrophil count, hemoglobin level (HGB), platelet count;
- Baseline disease characteristics and history: ECOG performance status, bulky disease, tumor SPD, Ann Arbor stage, NHL subtype, DLBCL cell origin, International prognostic index (IPI) score, double-expressor by IHC status, extra nodal involvement, active peripheral neuropathy status, baseline peripheral neuropathy active status;
- Anti-drug antibody (ADA) status for pola.

<div style=\"page-break-after: always\"></div>

Missing continuous covariates were imputed by the median value of the covariate. Missing categorical covariates were set to a separate \"Missing\" category. The imputation flags (1 or 0) were also provided for the categorical covariates that were derived from continuous covariates and for the continuous covariates.

The following covariates were included only in the exposure-efficacy analyses as they were not expected to affect safety: B-cell (CD19) count, NLR, tumor SPD, Ann Arbor stage (stage 1-2 vs. stage 3 vs. stage 4-5), DLBCL cell origin (ABC vs. GCB vs. unclassified or unknown), double-expressor by IHC status (DEL vs. no DEL), IPI score (IPI 1-2 vs. 3 vs. 4-5), and bulky disease (yes versus no).

The following covariates were included only in the exposure-safety analyses: baseline neutrophil count for the analysis of neutropenia; baseline hemoglobin level for anemia; baseline platelet count for thrombocytopenia; peripheral neuropathy history and peripheral neuropathy status at baseline for peripheral neuropathy.

## Results

## Exposure-safety

Figure 7 Logistic Regression for Grade ≥ 3 Febrile Neutropenia, unconjugated MMAE AUC (left plot), a,d Cmax (right plot). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions Dashed vertical lines show bounds of exposure groups.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 8 Logistic Regression for Grade ≥ 2 Peripheral Neuropathy, acMMAE AUC (left plot) , and Cmax (right plot). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions.Dashed vertical lines show bounds of exposure groups.

<!-- image -->

p-value =0.089 (n=429)

600

700

800

900

acMMAE Cycle 6 Cmax(ng/mL)

Figure 9 Logistic Regression for Grade ≥ 3 Infections and Infestations, acMMAE AUC (left plot) and Cmax (right plot). The red solid line and green shaded area represent the logistic regression model prediction and  90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

Probability of Grade &gt;=3 Infections and Infestations

0.8

0.6

0.4

0.2

0.0

400

500

1000

<div style=\"page-break-after: always\"></div>

Figure 10 Logistic Regression for Grade ≥ 3 Infections and Infestations, unconjugated MMAE AUC (left plot), and Cmax (right plot). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

<!-- image -->

Figure 11 Logistic Regression for Grade ≥ 3 Anemia, acMMAE AUC (left plot), and Cmax (right plot) The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 12Logistic Regression for Grade ≥ 3 Anemia, unconjugated MMAE AUC (left plot), and Cmax (right plot). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

<!-- image -->

Figure 13 Logistic Regression for Grade ≥ 3 Thrombocytopenia, acMMAE AUC (left plot), and Cmax (right plot). ). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

DLBCL

BLA\\_AE\\_Main.R)

Figure 14 Logistic Regression for Grade ≥ 3 Thrombocytopenia, unconjugated MMAE AUC (left plot), and Cmax (right plot). ). The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

## Exposure-Efficacy

Source: MainERilguresiACMMAEAUC\\_LogReg\\_AE\\_Vs\\_Exposure\\_CREOT.png (DLBCL\\_BLA\\_AE\\_Main.R)

Figure 15 Logistic Regression for CR, acMMAE AUC The red solid line and green shaded area represent the logistic regression model prediction and 90% confidence interval of predictions. Points show exposure of individual patients with events (p=1) and without events (p=0). Black squares and vertical green lines

<!-- image -->

<div style=\"page-break-after: always\"></div>

show observed fraction of subjects with events in each exposure group and 90% confidence interval for these fractions. Dashed vertical lines show bounds of exposure groups.

## 2.3.5. Discussion on clinical pharmacology

Overall, polatuzumab vedotin PK was characterized in newly diagnosed DLBCL patients in POLARIX study, and based on Pop PK analysis. Despite some clarification needed in the pop PK model validation, based on the provided study results, it is not expected that the PK of polatuzumab vedotin will be significantly different in DLBCL patients treated with polatuzumab vedotin in first-line.

Polatuzumab vedotin is indicated for first-line treatment of DLBCL in combination with R-CHP. The PK interaction between the administered drugs were assessed. In vivo DDI studies show that polatuzumab vedotin does not have a clinically relevant impact on the pharmacokinetics of doxorubicin nor cyclophosphamide when given in combination. However, given the confounding variabilities associated to the other DDI studies design, no clear conclusion can be drawn for polatuzumab vedotin potential interaction as perpetrator (i.e. on rituximab and obinutuzumab PKs) or victim (i.e. with -CHP as perpetrator). The applicant was invited to more soundly discuss the comparability of each study to study GO29044 in order to potentially manage DDI risks.

Among 435 previously untreated DLBCL patients treated with Polivy in combination with R-CHP in Study GO39942, 227 (52.2%) were ≥ 65 years of age. Patients aged ≥ 65 had an incidence of serious adverse reactions of 39.2% and 28.4% in patients aged &lt; 65. A similar incidence of serious adverse reactions was seen in elderly patients in the R-CHOP treatment arm.

Exposure-safety analysis suggested that higher acMMAE exposures (AUC and Cmax) were significantly correlated with higher incidence of Grade ≥ 2 peripheral neuropathy, Grade ≥ 3 anemia (only AUC), and Grade ≥ 3 thrombocytopenia. The covariate analyses were performed only for the acMMAE AUC models. The forwardaddition procedure identified HGB and LDH as the significant covariates for Grade ≥ 3 anemia at α = 0.01 level. Patients with higher baseline HGB had lower probability of Grade ≥ 3 anemia. Patients with higher baseline LDH had higher probabili ty of Grade ≥ 3 anemia. The exposure -response relationship remained significant in the presence of these covariates. HGB was retained in the model at α = 0.001 level during the backward elimination.

Higher unconjugated MMAE exposures (AUC, Cmax) were significantly correlated with higher incidence of Grade ≥ 3 neutropenia, Grade ≥ 3 infections and infestations, Grade ≥ 3 anemia, Grade ≥ 3 thrombocytopenia, and Grade ≥ 3 febrile neutropenia. The covariate analyses were performed only for the unconjugated MMAE AUC models. The forward-addition procedure identified HGB as a significant covariate for Grade ≥ 3 anemia, and Asian race for Grade ≥ 3 neutropenia at α = 0.01 level. Patients with higher HGB had lower probability of Grade ≥ 3 anemia, and Asian patients h ad higher probability of Grade ≥ 3 neutropenia. The exposure response relationship remained significant in the presence of these covariates in the model; both covariates were retained in the final model at α = 0.001 level during backward elimination.

Exposure-Efficacy cox analysis suggested a significant correlation (p = 0.01 by Cox regression) between acMMAE AUC and EFSeff, with higher exposure leading to a longer EFSeff. The forward-addition procedure identified baseline bulky disease as a significant cov ariate at α = 0.01 level. The exposure -response relationship remained significant in the presence of this covariate in the model. Only bulky disease remained in the final model at α = 0.001 level during the backward elimination.

The Cox analysis suggested no significant correlation between acMMAE AUC and OS. Probability of complete response at the end of treatment did not correlate with acMMAE exposure (AUC).

<div style=\"page-break-after: always\"></div>

In Studies GO39442 (POLARIX) and GO29365, 1.4% (6/427) and 5.2% (12/233) of patients tested positive for antibodies against polatuzumab vedotin, respectively, of which none were positive for neutralizing antibodies.

Sections 4.4 and 5.2 of the SmPC were updated accordingly.

## 2.3.6. Conclusions on clinical pharmacology

In general, the submitted clinical pharmacology studies are considered sufficient to characterize polatuzumab vedotin in the indication of first-line DLBCL treatment in combination with rituximab, cyclophosphamide, doxorubicine, and prednisone.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Study  GO29044: A  Phase  Ib/II  Study  Evaluating  the  Safety,  Tolerability  and  Anti-Tumor  Activity  of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma.

First Patient Enrolled: 29 November 2013 Last patient last visit: 20 December 2018

In the dose-finding portion of the study, the MTD of polatuzumab vedotin in combination with rituximab or obinutuzumab in combination with cyclophosphamide, doxorubicin, and prednisolone or prednisone [R-CHP or G-CHP] was determined. Following identification of the MTD, the dose-expansion portion of the study further  evaluated  the  safety  and  tolerability  and  clinical  activity  of  R-CHP  or  G-CHP  plus  polatuzumab vedotin in patients with newly diagnosed DLBCL.

The primary objectives of this study were to assess the safety and tolerability of the combination of pola+ R-CHP or G-CHP and to determine the MTD and schedule for pola+ R-CHP or G-CHP.

The secondary efficacy objectives of this study were the following: to make a preliminary assessment of efficacy as measured by CR rate determined by PET-CT scan, OR Rate, DOR, PFS, EFS and OS, to assess the potential relationships of such ADA formation with efficacy outcome measures

The exploratory efficacy objectives of  this  study were the following to assess the efficacy of therapy in different potential prognostic subgroups, including DLBCL genotypic subtypes (e.g. ABC, GCB) and high Bcl-2  expression,  to  assess  tumor  expression  of  CD79b,  to  assess  prevalence  and  the  correlation  of lymphoma  associated  mutations  with  outcome,  to  assess  MRD  as  quantified  by  measurements  of lymphoma-specific  markers  in  peripheral  blood,  to  evaluate  the  prognostic  significance  of  interim  PET assessment, to evaluate response, by IRC, as determined through use of the PET-CT scans based on a modified version of the Lugano Response Criteria for Malignant Lymphoma (Cheson et al. 2014), hereinafter referred to as Modified Lugano 2014 criteria (CR by PET at end of induction (EOI) by IRC, CR by CT at EOI by IRC, OR (defined as a CR or PR) at EOI, best response of CR or PR during the study, evaluate patients who have positive PET scans at EOI: CR at 12 months).

Design: Two  parallel  treatment arms explored doses of pola+R-CHP and G-CHP. The MTD or RP2D of polatuzumab vedotin in combination with R-CHP was identified before it was combined with G-CHP. This was an open-label study.

<div style=\"page-break-after: always\"></div>

Study treatment was given in every-21-day cycles, with the first day of treatment constituting Day 1 of the cycles. Patients were treated for a total of six or eight cycles in accordance with local institutional practice.

Figure 16: Overview of Study Design

<!-- image -->

Once a dose was identified for the expansion stage, the study restricted enrollment to a group of patients with high medical need (newly diagnosed DLBCL patients who were aged ≥18 years and who had an IPI of 2-5) to further assess safety and efficacy of the combination.

The dose escalation of polatuzumab vedotin combined with R-CHP began at a dose level of 1.0 mg/kg, because this was the highest dose level at which no DLTs or clinically significant AEs were observed during the Phase I study (Palanca-Wessels et al. 2015). The MTD of polatuzumab vedotin in combination with RCHP was identified  before  it  was  combined  with  G-CHP.  Once  the  MTD  was  determined,  polatuzumab vedotin was dosed at MTD-1 in combination with G-CHP to start the dose escalation of this combination. Rituximab was administered after the prednisone/prednisolone dosing and before the cyclophosphamide, doxorubicin,  and  polatuzumab  vedotin  infusions.  Six  to  eight  cycles  of  rituximab  at  375  mg/m2  were administered IV to patients every 21 days (or over 28 days for those patients who experienced toxicity that necessitated an extended cycle duration). No dose modifications of rituximab were allowed.

<div style=\"page-break-after: always\"></div>

Cyclophosphamide 750 mg/m2 was administered IV on Day 1, Doxorubicin 50 mg/m2 IV on Day 1 and Prednisone 100 mg/day by PO on Days 1-5.

## Main inclusion criteria

- Dose-Escalation Portion of the Study: Histologically confirmed B-cell NHL: Patients with newly diagnosed B-cell  NHL or relapsed/refractory B-cell NHL were eligible, No more than one prior systemic treatment regimen for B-cell NHL (single agent anti-CD20 MAb therapy was not counted as a prior treatment regimen), No prior treatment with anthracyclines

-Expansion Portion of the Study: Previously untreated patients with DLBCL, IPI score of 2-5.

## Statistical Hypothesis and Planned Sample Size

Since there was no pre-specified hypothesis, whether or not the efficacy endpoints were met could not be assessed using statistical tests. The sample size required for estimating the MTD was based on the doseescalation rules. All dose-escalation cohorts will consist of at least 3 patients. If a DLT is observed in 1 patient at a given dose level during the DLT observation period before dose escalation, additional patients will  be  enrolled  at  that  dose  level  for  a  total  of  at  least  6  patients.  Protocol  version  8  discontinued enrollments in the pola +G-CHP arm at 17 patients and the total number of patients in the expansion arm was approximately 60, instead of 80. The decision to discontinue enrollment in the pola+G-CHP arm was made because of final results from Study BO21005 (GOYA) which showed no additional efficacy benefit of G-CHOP compared to R-CHOP as determined by the study's primary endpoint of investigator assessed PFS. Regarding  efficacy  data,  CR  rate  was  estimated  by  the  number  and  percentage  of  responders  with corresponding 90% CIs was presented. Estimates of the median PFS, DOR, OS and the corresponding twosided 95% CI were presented along with the estimates for the 25th and 75th percentiles in all patients. The KM approach was used to estimate the distribution of DOR, PFS, EFS, and OS in all patients.

## Results

A total of 85 patients were actually enrolled; however, due to a data transfer error from IXRS to RAVE, data for 1 patient was not captured. As this patient did not receive any study medication, only the intentto-treat (ITT) analysis population was affected and data were captured for 84 patients.

There  were  3  patients  in  the  R-CHP  treatment  regimen  non-DLBCL  group,  51  patients  in  the  R-CHP treatment regimen DLBCL group, 5 patients in the G-CHP treatment regimen non-DLBCL group, and 25 patients in the G-CHP treatment regimen DLBCL group.

## Only data of patients with DLCBL in the R-CHP treatment regimen are described below:

A total of 50 patients in the R-CHP treatment regimen, DLBCL, were included in the efficacy analysis.

Study population was predominately White (43 [86.0%]) and female (26 [52.0%]), with a median age of 68.5 years (range: 4580 years). The majority of patients (37 [74.0%]) were ≥65 years old. A total of 12 (24.0%) patients had an ECOG score of 0 at baseline, 23 (46.0%) patients had a baseline score of 1, and 15 patients (30.0%) had a baseline score of 2. A total of 14 patients (28.0%) had an IPI score of 0-2 and 36 patients (72.0%) had an IPI score of 3-5.

<div style=\"page-break-after: always\"></div>

Pola dose cohorts were as follows: 2 patients, 1 mg/kg; 3 patients, 1.4 mg/kg; 5 patients, 1.8 mg/kg during dose-escalation phase and 40 patients, 1.8 mg/kg during dose-expansion phase.

At the last patient last visit, patients were on the study over a median period of 35.12 months (range 1.28 to 59.40 months).

8 were discontinued from the study. All these patients were from 1.8 mg/kg-dose expansion group (4 due to deaths and 4 due to diseases progressions).

The efficacy results are summarized below:

- The CR rate for all doses at the end of treatment window visit by CT/MRI with PET scan was 78.0% (39/50; 90% CI: 66.22, 87.14). In the 45 patients treated with 1.8 mg/kg pola, the CR rate was 100% (5/5; 90% CI: 54.93, 100.00) during the dose escalation phase and 75% (30/40; 90% CI: 61.29, 85.76) during the dose expansion phase

Table 1: Summary of Response at End of Treatment Window Visit by CT/MRI with PET Scan, Composite PD by Either Assessment Method, R-CHP Treatment Regimen - DLBCL

|                                 | R-CHP+POV (1.0) (N=2)   | R-CHP+POV (1.4) (N=3)     | R-CHP+POV（1.8) (N=5)       | EXP R-CHP+POV (1.8) (N=40)   | Total (N=50)             |
|---------------------------------|-------------------------|---------------------------|----------------------------|------------------------------|--------------------------|
| Responders Non-Responders       | 2 (100.08) 0            | 3 (100.0%) 0              | 5 (100.0%) 0               | 36 (90.0%) 4 (10.0%)         | 46 (92.0%) 4 1( 8.0%)    |
| 90* CI for Response Rales       | (22.36, 100.00)         | (36.84, 100.00)           | (54.93, 100.00)            | (78.56, 96.51)               | (82.62,97.22)            |
| Complete Response (CR) 90% CI   | 1 (50.0%) (2.53,97.47)  | 3(100.0%) (36.84, 100.00) | 5 (100.0%) (54.93, 100.00) | 30 (75.0%) (61.29, 85.76)    | 39(78.0%) (66.22, 87.14) |
| Partial Response (PR) 90%CI     | 1  (50.0%) (2.53,97.47) | 0 (0.00,63.16)            | 0 (0.00,45.07)             | 6 (15.0%) (6.74,27.47)       | 7 (14.0%) (6.76,24.69)   |
| Stable Disease (SD) 90% CI      | 0 (0.00,77.64)          | 0 (0.00,63.16)            | 0 (0.00,45.07)             | 0 (0.00,7.22)                | 0 (0.00,5.82)            |
| Progressive Disease (PD)* 90%CI | 0 (0.00,77.64)          | 0 (0.00,63.16)            | 0 (0.00, 45.07)            | 3(7.5%) (2.08, 18.26)        | 3(6.0%) (1.66, 14.78)    |
| Missing or unevaluable 90% CI   | 0 (0.00,77.64)          | 0 (0.00,63.16)            | 0 (0.00,45.07)             | 1(2.5%) (0.13, 11.32)        | 1 (2.0%) (0.10, 9.14)    |

g0? CI for rates were construcled using Clopper-Pearson method. Database lock is March 28，2019.

- Median PFS, DOR, and OS were not reached in any of the dose groups.

<div style=\"page-break-after: always\"></div>

Table 2: Efficacy Results of Pola+R-CHP in DLBCL Patients from Study GO29044 (Efficacy Evaluable population)

|              | Pola+R-CHP              | Pola+R-CHP              | Pola+R-CHP             | Pola+R-CHP             |
|--------------|-------------------------|-------------------------|------------------------|------------------------|
| Endpoint     | Dose escalation         | Dose escalation         | Dose escalation        | Dose- Expansion        |
|              | Pola 1.0 mg/kg N=2      | Pola 1.4 mg/kg N=3      | Pola 1.8 mg/kg* N=5    | Pola 1.8 mg/kg N=40    |
| PFS24 95% CI | 100.0% (100.00, 100.00) | 100.0% (100.00, 100.00) | 80.0% (44.94,100.00)   | 77.50% (64.56,90.44)   |
| DOR24 95% CI | 100.0% (100.00, 100.00) | 100.0% (100.00, 100.00) | 80.0% (44.94,100.00)   | 83.60% (71.59, 95.61)  |
| EFS24 95% CI | 100.0% (100.00, 100.00) | 100.0% (100.00,100.00)  | 80.0% (44.94,100.00)   | 65.0% (50.22,79.78)    |
| OS24 95% CI  | 100.0% (100.00, 100.00) | 100.0% (100.00, 100.00) | 100.0% (100.00,100.00) | 92.50% (84.34, 100.00) |

- Due to the lack of ADA-positive results, no conclusions can be drawn concerning a potential effect of ADA on efficacy results.

## Response by subgroups:

- Response by cell of origin subtype:

At the baseline, there were 12 patients with DLBCL subtype ABC. Response was observed in all 12 patients (100.0%); 11 patients had CR and 1 patient had PR.

A total of 22 patients had DLBCL subtype GCB. Response was observed in all 22 patients (100.0%); 19 patients had CR and 3 patients had PR.

- Response by BCL2 expressor status

BCL2 expression was negative in 18 patients. Of these, response was observed in 17 patients (94%); 15 patients had CR and 2 patient had PR. One patient had progressive disease.

BCL2 expression was positive in 15 patients. Response was observed in all 15 patients (100%); 11 patients had CR and 4 patients had PR.

- Response by MYC expressor status

MYC expression was negative in 13 patients. Response was observed in all 13 patients (100.0%); 12 patients had CR and 1 patient had PR.

MYC expression was positive in 19 patients. Of these, response was observed in 18 patients (94.7%); 13 patients had CR and 5 patients had PR. One patient had progressive disease.

- Response by BCL2/MYC double expressor

BCL2/MYC double expression was negative in 23 patients. Of these, response was observed in 22 patients (95.7%); 19 patients had CR and 3 patients had PR. One patient had progressive disease.

<div style=\"page-break-after: always\"></div>

BCL2/MYC double expression was positive in 9 patients. Response was observed in all 9 patients (100.0%); 6 patients had CR and 3 patients had PR.

- Response by CD79b H-Score

No patients with DLBCL with H-score IHC of 0.

Eight patients had DLBCL with CD79b H-score IHC 1 + . Response was observed in all 8 patients (100.0%); 7 patients had CR and 1 patient had PR.

Twelve patients had DLBCL CD79b H-score IHC 2 + . Response was observed in all 12 patients (100.0%); 10 patients had CR and 2 patients had PR. Seven patients had DLBCL CD79b H-score IHC 3 + . Response was observed in all 7 patients (100.0%); 5 patients had CR and 2 patients had PR.

## - PFS by subgroups

There  was  no  clinically  meaningful  difference  noted  in  PFS  results  as  assessed  in  the  subgroups  of biomarkers such as COO subtype, BCL2 expressor, MYC expressor, BCL2/MYC expresssor, and CD79b H score.

## Pola+G-CHP

Of the 25 patients in the safety and efficacy evaluable populations in this cohort, 21 patients were treated with 1.8 mg/kg pola and are included in the 1L DLBCL safety analyses presented in this document.

Pola dose cohorts were as follows: 4 patients, 1.4 mg/kg, 4 patients, 1.8 mg/kg during dose-escalation phase, 17 patients, 1.8 mg/kg during dose-expansion phase. Patients were on the study over a median period of 29.8 months (range: 2.5 -41.8 months). The majority of patients were male (60.0%); the ECOG score at baseline was 0 in 56.0% of patients, 1 in 28.0% patients, and 2 in 16% of patients.  A total of 16 patients (64.0%) had an IPI score of 0 -2 and 9 patients (36.0%) had an IPI score of 3 -5.

A total of 25 patients (dose escalation + dose expansion) in the G-CHP treatment regimen, DLBCL were included in the interim efficacy analysis. The efficacy results are summarized below:

<div style=\"page-break-after: always\"></div>

Table 27 Summary of Response at End of Treatment Window Visit by CT/MRl with PET Scan, Composite PD by Either Assessment Method, G-CHP Treatment Regimen - DLBCL (SE)

|                               | G-CHP+POV [1.4] (宝=业)   | G-CHP+POV (1.8) (N=4)     | EXP G-CHP+POV (1.8) (N=17)   | Total (N=25)             |
|-------------------------------|-------------------------|---------------------------|------------------------------|--------------------------|
| Responders                    | 3(75.08)                | (100.01)                  | 15 (68.24)                   | 22(88.08)                |
| Non-Responders                | 1[25.01)                | 0                         | 2(11.88)                     | 3(12.08)                 |
| 90f C1 for Response Rates     | (24.86.98.73)           | (47.29,100.00)            | (67.38,97.87)                | (71.83,96.65]            |
| Conplete Response (CR] 901 CI | 3(75.08) (24.86,98.73]  | 4(100.08) (47.29, 100.00) | 13(76.58) (53.95,91.54)      | 20(80.08) (62.46, 91.77) |
| Partial Response (PR) 90: CI  | 0 (0.00, 52.71)         | 0 (0.00, 52.71)           | 2(11.88) (2.13, 32.62)       | 2 ( 8.08) (1.44, 23.10)  |
| Btsble Dises9e (S0) 10 06     | 1(25.08) (1.27, 75.14)  | 0 (0.00, 52.71)           | 0 (0.00, 16.16)              | 1 ( 4.08) (0.20, 17.61)  |
| Disea9e (PD) 4 906 C1         | 0 (0.00,52.71)          | 0 (0.00,52.71)            | 0 (0.00, 16.16)              | (0.00, 11.29)            |
| Micsing_or unevaluable 908 C1 | (0.00, 52.71)           | 0 (0.00, 52.71)           | 2(11.88) (2.13, 32.62)       | 2 ( 8.08) (1.44, 23.10)  |

utompoyite sionofDigerue 19 a bared on first Fu for vioit by either CryMRl with Fer or CT/MRl'without PEr (exemple subject: C029041-266060-30852 at \"TREATMENT COHPLETION EARLY DISCONTINUATION\" VISit).

\"8102 '7t 48161 61 2999 9323912 *1102 '62 3292820 63 6999 339403 8480

Progr2m8 /9pt/B103tAT/es9d/edpt7884/go29044/t\\_se9p\\_5mpv.en9 /Outpub8 01NAY2018 0:21

- The 12-month PFS was 91.64% (95% CI: 80.52, 100.00). Median PFS was not reached.
- Median DOR was not reached.
- The 12-month EFS was 84.0% (95% CI: 69.63, 98.37). Median EFS was not reached.
- The 12-month OS was 92.0% (95% CI: 81.37, 100.00). The median OS was not reached

## Exposure-Response Analysis

The exposure-efficacy analysis was conducted for the 429 previously untreated patients with DLBCL from POLARIX Study GO39942 (pola + R-CHP arm), with an additional 439 previously untreated DLBCL patients from R-CHOP control arm for the Kaplan-Meier analysis only:

- To assess the relationships between pola exposure (Cycle 6 AUC for acMMAE) and progressionfree survival (PFS) as determined by the investigator;
- To assess the relationships between pola exposure (Cycle 6 AUC for acMMAE) and probability of complete  response  at  the  end  of  treatment  (CREOT)  by  FDGPET  as  determined  by  blinded independent central review.
- To assess the relationships between pola exposure (Cycle 6 AUC for acMMAE) and event-free survival for efficacy reasons as determined by the investigator (EFSeff);
- To assess the relationships between pola exposure (Cycle 6 AUC for acMMAE) and overall survival (OS).

<div style=\"page-break-after: always\"></div>

## Methodology:

The individual empirical Bayes estimates of pola PK parameters estimated by the population PK model were used to obtain the individual pola exposure measures, defined as Cycle 6 AUC and Cmax for acMMAE and unconjugated MMAE based on nominal dose (i.e., assuming that the subject received the planned 1.8 mg/kg Q3W doses during the entire study). Only AUC for acMMAE was used for the exposure-efficacy analysis.

## Results:

- The Cox analysis suggested a significant correlation (p=0.01 by Cox regression) between acMMAE AUC and PFS, with higher exposure leading to a longer PFS. The forward inclusion identified baseline bulky disease and B cell count as significant covariates at α=0.01 level. The exposure -response relationship  remained  significant  in  the  presence  of  those  covariates  in  the  model.  Only  bulky disease remained in the final model at α=0.001 level during the backward elimination.
- The Cox analysis suggested a significant correlation (p=0.01 by Cox regression) between acMMAE AUC and EFSeff, with higher exposure leading to a longer EFSeff. The forward inclusion identified baseline  bulky  disease  as  a  significant  covariate  at  α=0.01  level.  The  exposure -response relationship remained significant in the presence of this covariate in the model. Only bulky disease remained in the fin al model at α=0.001 level during the backward elimination.
- The Cox analysis suggested no significant correlation between acMMAE AUC and interim OS.
- Probability of CR at the end of treatment did not correlate with acMMAE exposure (AUC).

## 2.4.2. Main study

## Study GO39942 (POLARIX)

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.

## Methods

Approximately 875 patients were planned for enrollment in the global study; the population from which the primary analysis has been performed. After approximately 875 patients had been randomized into the study,  enrollment  outside  of  China  (i.e.,  global  enrollment)  was  closed  and  a  China  extension  cohort opened.

## Study participants

## Main Inclusion Criteria

- Previously untreated patients with CD20-positive DLBCL, included one of the following diagnoses by 2016 WHO classification of lymphoid neoplasms:

<div style=\"page-break-after: always\"></div>

- o DLBCL, not otherwise specified (NOS) included germinal center B-cell type, activated B-cell type
- o T-cell/histiocyte-rich large B-cell lymphoma
- o Epstein-Barr virus-positive DLBCL, NOS
- o ALK-positive large B-cell lymphoma
- o HHV8-positive DLBCL, NOS
- o High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
- o High-grade B-cell lymphoma, NOS
- Available, archived or freshly collected tumor tissue before study enrollment

The pathology report had to be available for review and a tissue block sent for retrospective central review of diagnosis.

- IPI score of 2-5
- Aged 18-80 years
- ECOG Performance Status of 0, 1, or 2
- Life expectancy ≥12 months
- At least one bi-dimensionally measurable lesion available, defined as &gt;1.5 cm in its longest dimension as measured by CT or MRI
- Left ventricular ejection fraction (LVEF) ≥ 50% on ca rdiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
- Adequate  hematologic  function  (unless  due  to  underlying  disease,  as  established  for  example,  by extensive bone marrow involvement or due to hypersplenism secondary to the involvement of the spleen by DLBCL per the investigator), defined as follows:
- o Hemoglobin ≥ 9.0 g/dL without packed RBC transfusion during 14 days before first treatment
- o ANC ≥ 1,000/μL
- o Platelet count ≥ 75,000/μL

## Main Exclusion Criteria

- Contraindicated to any of the individual components of R-CHOP
- Prior organ transplantation
- Grade &gt;1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
- History of indolent lymphoma
- Diagnosis of the following: follicular lymphoma grade 3B; B-cell lymphoma, unclassifiable, with features intermediate  between  DLBCL  and  classical  Hodgkin  lymphoma  (grey-zone  lymphoma);  primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; CNS lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
- Prior  treatment  with  cytotoxic  drugs  within  5  years  of  screening  for  any  condition  (e.g.,  cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody
- Prior use of any monoclonal antibody within 3 months of the start of Cycle 1; any investigational therapy within 28 days prior to the start of Cycle 1; vaccination with live vaccines within 28 days prior the start of Cycle 1

<div style=\"page-break-after: always\"></div>

- Prior radiotherapy to the mediastinal/pericardial region
- Prior therapy for DLBCL
- Corticosteroid  use &gt; 30  mg/day  of  prednisone  or  equivalent,  for  purposes  other  than  lymphoma symptom control
- o Patients who received corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent for reasons other than lymphoma symptom control had to be documented to be on a stable dose of at least 4 weeks' duration prior to the start of Cycle 1.
- o Patients who required lymphoma symptom control during screening received steroids (up to 30 mg/day  of  prednisone  or  equivalent  could  be  used  for  lymphoma  symptom  control  during screening)
- History of other malignancy that could have affected compliance with the protocol or interpretation of results
- Evidence of significant, uncontrolled, concomitant diseases that could have affected compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart  Association  Class  III  or  IV  cardiac  disease,  myocardial  infarction  within  the  last  6  months, unstable  arrhythmias,  or  unstable  angina)  or  pulmonary  disease  (including  obstructive  pulmonary disease and history of bronchospasm)
- Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
- History or presence of an abnormal ECG that was clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment or significant infections within 2 weeks before the start of Cycle 1
- Clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
- Any  of  the  following  abnormal  laboratory  values  (unless  any  of  these  abnormalities  were  due  to underlying lymphoma):
- o INR or PT &gt; 1.5 ULN in the absence of therapeutic anticoagulation
- o PTT or aPTT &gt; 1.5 ULN in the absence of a lupus anticoagulant
- o Serum AST and ALT ≥ 2.5 ULN
- o Total bilirubin ≥ 1.5 ULN
- o Serum creatinine clearance &lt; 40 mL/min (using Cockcroft-Gault formula)
- Patients with suspected active or latent tuberculosis
- Positive test results for chronic hepatitis B infection
- Positive test results for hepatitis C
- Known history of HIV seropositive status
- Positive results for the human T-lymphotrophic 1 virus (HTLV-1)
- Patients with a history of progressive multifocal leukoencephalopathy
- Pregnancy or lactation

<div style=\"page-break-after: always\"></div>

## Treatments

Patients received six cycles of either pola+R-CHP or standard R-CHOP chemotherapy at 21-day intervals. Both arms then received two additional cycles of single agent rituximab. The study design and treatment regimens are respectively shown in Figure 2 and Figure 3.

Arm A; pola+R-CHP (investigational arm): pola 1.8 mg/kg IV, placebo for vincristine IV, rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, and doxorubicin 50 mg/m2 IV each given on Day 1 and prednisone 100 mg/day orally (PO) given on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m2 IV was given as monotherapy in Cycles 7 and 8.

Arm B; R-CHOP (control arm): placebo for pola, rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, and vincristine 1.4 mg/m2 IV (maximum 2 mg/dose) each given on Day 1 and prednisone 100 mg/day PO given on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m2 IV was given as monotherapy in Cycles 7 and 8.

Figure 17: Study Design

<!-- image -->

DLBCL = diffuse large B-cell lymphoma; ECOG PS =Easterm Cooperative Oncology Group Performance Status; IPl = International Prognostic Index; Q21D = every 21 days; R = randomization; R-CHoP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP = rituximab plus cyclophosphamide, doxorubicin, and prednisone.

No crossover to the experimental arm was allowed.

<div style=\"page-break-after: always\"></div>

Figure 18: Schematic of Pola plus R-CHP and R-CHOP Regimens

<!-- image -->

## Administration schedule

In Cycles 1-6, rituximab infusion was to be completed prior to starting any other agent administered by infusion. The order of administration for Cycles 1-6 were: first prednisone, second rituximab, and third blinded polatuzumab vedotin/placebo. Subsequent infusions of blinded vincristine/placebo, cyclophosphamide, and doxorubicin were to be administered according to institutional preference. Cycle 7 and Cycle 8 consisted of rituximab as monotherapy.

The infusion of rituximab may be split over 2 days if the patient is at increased risk for an IRR (high tumor burden or high peripheral lymphocyte count).

Blinded pola/placebo could be administered on Day 2 per investigator preference due to infusion times for rituximab and blinded pola/placebo. In this instance, blinded vincristine/placebo, cyclophosphamide, and doxorubicin  could  also  be  administered  on  Day  1  following  the  completion  of  rituximab,  and  blinded pola/placebo  could  be  administered  on  Day  2  after  prednisone.  Alternative  study  drug  administration regimens could be considered with consultation of the Medical Monitor.

Should infusion-related reactions or other adverse events occur (e.g., during rituximab infusion), treatment could be administered over more than 1 day.

## Pre-Phase Steroids

Steroids prior to study treatment initiation were allowed according to guidelines described in Protocol. The pre-phase treatment was not considered part of study treatment. The purpose of the pre-phase treatment is to prevent tumor lysis syndrome (TLS) in patients with extensive disease and to reduce toxicity of the first cycle of study treatment (e.g., cytokine release syndrome). Staging study assessments (i.e., CT/MRI, PET-CT scan, tumor biopsy) were performed prior to initiation of pre-phase treatment.

## Premedication

<div style=\"page-break-after: always\"></div>

For Cycles 1-6, pola or its placebo were administered after the prednisone and rituximab components of RCHP/R-CHOP were administered, as infusion reactions due to rituximab are typically more common than those for pola. The initial dose was administered to patients who are well hydrated over 90 (± 10) minutes. As required, premedication (e.g., 500-1000 mg of oral acetaminophen or paracetamol and 50-100 mg diphenhydramine as per institutional standard practice) was administered to an individual patient before administration of pola /placebo, unless already been administered as a premedication for rituximab). If infusion-related  reactions  (IRRs)  were  observed  with  the  first  infusion  of  pola  in  the  absence  of premedication, premedication must be administered before subsequent doses as described in Table 3 .

Table 3: Premedication for Rituximab and Blinded Polatuzumab Vedotin/Placebo

| Timepoint                  | PatientsWhoRequire Premedication                                                                                                         | Premedication                                  | Administration                                                                                                                                    |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Cycle 1, Day 1             | All patients                                                                                                                             | Corticosteroid a                               | Complete≥1 hourpriortorituximabinfusion and polatuzumabvedotin/placebo.                                                                           |
| Cycle 1, Day 1             | All patients                                                                                                                             | Antihistamine drug Analgesic/ anti-pyretic c   | Administer≥30 minutesprior to rituximabinfusion; may be administered to patients prior to administration of any polatuzumabvedotin/placeboaswell. |
| Cycles 2 and beyond, Day 1 | Patients with no IRR during the previous infusion                                                                                        | Corticosteroid a                               | Complete≥1hourpriortorituximab andpolatuzumab vedotin/placebo infusion.                                                                           |
| Cycles 2 and beyond, Day 1 | Patients with no IRR during the previous infusion                                                                                        | Antihistamine drug Analgesic/ anti-pyretic c   | Administer≥30 minutesprior to infusion.These may be omitted or adapted at the investigator's discretion.                                          |
| Cycles 2 and beyond, Day 1 | Patients with Grade 1 or 2 IRR during the previous infusion                                                                              | Corticosteroid a                               | Complete ≥1 hour prior to rituximab and polatuzumab vedotin/placebo infusion.                                                                     |
| Cycles 2 and beyond, Day 1 | Patients with Grade 1 or 2 IRR during the previous infusion                                                                              | Antihistamine drug b Analgesic/ anti-pyretic c | Administer ≥ 30 minutes prior to rituximab and/or polatuzumabvedotin/placeboinfusion.                                                             |
| Cycles 2 and beyond, Day 1 | Patients with Grade 3 IRR, wheezing,urticaria, or other symptoms of anaphylaxis during the previous infusion Patients with bulky disease | Corticosteroid a                               | Complete≥1hour priortorituximab and/or polatuzumab vedotin/placebo infusion.                                                                      |
| Cycles 2 and beyond, Day 1 | Patients with Grade 3 IRR, wheezing,urticaria, or other symptoms of anaphylaxis during the previous infusion Patients with bulky disease | Antihistamine drug  Analgesic/ anti-pyretic c  | Administer≥30minutespriorto rituximab and/or polatuzumab vedotin/placebo infusion.                                                                |

IRR=infusion-related reaction.

- Part of study treatment: 100 mg of prednisone. May be substituted with 100 mg of prednisolone or 80 mg of methylprednisolone. Hydrocortisoneshould not beused,as it hasnot beeneffectiveinreducingratesof IRRs.InCycle7 andCycle8,corticosteroid used as premedication should be administered according toinstitutional standard.

For example, 50-100 mg of diphenhydramine.

cFor example, 650-1000 mg of acetaminophen/paracetamol.

The pola/placebo infusion could be slowed or interrupted for patients who experienced infusion-associated symptoms.  Following  the  initial  dose,  patients  were  observed  for  90  minutes  for  fever,  chills,  rigors, hypotension,  nausea,  or  other  infusion-associated  symptoms.  If  prior  infusions  were  well  tolerated, subsequent  doses  of  pola  could  be  administered  over  30  (±  10)  minutes,  followed  by  a  30-minute observation period after the infusion.

## Dose modifications

The  dose  of  blinded  polatuzumab  vedotin/placebo  and  blinded  vincristine/placebo  and  chemotherapy (cyclophosphamide or doxorubicin) can be reduced stepwise to a maximum of two levels for management of drug-related toxicities. If further dose reduction is indicated after two dose reductions, the patient must discontinue the specific study drug but may continue treatment with the remaining study drugs at the investigator's discretion in consultation with the Medical Monitor.

<div style=\"page-break-after: always\"></div>

If administration of R-CHP or R-CHOP is delayed, the administration of polatuzumab vedotin and R-CHP/RCHOP should be delayed for the same time frame; that is, all study drugs should be delayed for the same time frame so that they are all given together beginning on Day 1 of the same cycle.

Guidelines  on  dose  delays  and  dose  modifications  for  R-CHP,  blinded  pola/placebo,  and  blinded vincristine/placebo are described in the tables below. No dose modifications of rituximab were allowed.

Table 4: Steps of Dose Reduction for Blinded Polatuzumab Vedotin/Placebo and Blinded Vincristine/Placebo

| Dose Level            | Blinded Polatuzumab Vedotin or Placebo a   | Blinded Vincristine orPlaceboa   |
|-----------------------|--------------------------------------------|----------------------------------|
| Starting dose         | 1.8 mg/kg per cycle                        | 100% of starting dose per cycle  |
| First dose reduction  | 1.4 mg/kg per cycle                        | 75% of starting dose per cycle   |
| Second dose reduction | 1.0 mg/kg per cycle                        | 50% of starting dose per cycle   |
| Third dose reduction  | Discontinue drug                           | Discontinue drug                 |

Table 5: Recommended Steps of Dose Reduction for Cyclophosphamide

| Dose Level                | Cyclophosphamide                                   |
|---------------------------|----------------------------------------------------|
| Starting dose             | 100% of starting dose per cycle                    |
| First dose reduction 3    | 75% of starting dose per cycle                     |
| Maximum dose reduction 3  | 50% of starting dose per cycle or discontinue drug |
| Subsequent dose reduction | Discontinue drug                                   |

<div style=\"page-break-after: always\"></div>

Table 6: Recommended Steps of Dose Reduction for Doxorubicin

| Dose Level                | Doxorubicin                                        |
|---------------------------|----------------------------------------------------|
| Starting dose             | 100% of starting dose per cycle                    |
| First dose reduction a    | 75% of starting dose per cycle                     |
| Maximum dose reduction 3  | 50% of starting dose per cycle or discontinue drug |
| Subsequent dose reduction | Discontinue drug                                   |

## Objectives

This study evaluated the efficacy, safety, pharmacokinetics, and PROs of pola plus chemoimmunotherapy (pola+R-CHP) compared with SoC chemoimmunotherapy (RCHOP) in previously untreated patients with CD20-positive DLBCL. Efficacy objectives and corresponding endpoints for the study have been outlined in Table 7 below.

<div style=\"page-break-after: always\"></div>

Table 7: Objectives and Endpoints

<!-- image -->

| Objectives                                                                                               | Corresponding Endpoint/s                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| To evaluate the efficacy of pola+R-CHP compared with R-CHOP with respect to PFS                          | +PFS, defined as the time from randomization to the first occurrence of disease progression or relapse as assessed by the investigator, using the Lugano Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurs earlier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Secondary                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| To evaluate the efficacy of pola+R-CHP compared with R-CHOP with respect to secondary efficacy endpoints | Key secondary endpoints included in the hierarchical testing procedure:4 EFSer as determined by the investigator CR rate at end of treatment * by FDG- PET as determined by BlCR OS + Secondary endpoints that will not be adjusted for testing multiplicity: a CR rate at end of treatment by FDG- PET  as determined by the investigator ORR at the end of treatment by FDG- PETc as determined by investigator d ORR at the end of treatment by FDG-- PET as determined by BlCR d BOR rate as determined by investigator PFS24 as determined by the investigator DFS DOR EFSall PRO endpoints: Time to deterioration in EORTC QLQ-C30 physical functioning and fatigue and FACT-Lym LymS Proportion of patients achieving meaningful improvement in EoRTC QLQ-C30 physical functioning and fatigue, and FACT-Lym LymS +EORTC QLQ-C30 rate of treatment-related symptoms and FACT/GOG-NTX peripheral neuropathy rate |

| Objectives                                                                                        | Corresponding Endpoint/s                                                                                    |
|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Exploratory Efficacy                                                                              |                                                                                                             |
| To evaluate the efficacy of pola+R-CHP compared with R-CHOP with respect to exploratory endpoints | ·PRO endpoints: Allscales of the EORTC QLQ-C30, the FACT-Lym LymS, and FACT/GOG-NTX peripheral neuropathy * |

<div style=\"page-break-after: always\"></div>

| Exploratory Biomarker Objective                                                                                                                                                                                                                                                                                                                                                                                         | Exploratory Biomarker Objective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To identify biomarkers that are predictive of response to pola (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with acquired resistance to pola, are associated with susceptibility to developing adverse events, can provide evidence of pola activity, or can increase the knowledge and understanding of disease biology | PFS,EFS,PFS24,CR rate,OS,DFS, DOR, and PRO endpoints by exploratory biomarkers and molecular DLBCL prognostic subtypes such as cell-of-origin, DEL, and DHL/THL  ctDNA detectability in conjunction with FDG- PET response ctDNA as a method of molecular disease detection  ctDNA identification of emerging resistance ·Association of biomarkers (including molecular and proteomic subtypes and genomic profiles at baseline) with efficacy and/or adverse events associated with R- CHOP and pola+R-CHP treatment |
| Exploratory Health Status Utility Objective                                                                                                                                                                                                                                                                                                                                                                             | Exploratory Health Status Utility Objective                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| To assess health status of patients treated with pola with R-CHP compared with R-CHOP                                                                                                                                                                                                                                                                                                                                   | Health status (EQ-5D-5L) h                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

ADA=anti-drug antibody; BlCR = blinded independent central review; CR =complete response; ctDNA=circulating tumor DNA; DFS =disease-free survival; DLBCL=diffuse large B-cell lymphoma; DoR=duration of response; EFSs=event-free survival-all causes; EFSer=eventfree survival-efficacy; EORTC QLQ-C30=European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire; EQ-5D-5L=EuroQol 5-Dimension, 5-Level questionnaire; FACT/GOG-NTX=Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity; FACT-Lym LymS=Functional Assessment of Cancer tomography; IRF = Independent Review Facility; NCI=National Cancer Institute; NCl CTCAE v4.0= National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0; OS=overall survival; PFS=progression-free survival; PFS24=2-year progression-free survival rate; PK=pharmacokinetic; PRO=patient-reported outcome; R-CHoP=rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP =rituximab plus cyclophosphamide, doxorubicin, and prednisone.

- All analyses will be based on the investigator's assessment unless otherwise specified, using the Lugano Response Criteria for Malignant Lymphoma (Cheson et al. 2014).
- b End of treatment is defined as all planned chemoimmunotherapy treatment only; should any radiotherapy be administered, end of treatment tumor assessment shall occur prior to initiating radiotherapy.
- *Reffered to as PET-CT in results and outputs.
- d These secondary endpoints are included in Protocol, Section 6.4.2 and are presented in detail in final SAP
- e Results of the exploratory PRO endpoint will not be presented in this Primary CSR.
- ' Safety and immunogenicity objectives will be non-key secondary endpoints.
- ° Exploratory analyses for phamacokinetics are included in the PopPK and ER reports and will not be presented in this Primary CSR.
- hResults of Health status (EQ-5D-5L) will not be presented in this Primary CSR.

## Outcomes/endpoints

The primary and key secondary endpoints were tested in a hierarchical manner as detailed in the Statistical Methods section below. Endpoints for the study have been outlined in Table 7 above.

<div style=\"page-break-after: always\"></div>

## Assessment for disease response

The primary study endpoint was PFS as assessed by the investigator. Patients were assessed for disease response by the investigator using regular clinical and laboratory examinations and fluorodeoxyglucose positron  emission  tomography  (FDG-PET;  hereafter  referred  to  as  PET-CT)  and  dedicated  computed tomography (CT) scans (magnetic resonance imaging [MRI] scan were performed if CT scans with contrast were contraindicated in the patient), according to the Lugano Response Criteria for Malignant Lymphoma.

PET-CT  and  dedicated  CT  scans  were  obtained  at  screening  and  6-8  weeks  after  completion  of  study treatment. An interim assessment was obtained after Cycle 4 and including PET-CT and dedicated CT. If local practice prohibited obtaining both assessments after Cycle 4, PET-CT alone (preferred) or CT alone was  obtained  at  this  timepoint.  During  the  follow-up  period,  CT  scans  (PET-CT  also  acceptable)  were performed  every  6  months  (i.e.,  Months  6,  12,  18,  and  24)  until  the  end  of  Year  2  of  follow-up (approximately 2.5 years after the first dose) in accordance with study (clinic) visits and included the neck (if involved at baseline), chest, abdomen, and pelvis. During Years 3, 4, and 5 of follow-up, CT scans (PETCT acceptable) of sites of prior involvement were obtained every 12 months (at Months 36, 48, and 60). If disease  in  other  areas  were  suspected,  additional  areas  were  imaged  at  all  subsequent  imaging assessments.

Response was evaluated at the end of study treatment, or sooner in the event a patient discontinued early. After completion of therapy, all patients were followed at clinic visits conducted every 3 months for 2 years, and then every 6 months until Month 60. At each visit up to the Year 5, Month 60 assessment (or until disease progression if it occurs before 5 years), assessments included but were not exhaustive to: physical examination,  standard  hematologic  and  biochemistry  assessments,  vital  signs,  and  B-symptoms  (i.e., weight loss, night sweats, or fever).

After 5 years, patients were followed only for survival and initiation of a new antilymphoma therapy (NALT) by telephone contact approximately every 6 months until study termination, patient withdrawal of consent or death. After disease progression, patients were followed by telephone contact for survival, applicable adverse event reporting, and initiation of a NALT.

While the primary efficacy endpoint was investigator-assessed PFS, tumor assessments were collected by an Independent Review Facility (IRF) for the key secondary endpoint of PET-CT CR rate at the end of treatment by the Lugano Response Criteria for Malignant Lymphoma.

## Health status of patients

Information  on  health-related  quality  of  life  (HRQoL)  and  symptoms  from  self-reported  questionnaires provided critical feedback about patients' well-being which were used to better understand the patient experience  of  treatment.  These  Patient-reported  outcomes  (PROs),  important  disease  and  treatmentrelated symptoms, as well as functioning, were assessed with the FACTLym LymS and EORTC QLQ-C30. In addition, peripheral neuropathy was assessed using the FACT/GOG-NTX, as it is a treatment-related effect common  to  both  pola  and  vincristine.  The  FACT/GOG-NTX  evaluated  treatment-induced  neurologic symptoms (including sensory, hearing, motor, and dysfunction) and consisted of 11 questions. The EQ-5D5L was administered for the purpose of producing health utility scores for economic modeling.

## Independent Data Monitoring Committee (iDMC)

An iDMC has been used to monitor patient safety and efficacy. Since protocol version 5, the rationale for iDMC was updated to reflect monitoring of only safety, no longer including efficacy.

<div style=\"page-break-after: always\"></div>

## Sample size

## Sample Size of PFS in the Global Study

The planned enrolment for the global study was approximately 875 patients. Sample size considerations were based on the following assumptions:

- 1:1 randomization ratio in R-CHP + polatuzumab vedotin versus R-CHOP
- Planned enrolment for the global study was expected to complete in approximately 23 months
- A one-sided log-rank test
- 80% power at the 2.5% significance level
- A 31% reduction in the risk of disease progression, relapse, or death, i.e., the PFS hazard ratio of R-CHP + polatuzumab vedotin over R-CHOP is 0.69.
- PFS in the control arm follows a piece-wise exponential distribution, with the piece-wise hazard rate estimated using historical R-CHOP data

On the basis of this hazard rate assumption for the control arm and a hazard ratio of 0.69, the 3-year PFS rate was expected to improve from 62% (which was observed in the GOYA study among patients with IPI 2-5 who received R-CHOP) to 72%.

- An annual dropout rate of 5% assumed for both treatment arms

Based on these assumptions, approximately 228 investigator-assessed PFS events were needed to detect a hazard ratio of 0.69 in PFS (3-year PFS rate of 62% to 72%), with 80% power for the primary analysis of PFS. The minimal detectable difference (MDD) for the PFS hazard ratio at the primary PFS analysis was 0.771 (i.e., 22.9% reduction in the risk of disease progression, relapse, or death). The 3-year PFS was expected to improve from 62% to 70% under the MDD.

## Sample Size of OS in the Global Study

Considerations of sample size for OS was also based on patients enrolled in the global study. A formal interim OS analysis was to be performed at the time of the primary PFS analysis only if the PFS efficacy boundary was crossed and the other secondary endpoints higher in the hierarchical order than OS had passed the corresponding significance levels. The sample size considerations were based on the following assumptions:

- 1:1 randomization ratio in R-CHP + polatuzumab vedotin versus R-CHOP
- A one-sided log-rank test
- A 27% reduction in the risk of death, i.e., the OS hazard ratio of R-CHP + polatuzumab vedotin over R-CHOP is 0.73
- OS in the control arm follows an exponential distribution with a hazard rate of 0.006923
- An annual dropout rate of 1.5% assumed for both treatment arms

Based on these assumptions, approximately 134 and 178 OS events was to be observed at the interim and the final OS analysis, respectively. The power for detecting a hazard ratio of 0.73 in OS at the final analysis was 52%, and the corresponding MDD for the OS hazard ratio was 0.74.

## Sample Size for the Asia Subpopulation

<div style=\"page-break-after: always\"></div>

After the global enrolment closes, additional Chinese patients are to be recruited into the China extension cohort for the purposes of registration in China. A total of approximately 150 Chinese patients are to be enrolled into the global study population and the China extension cohort combined.

## Interim analysis

There were no planned interim analyses for PFS.

A formal OS interim analysis was to be performed at the time of the primary PFS analysis only if the PFS efficacy boundary was crossed and the other secondary endpoints higher in the hierarchical order than OS had passed the corresponding significance levels. OS was to be evaluated on the basis of the HaybittlePeto boundary (Haybittle 1971) for statistical significance, with the alpha boundary at the interim specified as 0.001.

## Randomisation

Patients will be randomised in a 1:1 ratio to receive either R-CHP + polatuzumab vedotin or R-CHOP. Both patients and the investigator will be blinded to the assigned active microtubule inhibitor (i.e., polatuzumab vedotin or vincristine) and placebo control.

During randomisation, permuted blocks will be employed using the following stratification factors:

- IPI score (IPI 2 versus IPI 3-5)
- Bulky disease, defined as one lesion ≥ 7.5 cm (present versus absent)
- Geographical region (Western Europe, United States, Canada, and Australia versus Asia versus Rest of World [remaining countries])

## Blinding (masking)

This is a double-blind study.

Study site personnel (with the exception of unblinded pharmacists) and patients will be blinded to treatment assignment during the study. The Sponsor and its agents will also be blinded to treatment assignment, with the exception of individuals who require access to patient treatment assignments to fulfill their job roles during a clinical trial. These roles include the unblinding group responsible, clinical supply chain managers, sample handling staff, operational assay group personnel, interactive voice or Web-based response system (IxRS) service provider, drug safety responsible, and iDMC members.

Because each patient will receive either polatuzumab vedotin or vincristine and the placebo form of the agent  the  patient  is  not  assigned  to,  the  IxRS  will  make  the  treatment  assignment.  The  unblinded pharmacist  will  provide  the  active  agent  and  the  placebo  agent  according  to  the  patient's  treatment assignment. The investigator will remain blinded to the treatment assignment.

While PK and anti-drug antibody (ADA) samples must be collected from patients assigned to the comparator arm to maintain the blinding of treatment assignment, PK and ADA assay results for these patients are generally not needed for the safe conduct or proper interpretation of this study. Laboratories responsible for  performing study drug PK and ADA assays will be unblinded to patients' treatment assignments to identify appropriate samples to be analyzed. PK samples from patients assigned to the comparator arm will not be analyzed for study drug PK concentration except by request (e.g., to evaluate a possible error in dosing). Baseline ADA samples will be analyzed for all patients. Post baseline ADA samples from patients assigned to the comparator arm will not be analyzed for ADAs except by request.

<div style=\"page-break-after: always\"></div>

If unblinding is necessary for immediate patient management (e.g., in the case of a serious adverse event for which patient management might be affected by knowledge of treatment assignment), the investigator will be able to break the treatment code by contacting the IxRS. The investigator is not required to contact the Medical Monitor prior to breaking the treatment code; however, the treatment code should not be broken except in medical emergency situations.

If  the  investigator  wishes  to  know  the  identity  of  the  study  drug  for  any  reason  other  than  a  medical emergency, he or she should contact the Medical Monitor directly. The investigator should document and provide  an  explanation  for  any  non-emergency  unblinding.  The  investigator  will  be  able  to  break  the treatment code by contacting the IxRS.

As  per  health  authority  and  applicable  legislation  reporting  requirements,  the  Sponsor  Drug  Safety representative will break the treatment code for all serious, unexpected, suspected adverse reactions that are considered by the investigator or Sponsor to be related to study drug. The patient may continue to receive treatment, and the investigator, patient, and Sponsor personnel, with the exception of the Drug Safety representative and personnel who must have access to patient treatment assignments to fulfill their roles (as defined above), will remain blinded to treatment assignment.

## Statistical methods

## Analysis populations

The ITT population is defined as all patients randomised during the global enrolment phase (including patients enrolled in mainland China during that phase), i.e., the global study, whether or not the patients received the assigned treatment. The global study is defined as the 879 patients randomised into the study on  or  before  27  June  2019.    The  ITT  patients  were  analysed  according  to  the  treatment  assigned  at randomisation by the interactive voice/Web response system (IxRS). The ITT population was used for all efficacy analyses.

The China extension cohort is defined as patients from mainland China who were randomised after 27 June 2019. Patients randomised during the China extension phase are not be included in the ITT population; they are not included in the analyses in this report from the Primary CSR.

## Multiplicity adjustment

To control the overall type I error rate at a one-sided 0.025 level of significance, a hierarchical testing procedure including po ssible α recycling was used to adjust for multiple statistical testing of the primary and key secondary efficacy endpoints. The test hierarchy and α spending plan for key secondary efficacy endpoints are described in the Figure 4 below:

<div style=\"page-break-after: always\"></div>

Figure 19: Test hierarchy and alpha-spending plan for key secondary efficacy endpoints in POLARIX study

<!-- image -->

BICR=blinded independent central review; EFSen=event-free survival for efficacy causes; OS=overall survival; PFS=progression-free survival.

A formal OS interim analysis will be performed at the time of the primary PFS analysis only if the PFS efficacy boundary is crossed, and the other secondary endpoints higher in the hierarchical order than OS have passed the corresponding significance levels.

Given the low likelihood of OS crossing the boundary at the interim OS analysis, a Haybittle-Peto boundary (Haybittle 1971) is chosen with 0.001 at the interim as the nominal alpha value to control the type I error in the group sequential analysis of OS.

The remaining secondary endpoints were tested without adjusting for multiplicity.

## Primary analysis

The primary efficacy endpoint is PFS, as determined by the investigator, defined as the time from the date of randomisation until the first occurrence of disease progression or relapse as assessed by the investigator using the 2014 Lugano Classification for Malignant Lymphoma (Cheson et al. 2014), or death from any cause, whichever occurs first. For patients who have not progressed, relapsed, or died as of the clinical cutoff date for analysis, PFS is censored on the date of last disease assessment when the patient is known to be progression free. If no tumor assessments are performed after the baseline visit or all post-baseline tumor  assessment  results  have  overall  responses  of  'not  evaluable,'  PFS  is  censored  on  the  date  of randomisation. Censoring rules for PFS are also summarized in the Table 8 below.

<div style=\"page-break-after: always\"></div>

Table 8: Censoring rules for PFS in the primary analysis (POLARIX study)

| Scenario 1                                                                                                     | DateofProgressionorCensoring                                     | Status      |
|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-------------|
| No adequate2post-baseline assessment andnodeath                                                                | Randomization date                                               | Censored    |
| Nodeathandnodisease progressionbefore datacutoff                                                               | Dateof lastadequate assessment beforedatacutoff                  | Censored    |
| Withdrawaloftreatmentdueto treatmenttoxicity,nodeathandno disease progression before data cutoff               | Date of last adequate assessment beforedatacutoff                | Censored    |
| Withdrawal of treatment dueto treatment toxicity,followed by disease progression or death                      | Dateofearliestdiseaseprogressionor death,beforedatacutoff        | Event       |
| New anti-cancertreatment?started due to efficacy reasons, followed by death or disease progression             | Date of earliest disease progression or death,before data cutoff | Event4.5    |
| New anti-cancer treatment?started dueto efficacyreasons,nodeath or disease progression                         | Date of last adequate assessment before data cutoff              | Censored4,5 |
| New anti-cancertreatment?started due to non-efficacy reasons, followedbydeathordisease progression             | Dateofearliestdiseaseprogressionor death,before data cutoff      | Event5      |
| New anticancer treatment?started due to non-efficacy reason, no deathbefore data cutoff or disease progression | Date of last adequate assessment                                 | Censored5   |
| Death or diseaseprogression following one or more consecutive missed assessments6                              | Date of earliest disease progression or death,before data cutoff | Event       |
| Oneormoremissedassessments followed by no adequate2 assessmentsordeath                                         | Dateoflastadequateassessment beforedatacutoff                    | Censored    |

1Sensitivity analyses maybe performed for other situations if significant imbalances between arms are observed.

2To be considered adequate, a tumor assessment not including PET should have CR, PR, SD and PD as outcome; and/or a tumor assessment including PET-CT should have CMR,PMR, NMR, or PMD using Lugano criteria. Assessments that are\"unevaluable\"and \"not done\"are considered not adequate.

3New anticancer treatment includes all non-protocol new anti-lymphoma treatment (NALT) for DLBCL. The protocol-permitted pre-planned radiotherapy will not be considered new anticancer treatment in any endpoint.

4lnsensitivity analyses,theimpactof NALTpriortoPDduetoefficacyreasonwill beassessed by discount method to investigate how the PFS results would have looked if the NALT was not available. More specifically, the time interval during which patients received NALT until the event or censoring time will be discounted at 10%, 30%, and 50% for both arms. Note that the primary analysis of PFScorresponds to a discount analysiswith a discount rate of O%onPFS time after NALT.

5As an additional sensitivity analysis to assess the overallimpact of NALT, for patients who have taken NALT prior to or in the absence of subsequent death or disease progression, their PFS will be censored at the time of their last adequatetumor assessment before thefirst NALT.

6The impact of missing scheduled tumor assessments on PFS will be assessed by performing a

Treatment comparison were made using a one-sided level 0.025 stratified log-rank test.

The randomisation stratification factors to be used in the efficacy analyses were IPI score, bulky disease, and geographical region. They were obtained from the IxRS at the time of randomisation.

The Kaplan-Meier (KM) method was used to estimate the PFS distribution for each treatment arm and to construct curves for the visual description of the difference between the treatment arms. Estimates of the

<div style=\"page-break-after: always\"></div>

treatment effect  were  expressed  as  hazard  ratios  using  a  stratified  Cox  proportional-hazards  analysis, including 95% confidence intervals. Median PFS was not expected to be reached in this study at the time of the primary PFS analysis clinical cutoff; hence, the 1-year and 2-year rates were used to describe PFS in addition to the hazard ratio. Results from an unstratified analysis were also provided.

## Key secondary analyses

## Event-Free Survival - Efficacy Causes

EFSeff is used to reflect EFS events that are primarily due to efficacy and will be defined as time from date of randomization to the earliest occurrence of any of the below listed events:

1. Disease progression/relapse
2. Death due to any cause

3. The primary efficacy reason determined by the investigator, other than disease progression/relapse, that leads to initiation of any non-protocol specified anti-lymphoma treatment (NALT)

4. If biopsy is obtained after treatment completion and is positive for residual disease regardless of whether NALT is initiated or not

For the third case above, the efficacy reason includes instances where a PET-CT scan, bone marrow test, CT/MRI, or physical finding is suggestive of residual disease; or instances where a biopsy confirms residual disease. EFSeff event timing is at the time of the test or biopsy leading to NALT, rather than the date of NALT initiation.

For patients without the occurrence of any above cases (no EFSeff event) at the time of analysis, EFSeff was censored on the date of last tumour assessment when the patient was known to be progression-free. For patients  who  did  not  have  post-baseline  tumour  assessments  or  all  post-baseline  tumour  assessment results  have  overall  responses  of  'not  evaluable',  EFSeff  was  censored  on  the  date  of  randomization. Censoring rules for EFSeff are also summarized in the Table 9 below.

<div style=\"page-break-after: always\"></div>

Table 9: Censoring rules for EFS eff (POLARIX study)

| Scenario                                                                                                                           | Date of Progression or Censoring                                           | Status   |
|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------|
| No adequate'post-baseline assessmentandnoEFSeff events2observedbeforedata cutoff                                                   | Randomization date                                                         | Censored |
| data cutoff                                                                                                                        | NoEFSefeventsobservedbeforeDateof lastadequateassessment before datacutoff | Censored |
| Withdrawal of treatment due to treatment toxicity, no EFSeff eventsobservedbeforedata cutoff                                       | Date of last adequate assessment before data cutoff                        | Censored |
| Withdrawal of treatment dueto treatment toxicity,followed by EFSerfevent                                                           | Date of earliest EFSefevent before dataEvent cutoff                        |          |
| New anticancer treatment started Date of last adequate assessment duetonon-efficacyreason',no EFSerreventobservedbeforedata cutoff | before data cutoff                                                         | Censored |
| Newanticancer treatmentstarted dueto non-efficacyreason', followedbyEFSeeventobserved                                              | DateofearliestEFSeffeventbeforedataEvent cutoff                            |          |
| EFSereventsobservedfollowing oneormoreconsecutivemissed INVassessments                                                             | DateofearliestEFSereventbeforedataEvent cutoff                             |          |
| Oneor moremissed assessmentsfollowedbyno adequateINVassessmentsor EFSeevents                                                       | Dateof lastadequateassessment beforedatacutoff                             | Censored |

1To be considered adequate, a tumor assessment not including PET should have CR, PR, SD and PD as outcome; and/or a tumor assessment including PET-CT should have CMR, PMR, NMR, or PMD using Lugano criteria. Assessments that are\"unevaluable\"and \"not done\" are considered not adequate.

2EFSef events are defined above (Section 4.4.2.4).

3New anticancer treatment includes all non-protocol new anti-lymphoma treatment for DLBCL. The protocol-permitted pre-planned radiotherapy will not be considered new anticancer treatment in any endpoint.

4EFSall considers this scenario as an event.

Treatment comparisons for EFSeff were performed using the stratified log-rank test. KM methodology was used  to  estimate  the  EFSeff  distribution  for  each  treatment  arm  and  construct  curves  for  the  visual description of the difference between the treatment arms. Estimates of the treatment effect were expressed as hazard ratios using a stratified Cox proportional-hazards analysis, including 95% confidence intervals.

## CR rate at end of treatment by PET-CT

CR rate at end of treatment by PET-CT by BICR or by the investigator is defined as the percentage of patients with CR at the end of treatment by PET-CT as determined by BICR or by investigator. Patients not meeting  these  criteria,  including  patients  without  the  end-of-treatment  tumor  assessments  or  if  their response at end of treatment is not evaluable, were considered non-CR patients.

An estimate of CR rate and its 95% CI were calculated with the Clopper-Pearson method for each treatment arm. The 95% CIs for the difference in CR rate between the two treatment arms was computed using the Wilson  method  (Wilson  1927).  The  CR  rate  was  compared  between  the  two  arms  using  the  CMH  test stratified by the same factors used in the PFS primary analysis.

<div style=\"page-break-after: always\"></div>

OS is defined as the period from the date of randomization until the date of death from any cause. For patients who have not died at the clinical cutoff date for analysis, OS was censored on the last date when the patients were known to be alive, as documented by investigator. Patients who did not have postbaseline information were censored at the date of randomization. The duration of OS was analysed with the same methodologies as EFSeff.

## Sensitivity analyses

The ITT  population  was  the  primary  population  for  all  efficacy  measures  and  was  the  only  population examined for all sensitivity analyses.

## 1. Impact of missing scheduled tumour assessments on PFS

The impact of missing scheduled tumour assessments on PFS was assessed by performing a sensitivity analysis based on the interval censoring analysis methods. The PFS survival curves were estimated using the non-parametric maximum likelihood estimate (NPMLE) (Turnbull 1974) for each treatment arm. Oneyear and 2-year rates of each treatment arm will be reported and their 95% confidence intervals will be constructed based on the Greenwood method.

For descriptive purpose, hypothesis testing will be performed based on the log-rank test proposed by Sun (Sun 1996) to compare the PFS between the treatment arms. The treatment effect will be estimated using a  stratified  proportional  hazard  regression  model  (Finkelstein  1986)  with  a  parametric  assumption  of piecewise exponential distribution for the baseline hazard function (Friedman et al. 1982; Royston and Parmar 2002).

## 2. Impact of NALT prior to or in the absence of Progression on PFS

The impact of NALT prior to PD due to efficacy reason was assessed by discount method to investigate how the PFS results would have looked if the NALT was not available. More specifically, the time interval during which patients received NALT until the event or censoring time was discounted at 10%, 30%, and 50% for both arms. Note that the primary analysis of PFS corresponds to a discount analysis with a discount rate of 0% on PFS time after NALT.

An additional sensitivity analysis was also performed to assess the overall impact of NALT. For patients who have taken NALT prior to or in the absence of subsequent death or disease progression, their PFS was censored at the time of their last adequate tumour assessment before the first NALT.

## 3. Restricted Mean Survival Time Analysis on PFS and OS

The restricted mean survival time (RMST) (Royston and Parmar, 2011) method will be used as an additional sensitivity analysis to measure the difference in the average event-free survival time between treatment and control arm from the randomization through a pre-specified time point. Specifically, unstratified nonparametric KM estimate of RMST by arm as well as the difference of RMST between arms will be evaluated. The  95%  confidence  intervals  (by  Greenwood  method)  and  p-values  (by  Z  test)  will  be  provided  for descriptive purpose. The RMST of PFS and OS will be estimated at month 12, 24, and 36.

## Subgroup analyses

To assess the consistency of the study results in subgroups defined by demographics (e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (including but not limited to ECOG performance status, cell of origin determined by gene expression profiling, IPI, aaIPI, co-expression of BCL2 and MYC by immune histochemistry (IHC) [double-expressor lymphoma], and MYC and BCL2 and/or BCL6 translocations by FISH [high-grade B-cell lymphoma]), the duration of PFS in these subgroups was examined.

## Changes to planned analyses

<div style=\"page-break-after: always\"></div>

The study first patient enrolled was on 15 November 2017 and the data cut-off was on 28 June 2021.

There were 6 amendments to the study protocol. Protocol versions 5 and 6 included some changes to the planned analyses, as described below.

Table 10: Changes to planned analyses in protocol amendments

| Protocol version          | Changes to planned analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Version 5 3 December 2019 | Sample size and analysis plan of the Asia subpopulation analysis adjusted. The planned futility analysis was removed. Given the timing of when the futility analysis was planned to occur, all patients would have been enrolled and completed study treatment in POLARIX. The rationale for iDMC was updated to reflect monitoring of only safety, no longer including efficacy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Version 6 23 October 2020 | Main changes involved updates to the timing of the primary analysis, the secondary efficacy analysis and the overall survival interim and final analyses The hierarchical testing procedure, including possible α recycling that will be used to adjust for multiple statistical testing of the primary and key secondary efficacy endpoints, was updated. The timing of the primary analysis was updated to occur when there are approximately 228 PFS events, and after all patients in the global study have been enrolled for at least 24 months, whichever comes later (vs when there are 236 PFS events in previous versions). The number of PFS events is selected to achieve statistical power of 80% for the target hazard ratio at the primary analysis and 24 months follow up, given that in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), most disease relapse occurs within this time frame. Other changes involve updates to the secondary efficacy analysis and the overall survival interim and final analyses. The timing of the Asian subpopulation analysis is clarified to occur no earlier than the primary analysis of the global cohort. |

The first version of the statistical analysis plan (SAP) was finalised on 18 June 2020, with two subsequent revisions on 9 September 2020 (version 2) and 12 October 2020 (version 3). All three SAP version were therefore finalised while the study was ongoing but prior to data cut-off.

Updates to the SAP include:

- -Censoring tables have been edited to clarify the efficacy analysis of PFS and event-free survival for efficacy causes (EFSeff).
- -EFSall will be analyzed using the same methods as PFS because both endpoints will be evaluated in the ITT population.
- -For time-to-event endpoints where the median survival time will not expect to be reached, 1-year and 2-year rates will be reported.

<div style=\"page-break-after: always\"></div>

- -The immunogenicity analysis population has been updated to be including all enrolled patients who have at least one serum ADA assessment.

## Results

## Participant flow

<!-- image -->

As of the CCOD (clinical cutoff date, 28-Jun-2021), 764 patients (86.9%) had completed treatment. A total of 737 patients (83.8%) were still on study, and 142 patients (16.2%) had discontinued the study. The most frequent reason for patients discontinuing the study was due to death (12.3%).

At the time of CCOD, 109 patients (12.4%) had discontinued from treatment (i.e. prior to completing all planned treatment cycles); 60 patients (13.7%) in the R-CHOP arm and 49 patients (11.1%) in the pola+RCHP arm (Table 11):

<div style=\"page-break-after: always\"></div>

Table 11: Summary of Study Drug Discontinuation (safety evaluable population)

<!-- image -->

## Compliance with Treatment and Treatment Delays

A high proportion of patients (91.7% [399 patients] receiving pola as part of the pola+RCHP regimen and 88.5% [386 patients] receiving vincristine as part of the R-CHOP regimen) completed the planned 6 cycles of study treatment. The median number of cycles of pola or vincristine received was 6.0 and the median relative dose intensity was 99.8% for pola and 100.0% for vincristine. The median treatment duration for both pola and vincristine was as expected (3.5 months).

Overall, no differences between treatment arms were observed in regards to CHP treatment. The median duration  of  exposure  to  CHP  (cyclophosphamide,  doxorubicin,  and  prednisone)  was  balanced  between treatment arms. Approximately 90% of patients in each treatment arm received 6 cycles of CHP treatment, corresponding to a median of 3.5 to 3.6 months of treatment

<div style=\"page-break-after: always\"></div>

A total of 10.1% (44 patients) in the pola+R-CHP arm and 8.4% (37 patients) in the R-CHOP arm had a treatment delay of &gt;7 days in at least one treatment cycle. The percentage of patients who had more than 1 treatment cycle delayed by &gt;7 days was the same in each arm (0.9% [4 patients]).

## Recruitment

Of  the  1063  patients  screened,  879  patients  were  randomized  into  the  study  and  184  patients  failed screening based on information collected in the IxRS. The first patient was randomized on 15 November 2017. The last patient was randomized on 27 June 2019.

The main reasons for screen failure were patients not meeting the following inclusion criteria: IPI score of 2-5 (29 patients), availability of archival or freshly collected tumor tissue before study enrollment (28 patients) and provision of signed written ICF (21 patients).

A  total  of  879  patients  were  enrolled  at  211  sites  in  22  countries,  in  3  regions.  The  top  recruiting geographical region in descending order were:

- Western Europe/US/Canada/Australia (603 patients [Australia, Austria, Belgium, Canada, Switzerland, Germany, Spain, France, UK, Italy, US]).
- Asia (160 patients [China, Japan, South Korea and Taiwan]).
- Rest of the World (116 patients [Brazil, Czech Republic, New Zealand, Poland, Russian Federation, Turkey, Ukraine]).

## Conduct of the study

## Protocol Amendment

The original global protocol dated 18 July 2017 was amended six times.

The key changes to the protocol are summarized below in Table 12.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of Select Key Changes to the Protocol

<!-- image -->

| Document Version, Protocol Amendment, Date   | SummaryofKeyChanges                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol Amendment. Version2,180ctober 2017  | AmendedaccordingtoVoluntaryHarmonizationProcedure(VHP)recommendationsassummarizedbelow: Inclusion criterion for sexual abstinence for men updated per vincristine and cyclophosphamide SmPCs. Clarification on the safety of immunization with live vaccines following rituximab therapy added. Pregnancy testing for women of childbearing potential, 7 days of study treatment and on Day 1 of each cycle of therapy, added.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Version3,3August 2018                        | Protocol AmendmentInclusion and exclusion criteriarevised as summarized below Inclusion criteria: Text added stating receipt of tumor samples for central pathology review of diagnosis not required for patient enrollment. Contraception inclusion criteria for women modified to specify when women must refrain from donating eggs. Exclusion criteria: Some exclusion criteria were grouped for simplification. Dose and durationof allowed corticosteroid use for lymphoma symptom control clarified. Textaddedstatingpatientswhohadreceivedcurative treatmentaswellaspatientswithlow-grade,early-stageprostate cancerwereeligibletoenrollinPoLARix. Text added toclarify exclusionbased on active infectionswasat the investigator'sdiscretion. In addition updates to align with common clinical practices were made. These changes can be found in more detail within the protocol |

<!-- image -->

| Version 4,9 October 2018                      | Protocol Amendment, Amended according to VHP recommendations as summarized below. Pregnancy testing performed for women of childbearing potential, 7 days of study treatment and on Day 1 of each cycle of therapy; clarification Cycle 1 to 8 added. Text stating exclusion based on active infections was at the investigator's discretion, added in Version 3, removed. Typographical error in the product name corrected.     |
|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol Amendment, Version 5.3 December 2019 | Sample size and analysis plan of the Asia subpopulation analysis adjusted. The planned futility analysis was removed. Given the timing of when the futility analysis was planned to occur, all patients would have been enrolled and completed study treatment in POLARIX. Performing the futility analysis would have not The rationale for iDMC was updated to reflect monitoring of only safety. no longer including efficacy. |
| Version 6, 10 December 2020                   | Protocol Amendment, Primarily statistical considerations and the analysis plan were updated as summarized below: Changes related to statistical analyses: interim and final analyses.                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                           | Timing of the primary analysis was updated to occur when there were approximately 228 PFS events, and after all patients in the global study were enrolled for at least 24 months, whichever comes later. The number of PFS events was selected to achieve statistical power of 80% for the target hazard ratio at the primary analysis and 24 months follow-up. given that in patients with previously untreated DLBCL, most disease relapse occurs within this time frame. Hierarchical testing procedure, including possible o. recycling that was used to adjust for multiple statistical testing of the primary and key secondary efficacy endpoints, was updated.   |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | Changes related to a Protocol Clarification Letter (PCL): Details from a PCL dated 12 May 2020, included. This letter was sent to sites where patients were enrolled or actively received study treatment and updates the protocol where local lab sensitivity for hepatitis B DNA by PCR is above 10 IU/ml.                                                                                                                                                                                                                                                                                                                                                              |
| Version 7.18 December2020 | the changes pertained to patients in China extension cohort. Additonally. further context to the statistical considerations and analysis plan were included. Additional changes made for increased clarity and consistency can be found in further detail within the protocol                                                                                                                                                                                                                                                                                                                                                                                             |

BICR = blinded independent central review; DNA = deoxyribonucleic acid; CR = complete response EOT = End of treatment; PCL = protocol clarification letter;PCR =polymerase chain reaction; PFS=progression-free survival; OS =overall survival;VHP= voluntary harmonization proce dure

## Protocol deviations

Major protocol deviations were reported under the following four categories: inclusion criteria, exclusion criteria,  procedural  and  medication.  Protocol  deviations  of  interest  were  chosen  on  the  basis  of  being considered likely to have had a direct impact on data important for interpretation of the study results (including efficacy and patient safety).

Overall,  50/879  patients  (5.7%)  had  at  least  one  protocol  deviation  of  interest.  The  most  frequently reported major protocol deviations of interest were: exclusion criteria not met (1.9%), followed by noncompliance  with  study  drug  treatment  modification  (tx  mod)  or  stoppage  rules  (either  temporary  or permanent)  (0.9%),  accidental  unblinding  of  a  subject  or  subjects  (0.8%),  and  incorrect  subject  kit given/administered (0.7%).

Table 13: Major Protocol Deviations of Interest (ITT Population)

<!-- image -->

| Deseription                                                                             | R-CHOP (N=439)   | Pola+R-CHP (N=440)   | Total (N=879)   |
|-----------------------------------------------------------------------------------------|------------------|----------------------|-----------------|
| Total number of patients with at least one major protocol deviation                     | 23(5.20)         | 27(6.16)             | 50(5.76)        |
| Total number of major protocol deviations                                               | 26               | 29                   | 55              |
| EXCLUSIONCRITERIA                                                                       |                  |                      |                 |
| Exclusion criteria not met                                                              | 5(1.1)           | 12 (2.76)            | 17(1.9)         |
| INCLUSION CRITERIA                                                                      |                  |                      |                 |
| Inclusion criteria not met                                                              | (0.2)            | 4 (0.9)              | 5(0.6)          |
| MEDICATION                                                                              |                  |                      |                 |
| Incorrect subject kit given/acministered                                                | 4 (0.96)         | 2 (0.56)             | 6(0.70)         |
| Non-compliance with study drug tx mod or stoppage rules (either temporary or peimanent) | 5 (1.10)         | 3 (0.76)             | (0.96)          |
| PROCEDURAL                                                                              |                  |                      |                 |
| >2 Tumor assessments not perfoimed (curing post-treatment phase)                        | 2(0.50)          | 3 (0.7)              | 5(0.6)          |
| Aecidental umblinding of site staff teem member or member (s)                           | 2 (0.50)         | 1 (0.2)              | 3 (0.3)         |
| Aecidental unblinding of a subject or subject (s)                                       | 4 (0.90)         | 3 (0.7)              | 7 (0.80)        |
| Any tumor assessments not performed (during treatment phase)                            | 1 (0.20)         | 0                    | (0.16)          |

CCOD:28JUN2021

Data Extract Date: 02AuG2021

## Baseline data

<div style=\"page-break-after: always\"></div>

Table 14: Demographics and Baseline Characteristics (ITT Population)

|             |                                           | R-CHOP (N= 439)   | Pola+R-CHP (N=440)   | Total (N= 879)   |
|-------------|-------------------------------------------|-------------------|----------------------|------------------|
| Age (years) | n                                         | 439               | 440                  | 879              |
| Age (years) | Mean (SD)                                 | 63.01 (11.87)     | 63.11 (11.36)        | 63.06 (11.61)    |
| Age (years) | Median                                    | 66.00             | 65.00                | 65.00            |
| Age (years) | 25%,75%                                   | 59.00, 71.00      | 58.00, 71.00         | 58.00, 71.00     |
| Age (years) | Min - Max                                 | 19.0- 80.0        | 19.0-80.0            | 19.0 -80.0       |
| Age (years) | 18-64                                     | 203 (46.2%)       | 209 (47.5%)          | 412 (46.9%)      |
| Age (years) | 265                                       | 236 (53.8%)       | 231 (52.5%)          | 467 (53.1%)      |
| Age (years) | 18-60                                     | 131 (29.8%)       | 140 (31.8%)          | 271 (30.8%)      |
| Age (years) | >60                                       | 308 (70.2%)       | 300 (68.2%)          | 608 (69.2%)      |
| Sex         | n                                         | 439               | 440                  | 879              |
| Sex         | Female                                    | 205 (46.7%)       | 201 (45.7%)          | 406 (46.2%)      |
| Sex         | Male                                      | 234 (53.3%)       | 239 (54.3%)          | 473 (53.8%)      |
| Race        | n                                         | 439               | 440                  | 879              |
| Race        | American Indian or Alaska Native          | 2 (0.5%)          | 1 (0.2%)             | 3 (0.3%)         |
| Race        | Asian                                     | 84 (19.1%)        | 85 (19.3%)           | 169 (19.2%)      |
| Race        | Black or African America                  | 8 (1.8%)          | 8 (1.8%)             | 16 (1.8%)        |
| Race        | Native Hawaiian or Other Pacific Islander | 3 (0.7%)          | 0                    | 3 (0.3%)         |
| Race        | White                                     | 236 (53.8%)       | 235 (53.4%)          | 471 (53.6%)      |
| Race        | Unknown                                   | 100 (22.8%)       | 105 (23.9%)          | 205 (23.3%)      |
|             | Other                                     | 6 (1.4%)          | 6 (1.4%)             | 12 (1.4%)        |
|             | n                                         | 439               | 440                  | 879              |
|             | Hispanic or Latino                        | 30 (6.8%)         | 18 (4.1%)            | 48 (5.5%)        |
|             | Not Hispanic or Latino                    | 306 (69.7%)       | 317 (72.0%)          | 623 (70.9%)      |
|             | Not Stated                                | 49 (11.2%)        | 66 (15.0%)           | 115 (13.1%)      |
|             | Unknown                                   | 54 (12.3%)        | 39 (8.9%)            | 93 (10.6%)       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Weight (kg) at Baseline             | n         | 436           | 437                                          | 873           |
|-------------------------------------|-----------|---------------|----------------------------------------------|---------------|
|                                     | Mean (SD) | 76.12 (18.68) | 75.92 (20.07)                                | 76.02 (19.38) |
|                                     | Median    | 75.0          | 74.4                                         | 74.5          |
|                                     | 25%,75%   | 63.0,85.0     | 61.6, 87.0                                   | 62.5, 86.4    |
|                                     | Min, Max  | 39.8-191.1    | 38.4-227.9                                   | 38.4 -227.9   |
| Height (cm) at Baseline             | n         | 436           | 438                                          | 874           |
|                                     | Mean (SD) |               | 167.73 (10.34)168.18 (10.16%) 167.95 (10.25) |               |
|                                     | Median    | 168.0         | 167.8                                        | 168.0         |
|                                     | 25%,75%   | 160.0,175.0   | 161.0, 175.0                                 | 160.0,175.0   |
|                                     | Min, Max  | 141.3-200.0   | 144.3-200.0                                  | 141.3-200.0   |
| ECoG Performance Status at Baseline | n         | 438           | 440                                          | 878           |
|                                     | 0         | 173 (39.4%)   | 175 (39.8%)                                  | 348 (39.6%)   |
|                                     |           | 190(43.3%)    | 199 (45.2%)                                  | 389 (44.3%)   |
|                                     | 2         | 75 (17.1%)    | 66 (15.0%)                                   | 141 (16.0%)   |
| Ann Arbor Stage                     | n         | 439           | 440                                          | 879           |
|                                     |           | 9 (2.1%)      | 2 (0.5%)                                     | 11 (1.3%)     |
|                                     |           | 43 (9.8%)     | 45 (10.2%)                                   | 88 (10.0%)    |
|                                     |           | 108 (24.6%)   | 124 (28.2%)                                  | 232 (26.4%)   |
|                                     | IV        | 279 (63.6%)   | 269 (61.1%)                                  | 548 (62.3%)   |
| Stratification - IPl Score (lxRS)   | n         | 439           | 440                                          | 618           |
|                                     | IP12      | 167 (38.0%)   | 167 (38.0%)                                  | 334 (38.0%)   |
|                                     | IP1 3-5   | 272 (62.0%)   | 273 (62.0%)                                  | 545 (62.0%)   |
| IPl at Screening (eCRF)             | n         | 439           | 440                                          | 879           |
|                                     |           | 0             | 1 (0.2%)                                     | 1 (0.1%)      |
|                                     | 2         | 165 (37.6%)   | 164 (37.3%)                                  | 329 (37.4%)   |
|                                     | 3         | 156 (35.5%)   | 174 (39.5%)                                  | 330 (37.5%)   |
|                                     | 4         | 96 (21.9%)    | 76 (17.3%)                                   | 172 (19.6%)   |
|                                     |           | 22 (5.0%)     | 25 (5.7%)                                    | 47 (5.3%)     |

<div style=\"page-break-after: always\"></div>

| Stratification -Bulky Disease (lxRS)      | n                          | 439                        | 440           | 879           |
|-------------------------------------------|----------------------------|----------------------------|---------------|---------------|
|                                           | Absent                     | 247 (56.3%)                | 247 (56.1%)   | 494 (56.2%)   |
|                                           | Present                    | 192 (43.7%)                | 193 (43.9%)   | 385 (43.8%)   |
| Baseline Bulky Disease (eCRF) n           |                            | 439                        | 440           | 879           |
|                                           | No                         | 244 (55.6%)                | 247 (56.1%)   | 491 (55.9%)   |
|                                           | Yes                        | 195 (44.4%)                | 193 (43.9%)   | 388 (44.1%)   |
| Stratification - Geographic Region (lxRS) | n                          | 439                        | 440           | 879           |
|                                           | Asia                       | 79 (18.0%)                 | 81 (18.4%)    | 160 (18.2%)   |
|                                           | Rest of World              | 59 (13.4%)                 | 57 (13.0%)    | 116 (13.2%)   |
|                                           | Westem                     | 301 (68.6%)                | 302 (68.6%)   | 603 (68.6%)   |
|                                           | Europe/US/Canada/Australia | Europe/US/Canada/Australia |               |               |
| Baseline LDH                              | n                          | 438                        | 437           | 875           |
|                                           | ≤ 1xULN                    | 154 (35.1%)                | 146 (33.2%)   | 300 (34.1%)   |
|                                           | >1x ULN                    | 284 (64.7%)                | 291 (66.1%)   | 575 (65.4%)   |
| Bone Marrow Involvement at Diagnosis      | n                          | 432                        | 429           | 861           |
|                                           | Indeterminate              | 11 (2.5%)                  | 11 (2.5%)     | 22 (2.5%)     |
|                                           | Positive                   | 72 (16.4%)                 | 76 (17.3%)    | 148 (16.8%)   |
|                                           | Negative                   | 349 (79.5%)                | 342 (77.7%)   | 691 (78.6%)   |
| No. of Extranodal Sites                   | n                          | 439                        | 440           | 879           |
|                                           | 0-1                        | 226 (51.5%)                | 227 (51.6%)   | 453 (51.5%)   |
|                                           | 22                         | 213 (48.5%)                | 213 (48.4%)   | 426 (48.5%)   |
| Time from Diagnosis to Study Dose (days)  | n                          | 437                        | 436           | 873           |
|                                           | Mean (SD)                  | 33.02 (35.74)              | 29.99 (21.46) | 31.51 (29.51) |
|                                           | Median                     | 27.00                      | 26.00         | 27.00         |
|                                           | 25th-75th                  | 19.00 - 41.00              | 16.00 - 37.50 | 17.00 -39.00  |
|                                           | Min - Max                  | 1.0 - 621.0                | 1.0 - 195.0   | 1.0 - 621.0   |

<div style=\"page-break-after: always\"></div>

| NHL Histologic Diagnosis (eCRF)                   | n                    | 439         | 440         | 879         |
|---------------------------------------------------|----------------------|-------------|-------------|-------------|
|                                                   | DLBCL, NOS, ABC, GCB | 367 (83.6%) | 373 (84.8%) | 740 (84.2%) |
|                                                   | HGBL, NOS, DHLTHL    | 50 (11.4%)  | 43 (9.8%)   | 93 (10.6%)  |
|                                                   | Other Large B-cell   | 22 (5.0%)   | 24 (5.5%)   | 46 (5.2%)   |
| CoO (Central Review)                              | n                    | 338         | 330         | 668         |
|                                                   | ABC                  | 119 (35.2%) | 102 (30.9%) | 221 (33.1%) |
|                                                   | GCB                  | 168 (49.7%) | 184 (55.8%) | 352 (52.7%) |
|                                                   | Unclassified         | 51 (15.1%)  | 44 (13.3%)  | 95 (14.2%)  |
| Double-Expressor Lymphoma by IHC (Central Review) | n                    | 366         | 362         | 728         |
|                                                   | DEL                  | 151 (41.3%) | 139 (38.4%) | 290 (39.8%) |
|                                                   | NON DEL              | 215 (58.7%) | 223 (61.6%) | 438 (60.2%) |
| Double/Triple-Hit Lymphoma (Central Review)       | n                    | 334         | 331         | 665         |
|                                                   | DH/TH+               | 19 (5.7%)   | 26 (7.9%)   | 45 (6.8%)   |
|                                                   | DH/TH-               | 315 (94.3%) | 305 (92.1%) | 620 (93.2%) |

COO = cellof-origin; DEL = double-expressor lymphoma; DH =double-hit; ECOG = Eastem Cooperative Oncology Group; eCRF = electronic case report form; IHC = immunohistochemistry; IPl = Intemational Prognostic Index; IxRS = interactive voice or Web-based response system; LDH = Lactate dehydrogenase; NHL = non-hodgkins lymphoma; TH = triple-hit; SD = standard deviation

Note: There was one patient in pola+R-CHoP recorded with IPl \"1\". This was a data entry error per eCRF and the patient was actually randomized as IPl *2\". Note: NHL Histologic Diagnosis (eCRF) are by local diagnosis/lab

By gene expression profiling, 25.1% of patients had ABC like DLBCL, 40.0% of patients had GCB like DLBCL, 10.8% were unclassified and 24.0% were unknown.

## Prior Disease

All patients (100%) in the ITT population had at least one medical history condition (pola+R-CHP and RCHOP arms). The most common medical history by SOC (≥30% in either arm) were: Metabolism and nutrition  disorders  (47.6%  pola+R-CHP  vs  51.1%  R-CHOP  ),  Vascular  disorders  (48.5%  vs  48.9), Gastrointestinal disorders (47.4% vs 45.7%), Musculoskeletal and connective tissue disorders (37.9% vs 35.4%). Patient medical history reported in the ITT population was reflective of the expected medical comorbidities  of  this  patient  population,  primarily  associated  with  median  age  65-66  years,  and  were generally well balanced between the arms with regard to system organ class (SOC) and individual medical history conditions.

<div style=\"page-break-after: always\"></div>

## Prior and concomitant therapy

Concomitant medication was defined as any medication (e.g., prescription drugs, over-the-counter drugs, vaccines,  herbal  or  homeopathic  remedies,  nutritional  supplements)  used  by  a  patient  in  addition  to protocol-mandated treatment from 7 days prior to initiation of study drug to the study completion/discontinuation visit.

All patients (100%) in the ITT population received at least one concomitant medication (pola+R-CHP and R-CHOP arms).

The  most  frequently  used  types  of  concomitant  medication  (ATC  level  1,  ≥90%  in  either  ar m) were: Alimentary  tract  and  metabolism  (97.5%  pola+R-CHP  vs  97.5%  R-CHOP),  Dermatologicals  (95.4%  vs 95.9%), Antineoplastic and immunomodulating agents (94.0% vs 96.1%), Nervous system (93.1% vs 93.4%), Respiratory system (91.0% vs 92.5%).

The majority of patients in the ITT population received at least one prior concomitant medication (84.1%, pola+R-CHP vs 86.5% R-CHOP).

Pre-phase steroid treatment was received by 37.7% of patients in the pola+R-CHP arm and 38.6% of patients in the R-CHOP arm within 7 days prior to Cycle 1 Day 1 (C1D1).

Concomitant GCSF was received by 92.9% of patients in the pola+R-CHP arm and 95.2% of patients in the R-CHOP arm. Concomitant GCSF for prophylaxis use was received by 90.1% of patients in the pola+R-CHP arm and 93.2% of patients in the R-CHOP arm.

Concomitant  medication  for  anti-infective  prophylaxis  use  were  received  by  61.6%  of  patients  in  the pola+R-CHP arm and 57.1% of patients in the R-CHOP arm.

Concomitant medication related to AEs were received by 91.5% of patients in the pola+R-CHP arm and 87.2% of patients in the R-CHOP arm.

## Numbers analysed

Table 15: Analysis Population

|                                                     |   R-CHOP (N) |   Pola+R-CHP (N) |   Total (N) |
|-----------------------------------------------------|--------------|------------------|-------------|
| Intent-to-Treat                                     |          439 |              440 |         879 |
| Safety-evaluable                                    |          438 |              435 |         873 |
| Number of patients received any dose of pola        |            0 |              435 |         435 |
| Number of patients received any dose of vincristine |          436 |                0 |         436 |

For each biomarker analyzed, the biomarker-evaluable population was defined as all randomized patients in the global study who have a valid baseline assessment for that specific biomarker. The PRO-evaluable

<div style=\"page-break-after: always\"></div>

population included all randomized patients in the global study who had a baseline and at least one postbaseline assessment.

## Outcomes and estimation

## Primary Efficacy Endpoint: Investigator-Assessed Progression-Free Survival

Table 16: Investigator-Assessed PFS (ITT Population)

<!-- image -->

|                                                                                                              | R-CHOP (0-439)                | Pola+R-CHP (N-440)                          |
|--------------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------------|
| Patients with event (8) Earliest contributing ewent Death Disease_Progression Patients Hlthouf ovent (8)     | 134(30.58) 20 114 305 (69.98) | 107 (24.38) 19 88 333 779.701               |
| Tine to event (months) Median 15 856 251 and 750-1lo Range                                                   | NE NE 15.8 - ME 0* - 37*      | 33.3 (33.3, ME) 25.4 - NE E-0               |
| Stratified Analysia p-vnlue (log-rank)                                                                       |                               | 0.0177                                      |
| Harard Ratio 15866                                                                                           |                               | 0.73 (0.57, 0.95)                           |
| Unstratifled Analyais p-value (log-rmnk)                                                                     |                               | 0.0326                                      |
| Hazard Ratio 15866 6 months duratlon Patients remaining at risk Event Free Rnte (W) 958 CI                   | 389 92.73 (90.27, 95.20)      | 0.76 (0.59, 0.98) 404 93.76 (91.49, 96.04)  |
| Difterence in Event Free Rate 15156                                                                          |                               | 1.03 [-2.33, 4.38]                          |
| 12 months duration Patients renaining at risk Event Pree Rate (0) 958 CI                                     | 330 79.77 (75.92, 83.61)      | 353 83.91 (80.43, 87.39)                    |
| Difterence in Event Free Rate 958 CI                                                                         |                               | 4.14 (-1.05, 9.32)                          |
| 18 months duration Patients remaining at risk Event Fmee Rate (W) 15856 Difference in Event Free Rnte 10 856 | 296 73.49 (69.21, 77.69)      | 327 79.84 (76.03, 83.65) 6.39 (0.69, 12.09) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 20: Kaplan-Meier Plot of Time to Investigator-Assessed PFS (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 17: Censoring Rules for Primary Analysis of Investigator-Assessed PFS: Patient Count (ITT Population)

| Scenario1                                                                                                 | Date of Progression or Censoring                                  | Status       | R-CHOP (N= 439)             | Pola+R- CHP (N= 440)       |
|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------|-----------------------------|----------------------------|
| Number of patients with:                                                                                  |                                                                   |              |                             |                            |
| No adequate² post-baseline assessment and no death                                                        | Randomization date                                                | Censored     | 7 ( 1.6%)                   | 5 ( 1.1%)                  |
| No death and no disease progression before data cutoff                                                    | Date of last adequate assessment before data cutoff               | Censored     | 298 (67.9%)                 | 328 (74.5%)                |
| Withdrawal of treatment due to nonefficacy reason, no death and no disease progression before data cutoff | Date of last adequate assessment before data cutoff               | Censored     | 10 (2.3%)4(0.9%)            |                            |
| Withdrawal of treatment due to non-efficacy reason, followed by disease progression or death              | Date of earliest disease progression or death, before data cutoff | Event        | 6 ( 1.4%)                   | 4 ( 0.9%)                  |
| New anti-cancer treatment started due to efficacy reasons,followed by death or disease progression        | Date of earliest disease progression or death, before data cutoff | Event4.5     | 4 ( 0.9%)                   | 3 ( 0.7%)                  |
| New anti-cancer treatment? started due to efficacy reasons,no death or disease progression                | Date of last adequate assessment before data cutoff               | Censored4.52 | 2 (0.5%)                    | 5 ( 1.1%)                  |
| New anti-cancer treatment? started due to non-efficacy reasons, followed by death or disease progression  | Date of earliest disease progression or death, before data cutoff | Event5       | 13 (3.0%)                   | 6 ( 1.4%)                  |
| New anti-cancer treatment started due to non-efficacy reason, no death or disease progression             | Date of last adequate assessment before data cutoff               |              | Censored529 (6.6%)19 (4.3%) |                            |
| Death or disease progression following one or more consecutive missed assessments6                        | Date of earliest disease progression or death, before data cutoff | Event        | 1 (0.2%)                    | 4 ( 0.9%)                  |
| One or more missed assessments followed by no adequate2 assessments or death                              | Date of last adequate assessment before data cutoff               |              |                             | Censored20 (4.6%)14 (3.2%) |

## 1. Impact of missing scheduled tumour assessments on PFS

The impact of missing scheduled tumor assessments on PFS, and the fact that the actual timing of PFS events usually cannot be observed exactly was assessed by performing a sensitivity analysis based on interval censoring analysis method. The result of the analysis was consistent with the result of the primary

<div style=\"page-break-after: always\"></div>

PFS analysis, and showed a higher reduction in the risk of PFS events for patients treated with pola+R-CHP compared with patients treated with R-CHOP. Stratified HR was 0.75 (95% CI: 0.58, 0.96) in favor of pola+R-CHP treatment.

## 2. Impact of NALT prior to or in the absence of Progression on PFS

The impact of initiation of NALT prior to or in the absence of subsequent death or disease progression was assessed by performing sensitivity analyses by discount method, and by censoring PFS at the last adequate tumor assessment before the initiation of NALT. Results from these analyses were consistent with the result of analysis of the primary endpoint indicating that there was minimal impact of NALT prior to PD on the PFS results.

Stratified HRs for PFS, after discounting time after the initiation of NALT by 10%, 30%, and 50% for both arms, were:

- 10% discount: 0.73 (95%CI: 0.57, 0.95) favoring pola+R-CHP treatment
- 30% discount: 0.73 (95% CI: 0.57, 0.95) favoring pola+R-CHP treatment
- 50% discount: 0.73 (95% CI: 0.57, 0.94) favoring pola+R-CHP treatment

Stratified HR for PFS censored at the last adequate tumor assessment before the initiation of NALT was 0.77 (95% CI: 0.59, 1.01) favoring pola+R-CHP treatment.

## 3. Restricted Mean Survival Time Analysis on PFS and OS

The  difference  in  the  average  event-free  survival  time  between  treatment  and  control  arm  from randomization to 12, 24 and 36 months after randomization was assessed using restricted mean survival time (RMST) method to provide an alternative measure of treatment effect to the hazard ratio. RMST estimates suggested that patients treated with pola+R-CHP had longer mean PFS duration than patients treated with R-CHOP.

Mean survival time at various milestones (pola+R-CHP vs. R-CHOP) were:

- 12 months: 11.1 months vs. 10.9 months (treatment difference= 0.2 [95% CI: -0.1, 0.5] favoring pola+R-CHP treatment)
- 24 months: 20.6 months vs. 19.6 months (treatment difference= 1.0 [95% CI: 0.1, 2.0] favoring pola+R-CHP treatment)
- 36 months: 28.4 months vs. 27.4 months (treatment difference= 1.0 [95% CI: -1.2, 3.1] favoring pola+R-CHP treatment. Please note that, since the median PFS follow-up was 24.7 months in both arms, the 36 month RMST estimates were not mature and is subject to change with longer followup.

## Subgroup Analyses of Investigator-Assessed Progression-Free Survival

There was a directionally consistent treatment effect supporting the PFS benefit of pola+R-CHP in the majority of subgroups (HR &lt;1), and all 95% CIs for HR in the major subgroups (with sample size &gt; 100) include 0.73, i.e., the estimated stratified HR in the ITT population.

<div style=\"page-break-after: always\"></div>

Given the known limitations of exploratory subgroup analyses (Wang et al, 2007; Alosh et al, 2016), results should not be over interpreted and there is no statistical evidence for heterogeneity of treatment effect in any of the subgroups.

Figure 21: Forest Plot of Hazard Ratio of Investigator-Assessed PFS by Baseline Risk Factors (ITT Population)

<!-- image -->

|                                                                                                                     |               | R-CHOP   | R-CHOP                  | Pel+R-CHP (Nn440)   | Pel+R-CHP (Nn440)          | Harad            |                                                      |
|---------------------------------------------------------------------------------------------------------------------|---------------|----------|-------------------------|---------------------|----------------------------|------------------|------------------------------------------------------|
| Baseline Risk Fachors                                                                                               | Total         |          | 2'Tear Rate             |                     | 2Year Rate                 | 95Wld Ratio      | PoarR-CHP R-CHOP beder beter                         |
| APatents                                                                                                            | 879           | 439      | 70.20                   | 40                  | 76.71                      | 0.76 (0.59,0.9)  |                                                      |
| Age Group 90                                                                                                        | 出             |          | 68.21                   |                     | 5.3                        | 0.74             | 05L105 10.55.1.10                                    |
| Age Group                                                                                                           |               |          |                         |                     |                            |                  |                                                      |
| Ses Male Femsle                                                                                                     |               |          | 75.19                   |                     | 5.17 FF.7O                 | 0.93             | 0.2.090 (0.62, 1.38)                                 |
| RacE mrican indan or Alaska Nutive AS B gr AricanAmnrican White Nathve Hawaian or gther Pacilc hlarder Unknewm Oeer | 169 471 265 3 | 2 100    | 100:00 611 100:50 72.63 | 205 105             | 3404 100.00 62 66.67 77.84 | 0.64 0.01 071 HL | NC 1036.1.12 (5.00,NE) 02.125 1007.20 10.42,1.21) ML |
| ECOG 01                                                                                                             | 141           |          | 7122 6-19               | 374                 | 67.24                      | 075 110          | 0.099 (0.46,1.43)                                    |
| Saficaton-IPi scere (xRS)                                                                                           |               |          |                         |                     | 3516 79.32                 | 0.99 0.67        | 10.63.1.56 0.49,0.91)                                |
| Absert Pesent                                                                                                       |               |          | 70.68                   | 47 193              | 82.68 原.                   |                  | 10.38.0.801 0.72.1.47                                |
| Siiication-Geographic Region (aRS) Acia Wmtom Europe/LSACanadyRanila Restulweld                                     | 116           |          | 67.25                   |                     | 7424 28.37 70.80           | 180              | 0.35.L 1035,1051 (0.41.1.52)                         |

Unstratifiedhazard ratio isdisplayed CCOD:28JUN2021Data ExtractDate:02AUG2021

<!-- image -->

|                                                                     |           | R-CHOP (N=439)   | R-CHOP (N=439)   | Pola+R-CHP (N-149)   | Pola+R-CHP (N-149)   | Hazard         |                                |                        |
|---------------------------------------------------------------------|-----------|------------------|------------------|----------------------|----------------------|----------------|--------------------------------|------------------------|
| Baseine Risk Factors                                                | Total     |                  | 2Year Rae        |                      | 2Year Rate           | Ratio          | 95%Wald                        | Poa-R-CHP R-CHOP beBer |
| AllPatients                                                         | 879       | 439              | 70.20            | 440                  | 76.71                | 0.76           | (0.59,0.96)                    |                        |
| Ann Arbor Sage H M                                                  | 5.48      |                  | 孵 66.14          | 692                  | 72.55                | 0.78           | (0.58,1.05)                    |                        |
| IPI(eCRF) 1-2 3 4-5                                                 | 8         | 118              | 79.49 5838 59.86 | 101                  | 78.5 81.39 65.95     | 0.79           | 9.59.172 1037.087 (051,122     |                        |
| Baseline Bulky Disease Yes No                                       |           |                  |                  |                      | 8268                 |                | 973.148 10.38,0.80)            |                        |
| Baseline LDH CULN >1ULN                                             |           |                  | 75.64 67.19      |                      | 78.93 75.38          | 081 0.73       | 10.51.130) 10.54,1.00)         |                        |
| Bone marrowivolement Positve Neganve Inoiseminate                   | 148 691 2 | 6PE 11           | 5195 73          | P 342 11             | 29.5 78,00 70.00     | 0.69 0.44 0.82 | 040.1.1 10.61.1.10) (010,1.85) |                        |
| No.of extanodal sites 0-1 3a2                                       |           |                  | 74.47 65.77      |                      |                      | 8.72           | 1                              |                        |
| NHL Subtype (eCRF) PUBCLNOS.ABC.GCB JHLOHOSONJOH Other Large B-oell | 46        |                  | 76.19            | 24                   | 58.40                | 1.90           | 8：8 (0.66.5.64)                |                        |

Unstratified hazard ratio isdisplayed CCOD:28JUN2021Data ExtractDate:02AUG2021

## Secondary Efficacy Endpoint: Investigator-Assessed Event-Free Survival for Efficacy Reasons

EFSeff  was  defined  as  the  time  from  the  date  of  randomization  to  the  earliest  occurrence  of  disease progression/relapse, death, biopsy that is positive for residual disease after treatment completion, or start of a NALT due to efficacy reasons. A higher proportion of patients in the R-CHOP arm received NALT (30.3%) compared to pola+R-CHP arm (22.5%).

<div style=\"page-break-after: always\"></div>

At the time of the CCOD, 112 patients (25.5%) in the pola+R-CHP arm, and 138 patients (31.4%) in the R-CHOP arm had an EFS event. Results of the secondary endpoint EFSeff, were statistically significant and highly consistent with results of the primary endpoint of investigator-assessed PFS and was supportive of the clinical benefit for pola+R-CHP compared with R-CHOP. A statistically significant reduction by 25% in the risk of an EFSeff event was observed in the pola+R-CHP arm compared with the R-CHOP arm (stratified HR: 0.75 [95% CI: 0.58, 0.96], two-sided p-value = 0.0244, twosided α=0.05; Table 18). Median EFSeff estimates were not considered mature for either treatment arm as of the CCOD.

Table 18: EFSeff (ITT population)

<!-- image -->

| Time to Event Summary for EFSeff (by INv). Intent-to-Treat Patients Protocol: G039942   |                                                  |                           |                           |                           |                           |
|-----------------------------------------------------------------------------------------|--------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Patients with event (名)                                                                 | 138(31.48)                                       | 112 (25.58)               | 112 (25.58)               | 112 (25.58)               | 112 (25.58)               |
| Earliest contributing event                                                             | 20                                               | 18                        | 18                        | 18                        | 18                        |
| Death Disease Progression NALr due to efficacy reasons or                               | 106                                              | 86                        | 86                        | 86                        | 86                        |
| Time to event (months) Median 95t CI 25% and 75%-ile Range                              | 12 301(68.6%)                                    | 348 82.52 (78.93,86.12)   | 348 82.52 (78.93,86.12)   | 348 82.52 (78.93,86.12)   | 348 82.52 (78.93,86.12)   |
| positive biopsy Patients without event ($)                                              |                                                  |                           |                           |                           |                           |
| Difference in Event Free Rate 95+ CI 18 months duration Patients remaining at risk      |                                                  | 328(74.58)                | 328(74.58)                | 328(74.58)                | 328(74.58)                |
| Stratified Analysis p-value (log-rank)                                                  | NE NE 13.2 - NE                                  | 33.3 (33.3, NE) 24.9 - NE | 33.3 (33.3, NE) 24.9 - NE | 33.3 (33.3, NE) 24.9 - NE | 33.3 (33.3, NE) 24.9 - NE |
| 95+ CI 6 months duration                                                                | 0+ = 37+ 0.0244                                  |                           |                           |                           |                           |
| Patients remaining at risk Event Free Rate () Event Free Rate () 958 CI                 | 327 78.67 (74.76, 82.58) 294 72.62 (68.35,76.89) | 402                       | 402                       | 402                       | 402                       |
| Hazard Ratio                                                                            | 0.75 (0.58,0.96)                                 | (74.81, 82.58)            | (74.81, 82.58)            | (74.81, 82.58)            | (74.81, 82.58)            |
| Event Free Rate (&) 95& CI 10456                                                        |                                                  |                           |                           |                           |                           |
| 956 CI Difference in Event Free Rate                                                    | 386 91.57 (88.94, 94.21) 1.73                    | 93.30 (90.94,95.66)       | 93.30 (90.94,95.66)       | 93.30 (90.94,95.66)       | 93.30 (90.94,95.66)       |
| 10456 12 months duration Patients remaining at risk                                     | (-1.81, 5.26)                                    |                           |                           |                           |                           |
|                                                                                         | 3.85 (-1.46, 9.17)                               |                           |                           |                           |                           |
| Difference in Event Free Rate                                                           |                                                  |                           |                           |                           |                           |
|                                                                                         | 218                                              | 75.57                     | 75.57                     | 75.57                     | 75.57                     |
|                                                                                         |                                                  | 243                       | 243                       | 243                       | 243                       |
| 24 months duration                                                                      |                                                  |                           |                           |                           |                           |
|                                                                                         | 69.39                                            |                           |                           |                           |                           |
| Event Free Rate ()                                                                      |                                                  |                           |                           |                           |                           |
| Patients remaining at risk                                                              |                                                  |                           |                           |                           |                           |
|                                                                                         |                                                  | 6.07                      | 6.07                      | 6.07                      | 6.07                      |
|                                                                                         |                                                  | (0.30, 11.85)             | (0.30, 11.85)             | (0.30, 11.85)             | (0.30, 11.85)             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Secondary Efficacy Endpoint: New anti-lymphoma treatment

NALT  could  be  administered  after  the  patient  had  completed  study  treatment,  and  included  both radiotherapy or systemically administered therapies. NALT was allowed to be administered with or without a disease progression documented in the patient. Follow-up anti-lymphoma treatments is described in Table 19.

<div style=\"page-break-after: always\"></div>

Table 19: Follow-up Anti-Lymphoma Treatments (ITT Population)

|                                                                                 | R-CHOP (N-439)     | Pola+R-CHP (N=440)   | Total (N-879)   |
|---------------------------------------------------------------------------------|--------------------|----------------------|-----------------|
| Total number of patients with at least one NALT treatment                       | 133(30.38)         | 99(22.58)            | 232 (26.48)     |
| Total number of NALT treatments                                                 | 290                | 179                  | 469             |
| Totalnumber of patients with at least one NAlT treatment before Prs event       | 16 ( 3.68)         | 7(1.68)              | 23( 2.68)       |
| Total number of patients with at least one NALT treatment after PFS event       | 93(21.2%)          | 64(14.58)            | 157 (17.94)     |
| Total number of patients with at least one NALT treatment and without Prs event | 31( 7.18)29( 6.68) |                      | 60(6.8%)        |
| Radiotherapy Total number of patients with at least one treatment               | 57(13.08)41( 9.38) |                      | 98 (11.14)      |
| Total number of treatments                                                      | 73                 | 42                   | 115             |
| Total number of patients with pre-planned treatment                             | 18(4.16)           | 11 ( 2.58)           | 29( 3.34)       |
| Total number of patients with unplanned treatment                               | 391 8.9%13016.88)  |                      | 69( 7.88)       |
| Systemic therapy Total number of patients with at least one treatment           |                    | 103(23.56)75 (17.06) | 178 (20.38)     |
| Total number of treatments                                                      | 217                | 137                  | 354             |
| Total number of patients received stem cell transplants                         | 31 ( 7.18)         | 17( 3.98)            | 48( 5.54)       |
| Autologous transplant                                                           | 30( 6.88)          | 17( 3.98)            | 47( 5.38)       |
| Allogeneic transplant                                                           | 1(0.28)            | 0                    | 1 (0.14)        |
| Total number of patients received CAR-T                                         | 16( 3.66)          | 9( 2.0%)             | 25 ( 2.86)      |

Data Extract Date: 02AuG2021

CCOD:28JUN20211

In addition, 8 patients received pola as a NALT (either alone or in combination) in the R-CHOP arm, and no patients in the pola+R-CHP arm received pola as NALT.

## Secondary Efficacy Endpoint: BICR-Assessed Complete Response Rate at End of Treatment (by PET-CT)

At the end of the treatment, BICR-assessed CR rate was high in both arms. A numerically higher proportion of patients treated with pola+R-CHP had complete response at the end of treatment compared to patients treated with R-CHOP (78.0% [95% CI: 73.79, 81.74] vs. 74.0% [95% CI: 69.66, 78.07]; Table 20). The treatment difference was 3.9% (95% CI: -1.9, 9.7) and was not statistically significant (two-sided p-value = 0.1557, twosided α boundary of 0.01).

<div style=\"page-break-after: always\"></div>

Table 20: Summary of BICR-Assessed CR Rate at EOT (ITT Population)

<!-- image -->

In addition, concordance between BICR and Investigator assessments of CR was high (88.7%) and was balanced between treatment arms (88.9% vs. 88.6%; Table 21).

Table 21: Summary of Concordance Between BICR- and Investigator-Assessed CR Status at EOT by PETCT (ITT Population)

<!-- image -->

|                                              | R-CHOP (N=439)   | Pola+R-CHP (N-140)   | Total (N-879)   | Total (N-879)   |
|----------------------------------------------|------------------|----------------------|-----------------|-----------------|
| Number of patients evaluable for concordance | 422              | 422                  | 844             | 844             |
| CR. Concordance Concordance                  | 374(88.6%)       | 375 (88.99)          | 749(88.7%)      |                 |
|                                              | 297(79.48)       | 313(83.54)           | 610(81.48)      |                 |
| No CR per investigator and no CR per BICR    | 77(20.66)        | 62(16.54)            | 139 (18.6%)     |                 |
| CR Discordance                               |                  |                      |                 |                 |
| Discordance                                  | 48(11.48)        | 47(11.18)            | 95 (11.38)      |                 |
|                                              | 20(41.7%)        | 17(36.24)            | 37(38.9%)       |                 |
|                                              | 28(58.36)        | 30(63.8%)            | 58 (61.16)      |                 |

CCOD:28.JUN2021 Data Extract Date: 02AuG2021

## Secondary Efficacy Endpoint: Overall Survival

The frequency of OS events (deaths) were low in both arms (Table 22). A total of 53 deaths (12.0% patients) were reported in the pola+R-CHP arm, and 57 deaths (13.0% patients) were reported in the RCHOP arm. With very few events in both arms, OS results were still immature at the time of the interim analysis of OS and did not meet the pre-specified threshold for statistical significance (stratified HR: 0.94 [95%  CI:  0.65,  1.37];  two-sided  log-rank  p-value  =  0.7524,  twosided  α  boundary=  0.002).  The unstratified analysis of OS showed results similar to the stratified analysis. A KM curve is shown in Figure 7. Milestone OS results for the pola+R-CHP arm and the R-CHOP arm were 92.2% and 94.6% at 1 year, and 88.7% and 88.6% at 2 years, respectively.

<div style=\"page-break-after: always\"></div>

Table 22: Summary of OS (ITT Population)

<!-- image -->

|                                                                                                               | R-CHOP (N=439)                   | PolaIR-CHP (N=440)                     |
|---------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------|
| Fatients with event (&) Earliest contributing event Death Patients without event (%)                          | 57 (13.0%) 57 382(87.0%)         | 53(12.0%) 53 387 (88.0%)               |
| Time to event (months) Median 95% CI 25% and 75%-ile Range                                                    | NE NE 39.3 - NE 42+              | NE NE NE - 43+                         |
| Stratified Analysis p-value (log-rank)                                                                        |                                  | 0.7524                                 |
| Hazard Ratio 95: CI                                                                                           | 0.94                             | (0.65, 1.37)                           |
| Hazard Ratio 95% CI 6 months duration Event Free Rate (&) 10 56                                               | 0.92 (0.63, 1.34)                |                                        |
| Patients remaining at risk                                                                                    | 414 96.97 (95.35, 98.59)         | 423 96.80 (95.16, 98.45)               |
| 12 months duration Patients remaining at risk Event Free Rate (6) 956 CI Difference in Event Free Rate 95% CI | 401 94.62 (92.48,96.76) 2.45     | 397 92.17 (89.64, 94.70) (-5.76, 0.86) |
| 18months duration Patients remaining at risk Event Free Rate () I0 $56                                        | 376 90.79                        | 384 90.07                              |
| Difference in Event Free Rate 95% CI                                                                          | (88.03,93.54) -0.72              | (87.25, 92.89) (-4.66, 3.23)           |
| 24 months duration Patients remaining at risk Event Free Rate ()                                              | 355 88.61                        | 362 88.66                              |
| Difference in Event Free Rate 958 CI                                                                          | 0.05 (-4.21, 4.31) 132 86.31     | 140                                    |
| 30 months duration Patients remaining at risk Event Free Rate （) 95% CI Difference in Event Free Rate         | (82.89,89.73) 0.94               | 87.25 (83.89,90.61)                    |
| 956 CI                                                                                                        | (-3.86, 5.73)                    | 15 86.46                               |
| 36 months duration Patients remaining at risk Event Free Rate (%)                                             | 20 85.58                         | (82.79, 90.13)                         |
| 956 CI Difference in Event Free Rate 10$56                                                                    | (81.90, 89.26) 0.88 (-4.32,6.07) |                                        |

<div style=\"page-break-after: always\"></div>

Figure 22: Kaplan-Meier Plot of Time to OS (ITT Population)

<!-- image -->

## Others Secondary Efficacy Endpoints relative to response rates assessment:

Investigator-Assessed Complete Response Rate at End of Treatment (by PET-CT)

Investigator-assessed CR rates were high, and comparable to BICR-assessed CR rates (Section 5.1.3.2) in both arms. At the end of treatment, 75.0% (95% CI: 70.68, 78.98) patients in the pola+R-CHP arm, and 72.2% (95% CI: 67.76, 76.35) patients in the R-CHOP arm had complete response as assessed by the Investigator (Table 21). The difference in CR rate between the pola+R-CHP arm and the R-CHOP arm was 2.79 (95% CI: -3.20, 8.75). This analysis was not formally tested.

## Investigator-Assessed Objective Response Rate at End of Treatment

At the end of treatment, a high proportion of patients achieved Investigator-assessed ORR (i.e. CR or PR) in both arms (84.5% [95% CI: 80.82, 87.79] vs. 80.9% [95% CI: 76.87, 84.44]), with patients in the pola+R-CHP arm achieving a better response in terms of ORR compared to patients in the R-CHOP arm (treatment difference=3.68% [95% CI: -1.49, 8.84]).

## BICR-Assessed Objective Response Rate at End of Treatment

Similar to the Investigator-assessed ORR (Section 5.1.3.5), a high proportion of patients achieved BICRassessed ORR (i.e. CR or PR) in both arms at the end of treatment (85.5% [95% CI: 81.81, 88.61] vs. 83.8% [95% CI: 80.04, 87.15]). Treatment difference between the pola+R-CHP arm and the R-CHOP arm was 1.63% (95% CI: -3.32, 6.57).

## Investigator-Assessed Best Overall Response Rate

Investigator-assessed BOR revealed high response rates (i.e. best response of CR or PR while on study) in both the pola+R-CHP arm (95.9% [95% CI: 93.61, 97.56]) and the R-CHOP arm (94.1% [95% CI: 91.44,

<div style=\"page-break-after: always\"></div>

96.10]). Best CR rate as of the CCOD was 86.6% (95% CI: 83.05, 89.63) in the pola+R-CHP arm and 82.7% (95% CI: 78.82, 86.11) in the R-CHOP arm.

## Secondary Efficacy Endpoint: Investigator-Assessed Duration of Response

DOR was defined as the time from the date of the first occurrence of a documented clinical response (CR or PR) to the date of progression, relapse, or death from any cause for the subgroup of patients with a BOR of CR or PR, all assessed by the investigator.

Of the patients who achieved a best overall response of CR or PR, 94 patients (22.3%) in the pola+R-CHP arm,  and  116  patients  (28.1%)  in  the  R-CHOP  arm  had  subsequent  disease  progression  or  death.  In patients who achieved CR or PR, treatment with pola+R-CHP reduced the risk of progression or death by 26% compared to R-CHOP treatment (stratified HR: 0.74 [95% CI: 0.56, 0.98]). The favorability of the pola+R-CHP treatment compared to R-CHOP treatment in DOR suggests that even though response rates are high in both treatment arms, response was more durable in the pola+R-CHP arm. KM curves for DOR started to separate at approximately 5 months after the first response in favor of the pola+R-CHP arm, and remained separated for the duration of the study (section 5.1.3.8 of the CSR). Milestone DOR results for the pola+R-CHP arm and the R-CHOP arm were 83.8% and 78.2% at 1 year, and 75.7% and 71.7% at 2 years, respectively, after first response.

## Investigator-Assessed Disease-Free Survival

DFS was defined as the time from the date of the first occurrence of a documented CR to the date of relapse or death from any cause for the subgroup of patients with a BOR of CR, all assessed by the investigator.

A lower proportion of patients in the pola+R-CHP arm progressed or died subsequent to achieving a CR, compared to patients in the R-CHOP arm (62 patients [16.3%] vs. 79 patients [21.8%]). In patients who achieved CR, treatment with pola+R-CHP reduced the risk of progression or death by 30% compared to treatment with R-CHOP (stratified HR: 0.70 [95% CI: 0.50, 0.98]). The favorability of the

Pola+R-CHP arm compared to the R-CHOP arm in DFS suggests that even though CR was high in both treatment arms, remission status was more durable in the pola+R-CHP arm.

KM curves began to separate at approximately 6 months after randomization in favor of pola+R-CHP, and the separation was maintained for the duration of follow-up (section 5.1.3.9 of the CSR).

Milestone DFS results for the pola+R-CHP arm and the R-CHOP arm were 90.1% and 83.4% at 1 year, and 81.8% and 77.4% at 2 years after first CR, respectively.

## Investigator-Assessed Progression-Free Survival Rate at 24 Months After Randomization

A higher proportion of patients in the pola+R-CHP arm remained alive and progression-free 24 months after randomization. The estimated 2-year investigator-assessed PFS was 76.7% in patients treated with pola+R-CHP compared to 70.2% in patients treated with R-CHOP (absolute difference of 6.5% [95% CI: 0.52, 12.5]). This analysis was not formally tested.

## Investigator-Assessed Event-Free Survival-All Causes

EFSall  differs  from  EFSeff,  and  was  defined  as  the  time  from  randomization  to  disease  progression  or relapse,  as  determined  by  the  investigator,  death  from  any  cause,  or  initiation  of  any  NALT.  A  higher proportion of patients in the R-CHOP arm received NALT (30.3%) compared to pola+R-CHP arm (22.5%).

<div style=\"page-break-after: always\"></div>

The results for EFSall was consistent with the results for EFSeff. At the time of CCOD, 133 patients (30.2%) in the pola+R-CHP arm, and 165 patients (37.6%) in the R-CHOP arm had an EFSall event. The risk of an EFSall  event  was  reduced  by  27%  following  pola+R-CHP  treatment  compared  to  R-CHOP  treatment (stratified HR: 0.73 [95% CI: 0.58, 0.92]). This analysis was not formally tested.

## Secondary Efficacy Endpoint: Patient-Reported Outcomes

Completion rates of all questionnaires w ere high (≥95%) at baseline in both arms, and remained ≥80% at each subsequent timepoint.

## Responder analysis

## - Physical functioning

Patients in both arms showed high levels of physical functioning at baseline (mean: 80.04 vs. 80.55) with scores improving over time. As of the CCOD, a higher proportion of patients in the pola+R-CHP arm (42.4% [95% CI: 37.56, 47.30]) experienced clinically meaningful improvement in physical functioning, i.e. ≥7 -point increase, as measured by EORTC QLQ-C30 physical functioning scale compared to the R-CHOP arm (39.6% [95% CI: 34.81, 44.47]). The difference in response rates between pola+R-CHP and R-CHOP treatments was 2.81 (95% CI: -4.06, 9.64).

## - Fatigue

Patients in both arms reported fatigue at baseline (mean: 37.32 vs. 35.11). As of the CCOD, the proportion of  patients  experiencing  a  clinically  meaningful  improvement  in  fatigue  (i.e.  ≥9 -point  decrease,  as measured by EORTC QLQ-C30 fatigue scale) was higher in the pola+R-CHP arm compared to the R-CHOP arm (74.8% [95% CI: 70.34, 78.93] vs. 68.2% [63.47, 72.68], treatment difference= 6.61 [95% CI: 0.28, 12.88]).

## - Lymphoma symptoms

Patients in both arms reported lymphoma symptoms at baseline (mean: 44.7 vs. 45.3).

As of the CCOD, the proportion of patients experiencing a clinically meaningful improvement in lymphoma symptoms (i.e. a ≥3 -point increase per FACT-Lym LymS) was high and comparable between treatment arms (82.3% [95% CI: 78.30, 85.88] vs. 81.3% [95% CI: 77.20, 84.96], treatment difference = 1.01 (95% CI: -4.43, 6.45)).

## Time to Deterioration Analysis

## - Physical functioning

A total of 183 patients (41.6%) in the pola+R-CHP arm, and 187 patients (42.6%) in the R-CHOP arm had a clinically meaningful deterioration (i.e. ≥10 -point decrease) from baseline in physical functioning as of the CCOD. No difference in the risk of deterioration of physical functioning was observed between arms (stratified HR: 0.97 [95% CI: 0.79, 1.19]). The median time to clinically meaningful deterioration in physical functioning was not reached in the pola+R-CHP arm and was 25.5 months in the R-CHOP arm. Results of unstratified analysis was similar to the results of stratified analysis. Deterioration event-free rates in the pola+R-CHP arm and the R-CHOP arm were 57.0%, and 56.6%, respectively at 1 year and 54.9% and 53.3%, respectively at 2 years.

## - Fatigue

<div style=\"page-break-after: always\"></div>

Patients in the R-CHOP arm experienced clinically meaningful deterioration in fatigue

(i.e. ≥ 10 -point increase in fatigue scale from baseline) earlier (median TTD: 3.0 months) than patients in the pola+R-CHP arm (6.7 months). As of the CCOD, a total of 223 patients (50.7%) in the pola+R-CHP arm, and 230 patients (52.4%) in the R-CHOP arm had a clinically meaningful deterioration in fatigue scores (stratified HR: 0.94 [95% CI: 0.78, 1.13]). Results of unstratified analysis was similar to the results of stratified analysis. Deterioration event-free rates in the pola+R-CHP arm and the R-CHOP arm were 48.8%, and 44.1%, respectively at 1 year, and 45.2% and 41.8%, respectively at 2 years.

- Lymphoma symptoms

As of the CCOD, a total of 148 patients (33.6%) in the pola+R-CHP arm, and 138 patients (31.4%) in the R-CHOP arm had a clinically meaningful det erioration in lymphoma symptom (i.e. a ≥3 -point decrease from baseline).  No  difference  in  the  risk  of  deterioration  of  lymphoma  scores  was  observed  between  arms (stratified HR: 1.03 [0.81, 1.30]). Results of unstratified analyses was similar to the results of stratified analysis.

Medians were not reached in either arm. Deterioration event-free rates in the pola+R-CHP arm and the R-

CHOP arm were 66.4%, and 68.0%, respectively at 1 year, and 63.5% and 64.0%, respectively at 2 years.

- Fever

A total of 74 patients (16.8%) in the pola+R-CHP arm, and 73 patients (16.6%) in the R-CHOP arm had a clinically meaningful deterioration in fever score. No difference in the risk of deterioration of fever score was observed between arms (stratified HR: 0.94 [0.68, 1.30]). Results of unstratified analysis was similar to the results of stratified analysis. Medians were not achieved in either arm. Deterioration event-free rates in the pola+R-CHP arm and the R-CHOP arm were 84.1%, and 83.2%, respectively at 1 year, and 81.0% and 81.5%, respectively at 2 years.

- Weight loss

A total of 161 patients (36.6%) in the pola+R-CHP arm, and 161 patients (36.7%) in the R-CHOP arm had a clinically meaningful deterioration in weight loss score. No difference in the risk of deterioration of weight loss score was observed between arms (stratified HR: 0.97 [0.78, 1.20]). Results of unstratified analysis was similar to the results of stratified analysis. Medians were not achieved in either arm. Deterioration event-free rates in the pola+R-CHP arm and the R-CHOP arm were 60.8%, and 63.1%, respectively at 1 year, and 58.8% and 58.7%, respectively at 2 years.

- Night sweats

A total of 101 patients (23.0%) in the pola+R-CHP arm, and 119 patients (27.1%) in the R-CHOP arm had a clinically meaningful deterioration in night sweat score. Treatment with pola+R-CHP reduced the risk of deterioration of night sweat score by 22% compared to R-CHOP (stratified HR: 0.78 [0.60, 1.02]). Results of unstratified analysis was similar to the results of stratified analysis. Medians were not achieved in either arm, however KM plots separated approximately 4 months after randomization and the separation was maintained throughout the duration of follow-up. Deterioration event-free rates in the pola+R-CHP arm and the R-CHOP arm were 76.9%, and 74.2%, respectively at 1 year, and 74.8% and 68.9%, respectively at 2 years.

## Secondary Efficacy Endpoint: Treatment-Related Symptoms and Peripheral Neuropathy

EORTC QLQ-C30 treatment-related symptom and the FACT/GOG-Ntx peripheral neuropathy scores between treatment arms were compared using mixed effects model for repeated measures.

<div style=\"page-break-after: always\"></div>

## - Treatment-Related Symptoms

While on treatment, a small improvement in scores for constipation was observed in the pola + R-CHP arm compared to the R-CHOP arm (range of mean change from baseline: -4.9 to -7.6 vs. -1.1 to -5.3). A small increase in diarrhea scores in the pola + R-CHP arm compared to the R-CHOP arm was observed at Cycle 2 (mean change from baseline: 6.3 vs. -0.02), however subsequent scores improved (range of mean change from baseline: 1.2 to 1.6 vs. -0.6 to 0.1). Scores for nausea and vomiting were very low at baseline (mean [SE]: 8.4 [0.916] vs. 6.2 [0.722]), and no difference was observed while on treatment (range of mean change from baseline:  1.7  to  1.7  vs.  -0.1  to  1.2).  Any  increase  observed  was  reversed  by  treatment completion.

- Peripheral Neuropathy

Both arms showed low levels of peripheral neuropathy at baseline (baseline mean [SE]: 39.8 [0.221] vs. 39.5 [0.248]). The possible range for the scores is 0 -44 for this subscale, with higher scores representative of lower levels of peripheral neuropathy. Patients in the R-CHOP arm experienced increases in peripheral neuropathy earlier (Cycle 4; mean change from baseline: pola+R-CHP: -0.5 vs. R-CHOP: -1.5) than patients in the pola + R-CHP arm (Cycle 6; -2.0 vs. -2.9). In addition, timepoints subsequent Cycle 4 showed larger increases in peripheral neuropathy (i.e. larger decreases in the mean scores) for R-CHOP (range of mean change from baseline: -2.2 to -3.5) than for pola+R-CHP (-1.0 to -2.7) while on treatment.

## Ancillary analyses

## Biomarker Analyses

## Methods

The  cell-of-origin  (COO)  status  of  individual  patients  was  determined  by  the  Nanostring  Lymphoma Subtyping (LST) (Scott et al. 2014; Scott et al. 2015) assay using RNA extracted from baseline formalin fixed paraffin embedded (FFPE) tissue samples/slides performed centrally at Expression Analysis.

Baseline protein expression of BCL2 and MYC in tumor cells was assessed centrally by immunohistochemistry (IHC) assays at Ventana (ex-China) or Roche Oncology Biomarker Development (OBD) China lab (for patients enrolled in mainland China only) using the analytically validated BCL2 (124) mAB and MYC (Y69) IHC assays on the Ventana Benchmark XT platform. BCL2+ was defined as ≥50% tumor cells with moderate (IHC 2+) or strong (IHC 3+) staining intensity. MYC+was defined as ≥ 40% tumor nuclei with positive MYC staining at any intensity above background staining (Punnoose et al 2020; Morschhauser et al 2021).

Gene translocations involving BCL2, BCL6, and MYC (dual translocations in BCL2 or BCL6 and MYC [DHL]; or triple translocations in BCL2, BCL6 and MYC [THL]) defined specific DLBCL subgroups with particularly poor  outcomes  using  SoC  therapies.  In  POLARIX,  translocations  involving  these  three  genes  were determined using baseline FFPE tissue slides by florescent in-situ hybridization (FISH) assay performed centrally at Histogenix (ex-China) or KingMed (for patients enrolled in mainland China only).

The translocation status of individual genes was evaluated for at least 50 tumor nuclei within the tumor region as annotated by a pathologist on the HE reference slide.

<div style=\"page-break-after: always\"></div>

Negative cutoff values for individual FISH assay are determined by the vendors using tonsil samples from healthy donors. Given that BCL6 translocation mainly occurs concurrently with MYC translocation (Scott et al 2018), BCL6 FISH assay was performed only in patients with positive MYC translocation results (not performed in patients from mainland China).

## Results

Exploratory analyses of unstratified Investigator-assessed PFS in subgroups by baseline molecular DLBCL subtypes (by centrally tested COO, centrally tested IHC for BCL2 and MYC [DEL], and centrally tested FISH for rearrangements in MYC, BCL2, and BCL6 [DHL/THL]) were performed (Figure 8). Treatment with pola + RCHP resulted  in  numerically  higher  PFS  over  R-CHOP  among  patients  in  some  of  the  more  commonly represented high risk patient subgroups: · for the ABC-DLBCL subgroup, the 2-year investigator-assessed PFS rate was 83.9% in the pola + R-CHP arm vs. 58.8% in the R-CHOP arm (HR: 0.35 [95% CI: 0.21, 0.60]) · for the DEL subgroup, the 2-year investigator-assessed PFS rate was 75.5% in the pola + R-CHP arm vs. 63.1% in the R-CHOP arm (HR: 0.64 [95% CI: 0.42, 0.97]). The numbers of patients in the DH+/TH+ subgroup  (pola + R-CHP:  26  patients,  R-CHOP:  19  patients),  and  PFS  events  identified  in  the  DH/TH + subgroup are too small to make a meaningful assessment.

Figure 23: Forest Plot of Hazard Ratio of Investigator-Assessed PFS by Molecular DLBCL Subtypes (ITT Population)

<!-- image -->

|                                                                                   |                                                                                   |                                                                                   | R-CHOP (N=439)   | Pola+R-CHP (N=440)   | Pola+R-CHP (N=440)   |              |              |                   |               |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------|----------------------|----------------------|--------------|--------------|-------------------|---------------|
| Biomarker RiskFactors                                                             | Total n                                                                           |                                                                                   | n 2YearRate      |                      | n 2YearRate          | Hazard Ratio | 95% Wald CI  | Pola+R-CHP better | R-CHOP better |
| All Patients                                                                      | 879                                                                               | 439                                                                               | 70.20            | 440                  | 76.71                | 0.76         | (0.59, 0.98) |                   |               |
| Cellof Origin                                                                     |                                                                                   |                                                                                   |                  |                      |                      |              |              |                   |               |
| GCB                                                                               | 352                                                                               | 168                                                                               | 76.91            | 184                  | 75.14                | 1.02         | (0.68, 1.54) |                   |               |
| ABC                                                                               | 221                                                                               | 119                                                                               | 58.84            | 102                  | 068                  | 0.35         | (0.21,0.60)  |                   |               |
| Unclassified                                                                      | 95                                                                                | 51                                                                                | 86.23            | 44                   | 72.96                | 1.85         | (0.75, 4.52) |                   |               |
| Unknown                                                                           | 211                                                                               | 101                                                                               | 64.31            | 110                  | 73.75                | 0.72         | (0.44.1.20)  |                   |               |
| DoubleExpressor by IHC                                                            |                                                                                   |                                                                                   |                  |                      |                      |              |              |                   |               |
| DEL                                                                               | 290                                                                               | 151                                                                               | 63.05            | 139                  | 75.53                | 0.64         | (0.42,0.97)  |                   |               |
| Non DEL                                                                           | 438                                                                               | 215                                                                               | 75.68            | 223                  | 77.69                | 0.87         | (0.59.1.26)  |                   |               |
| Unknown                                                                           | 151                                                                               | 73                                                                                | 69.83            | B                    | 75.96                | 0.77         | (0.41,1.45)  |                   |               |
| Double Triple Hit Lymphoma                                                        |                                                                                   |                                                                                   |                  |                      |                      |              |              |                   |               |
| DH/TH+                                                                            | 45                                                                                | 19                                                                                | 88.89            | 26                   | 69.02                | 3.81         | (0.82.17.64) |                   |               |
| DH/TH-                                                                            | 620                                                                               | 315                                                                               | 70.28            | 305                  | 76.76                | 0.73         | (0.54,0.99)  |                   |               |
| Unknown                                                                           | 214                                                                               | 105                                                                               | 66.43            | 109                  | 78.45                | 0.63         | (0.37, 1.06) |                   |               |
|                                                                                   |                                                                                   |                                                                                   |                  |                      |                      |              | 1/100        | 1                 | 100           |
| Unstratified hazard ratio is displayed. CCOD:28JUN2021Data Extract Date:02AUG2021 | Unstratified hazard ratio is displayed. CCOD:28JUN2021Data Extract Date:02AUG2021 | Unstratified hazard ratio is displayed. CCOD:28JUN2021Data Extract Date:02AUG2021 |                  |                      |                      |              |              |                   |               |

The observed investigator-assessed progression free survival (PFS) hazard ratio was 0.48 [95% CI: 0.211.08] in patients with HGBL.

## Summary of main study(ies)

The  following  table  summarises  the  efficacy  results  from  the  main  studies  supporting  the  present

<div style=\"page-break-after: always\"></div>

application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 23: Summary of Efficacy for trial POLARIX

| Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.   | Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.   | Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.   | Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.        | Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.        | Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                     | Study GO39942 (POLARIX)                                                                                                                                                                                                                                                                              | Study GO39942 (POLARIX)                                                                                                                                                                                                                                                                              | Study GO39942 (POLARIX)                                                                                                                                                                                                                                                                                   | Study GO39942 (POLARIX)                                                                                                                                                                                                                                                                                   | Study GO39942 (POLARIX)                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                                               | Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma                                                      | Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma                                                      | Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma                                                           | Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma                                                           | Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma                                                      |
| Design                                                                                                                                                                                                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                       | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                       | 65 months after the first patient enrolled not applicable Chinese extension cohort (until a total of approximately 150 patients)                                                                                                                                                                          | 65 months after the first patient enrolled not applicable Chinese extension cohort (until a total of approximately 150 patients)                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                                    | group descriptor                                                                                                                                                                                                                                                                                     | group descriptor                                                                                                                                                                                                                                                                                     | pola+R-CHP (n=440): pola was administered by IV infusion at 1.8 mg/kg on Day 1 of each 21-day cycle for 6 cycles; R-CHP and placebo for vincristine was administered concurrently every 21 days for each 21-day cycle. Rituximab was administered as monotherapy in Cycle 7 and Cycle 8.                  | pola+R-CHP (n=440): pola was administered by IV infusion at 1.8 mg/kg on Day 1 of each 21-day cycle for 6 cycles; R-CHP and placebo for vincristine was administered concurrently every 21 days for each 21-day cycle. Rituximab was administered as monotherapy in Cycle 7 and Cycle 8.                  |                                                                                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                                                    | group descriptor                                                                                                                                                                                                                                                                                     | group descriptor                                                                                                                                                                                                                                                                                     | R-CHOP (n=439) was administered on Day 1 of each 21-day cycle for 6 cycles; placebo for pola was administered concurrently every 21 days for each 21-day cycle. Rituximab was administered as monotherapy in Cycle 7 and Cycle 8.                                                                         | R-CHOP (n=439) was administered on Day 1 of each 21-day cycle for 6 cycles; placebo for pola was administered concurrently every 21 days for each 21-day cycle. Rituximab was administered as monotherapy in Cycle 7 and Cycle 8.                                                                         |                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Primary endpoint                                                                                                                                                                                                                                                                                     | PFS                                                                                                                                                                                                                                                                                                  | Progression free survival, defined as the time from randomization to the first occurrence of disease progression or relapse as assessed by the investigator, using the Lugano Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurs earlier                                 | Progression free survival, defined as the time from randomization to the first occurrence of disease progression or relapse as assessed by the investigator, using the Lugano Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurs earlier                                 |                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Secondary                                                                                                                                                                                                                                                                                            | EFSeff                                                                                                                                                                                                                                                                                               | Investigator-Assessed Event-Free Survival for Efficacy Reasons, defined as the time from the date of randomization to the earliest occurrence of disease progression/relapse, death, biopsy that is positive for residual disease after treatment completion, or start of a NALT due to efficacy reasons. | Investigator-Assessed Event-Free Survival for Efficacy Reasons, defined as the time from the date of randomization to the earliest occurrence of disease progression/relapse, death, biopsy that is positive for residual disease after treatment completion, or start of a NALT due to efficacy reasons. |                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Secondary                                                                                                                                                                                                                                                                                            | CR rate at end of treatment                                                                                                                                                                                                                                                                          | BICR-Assessed Complete Response Rate at End of Treatment by PET-CT                                                                                                                                                                                                                                        | BICR-Assessed Complete Response Rate at End of Treatment by PET-CT                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Secondary                                                                                                                                                                                                                                                                                            | OS                                                                                                                                                                                                                                                                                                   | Overall Survival                                                                                                                                                                                                                                                                                          | Overall Survival                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                      |
| Database lock 28 June 2021                                                                                                                                                                                                                                                                           | Database lock 28 June 2021                                                                                                                                                                                                                                                                           | Database lock 28 June 2021                                                                                                                                                                                                                                                                           | Database lock 28 June 2021                                                                                                                                                                                                                                                                                | Database lock 28 June 2021                                                                                                                                                                                                                                                                                | Database lock 28 June 2021                                                                                                                                                                                                                                                                           |
| Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                 |
| Analysis description                                                                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                     | Primary Analysis                                                                                                                                                                                                                                                                                     | Primary Analysis                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                     |
| Analysis population and time point description                                                                                                                                                                                                                                                       | Intent to treat                                                                                                                                                                                                                                                                                      | Intent to treat                                                                                                                                                                                                                                                                                      | Intent to treat                                                                                                                                                                                                                                                                                           | Intent to treat                                                                                                                                                                                                                                                                                           | Intent to treat                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                      | Treatment group                                                                                                                                                                                                                                                                                      | R-CHOP                                                                                                                                                                                                                                                                                               | R-CHOP                                                                                                                                                                                                                                                                                                    | Pola +R-CHP                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                      | Number of patients                                                                                                                                                                                                                                                                                   | 440                                                                                                                                                                                                                                                                                                  | 440                                                                                                                                                                                                                                                                                                       | 439                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                | PFS Number of patients with event (%)    | 134 (30.5%)                 | 107 (24.3%)           |
|--------------------------------|------------------------------------------|-----------------------------|-----------------------|
|                                | EFSeff Number of patients with event (%) | 138 (31.4%)                 | 112 (25.5%)           |
|                                | CR rate at end of treatment 95% CI       | 74% (69.66, 78.07)          | 78% (73.79, 81.74)    |
|                                | OS Number of death (%)                   | 57 (13.0%)                  | 53 (12.0%)            |
| Effect estimate per comparison | PFS                                      | Comparison groups           | Pola+R-CHP vs. R-CHOP |
| Effect estimate per comparison | PFS                                      | Stratified HR               | 0.73                  |
| Effect estimate per comparison | PFS                                      | 95% CI                      | 0.57, 0.95            |
| Effect estimate per comparison | PFS                                      | P-value                     | 0.0177                |
| Effect estimate per comparison | EFSeff                                   | Comparison groups           | Pola+R-CHP vs. R-CHOP |
| Effect estimate per comparison | EFSeff                                   | Stratified HR               | 0.75                  |
| Effect estimate per comparison | EFSeff                                   | 95% CI                      | 0.58, 0.96            |
| Effect estimate per comparison | EFSeff                                   | P-value                     | 0.0244                |
| Effect estimate per comparison | CR rate at EOT                           | Comparison groups           | Pola+R-CHP vs. R-CHOP |
| Effect estimate per comparison | CR rate at EOT                           | Difference in response rate | 3.92                  |
| Effect estimate per comparison | CR rate at EOT                           | variability statistic       | -1.89, 9.70           |
| Effect estimate per comparison | CR rate at EOT                           | P-value                     | 0.1557                |
| Effect estimate per comparison | OS                                       | Comparison groups           | Pola+R-CHP vs. R-CHOP |
| Effect estimate per comparison | OS                                       | Stratified HR               | 0.94                  |
| Effect estimate per comparison | OS                                       | 95% CI                      | 0.65, 1.37            |
| Effect estimate per comparison | OS                                       | P-value                     | 0.6720                |
| Notes                          | none                                     | none                        | none                  |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The  pivotal  study  (Study  GO39942:  POLARIX)  is  a  phase  III,  multicenter,  randomized,  double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with RCHP versus R-CHOP in previously untreated patients with diffuse large B-cell lymphoma.

Inclusion  and  exclusion  criteria  are  acceptable  and  are  in  accordance  with  the  claimed  indication.  The inclusion  of  IPI  2-5  allows  to  include  higher  risk  populations  who  historically  had  poor  outcomes  with standard-of-care therapy, and also reflects the patient population included in the early GO29044 trial. Stratification factors (IPi score, bulky disease, geographical region) are deemed appropriate.

Patients  received  six  cycles  of  either  pola+R-CHP  (and  vincristine  placebo)  or  standard  R-CHOP chemotherapy  (and  polatuzumab  vedotin  placebo)  at  21-day  intervals.  Both  arms  then  received  two additional  cycles  of  single  agent  rituximab.  The  approach  to  withdraw  vincristine  from  the  pola-based regimen is acknowledged in order to exclude a risk of cumulative neurotoxicity. The polatuzumab vedotin

<div style=\"page-break-after: always\"></div>

dose of 1.8 mg/kg given every 21 days in combination with R/G-CHP for 6 or 8 cycles was determined in the dose-finding study (Study GO29044) which is acceptable.

This design is acceptable as R-CHOP remains the standard of care therapy in previously untreated DLBCL. While R-CHOP may cure approximately 60% of patients with previously untreated DLBCL (Sehn and Salles 2021), alternative strategies have so far been unable to demonstrate meaningful benefit over R-CHOP. These  include:  increased  dose  density  with  R-CHOP  given  at  14  day  intervals  (Delarue  et  al  2013; Cunningham et al. 2013); dose intensification with dose-adjusted etoposide plus prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R), Bartlett et al 2019; substitution strategies such as the novel anti-CD20 monoclonal antibody obinutuzumab (Votolo et al 2017).

The  efficacy  analysis  set,  multiplicity  adjustment  procedure  and  statistical  methods  are  generally acceptable.

The primary endpoint is the PFS, defined as the time from randomization to the first occurrence of disease progression or relapse as assessed by the investigator, using the Lugano Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurs earlier. The PFS primary censoring rules follow the recommendations of the EMA guideline, with a set of sensitivity analyses to assess the potential impact of missing assessments or use of new anti-lymphoma therapy. It was agreed in the 2017 SA that a blinded independent central review of PFS was not required based on the study design.

Key secondary endpoints were included in the hierarchical testing procedure: EFSeff as determined by the investigator, CR rate at end of treatment by FDGPET as determined by BICR and OS.

Several important changes were made to the planned analyses, mostly as part of protocol amendments 5 and 6, including modifications to the hierarchical testing strategy and timing of the primary analysis. It is noted that the actual number of PFS events observed according to the updated rule is, in the end, relatively close to the original plan. For this reason, and given the double-blind nature of the study, these updates to planned analyses are not thought to have major impact on the overall interpretation of the study results. The difference in EFS only reached statistical significance because CR rate at end of treatment by PET-CT as determined by BICR was shifted to a lower position in hierarchy. This adds some uncertainty on the hypotheses and the confirmatory interpretation of EFS. However, since there is currently no reason to assume that the blind was compromised, this uncertainty is small.

Major protocol deviations were reported under the following four categories: inclusion criteria, exclusion criteria, procedural and medication. Number of major protocol deviations were low and balanced in both arms (29 in pola + R-CHP arm and 26 in R-CHOP arm). This should not impact efficacy data.

## Efficacy data and additional analyses

A total of 879 patients were included in the intent-to-treat (ITT) population, 440 in pola+R-CHP arm and 439 in R-CHOP arm. Treatment arms were generally well-balanced with respect to demographic (age, sex, race, height, weight, geographic region) and baseline characteristics (ECOG performance status, Ann Arbor stage, IPI Score, presence of Bulky disease or not, bone marrow involvement, number of extranodal sites and NHL histologic diagnosis).

<div style=\"page-break-after: always\"></div>

For both regimens, treatment exposure remained high. A high proportion of patients (91.7% receiving pola as  part  of  the  pola+RCHP  regimen  and  88.5%  receiving  vincristine  as  part  of  the  R-CHOP  regimen) completed the planned 6 cycles of study treatment. Approximately 90% of patients in each treatment arm received 6 cycles of CHP treatment.

At the CCOD, the median duration of PFS follow-up was 24.7 months in both arms with a minimum of 24 months from study enrolment in both arms. A statistically significant improvement in the primary endpoint of Investigator-assessed PFS is observed following treatment with pola+R-CHP compared to R-CHOP. A reduction in the risk of progression/relapse or death by 27% is observed in patients treated in pola+R-CHP arm (stratified HR: 0.73 [95% CI: 0.57, 0.95]; two-sided log-rank p-value=0.0177, twosided α=0.05). Fewer patients in the pola+R-CHP arm had progressed or died compared to the R-CHOP arm (107 [24.3%] vs.134 [30.5%]).

Low maturity of PFS is reflected in relevant subgroups. Point estimates raise concern that there may be no benefit over R-CHOP in patients with IPI 2 as well as patients with bulky disease. It is currently unclear from the submitted data whether there were too few events in these patients to observe a treatment effect (confidence intervals are admittedly rather wide); of note IPI score and bulky disease were stratification factors. The study, however, is not powered to independently show effects in subgroups. Moreover, the substitution setting must be considered; there is a benefit of vincristine compared to which polatuzumab is overall superior. These analyses are neither type 1 error controlled nor powered for independent inferences; moreover there are no truly worrying outlying observations.

Results  of  all  sensitivity  analyses  were  consistent  with  results  of  the  primary  analysis  of  Investigatorassessed PFS in the ITT population. Of note, in some of these analyses, the significance threshold is crossed. These results confirm the slight improvement of PFS observed in the primary analysis.

Further, with a median of two years follow up, curves remain separated. The follow-up time of at least 24 months is considered sufficient as most relapses occur within the first 12-18 months. Patients with DLBCL without relapse at 24 months is considered to have a relapse risk of 8% and a survival similar to the normal population (Maurer et al. 2014).

Regarding the key secondary efficacy endpoints: EFSeff, a significant reduction in the risk of occurrence of disease by 25% was observed in patients treated in pola+R-CHP arm compared in patients treated in RCHOP arm (stratified HR: 0.75 [95% CI: 0.58, 0.96]). Only a difference of 26 events was observed between both arms (2 due to death, 20 due to disease progression and 4 due to start of a NALT or a positive biopsy).

BICR-assessed CR rate was high (78.0% [95%CI: 73.79, 81.74] vs. 74.0% [95% CI: 69.66, 78.07]) but similar in both arms (treatment difference: 3.92 [95% CI: -1.89, 9.70]). In addition, concordance between BICR and Investigator assessments of CR was high (88.7%).

Notably, this is a curative setting. As stated in the introduction, 'R-CHOP may cure approximately 60% of patients with previously untreated DLBCL'. Moreover, the test regimen is a substitution of polatuzumab for vincristine. The treatment duration of test versus reference is limited to 6 cycles of 21 days, which is 18 weeks.

The OS results provided in this report come from the interim OS analysis performed at the time of the PFS analysis (stratified HR: 0.94 [95% CI: 0.65, 1.37]). The immaturity of OS data is expected to be a limitation to the interpretation of efficacy results. More generally, the study lacks power for OS, even for the final

<div style=\"page-break-after: always\"></div>

analysis. This issue was discussed with the Applicant at the time of the 2017 scientific advice. It is noted that a total of 53 deaths (12.0% patients) were reported in the pola+R-CHP arm, and 57 deaths (13.0% patients)  were  reported  in  the  R-CHOP  arm.  With very  few  events  in  both arms,  OS  results  were  still immature at the time of the interim analysis of OS and did not meet the pre-specified threshold for statistical significance (stratified HR: 0.94 [95% CI: 0.65, 1.37])'. Finally, a 60% cure rate is anticipated in the control arm. Therefore, duration of follow-up rather than 'maturity' of OS seems to be the key parameter here.

Follow-up anti-lymphoma treatments have been provided by the MAH. The number of patients each receiving radiotherapy, systemic therapy, chimeric antigen receptors cell therapy (CAR-T) were slighlty higher in the R-CHOP arm compared to the pola+R-CHP arm. It is interesting to note that in the pola+RCHP arm, 3.9% of patients received stem cell transplants (n=30), compared with 7.1% in the R-CHOP arm (n=17). Also, in the pola+R-CHP arm 2.0% of patients received CAR-T (n=16), compared with 3.6% (n=9) in the R-CHOP arm.

Patient-reported outcomes analysis showed that impacts of pola+R-CHP and R-CHOP regimens on improvement in physical functioning, fatigue, lymphoma symptoms were similar. Also, no improvement in treatment-related symptoms and peripheral neuropathy were observed between both regimens.

Finally, for the HGBCL subgroup (N=93) the HR was 0.48 (0.21,1.08). Although HGBCL is a separate disease entity according to the WHO classification of 2016, a specific mention of HGBCL in the indication required extrapolation of efficacy and B/R from a DLBCL- to a HGBL population; these considerations were not possible on the current data. The initial indication as proposed by the MAH:  ' Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL)' is acceptable by the CHMP.

The recommended dose of Polivy is 1.8 mg/kg, given as an intravenous infusion every 21 days in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for 6 cycles. Polivy, rituximab, cyclophosphamide and doxorubicin can be administered in any order on Day 1 after the administration of prednisone. Prednisone is administered on Days 1-5 of each cycle. Cycles 7 and 8 consist of rituximab as monotherapy.

Per current Polivy SmPC Annex II.E, provision of efficacy and safety data by Q4 2021 is the last remaining specific obligation (SOB-CLIN-003) to the CMA of Polivy for the treatment of patients with relapsed/refractory DLBCL who are not candidates for haematopoietic stem cell transplant. The MAH believes that with the submission of this Type II variation, all specific obligations related to the conditional marketing authorization (CMA) are fulfilled. As a result, the MAH is requesting a full marketing authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 (marketing authorisation not subject to specific obligations).

Interim OS results are still immature and could be considered as not sufficiently robust.  However, OS interim results do not indicate detrimental effect of polatuzumab vedotin. The pivotal POLARIX study met its primary endpoint PFS and no meaningful differences in safety risks have been retrieved. Therefore, efficacy and safety data provided from untreated patients could be considered as confirmatory safety and efficacy data for treatment of patients with relapsed/refractory DLCBL. Therefore, obligations related to CMA are considered fulfilled.

The MAH have presented data based on a double blinded RCT where efficacy and safety of the substitution of vincristine with polatuzumab in the well-established 1L regimen R-CHOP have been assessed for 1L DLBCL. The study is statistically positive by acceptable standards. The MAH will provide the final OS results by Q4 2022 as a post approval measure.  This is acceptable in order to obtain more long-term efficacy and safety data in this first line indication (see RMP). The CHMP also requested data

<div style=\"page-break-after: always\"></div>

from an additional Chinese cohort. The MAH has requested approval for providing and opening access to Chinese Human Genetic Resources abroad from the Human Genetics Resources Administration of China (HGRAC) and would be able to provide the data from China extension cohort, in the form of Asia subpopulation CSR, if granted by HGRAC.

## 2.4.4. Conclusions on the clinical efficacy

A statistically significant improvement in the primary endpoint of Investigator-assessed PFS is observed following treatment with pola+R-CHP compared to R-CHOP. A reduction in the risk of progression/relapse or death by 27% is observed in patients treated in pola+R-CHP arm (HR: 0.73 [95% CI: 0.57, 0.95]. Results of secondary and sensitivity analyses were consistent with results of the primary analysis.

The PFS gain is sufficient to establish the efficacy and positive B/R of polatuzumab as substitute for vincristine. Further, as outlined above, given that treatment was 4-5 months and median time of followup is more than two years, it does not seem reasonable to anticipate any emerging detriment in OS of polatuzumab when substituted for vincristine.

Obligations related to CMA are considered fulfilled. The updated CSR at the time of final overall survival analysis containing final OS data -is expected to be submitted (see RMP).

Further, following the recommendation of the CHMP, the Applicant will submit the data from the China extension cohort of Study GO39942 (POLARIX) that are analyzed within an Asia subpopulation analysis and are reported in an Asia subpopulation CSR that includes all Chinese patients enrolled in the China extension and in the main global study, as well as patients from other Asian countries who were enrolled in the main global study Polarix.

## 2.5. Clinical safety

## Introduction

As of 31 August 2021, polatuzumab in combination with bendamustine and rituximab (BR) is approved for the treatment of relapsed/refractory (R/R) DLBCL in &gt;65 countries/regions including the European Union (EU) and United States (US).

The claimed indication in this application is in the first-line DLBCL setting for pola in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). Safety data for pola 1.8 mg/kg in combination with R-CHP in patients with previously untreated DLBCL is based on the pivotal study POLARIX. At the time of the primary analysis (CCOD: 28 June 2021), the safety-evaluable population comprised of 873 patients who received at least one dose of study treatment with 435 patients in the pola+R-CHP arm and 438 patients in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) arm.

Additional supportive data are presented from a cohort of patients with previously untreated DLBCL (n=66) who received pola 1.8 mg/kg in combination with R-CHP (n=45) or G-CHP (n=21) in the GO29044 study.

The pooled population comprised all patients from POLARIX and GO29044 with previously untreated DLBCL receiving pola 1.8 mg/kg in combination with R-CHP/G-CHP (n=501).

<div style=\"page-break-after: always\"></div>

Table 24. Summary of Studies Contributing to Safety Evaluation

<!-- image -->

| Study Number                 | Overall Design                                                       | PatientPopulation                                                                                                           | DoseandSchedule                                                                                                                                                                                                                                                      | Number of Patients (Safety AnalysisPopulation)                                                                                                                                                                                                | Cutoff Date                  | Study Endpoints                                                              |
|------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------------|
| PivotalPhase IlI Study       | PivotalPhase IlI Study                                               | PivotalPhase IlI Study                                                                                                      | PivotalPhase IlI Study                                                                                                                                                                                                                                               | PivotalPhase IlI Study                                                                                                                                                                                                                        | PivotalPhase IlI Study       | PivotalPhase IlI Study                                                       |
| POLARIX (GO39942)            | Phase Ill, randomized, multicenter, double-blind, placebo-controlled | untreated patients Previously with CD20-positive DLBCL                                                                      | Pola 1.8 mg/kg+vincristine placebo+R-CHP q21 days x6 cycles Pola placebo+R-CHOP q 21 days x6 cycles Rituximab 375 mg/m2 as monotherapy in Cycles7 and 8inboth arms All study treatments given IV except forprednisone,whichwasgivenorally                            | Pola 1.8 mg/kg+R-CHP: N=435 Total 1LDLBCL:N=873 R-CHOP: N=438                                                                                                                                                                                 | 28 June 2021                 | tolerability, Safety, anti-tumor activity                                    |
| SupportivePhase Ilb/ll Study | SupportivePhase Ilb/ll Study                                         | SupportivePhase Ilb/ll Study                                                                                                | SupportivePhase Ilb/ll Study                                                                                                                                                                                                                                         | SupportivePhase Ilb/ll Study                                                                                                                                                                                                                  | SupportivePhase Ilb/ll Study | SupportivePhase Ilb/ll Study                                                 |
| GO29044                      | Phase Ilb/ll, open-label, multicenter, single-arm (Pola+R/G-CHP)     | Dose escalation: newly diagnosed or R/R B-cell NHL systemic therapy) (≤1 prior line of Expansion: Previously untreatedDLBCL | Pola 1.0-1.8 mg/kg + R-CHP q 21 days x 6-8 cycles q 21 days x 6-8 cycles Pola 1.4-1.8 mg/kg + G-CHP Pola 1.8 mg/kg + R-CHP q21 days x 6-8 cycles Pola 1.8 mg/kg + G-CHP q21 days x6-8 cycles All study treatments given IV except forprednisone,whichwasgiven orally | Other B-cell NHL a Pola 1.8 mg/kg+R-CHP: N=1 Pola 1.8 mg/kg+G-CHP: N=2 Pola 1.4 mg/kg+G-CHP: N=2 Pola 1.0 mg/kg+R-CHP: N=1 DLBCL b Pola 1.8 mg/kg+R-CHP: N=45 Pola1.8mg/kg+G-CHP:N=21 Pola 1.0-1.4 mg/kg+R-CHP: N=5 Pola 1.4 mg/kg+G-CHP: N=4 | 28 March 2019                | Phlb: MTD of combination pola in with chemotherapy Phll: Safety and efficacy |

CHP=cyclophosphamide, doxorubicin, and prednisone; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; DLBCL=difuse large B-cell lymphoma;

G=obinutuzumab; MTD=maximum tolerated dose; NHL=non-Hodgkin's lymphoma; Pola=polatuzumab vedotin; q=every; R=rituximab; R/R=relapsed or refractory.

a One additional patient received pola at 2.4 mg/kg instead of the protocol-defined 1.8 mg/kg due to a medication error.

b Only data in 66 patients with previously untreated DLBCL who received pola 1.8 mg/kg+R-CHP (n=45) or pola 1.8 mg/kg+G-CHP (n=21) are presented in this SCS

## Patient exposure

## Study POLARIX

After initiation of study drug, all AEs regardless of relationship to study drug were reported until 90 days after the last dose of study drug, unless the patient begins a new anti-lymphoma therapy (NALT). This was defined as the treatment-emergent AE interval. All adverse events of special interest considered related to study drug by the investigator were reported until 12 months after the last dose of study drug.

The median Relative Dose Intensity (RDI) was &gt;99.8% for all components of treatment in each arm. There was 93.6% (407/435) of patients in the pola+R-CHP arm and 90.6% (397/438) of patients the R-CHOP arm receiving at least 6 cycles of any study drug; 89.2% of patients in the pola+R-CHP arm and 86.3% of patients in the R-CHOP arm received 8 cycles of rituximab. A higher number of patients received all six planned doses of pola in the pola+R-CHP arm (91.7% among patients who received any dose of pola [n=435]) compared to the number of patients who received all six planned doses of vincristine in the RCHOP arm (88.5% among patients who received any dose of vincristine [n=436]).

Patients in the pola+R-CHP arm received a median of 6 cycles of pola (range 1-6), corresponding to a median treatment duration of 3.5 months. Mean (SD) cumulative dose of pola received by patients in the pola+R-CHP arm was 774.5 mg (228.9 mg).

Patients in the R-CHOP arm received a median of 6 cycles of vincristine (range 1-6), corresponding to a median treatment duration of 3.5 months . Mean (SD) cumulative dose of vincristine received by patients in the R-CHOP arm was 11.2 mg (2.1 mg).

<div style=\"page-break-after: always\"></div>

Patients in both the pola+R-CHP and R-CHOP arms also received a median of 8 cycles of rituximab (range 1-8). This corresponds to a median treatment duration of 4.9 months in both treatment arms . A total of 89.2% of patients in the pola+R-CHP arm and 86.3% of patients in the R-CHOP arm completed 8 cycles of rituximab.

Table 25. Summary of Study Drug Exposure (SE Population, POLARIX)

<!-- image -->

|                             | R-CHOP (N-438)              | R-CHOP (N-438)              | R-CHOP (N-438)              | R-CHOP (N-438)              | R-CHOP (N-438)              | Pola+R-CHP (N-435)          | Pola+R-CHP (N-435)          | Pola+R-CHP (N-435)          | Pola+R-CHP (N-435)          | Pola+R-CHP (N-435)          |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | RTX                         | CYC                         | DOX                         | VIN                         | PRED                        | Pola                        | RTX                         | CYC                         | DOX                         | PRED                        |
| Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) | Treatment Duration (months) |
| n                           | 438                         | 436                         | 436                         | 436                         | 438                         | 435                         | 435                         | 435                         | 435                         | 435                         |
| Mean (SD)                   | 4.6 (1.2)                   | 3.4 (0.7)                   | 3.4 (0.7)                   | 3.4 (0.7)                   | 3.5 (0.7)                   | 3.4 (0.6)                   | 4.7 (0.9)                   | 3.5 (0.6)                   | 3.5 (0.6)                   | 3.6 (0.6)                   |
| Median                      | 4.9                         | 3.5                         | 3.5                         | 3.5                         | 3.6                         | 3.5                         | 4.9                         | 3.5                         | 3.5                         | 3.6                         |
| Min-Max                     | 0- 11                       | 0-8                         | 0-8                         | 0-8                         | 0-6                         | 0-5                         | 0-8                         | 0-5                         | 0-5                         | 0-5                         |
| Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            | Number of cycles            |
| n                           | 438                         | 436                         | 436                         | 436                         | 438                         | 435                         | 435                         | 435                         | 435                         | 435                         |
| Mean (SD)                   | 7.4 (1.6)                   | 5.7 (1.0)                   | 5.7 (1.0)                   | 5.7 (1.0)                   | 5.7 (1.0)                   | 5.8 (0.8)                   | 7.6 (1.3)                   | 5.8 (0.8)                   | 5.8 (0.8)                   | 5.8 (0.8)                   |
| Median                      | 8.0                         | 6.0                         | 6.0                         | 6.0                         | 6.0                         | 6.0                         | 8.0                         | 6.0                         | 6.0                         | 6.0                         |
| Min-Max                     | 1-8                         | 1-6                         | 1 -6                        | 1 -6                        | 1 -6                        | 1 -6                        | 1-8                         | 1 -6                        | 1 -6                        | 1 -6                        |
| 1-5                         | 42 (9.6%)                   | 39 (8.9%)                   | 39 (8.9%6)                  | 50 (11.5%)                  | 45 (10.3%6)                 | 36 (8.3%)                   | 31 (7.1%)                   | 29 (6.7%)                   | 29 (6.796)                  | 29 (6.7%)                   |
| 6                           | 14 (3.2%)                   | 397 (91.19)                 | 397 (91.1%)                 | 386 (88.5%)                 | 393 (89.7%6)                | 399 (91.7%)                 | 7 (1.6%)                    | 406 (93.3%)                 | 406 (93.3%)                 | 406 (93.3%)                 |
| 7                           | 4 (0.9%)                    |                             |                             |                             |                             |                             | 9 (2.1%)                    |                             |                             |                             |
| 8                           | 378 (86.3%)                 |                             |                             |                             |                             |                             | 388 (89.2%)                 |                             |                             |                             |
| Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) | Relative Dose Intensity (%) |
| n                           | 435                         | 433                         | 433                         | 436                         | 438                         | 432                         | 431                         | 431                         | 431                         | 435                         |
| Mean (SD)                   | 99.1 (2.7)                  | 98.6 (3.9)                  | 98.7 (4.1)                  | 98.5 (5.0)                  | 98.4 (8.3)                  | 98.1 (5.2)                  | 99.0 (3.3)                  | 98.5 (3.9)                  | 98.5 (4.0)                  | 98.4 (7.7)                  |
| Median                      | 100.0                       | 100.0                       | 100.0                       | 100.0                       | 100.0                       | 99.8                        | 100.0                       | 100.0                       | 100.0                       | 100.0                       |
| Min-Max                     | 84 - 108                    | 65-109                      | 64 - 109                    | 63-103                      | 20 - 123                    | 64 - 111                    | 64 - 116                    | 64 - 106                    | 65 - 106                    | 26 - 127                    |
| Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  | Total cumulative dose (mg)  |
| n                           | 438                         | 436                         | 436                         | 436                         | 438                         | 435                         | 435                         | 435                         | 435                         | 435                         |
| Mean (SD)                   | 5128.1                      | 7864.6                      | 524.7                       | 11.2                        | 2817.4                      | 774.5                       | 5247.3                      | 7983.6                      | 532.4                       | 2864.6                      |
|                             | (1284.7)                    | (1717.9)                    | (115.2)                     | (2.1)                       | (539.2)                     | (228.9)                     | (1141.1)                    | (1544.1)                    | (103.0)                     | (447.7)                     |
| Median                      | 5329.0                      | 8042.1                      | 540.0                       | 12.0                        | 3000.0                      | 762.0                       | 5380.0                      | 8150.0                      | 540.0                       | 3000.0                      |
| Min-Max                     | 570-9452                    | 750- 14185                  | 66 - 948                    | 2-12                        | 100-3700                    | 102-2125                    | 600-9318                    | 1200-14198                  | 80-947                      | 500-3800                    |

Source: t\\_ex\\_SE\\_28JUN2021\\_39942

CYC=cyclophosphamide; DOX-doxorubicin; Pola-Polatuzumab vedotin; PRED=prednisone; RTX-rituximab; VIN-vincristine.

## Supportive study GO29044

After initiation of study drug, all AEs regardless of relationship to study drug were reported until 90 days after the last dose of study drug. After this period, investigators reported any SAEs or deaths believed to be related to prior study drug treatment. Second malignancies were reported indefinitely for patients who received obinutuzumab, regardless of relationship to study treatment.

Median RDI was &gt;99.8% for all treatment components. Patients received pola in combination with R-CHP or G-CHP over a median period of 3.5 months (range: 0-6 months). The median number of cycles received was 6.0 (range: 1-8), and the mean (SD) cumulative dose was 857.8 (252.8) mg.

- R-CHP Treatment Regimen - DLBCL

Patients received polatuzumab vedotin over a median period of 3.49 months (range: 0.7-5.5 months). The median number of cycles received was 6.0 (range: 2.0-8.0), and the total cumulative dose was 864.00 mg (range: 212.0-1344.0 mg). The median missed doses were 0.0 doses (range: 0-1 doses).

Patients received rituximab over a median period of 3.50 months (range: 0.7-5.6 months). The median number of cycles received was 6.0 (range: 2.0-8.0). The total cumulative dose was 4625.00 mg (range: 1170.0-5920.0 mg). The median missed doses were 0.0 doses (range: 0-1 doses).

Patients received cyclophosphamide and doxorubicin over a median period of 3.51 months (range: 0.7-5.6 months). The median number of cycles received was 6.0 (range: 2.0-8.0). The total cumulative dose was 9270.00 mg (range: 2340.0-11800.0 mg) and 618.00 mg (range: 156.0-792.0 mg) for cyclophosphamide and  doxorubicin,  respectively.  The  median  missed  doses  were  0.0  doses  (range:  0-1  doses)  for  both cyclophosphamide and doxorubicin.

<div style=\"page-break-after: always\"></div>

Patients received prednisone over a median period of 3.66 months (range: 0.9-5.7 months). The median number of cycles received for both drug was 6.0 (range: 2.0-8.0). The median total cumulative dose was 3000.00 mg (range: 1000.0-4000.0 mg). The median missed doses were 0.0 doses (range: 0-1 doses).

## · G-CHP Treatment Regimen - DLBCL

Patients received polatuzumab vedotin over a median period of 3.43 months (range: 0.0-5.0 months). The median number of cycles received was 6.0 (range: 1.0-8.0), and the total cumulative dose was 828.00 mg (range: 126.0-1375.2 mg). There were no missed doses for polatuzumab vedotin.

Patients received obinutuzumab over a median period of 3.46 months (range: 0.7-5.1 months). The median number of cycles received was 6.0 (range: 1.0-8.0). The total cumulative dose was 8000.00 mg (range: 3000.0-10000.0 mg). The median missed doses were 0.0 doses (range: 0-1 doses).

Patients received cyclophosphamide and doxorubicin over a median period of 3.45 months (range: 0.0-5.1 months). The median number of cycles received was 6.0 (range: 1.0-8.0). The total cumulative dose was 8865.00 mg (range: 1329.0-11864.0 mg) and 576.00 mg (range: 89.0-792.0 mg) for cyclophosphamide and doxorubicin, respectively. There were no missed doses for both cyclophosphamide and doxorubicin.

Patients received prednisone over a median period of 3.61 months (range: 0.2-5.3 months). The median number of cycles received was 6.0 (range: 1.0-8.0). The total cumulative dose was 3000.00 mg (range: 500.0- 4000.0 mg). There were no missed doses for prednisone.

<div style=\"page-break-after: always\"></div>

## Pooled safety population

Relative dose intensity was high with a median RDI of &gt;99.8% for all components of study treatment.

Patients received a median of 6.0 cycles of pola (range 1-8), corresponding to a median treatment duration of 3.5 months (Table 5). Mean (SD) cumulative dose of pola received by patients in the pooled safety population was 785.5 mg (233.6 mg).

Patients in the pooled safety population received a median of 8.0 cycles of rituximab (range 1-8) or 6.0 cycles of obinutuzumab (range 1-8). This corresponds to a median treatment duration of 4.9 months for rituximab and 3.5 months for obinutuzumab.

The median number of cycles of exposure to CHP (cyclophosphamide, doxorubicin, and prednisone) in the pooled  safety  population  was  6.0  (range  1  -  8),  corresponding  to  a  median  of  3.5  to  3.6  months  of treatment.

Table 26. Extent of Exposure to Study Treatment, Safety-Evaluable Patients

<!-- image -->

| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000                                                                                                                                                                                                                                             | An agency of the European Union                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000                                                                                                                                                                                                                                             | An agency of the European Union                                 |
| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000                                                                                                                                                                                                                                             | An agency of the European Union                                 |
| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000                                                                                                                                                                                                                                             | An agency of the European Union                                 |
| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000                                                                                                                                                                                                                                             | An agency of the European Union                                 |
| Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 | An agency of the European Union An agency of the European Union |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                  | R-CHOP (POLARIX) N=438                    | R-CHOP (POLARIX) N=438          | Pola+R-CHP (POLARIX) N=435                | Pola+R-CHP (POLARIX) N=435      | Pola (1.8 mg/kg) + R-CHP/G-CHP (G029044) N=66   | Pola (1.8 mg/kg) + R-CHP/G-CHP (G029044) N=66   | All Pola (1.8 mg/kg) + R-CHP/G-CHP (POLARIX+GO29044) N=501   | All Pola (1.8 mg/kg) + R-CHP/G-CHP (POLARIX+GO29044) N=501   |
|------------------|-------------------------------------------|---------------------------------|-------------------------------------------|---------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Treatment        | Median treatment duration, months (range) | Median number of cycles (range) | Median treatment duration, months (range) | Median number of cycles (range) | Median treatment duration, months (range)       | Median number of cycles (abue)                  | Median treatment duration, months (range)                    | Median number of cycles (range)                              |
| Pola             |                                           |                                 | 3.5(0 -5)                                 | 6.0 (1-6)                       | 3.5 (0 -6)                                      | 6.0 (1-8)                                       | 3.5 (0 -6)                                                   | 6.0 (1-8)                                                    |
| Vincristine      | 3.5 (0-8)                                 | 6.0 (1-6)                       |                                           |                                 |                                                 |                                                 |                                                              |                                                              |
| Rituximab        | 4.9 (0 - 11)                              | 8.0 (1-8)                       | 4.9 (0-8)                                 | 8.0 (1-8)                       | 3.6 (1-6)                                       | 6.0 (2-8)                                       | 4.9 (0-8)                                                    | 8.0 (1-8)                                                    |
| Obinutuzumab     |                                           |                                 |                                           |                                 | 3.5 (1 - 5)                                     | 6.0 (1-8)                                       | 3.5 (1 - 5)                                                  | 6.0 (1-8)                                                    |
| Cyclophosphamide | 3.5 (0-8)                                 | 6.0 (1-6)                       | 3.5 (0 -5)                                | 6.0 (1-6)                       | 3.5 (0-6)                                       | 6.0 (1-8)                                       | 3.5 (0 -6)                                                   | 6.0 (1-8)                                                    |
| Doxorubicin      | 3.5 (0-8)                                 | 6.0 (1-6)                       | 3.5(0 -5)                                 | 6.0 (1-6)                       | 3.5 (0 -6)                                      | 6.0 (1-8)                                       | 3.5(0-6)                                                     | 6.0(1-8)                                                     |
| Prednisone       | 3.6 (0 -6)                                | 6.0(1-6)                        | 3.6 (0 -5)                                | 6.0 (1-6)                       | 3.6 (0 -6)                                      | 6.0 (1-8)                                       | 3.6 (0-6)                                                    | 6.0(1-8)                                                     |

G=obinutuzumab; Pola=polatuzumab vedotin; R-CHP=rituximab plus cyclophosphamide, doxorubicin and prednisone; R-CHOP=rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.

Source:outputt\\_ex\\_1LP\\_SE

## Adverse events

Table  27.  Overview  of  Adverse  Event  Profile  in  Previously  Untreated  DLBCL  Patients,  Safety-Evaluable Patients

```
Overall AE Profile, Patients with lL DLBCL,Safety-Evaluable Patients Protocols:G039942, G029044
```

<!-- image -->

G029044 Database 1ock date: 28MAR2019.

## Study POLARIX

The most common AEs (≥ 50% of patients in either arm) by System Organ Class (SOC) were (pola+R -CHP arm and R-CHOP arm, respectively):

- -Gastrointestinal disorders (76.1% and 71.9%)

<div style=\"page-break-after: always\"></div>

- -Nervous system disorders (65.7% and 68.7%)
- -General disorders and administration site conditions (65.7% and 68.7%)
- -Blood and lymphatic system disorders (54.5% and 50.5%)

AEs reported by ≥ 20% of patients in either treatment arm ( pola+R-CHP and R-CHOP) were: nausea (41.6% and 36.8%), neutropenia (30.8% and 32.6%), constipation (28.7% and 29.0%), anemia (28.7% and 26.0%), fatigue (25.7% and 26.5%), diarrhea (30.8% and 20.1%), alopecia (24.4% and 24.0%), peripheral neuropathy (24.1% and 22.6%), and peripheral sensory neuropathy (19.5% and 21.5%).

Grade 1-2 AEs (highest grade) were reported in 37.2% of patients in the pola+R-CHP arm and 38.6% of patients in the R-CHOP arm. The proportion of patients with Grade 3-4 AEs (highest grade) in the pola+RCHP arm (57.7%) was comparable with the R-CHOP arm (57.5%).

The most common Grade 34 AEs by highest grade (≥ 5% of patients in either arm) and by SOC were (pola+R-CHP arm and R-CHOP arm, respectively):

- Blood and lymphatic disorders (42.1% and 39.7%)
- Infections and infestations (14.0% and 11.2%)
- Investigations (13.6% and 13.7%)
- Metabolism and nutrition disorders (9.2% and 7.8%)
- Gastrointestinal Disorders (9.4% and 8.2%)
- General Disorders and administration site conditions (5.5% and 5.3%)
- Nervous system disorders (3.9% and 5.3%)

A summary of the most common Grade 34 AEs by highest grade (≥ 2% of patients in either arm) and by PT is shown in Table 9. The majority of Grade 3-4 AEs were associated with myelosuppression.

## Supportive study GO29044

All patients (66/66; 100%) in the pola+R-CHP/G-CHP population had at least one AE.

The  most  common  AEs  (≥  50%  of  patients)  by  SOC  were  General  disorders  and  administration  site conditions  (83.3%),  Gastrointestinal  disorders  (80.3%),  Nervous  system  disorders  (66.7%),  Blood  and lymphatic system disorders (63.6%), and Infections and infestations (53.0%).

The most commonly reported AEs (≥20% of patients) by PT were diarrhea (50.0%), fatigue (48.5%), nausea  (47.0%),  neutropenia  (40.9%),  anemia  (28.8%),  constipation  (25.8%),  pyrexia  (21.2%)  and weight decreased (21.2%)

## Pooled safety population

The proportion of patients with at least one AE in the pooled safety population (98.2% [492/501 patients]) was  comparable  to  the  R-CHOP  arm  from  POLARIX  (98.4%  [431/438  patients]).  The  most  frequently reported AEs of any grade in the pooled safety population were consistent with the pola+R-CHP arm in POLARIX and the majority of AEs were non-serious.

Table 28 Adverse Events by Preferred Term Occurring in ≥10% of Patients in either POLARIX Treatment Arm in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

<div style=\"page-break-after: always\"></div>

Sumary of Adverse Events with an Incidence Rate of at Least los by Preferred Term, Patients with lL DLBCL, Safetv-Evaluable Patients Prot0c01s: G039942, G029044

| MedDRA Preferred Tem          | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mq/kq) +R-CHP/G-CHP (G029044) (N=66)   | All Pola (l.8 mq/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|-------------------------------|----------------------------|--------------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Nausea                        | 161 (36.8%)                | 181                            | (41.6%)                        | 31 (47.0%)                                       | 212 (42.38)                                                     |
| Neutropenia                   | 143 (32.6%)                | 134                            | (30.8%)                        | 27 (40.98)                                       | 161 (32.18)                                                     |
| Diarrhoea                     | 88 (20.1%)                 | 134                            | (30.8%)                        | 33 (50.0%)                                       | 167 (33.3%)                                                     |
| Constipation                  | 127                        | (29.0%) 125                    | (28.7%)                        | 17 (25.88)                                       | 142 (28.38)                                                     |
| Fatique                       | 116                        | (26.58) 112                    | (25.78)                        | 32 (48.58)                                       | 144 (28.78)                                                     |
| Anaemia                       | 114 (26.0%)                | 125                            | (28.7%)                        | 19 (28.88)                                       | 144 (28.78)                                                     |
| Alopecia                      | 105 (24.0%)                | 106                            | (24.4%)                        | 13 (19.78)                                       | 119 (23.8%)                                                     |
| Neuropathy peripheral         | 66 (22.68)                 | 105                            | (24.1:)                        | 10 (15.28)                                       | 115 (23.0%)                                                     |
| Peripheral sensory neuropathy | 94 (21.5%)                 | 85                             | (19.58)                        | 10 (15.28)                                       | 95 (19.0%)                                                      |
| Decreased appetite            | 62 (14.28)                 |                                | 71 (16.3%)                     | 10 (15.28)                                       | 81 (16.28)                                                      |
| Pyrexia                       | 55 (12.6)                  |                                | 68 (15.6%)                     | 14 (21.28)                                       | 82 (16.48)                                                      |
| Vomiting                      | 63 (14.4)                  | 65                             | (14.9%)                        | 11 (16.7%)                                       | 76 (15.28)                                                      |
| Weiqht decreased              | 52 (11.9%)                 |                                | 55 (12.6%)                     | 14 (21.28)                                       | 69 (13.8%)                                                      |
| Asthenia                      | 53 (12.1)                  |                                | 53 (12.2%)                     | 12 (18.28)                                       | 65 (13.0%)                                                      |
| Febrile neutropenia           | 35 ( 8.0%)                 |                                | 62 (14.3)                      | 12 (18.28)                                       | 74 (14.8%)                                                      |
| Headache                      | 57                         | (13.0号)                        | 56 (12.9)                      | 7 (10.6%)                                        | 63 (12.6%)                                                      |
| Couqh                         | 53 (12.1)                  |                                | 56 (12.9)                      | 8 (12.1%)                                        | 64 (12.8%)                                                      |
| Dysqeusia                     | 57                         | (13.0%)                        | 49 (11.3%)                     | 6 (9.18)                                         | 55 (11.0%)                                                      |
| Back pain                     | 48 (11.0%)                 |                                | 41 (9.4%)                      | 7 (10.6%)                                        | 48 (9.6%)                                                       |
| Dyspnoea                      | 36                         | (8.28)                         | 48 (11.0%)                     | 6 (9.18)                                         | 54 (10.8%)                                                      |

G039942 CC0D: 28JUN2021. Data extract date: 02AUG2021.

G029044 Database 1ock date: 28MAR2019.

<!-- image -->

## AEs by severity

Table 29 Grade 34 Adverse Events by Preferred Term Occurring in ≥ 2% of Patients in either POLARIX Treatment Arm in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

| MedDRA Preferred Term        | R-CHOP (POLARIX) N=438   | Pola-R-CHP (POLARIX) N=435   | Pola (1.8 mg/kg) +R-CHP/G-CHP (GO29044) N=66   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP （POLARIX+GO29044) N=501   |
|------------------------------|--------------------------|------------------------------|------------------------------------------------|-------------------------------------------------------------|
| Neutropenia                  | 135 (30.8)               | 123 (28.3)                   | 20 (30.3)                                      | 143 (28.5)                                                  |
| Febrile neutropenia          | 35 (8.0)                 | 60 (13.8)                    | 12 (18.24)                                     | 72 (14.4)                                                   |
| Anaemia                      | 37 (8.4)                 | 52 (12.0)                    | 3 (4.5)                                        | 55 (11.0)                                                   |
| Neutrophil count decreased   | 28 (6.4)                 | 30 (6.99)                    | 0                                              | 30 (6.0%)                                                   |
| Leukopenia                   | 30 (6.8$)                | 25 (5.7)                     | 5 (7.6)                                        | 30 (6.0%)                                                   |
| Thrombocytopenia             | 19 (4.3)                 | 14 (3.25)                    | 6 (9.1$)                                       | 20 (4.0%)                                                   |
| Whitebloodcellcountdecreased | 14 (3.2)                 | 18 (4.1)                     | 2 (3.0)                                        | 20 (4.05)                                                   |
| Pnewmonia                    | 17 (3.96)                | 14 (3.2)                     | 5 (7.6)                                        | 19 (3.8)                                                    |
| Lymphocyte count decreased   | 15 (3.4)                 | 13 (3.0%)                    | 0                                              | 13 (2.6)                                                    |
| Diarrhoea                    | 8(1.8)                   | 17 (3.9)                     | (1.5)                                          | 18 (3.66)                                                   |
| Lymphopenia                  | 10(2.3)                  | 7 (1.66)                     | 1 (1.55)                                       | 8 (1.6)                                                     |
| Syncope                      | 9(2.1)                   | 8 (1.8%)                     | (4.5)                                          | 11 (2.2)                                                    |
| Hypertension                 | 10 (2.3)                 | 6 (1.45)                     | 2 (3.0)                                        | 8 (1.6)                                                     |
| Hyponatraemia                | 9 (2.1)                  | 6 (1.4)                      | 1 (1.5)                                        | (1.4)                                                       |
| Fatigue                      | 11 (2.5)                 | 4 (0.96)                     | (1.5)                                          | 5 (1.0%)                                                    |
| Plateletcountdecreased       | 3(0.7)                   | 9 (2.15)                     | 0                                              | 9 (1.85)                                                    |

multiple occurrences of the same AE in an individual are counted only once.Includes treatment-emergent AE only,which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT,whichever is earlier.

Adapted by PDRD frcm output t\\_ae\\_pt\\_ctc34\\_pi2\\_iLP\\_SE and output t\\_ae\\_soc\\_pt\\_grd\\_1LP\\_SE

## Adverse drug reactions

The ADRs identified in previously untreated DLBCL patients treated with pola+R-CHP from POLARIX were pooled with ADRs in R/R DLBCL patients treated with pola in combination with BR from study GO29365 (N=151; data cut-off 02 January 2020) and represents a pooled safety population of 586 patients. Data outputs for Study GO29365 (N=151) were regenerated using the same CCOD of 02 January 2020 as used in the current EU SmPC in order to apply the updated MedDRA preferred terms grouping strategy as used for Study GO39942, to allow for alignment and pooling of ADRs.

<div style=\"page-break-after: always\"></div>

Table 30 Summary of pola ADRs in pooled safety population of previously untreated DLBCL patients treated with pola+R-CHP and R/R DLBCL patients with pola+BR

| Infections and Infestations          | Infections and Infestations                                                         |
|--------------------------------------|-------------------------------------------------------------------------------------|
| Very common                          | pneumonia, upper respiratory tract infection                                        |
| Common                               | sepsis, herpes vinus infection, cytomegalovirus infection, urinary tract infectionc |
| Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders                                                |
| Very common                          | febrile neutropenia, neutropenia, thrombocytopenia, anemia, leukopenia              |
| Common                               | lymphopenia, pancytopenia                                                           |
| Metabolism and Nutrition Disorders   | Metabolism and Nutrition Disorders                                                  |
| Very common                          | hypokalaemia, decreased appetite                                                    |
| Common                               | hypocalcaemia, hypoalbuminaemia                                                     |
| Nervous System Disorders             | Nervous System Disorders                                                            |
| Very common                          | neuropathy peripheral                                                               |
| Common                               |                                                                                     |

| Eye disorders                                        | Eye disorders                                                       |
|------------------------------------------------------|---------------------------------------------------------------------|
| Uncommon                                             | vision blumedb                                                      |
| Respiratory, Thoracic and Mediastinal Disorders      | Respiratory, Thoracic and Mediastinal Disorders                     |
| Very common                                          | cough                                                               |
| Common                                               | pneumonitis, dyspnoea                                               |
| Gastrointestinal Disorders                           | Gastrointestinal Disorders                                          |
| Very common                                          | diamhea, nausea, constipation, vomiting, mucositis', abdominal pain |
| Skin and Subcutaneous Tissue Disorders               | Skin and Subcutaneous Tissue Disorders                              |
| Very common                                          | alopeciac                                                           |
| Common                                               | pruritus, skin infections5, rashF, dry skinc                        |
| Musculoskeletal Disorders                            | Musculoskeletal Disorders                                           |
| Common                                               | arthralgia, myalgiar                                                |
| General Disorders and Administration Site Conditions | General Disorders and Administration Site Conditions                |
| Very common                                          | pyrexia, fatigue, asthenia                                          |
| Common                                               | peripheral edemaf, chills                                           |
| Investigations                                       | Investigations                                                      |
| Very Common                                          | weight decreased                                                    |
| Common                                               | transaminases increased, lipase increaseb, hypophosphataemia        |
| Injury, Poisoning, and Procedural                    | Injury, Poisoning, and Procedural                                   |
| Very common                                          | infusion related reaction                                           |

Rare and very rare ADRs: none

Source: Manual Table of Pooled ADRs.pdf

Analysis of safety data based on ≥2% difference in AE incidence between the pola+R -CHP arm versus the R-CHOP  control  arm  and  medical  relevance  from  Study  GO39942  (POLARIX)  identified  the  following additional ADRs: mucositis, peripheral edema, rash, dyspnea, dry skin and skin infections.

<div style=\"page-break-after: always\"></div>

Analysis  of  safety  data  based  on  a  &lt;2%  difference  in  AE  incidence  identified  the  following  additional medically relevant ADRs: alopecia, myalgia and urinary tract infection.

## Adverse events of special interest

Events of neutropenia, peripheral neuropathy (PN), infections, hepatic toxicity, anemia, thrombocytopenia, tumor  lysis  syndrome  (TLS),  pulmonary  toxicity  and  secondary  malignancies  of  all  grades  have  been observed in patients treated with pola as a single agent or in combination treatments, therefore, these events  have  been  considered  as  adverse  events  of  particular  interest  (AEPIs).  Hyperglycemia,  cardiac arrhythmia and infusion-related reactions (IRR) were also AEPIs.

- Peripheral neuropathy

## Study POLARIX

Overall, the proportion of patients who experienced PN (52.9%) in the pola+R-CHP arm was comparable with the R-CHOP arm (53.9%) and the majority of patients experienced low grade PN.

Among patients in pola+R-CHP arm who developed PN events, 170/230 (73.9%) had Grade 1 PN and 53/230 (23.0%) had Grade 2 PN. This compares with 163/236 (69.1%) patients in the R-CHOP arm with Grade 1 PN and 68/236 (28.8%) patients with Grade 2 PN, indicating that a higher proportion of patients in the pola+R-CHP arm experienced low-grade PN compared with the R-CHOP arm.

The proportion of patients who experienced Grade 3 PN (highest grade) was 1.6% (7 patients) in the pola+R-CHP arm and 1.1% (5 patients) in the R-CHOP arm. No patients in either arm experienced Grade 4 or Grade 5 PN events.

The most commonly reported PN events by PT (≥ 2% of patients in either arm) were neuropathy peripheral (24.1% and 22.6%), peripheral sensory neuropathy (19.5% and 21.5%), paraesthesia (6.7% and 4.6%), hypoaesthesia  (3.7%  and  3.2%),  polyneuropathy  (1.4%  and 2.5%),  and peripheral  motor neuropathy (0.7% and 2.3%) in the pola+R-CHP and R-CHOP arms, respectively.

The majority of patients (93.8% in the pola+R-CHP arm and 92.2% in the R-CHOP arm) had no prior history of PN. In the pola+R-CHP arm, of the 230 patients who experienced a PN event during treatment, 16 patients had a history of prior PN, and of these, 14 patients had ongoing PN at baseline. In the R-CHOP arm, of the 236 patients who experienced a PN event during treatment, 14 patients had a history of prior PN, and of these, 10 patients had ongoing PN at baseline. The proportion of patients who experienced a serious PN event was the same in each arm (0.2% [1 patient]).

Median time to onset of first PN was 2.27 months (range: 0.0 - 6.7 months) in the pola+R-CHP arm and 1.87 months (range: 0.0 - 8.1 months) in the R-CHOP arm.

Resolution of PN was reported in the majority of patients at the time of CCOD, with more patients having had resolution of PN in the R-CHOP arm (66.9% [158/236 patients with events]) compared with the pola+RCHP arm (57.8% [133/230 patients with events]).

The later time to onset of PN events in the pola+R-CHP arm compared with the R-CHOP arm, in combination with similar median time to PN resolution (4.04 months [range: 0.0 - 36.0 months] in the pola+R-CHP arm and 4.60 months [range: 0.0 - 34.9 months] in the R-CHOP arm), likely contributed to more patients with unresolved PN in the Pola+RCHP arm at the time of CCOD.

Doses modifications to manage peripheral neuropathy are commented in section 5.4.2. of this report.

## Supportive study GO29044

<div style=\"page-break-after: always\"></div>

A total of 26/66 patients (39.4%) experienced 36 peripheral neuropathy events during the study (Table 15). Twenty-five (of 62) patients with no prior history of PN experienced treatment-emergent peripheral neuropathy and 1 of 4 patients with PN ongoing at baseline experienced a worsening of PN during the study.

Eighteen patients experienced Grade 1 PN (worst grade) and 6 patients experienced Grade 2 PN (worst grade). Two patients had Grade 3 events (1 during post-treatment follow up and 1 during treatment, dose not changed). Three patients had study treatment (pola) dose reduced due to a PN event (2 Grade 2 events, 1 Grade 1 event) and 1 patient discontinued study treatment (pola) due to Grade 2 peripheral neuropathy.

At the time of the CCOD for the final analysis for GO29044 all PN events were reported as resolved in 20 of the 26 patients with PN events. Median time to onset of first treatment-emergent peripheral neuropathy event was 2.51 months (range 0.1-8.0 months). Median time to resolution of first treatment-emergent peripheral neuropathy was 2.40 months (range: 0.1 - 25.0 months).

## Pooled safety population

Overall, the proportion of patients who experienced PN in the pooled safety population (51.1% [256/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (53.9% [236/438 patients]).

Table 31 Overview of AEPI Peripheral neuropathy in previously untreated DLBCL patients, safety-evaluable patients

Overall AE Profile -AEPI Peripheral Neuropathy,Patients with lL DLBCL，Safety-Evaluable Patients Protoco1s:G039942，G029044

G039942 CCOD:28JUN2021.Data extractdate:02AUG2021.

G029044 Database1ock date:28MAR2019.

<!-- image -->

- Neutropenia including Febrile Neutropenia

## Study POLARIX

Overall,  the  proportion  of  patients  who  experienced  neutropenia  (including  febrile  neutropenia)  in  the pola+R-CHP arm (46.0%) was generally comparable with the R-CHOP arm (42.7%).

The proportion of patients who experienced a serious neutropenia event in the pola+R-CHP arm (11.5%) was higher than in the R-CHOP arm (8.4%) and was mainly due to a higher incidence of serious febrile neutropenia in the pola+R-CHP arm (9.9%) than in the R-CHOP arm (6.4%).

Median time to onset of first neutropenia (all grades) was 0.49 months (range: 0.1 - 7.2 months) in the pola+R-CHP arm and 0.43 months (range: 0.1 - 6.4 months) in the R-CHOP arm. Neutropenia was reported as resolved in 98.0% (196/200 patients with events) in the pola+R-CHP arm and 97.9% (183/187 patients

<div style=\"page-break-after: always\"></div>

with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of neutropenia was 0.23 months (range: 0.0 - 16.5 months) in the pola+R-CHP arm and 0.26 months (range: 0.0 - 18.5 months) in the RCHOP arm.

## Supportive study GO29044

A total of 34/66 patients (51.5%) experienced 60 neutropenia events (including febrile neutropenia) with a median time to onset of 0.26 months (range: 0.0-6.7 months).

Twelve  patients  (18.2%)  experienced  15  febrile  neutropenia  events;  7  patients  had  Grade  3  febrile neutropenia events and 5 patients had Grade 4 febrile neutropenia.

Eleven patients (16.7%) experienced an SAE of neutropenia and 9 patients (13.6%) had an SAE of febrile neutropenia.

One patient discontinued study treatment due to a serious event of Grade 4 febrile neutropenia, 2 patients had their study treatment interrupted (1 due to Grade 3 neutropenia; 1 due to Grade 4 febrile neutropenia), and 1 patient had their study treatment dose reduced due to Grade 3 neutropenia.

All events of neutropenia and all but one of the events of febrile neutropenia were reported as resolved at data cut-off. Median time to resolution of neutropenia was 0.23 months (range 0-9.2 months).

## Pooled safety population

The proportion of patients who experienced neutropenia (including febrile neutropenia) in the pooled safety population  (46.7%  [234/501  patients])  was  consistent  with  the  pola+R-CHP  arm  from  POLARIX  and comparable with the R-CHOP arm (42.7% [187/438 patients])

Table 32 Overview of AEPI Neutropenia in Previously untreated DLBCL patients, Safety-evaluable patients

Overall AE Profile-AEpI Neutropenia, Patients with 1L DLBCL, Safety-Evaluable Patients Protoco1s:G039942，G029044

|                                                                                                               | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+GO29044) (N=501)   |
|---------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs                                             | 187 (42.75) 443            | 200 (46.0%) 456                | 34(51.5) 60                                      | 234(46.7) 516                                                 |
| Total number of patients with at least one                                                                    |                            |                                |                                                  |                                                               |
| Grade 5 AE                                                                                                    | 0                          | 0                              | 0                                                | 0                                                             |
| Grade 3-5AE                                                                                                   | 176 (40.2)                 | 182 (41.8)                     | 27 (40.9)                                        | 209 (41.7)                                                    |
| Serious AE                                                                                                    | 37 8.4)                    | 50 (11.5$)                     | 11 (16.7)                                        | 61 (12.2$)                                                    |
| Serious Related AE to any study drug                                                                          | 34 7.8)                    | 49 (11.3) 0                    | 9 (13.6) 0                                       | 58 (11.6) 0                                                   |
| AE leading to study discontinuation                                                                           | 0                          | 2 0.5)                         | 1 (1.5)                                          | 3 0.6)                                                        |
| AE leading to any study treatment dose discontinuation                                                        | 0 7                        | 7                              | 2 （ 3.0)                                         | 6 1.8)                                                        |
| AE AE leading leading to to any study treatment dose interruption any study treatment dose reduction          | 28 1.6) 6.4)               | 23 1.6) 5.3)                   | 10 (15.2)                                        | 33 6.6)                                                       |
| AE leading 04 polatuzumab vedotin/placebo discontinuation                                                     | 0                          | 0                              | 1 (1.5)                                          | 1 (0.2$)                                                      |
|                                                                                                               | 2 0.5)                     | 2                              | 1                                                | 3 (0.6)                                                       |
| AE leading 04 polatuzuumab vedotin/placebo dosereduction                                                      | 13 3.0)                    | 12 0.5) 2.8)                   | 2 (3.0) 1.5)                                     | 14 (2.85)                                                     |
| AE AE leading leading 04 04 polatuzumab vedotin/placebo dose interruption vincristine/placebo discontinuation | 0 2 0.55)                  | 0 1 0.24)                      | 0                                                | 0 1 (0.2)                                                     |
| AE leading to vincristine/placebo dose reduction                                                              | 13 3.0$)                   | 12 2.8)                        |                                                  | 12 (2.4)                                                      |
| AE leading to vincristine/placebo dose interruption                                                           |                            |                                | 0                                                |                                                               |

<!-- image -->

- Anemia

## Study POLARIX

Overall,  the  proportion  of  patients  who  experienced  anemia  in  the  pola+R-CHP  arm  (28.7%)  was comparable with the R-CHOP arm (26.9%).

<div style=\"page-break-after: always\"></div>

Median time to onset of first anemia (all grades) was 1.12 months (range: 0.0 - 7.4 months) in the pola+RCHP arm and 1.05 months (range: 0.0 - 4.6 months) in the R-CHOP arm. Anemia was reported as resolved in 84.8% (106/125 patients with events) in the pola+R-CHP arm and 86.4% (102/118 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of anemia was 0.69 months (range: 0.0 21.0 months) in the pola+R-CHP arm and 0.72 months (range: 0.0 - 17.7 months) in the R-CHOP arm.

## Supportive study GO29044

A total of 19/66 patients (28.8%) experienced 36 anemia events with a median time to onset of 0.99 months (range: 0.2-3.1 months).

In all but two patients (1 patient with Grade 1 event, 1 patient with Grade 2 event) anemia was reported as resolved at data cut-off. Median time to resolution of anemia was 0.90 months (range 0-8.7 months).

## Pooled safety population

The proportion of patients who experienced anemia in the pooled pola+R-CHP/G-CHP arm (28.7% [144/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (26.9% [118/438 patients]).

Table 33 Overview of AEPI Anemia in previously untreated DLBCL patients, Safety-evaluable patients Overall AE Profile-AEPI Anemia,Patients with 1L DLBCL， Safety-Evaluable Patients

Prot0co1s:G039942,G029044

|                                                                                                        | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (GO29044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX +GO29044) (N=501)   |
|--------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Totalnumber ofpatients withatleastoneAE Total number of AEs                                            | 118 (26.9%) 178            | 125 (28.7%) 190                | 19 (28.8%) 36                                    | 144 (28.78) 226                                                |
| Totalnumber of patients withat leastone                                                                |                            |                                |                                                  |                                                                |
| Grade5AE                                                                                               | 0                          | 0                              | 0                                                | 0                                                              |
| Gradle3-5AE                                                                                            | 38 8.78)                   | 52 (12.08)                     | 3 4.58) 0                                        | 55 (11.0%)                                                     |
| Serious AE                                                                                             | 6 1.4%)                    | 4 0.98)                        |                                                  | 4 0.8%)                                                        |
| Serious Related AE to any study drug                                                                   | 4 0.98)                    | 4 0.98)                        | 0                                                | 4 0.8%)                                                        |
| AE leading to study discontinuation                                                                    | 0                          | 0                              | 0                                                | 0                                                              |
| AE leading to any study treatment dose discontinuation                                                 | 0                          | 0                              | 0                                                | 0                                                              |
| AE leading to any study treatment dose reduction                                                       | 2 (0.5%)                   | 0                              | 0                                                | 0 2 (0.4%)                                                     |
| AE leading toany studytreatmentdoseinterruption AE leading topolatuzumabvedotin/placebodiscontinuation | 1 (0.2%) 0                 | 2 (0.58) 0                     | 0 0                                              | 0                                                              |
| AE leading topolatuzumabvedlotin/placebodoseredluction                                                 | 0                          | 0                              | 0                                                | 0                                                              |
| AE leading topolatuzumabvedotin/placebodoseinterruption                                                | 1 (0.28)                   | 2 (0.5%)                       | 0                                                | 2 (0.48)                                                       |
| AE leading to vincristine/placebo discontinuation                                                      | 0                          | 0                              | 0                                                | 0                                                              |
| AE leading to vincristine/placebo dose reduction                                                       | 0                          |                                | 0                                                | 0                                                              |
| AE leading to vincristine/placebo dose interruption                                                    | 1 0.2%)                    | 2 (0.5%)                       | 0                                                | 2 (0.4%)                                                       |

ofthesame AE in one individualare countedonly once except for\"Total number ofAEs\"row in which multipleoccurrences of the same AE are\\_counted separately. Includes treatment-emergent AEs curing AE reporting period only, which is defined as new\\_or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT,whichever is earlier.

G039942 CCOD:28JUN2021.Data extraCt date:02AUG2021.

G029044Database1ockdate:28MAR2019.

- Thrombocytopenia

## Study POLARIX

Overall, the proportion of patients who experienced thrombocytopenia in the pola+R-CHP arm (13.3%) was comparable with the R-CHOP arm (13.2%).

Median time to onset of first thrombocytopenia (all grades) was 1.68 months (range: 0.2 - 7.2 months) in the pola+R-CHP arm and 0.41 months (range: 0.1 - 7.7 months) in the R-CHOP arm. Thrombocytopenia was reported as resolved in 94.8% (55/58 patients with events) in the pola+R-CHP arm and 86.2% (50/58 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of thrombocytopenia was 0.36 months (range: 0.1 - 13.2 months) in the pola+R-CHP arm and 0.36 months (range: 0.0 - 24.1 months) in the R-CHOP arm.

## Supportive study GO29044

<div style=\"page-break-after: always\"></div>

A total of 14/66 patients (21.2%) experienced 26 thrombocytopenia events (Table 18), with a median time to onset of 0.87 months (range: 0.1-5.1 months).

Thrombocytopenia was reported as resolved in all but one patient at data cut-off. Median time to resolution of thrombocytopenia was 0.46 months (range 0.1-12.6 months).

## Pooled safety population

The proportion of  patients  who  experienced  thrombocytopenia  in  the  pooled  safety  population  (14.4% [72/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the RCHOP arm (13.2% [58/438 patients]).

Table 34 Overview of AEPI Thrombocytopenia in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile-AEPI Thrombocytopenia,Patients with IL DLBCL,Safety-Evaluable Patients Protocols:G039942, G029044

|                                                                                                               | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8mg/kg) +R-CHP/G-CHP (POLARIX+G029044) (N=501)   |
|---------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|--------------------------------------------------------------|
| Total1 number of patients with at least one AE Total number of AEs                                            | 58(13.2) 123               | 58(13.3) 102                   | 14 (21.2) 26                                     | 72(14.45) 128                                                |
| Totalnumber of patients with at least one                                                                     |                            |                                |                                                  |                                                              |
| Grade 5 AE                                                                                                    | 0                          | 0                              | 0                                                | 0 (5.8)                                                      |
| Grade3-5 AE                                                                                                   | 22 5.05)                   | 23 （ 5.3)                      | 6 (9.15)                                         | 29 2 0.4)                                                    |
| Serious AE                                                                                                    | 1 0.2$)                    | 2 （ 0.5)                       | 0                                                |                                                              |
| Serious Related AE to any study drug AE                                                                       | 1 0.2$) 0                  | 20 （ 0.5)                      |                                                  | 20 ( 0.4)                                                    |
| leading to study discontinuation                                                                              | 0                          | 1 （ 0.2)                       | 1 (1.5)                                          | 0.4)                                                         |
| AE leading to any study treatment dose discontinuation                                                        | 2                          |                                | 0                                                | 2 0.45)                                                      |
| AE leading to any study treatment dose reduction AE leading to any study treatment dose interruption          | (0.5) 0                    | 2 （ 0.5) 0                     | 2 (3.0)                                          | 22 ( 0.4)                                                    |
| AE leading to polatuzumab vedotin/placebo discontinuation                                                     | 0                          | 1 (0.25)                       | 1 (1.5)                                          | 2 (0.4)                                                      |
| AE leading to polatuzumab vedotin/placebo dose reduction                                                      | 2 (0.5) 0                  | 0                              | 0 0                                              | 0 0                                                          |
| AE AE leading leading to vincristine/placebo discontinuation 04 polatuzumab vedotin/placebo dose interruption | 0                          | 0 1 (0.2)                      |                                                  | i (0.2)                                                      |
| AE leading to vincristine/placebo dose reduction                                                              | 2 (0.5)                    | 0                              | 0                                                | 0                                                            |
| AE leading to vincristine/placebo dose interruption                                                           | 0                          | 0                              | 0                                                | 0                                                            |

<!-- image -->

- Infection

## Study POLARIX

Overall, the proportion of patients who experienced infections in the pola+R-CHP arm (49.7%) was higher than the R-CHOP arm (42.7%).

The proportion of patients who experienced Grade 3-4 infections (highest grade) was 14.0% in the pola+RCHP arm and 11.2% in the R-CHOP arm. The proportion of patients who experienced Grade 5 infections (highest grade) was 1.1% (5 patients) in the pola+R-CHP arm and 1.4% (6 patients) in the R-CHOP arm. Grade 5 infections by PT occurring in the pola+R-CHP arm were pneumonia (4 patients) and sepsis (1 patient) and in the R-CHOP arm were pneumonia (3 patients), septic shock (2 patients) and sepsis (1 patient).

Median time to onset of first infection was 1.92 months (range: 0.0 - 8.3 months) in the pola+R-CHP arm and 1.58 months (range: 0.0 - 7.8 months) in the R-CHOP arm.

Infection was reported as resolved in 87.0% (188/216 patients with events) in the pola+R-CHP arm and 84.5% (158/187 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of infection was 0.39 months (range: 0.0 - 21.5 months) in the pola+R-CHP arm and 0.46 months (range: 0.0 - 17.8 months) in the R-CHOP arm.

<div style=\"page-break-after: always\"></div>

A low number of opportunistic infections was reported in both treatment arms (1.6% [7 patients] in the pola+R-CHP arm and 0.7% [3 patients] in the R-CHOP arm).

No patients in the pola+R-CHP arm experienced an AE of hepatitis B virus (HBV) reactivation during the study; 1 patient in the R-CHOP arm experienced a Grade 2 AE of HBV reactivation.

Based on laboratory data, 44 patients (10.1%) in the pola+R-CHP arm and 50 patients (11.4%) in the RCHOP  arm  had  a  previous  history  of  HBV  infection  and  were  considered  at  risk  of  developing  HBV reactivation. Of the patients at risk, 2/44 in the pola+R-CHP arm and 7/50 in the R-CHOP arm had evidence of HBV reactivation any time post-baseline. Both patients in the pola+R-CHP arm and 5/7 patients in the RCHOP arm had evidence of HBV reactivation during the follow up period.

## Supportive study GO29044

A total of 35/66 patients (53.0%) experienced 58 events of infection, with a median time to onset of 1.58 months (range: 0.2-6.6 months).

Grade ≥3 infections were reported in 11 patients (16.7%); 8 patients had Grade 3 infections and 2 patients had a Grade 4 infection. One patient experienced a Grade 5 infection (septic shock, unrelated).

Nine patients (13.6%) experienced a serious infection. Two patients discontinued study treatment due to an infection (Escherichia urinary tract infection [Grade 2]; septic shock [Grade 5]), 3 patients had their study treatment interrupted (ophthalmic herpes zoster [Grade 3], bronchitis [Grade 2], and pneumonia [Grade 3]). One patient had their study treatment dose reduced due to an infection AE.

No opportunistic infections or hepatitis B reactivation events were reported in any patient.

All but one of the infections were reported as resolved at data cut-off with a median time to resolution of 0.49 months (range 0.1-1.5 months).

No patients had evidence of HBV reactivation during the study.

## Pooled safety population

Table 35 Overview of AEPI Infections in Previously untreated DLBCL patients, Safety-evaluable Patients Overall AE Profile -AEpI Infections and Infestations, Patients with 1L DLBCL Safety-Evaluable Patients

Protoco1s:G039942,G029044

|                                                                   | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+GO29044) (N=501)   |
|-------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 187(42.7) 343              | 216 (49.7) 409                 | 35 (53.0) 58                                     | 251 (50.1) 467                                                |
| Total number of patients with at least one                        |                            |                                |                                                  |                                                               |
| Grade 5AE                                                         | 6 1.4)                     | 5 (1.1)                        | 1 (1.5)                                          | 6 (1.2)                                                       |
| Grade 3-5 AE                                                      | 55 (12.65)                 | 66 (15.24)                     | 11 (16.74)                                       | 77 (15.4)                                                     |
| Serious AE                                                        | 45 (10.3)                  | 61 (14.0)                      | 9 (13.6)                                         | 70 (14.0)                                                     |
| Serious Related AE to any study drug                              | 28 6.4)                    | 45 (10.3)                      | 6 9.1)                                           | 51 (10.2)                                                     |
| AE leading to study discontinuation                               | 6 1.4)                     | 5 1.1)                         | 2 3.0)                                           | 7 1.4)                                                        |
| AE leading to any study treatment dose discontinuation            | 10 2.3)                    | 7 1. 6)                        | 3 (4.5)                                          | 10 2.05)                                                      |
| AE leading to any study treatment dose reduction                  | 4 0.93)                    | 1 0.23)                        | 1 ( 1.5)                                         | 2 0.45)                                                       |
| AE leading to any study treatment dose interruption               | 22 5.05)                   | 27 6.2)                        | 3 4.5)                                           | 30 6.0)                                                       |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 7 1.6)                     | 5 1.1$)                        | 2 (3.0)                                          | 7 1.4$)                                                       |
| AE leading to polatuzumab vedotin/placebo dose reduction          | 1 0.2)                     | 0                              | 0                                                | 0                                                             |
| AE leading topolatuzumabvedotin/placebodoseinterruption           | 20 4.6)                    | 21 4.8)                        | 3 (4.5)                                          | 24 4.8$)                                                      |
| AE leading to vincristine/placebo discontinuation                 | 7 1.6)                     | 5 1.1)                         | 0                                                | 5 1.0$)                                                       |
| AE leading to vincristine/placebo dose reduction                  | 2 0.5)                     | 0                              | 0                                                | 0                                                             |
| AE leading to vincristine/placebo dose interruption               | 19 4.3)                    | 22 5.1)                        | 0                                                | 22 (4.4)                                                      |

Investigator text for AEs encoded using MedDRA yersion 24.0. Percentages are based on N in the column headings. Multiple occurrences same AE are counted separately.Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT,whichever is earlier.

GO39942 CCOD:28JUN2021.Data extract date:02AUG2021.

G029044 Database 1ock date: 28MAR2019.

- Hepatic toxicity

## Study POLARIX

<div style=\"page-break-after: always\"></div>

Overall, the proportion of patients who experienced hepatic toxicity in the pola+R-CHP arm (10.6%) was slightly higher than the R-CHOP arm (7.3%). The majority of hepatic toxicity events were low-grade liver enzyme elevations in both the treatment arms. No patients experienced Grade 4 or Grade 5 hepatic toxicity events.

Median time to onset of first hepatic toxicity event was 0.85 months (range: 0.0 - 6.7 months) in the pola+R-CHP arm and 0.69 months (range: 0.0 - 5.2 months) in the R-CHOP arm.

Hepatic toxicity was reported as resolved in 87.0% (40/46 patients with events) in the pola+R-CHP arm and 84.4% (27/32 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of hepatic toxicity was 0.56 months (range: 0.1 - 9.1 months) in the pola+R-CHP arm and 0.54 months (range: 0.1 - 14.3 months) in the RCHOP arm.

Using an algorithm based on laboratory values of liver enzymes in combination with elevated bilirubin levels/clinical jaundice, potential cases of drug-induced liver injury (DILI) were identified in 1 patient in the pola+R-CHP arm and 2 patients in the R-CHOP arm. All cases were confounded by concomitant medical conditions and the underlying illness.

In the pola+R-CHP arm, 1 case of potential DILI was identified:

- -Patient 10688 - This 55-year-old female patient presented Grade 4 cytopenia on Study Day 10. On Study  Day  12,  the  patient  experienced  life-threatening  sepsis  with  a  blood  culture  positive  for Staphylococcus  aureus,  and  was  treated  with  antibiotics.  The  events  of  cytopenia  and  sepsis resolved by Study Day 16. Elevated ALT and bilirubin were noted on Study Day 23; however, no AEs relating to the abnormal liver enzymes were reported. The patient received study treatment on Study Day 23 (Cycle 2, Day 1) as planned. This case is confounded by the event of sepsis in the period preceding the ALT and bilirubin increase.

In the R-CHOP arm, 2 cases of potential DILI were identified:

- -Patient number 10762- The first was a 49-year-old male patient with a medical history of biliary tract infection. On Study Day 10, laboratory work-up showed Grade 4 neutropenia and Grade 1 abnormal hepatic function. On Study Day 11, the patient was hospitalized for fever and persistent neutropenia. A blood culture was positive for Escherichia coli and the patient was diagnosed with Escherichia sepsis. The abnormal hepatic function worsened to Grade 3. The patient was treated with antibiotics and the events of neutropenia, sepsis and abnormal hepatic function resolved by Study Day 22. This case is confounded by the event of E.coli sepsis and history of prior biliary tract infection.
- -Patient number 10802 - The second patient, a 69-year-old male received study treatment (Cycle 5 Day 1) on Study Day 83. On Study Day 89, the patient was hospitalized with Grade 4 febrile neutropenia. On Study Day 90, the patient was diagnosed with Grade 3 pneumonia, and laboratory work-up showed elevated liver enzymes, total bilirubin, creatinine, urea, C-reactive protein, and decreased platelets, WBC count and hemoglobin. The patient was diagnosed with life-threatening Grade 4 multiple organ dysfunction syndrome and was discontinued from study treatment. The patient died due to multiple organ dysfunction syndrome on Study Day 157. No other AEs related to abnormal liver function were reported. This case is confounded by multiple organ dysfunction in the setting of febrile neutropenia.

## Supportive study GO29044

Five of 66 patients (7.6%) experienced 8 hepatic toxicity events with a median time to onset of 2.00 months (range: 0.3-4.1  mo nths). One patient experienced a Grade ≥3  hepatic toxicity  AE  (gamma -glutamyltransferase increased [Grade 3]). All other events were Grade ≤ 2.

<div style=\"page-break-after: always\"></div>

No hepatic toxicity SAEs were reported and no patient had their study treatment dose changed as a result of a hepatic toxicity event. All hepatic toxicity events were reported as resolved at data cut-off. Median time to resolution of hepatic toxicity was 0.61 months (range 0.1-3.1 months).

## Pooled safety population

The proportion of patients who experienced hepatic toxicity in the pooled safety population (10.2% [51/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and slightly higher than that in the RCHOP arm (7.3% [32/438 patients]).

Table  36  Overview  of  AEPI  Hepatic  toxicity  in  Previously  untreated  DLBCL  patients,  Safety-evaluable Patients

Overall AE Profile-AEPI Hepatic Toxicity,Patients with IL DLBCL,Safety-Evaluable Patients Protoco1s:G039942,G029044

<!-- image -->

- Carcinogenicity / Secondary malignancies

## Study POLARIX

Overall, the proportion of patients who experienced a carcinogenicity/secondary malignancy during the treatment-emergent AE interval (90 days after last dose of study drug or prior to NALT, whichever is earlier) in the pola+R-CHP arm (0.9% [4 patients]) was comparable with the R-CHOP arm (1.1% [5 patients]).

Grade 3-4 carcinogenicity events (highest grade) were reported in 0.9% (4 patients) in the pola+R-CHP arm and 0.5% (2 patients) in the R-CHOP arm. No patients experienced a Grade 5 carcinogenicity event. The proportion of patients who experienced a serious carcinogenicity event in the pola+R-CHP arm (0.7% [3  patients])  was  comparable  with  the  R-CHOP  arm  (0.2%  [1  patient]).  No  patients  in  either  arm experienced  a  carcinogenicity  event  that  led  to  study  treatment  discontinuation,  dose  reduction  or treatment interruption.

Median time to onset of first carcinogenicity event was 5.86 months (range: 2.7 - 6.5 months) in the pola+R-CHP arm and 5.06 months (range: 3.4 - 6.8 months) in the R-CHOP arm. Carcinogenicity events were reported as resolved in 1 of 4 patients with events in the pola+R-CHP arm and 3 of 5 patients with events in the R-CHOP arm, as of the CCOD. Median time to resolution of the carcinogenicity event was 3.25 months in the patient in the pola+R-CHP arm and 5.06 months (range: 0.0 - 12.2 months) for the 3 patients in the R-CHOP arm.

<div style=\"page-break-after: always\"></div>

Carcinogenicity events were distributed across a range of tumor types in individual patients. In the pola+RCHP arm 1 patient had adenocarcinoma of colon, 1 patient had adenocarcinoma of the pancreas, 1 patient had colorectal cancer, and 1 patient had papillary renal cell carcinoma. In the R-CHOP arm, 1 patient had adenocarcinoma, 1 patient had basal cell carcinoma, 1 patient had Hodgkin's disease, 1 patient had a lung neoplasm and 1 patient had malignant melanoma in situ.

Carcinogenicity events reported over the entire study period (which included the treatment emergent AE interval and up until CCOD) were reported in an additional 1 patient in the pola  R-CHP arm (colorectal cancer)  and  4  patients  in  the  R-CHOP  arm:  One  patient  had  acute  myeloid  leukemia,  1  patient  had adenocarcinoma, 1 patient had lung neoplasm malignant, and 1 patient had prostate cancer.

## Study GO29044

No carcinogenicity/secondary malignancy events were reported in any patient

## Pooled safety population

Table 37 Overview of AEPI Secondary Malignancy / Carcinogenicity in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile -AEPI Carcinogenicity, Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s:G039942, G029044

3

|                                                              | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | Al1 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   |
|--------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Totalnumber ofpatients withatleast oneAE Total number of AEs | (1.1) 9                    | (0.9%)                         | 0 0                                              | 4 (0.8%)                                                        |
| Total number of patients withatleast one                     |                            |                                |                                                  |                                                                 |
| Grade5AE                                                     | 0 2                        | 0 4 (0.9%)                     | 0                                                | 0                                                               |
| Gradle3-5AE                                                  | (0.58)                     |                                | 0                                                | 4 (0.8%)                                                        |
| Serious AE                                                   | 1 (0.28)                   | (0.7%)                         | 0                                                | 3 (0.6%)                                                        |
| Serious RelatedAE to anystudlydrug                           | 0                          | 1 (0.28)                       | 0                                                | 1 (0.28)                                                        |
| AE leading to study discontinuation                          | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading toanystudy treatment dose discontinuation         | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to any study treatment dose reduction             | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading 04 any study treatment dose interruption          | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to polatuzumab vedotin/placebo discontinuation    | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading topolatuzumabvedotin/placebodosereduction         | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading topolatuzumabvedotin/placebodoseinterruption      | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo discontinuation            | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo dose reduction             | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading tovincristine/placebo dose interruption           | 0                          |                                | 0                                                | 0                                                               |

Investigator text for AEs encoded using MedDRA version 24.o.Percentages are based on N in the column headings.Muitiple occurrences of the\\_same AE in one individual\\_are counted only once except\\_for \"Total number of AEs\" row in which multiple occurrences of the same AE are\\_counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study crug or prior to NALT,whichever is earlier.

GO39942 CC0D:28JUN2021.Data extract date:02AUG2021.

G029044 Database 1ock date:28MAR2019.

- •

Pulmonary toxicity

## Study POLARIX

The proportion of patients who experienced a pulmonary toxicity event was the same in both arms (1.6% [7 patients]).

Median time to onset of first pulmonary toxicity event was 2.14 months (range: 2.0 - 4.4 months) in the pola+R-CHP arm and 2.73 months (range: 0.0 - 6.0 months) in the R-CHOP arm. Pulmonary toxicity was reported as resolved in 7/7 patients with events in the pola+R-CHP arm and 5/7 patients with events in the R-CHOP arm, as of the CCOD.

Median time to resolution of pulmonary toxicity was 0.59 months (range: 0.1 - 3.8 months) in the pola+RCHP arm and 0.72 months (range: 0.3 - 4.2 months) in the RCHOP arm.

## Study GO29044

<div style=\"page-break-after: always\"></div>

One of 66 patients (1.5%) experienced a pulmonary toxicity event with a time to onset of 3.78 months. The non-serious event of Grade 2 pneumonitis did not lead to a change in study treatment and was reported as resolved at data cut-off for the final analysis.

## Pooled safety population

The proportion of patients who experienced a pulmonary toxicity event in the pooled safety population (1.6% [8/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (1.6% [7/438 patients]).

Table 38 Overview of AEPI Pulmonary Toxicity in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile -AEPI Pulmonary Toxicity,Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s:G039942,C029044

<!-- image -->

- Infusion-related reactions

As all components of the study treatment were administered on Day 1 of the first and subsequent treatment cycles, infusion-related reactions (IRRs) described in this section were identified based on entries in the Adverse Event page of the eCRF which met the following criteria:

- AEs suspected by the investigator to be caused by any study drug of the combination treatment (pola+RCHP or R-CHOP) that occurred during infusion or within 24 hours after end of infusion.
- AE PT was one of the PTs identified as associated with Infusion-Related Reaction

## Study POLARIX

Overall, the proportion of patients who experienced IRRs in the pola+R-CHP arm (13.3%) was comparable with the R-CHOP arm (16.0%). Most IRR events were low grade and non-serious.

No patient in the pola+R-CHP arm and 1 patient (0.2%) in the R-CHOP arm experienced an IRR that led to study treatment discontinuation.

No patient in either arm experienced an IRR that led to any study treatment dose reduction. The proportion of patients who experienced IRRs that led to study treatment interruption in the pola+R-CHP arm (4.1%) was comparable with the R-CHOP arm (5.7%).

IRRs were reported as resolved in 100% (58/58 patients with events) in the pola+R-CHP arm and 98.6% (69/70 patients with events) in the R-CHOP arm, as of the CCOD.

<div style=\"page-break-after: always\"></div>

Doses modifications to manage infusion-related reactions and prophylaxis treatment are commented in section 5.4.2. of this report.

## Study GO29044

A total of 30/66 patients (45.5%) experienced 51 IRR events (Table 23) occurring within 24 hours of the first dose of any study drug.

One patient experienced a Grade ≥ 3 IRR (Grade 3 hypertension). All other IRRs were Grade ≤ 2. No patient experienced a serious IRR event and no patients discontinued study treatment or had their dose reduced due to an IRR. Seven patients had their study treatment dose interrupted due to an IRR. IRRs in all but 2 patients were reported as resolved at data cut-off.

## Pooled safety population

The proportion of patients who experienced IRRs in the pooled safety population (17.6% [88/501 patients]) was generally consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (16.0% [70/438 patients]) from POLARIX.

Table 39 Overview of AEPI Infusion Related Reactions in Previously untreated DLBCL patients, Safetyevaluable Patients

Overall AE Profile -AEPI Infusion Related Reactions, Patients with 1L DLBCL,Safety-Evaluable Patients Protoco1s:G039942,G029044

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | R-CHOP (POLARIX) (N=438)                                    | Pola-R-CHP (POLARIX) (N=435)                        | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola(1.8mg/kg) +R-CHP/G-CHP （POLARIX+GO29044) (N=501)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------|-------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 70(16.0) 106                                                | 58 (13.3) 83                                        | 30(45.5) 51                                      | 88(17.6) 134                                                |
| Total number of patients with at least one Grade5AE Grade 3-5 AE Serious AE Serious Related AE to any study drug AE leading to study discontinuation AE leading to any study treatment dose discontinuation AE leading to any study treatment dose reduction AE leading to any study treatment dose interruption AE leading to polatuzumab vedotin/placebo discontinuation AE leading to polatuzumab vedotin/placebo dose reduction AE leading topolatuzumabvedotin/placebo doseinterruption AE leading to vincristine/placebo discontinuation AE leading to vincristine/placebo dose reduction AE leading to vincristine/placebo dose interruption | 0 7 1.6) 3 0.7) 3 0.7) 0 1 0.2) 0 25 (5.7) 0 0 1 0.2) 0 0 0 | 0 5 1.1$) 2 0.5$) 2 (0.5) 0 0 0 18 4.1) 0 0 0 0 0 0 | 0 1 1.5) 0 0 0 0 0 7 (10.6) 0 0 0 0 0 0          | 0 6 1.2$) 2 (0.4) 2 (0.4) 0 0 0 25 (5.0%) 0 0 0 0 0 0       |

<!-- image -->

- Tumor Lysis Syndrome

## Study POLARIX

Overall, the proportion of patients who experienced TLS in the pola+R-CHP arm (0.5% [2 patients]) was comparable with the R-CHOP arm (0.9% [4 patients]).

No patients in either treatment arm experienced TLS that led to study treatment discontinuation or study treatment dose reduction. No patient in the pola+R-CHP arm and 1 patient (0.2%) in the R-CHOP arm experienced TLS that led to interruption of study treatment.

Median time to onset of first TLS was 0.05 months (range: 0.0 - 0.1 months) in the pola+R-CHP arm and 0.26 months (range: 0.1 - 1.4 months) in the R-CHOP arm. TLS was reported as resolved in all patients in the pola+R-CHP and R-CHOP arms, as of the CCOD. Median time to resolution of TLS was 0.13 months (range: 0.1 - 0.2 months) in the pola+R-CHP arm and 0.20 months (range: 0.1 - 0.4 months) in the RCHOP arm.

<div style=\"page-break-after: always\"></div>

## Study GO29044

No TLS events were reported in any patient.

## Pooled safety population

The proportion of patients who experienced TLS in the pooled safety population (0.4% [2/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (0.9% [4/438 patients]).

Table 40 Overview of AEPI Tumor lysis syndrome in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile-AEPI Tumor Lysis Symdrome，Patients with 1LDLBCL，Safety-Evaluable Patients Protoco1s:G039942， G029044

|                                                                                                                                                                                                                                                                              | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+GO29044) (N=501)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Total number of patients with atleast oneAE Total number of AEs                                                                                                                                                                                                              | 4 (0.9%) S                 | 2 (0.58) 2                     | 0 0                                              | 2 (0.4%) 2                                                    |
| Total number of patients with at least one Grade 5AE Grade3-5AE Serious AE Serious RelatedAE to anystudy drug AE AE leading leading to to study discontinuation AE leading to AE leading 04 AE leading 04 AE AE leading leading to to AE leading to AE leading to AE leading | 0 3 (0.78)                 | 0 2 (0.58) 1 (0.2%)            |                                                  | 0                                                             |
| any study treatment dose reduction any study treatment dose interruption vincristine/placebodiscontinuation vincristine/placebo dose reduction to vincristine/placebo doseinterruption                                                                                       | 1 (0.28) 1 (0.28)          | 1 (0.2%) 0 0 0 0 0 0 0 0       | 0 0 0 0 0 0 0 0 0 0 0 0 0                        | 2 (0.48) 1 (0.28) 1 (0.2%) 0 0 0 0 0 0 0 0 0                  |
|                                                                                                                                                                                                                                                                              | 0 (0.28)                   | 0                              | 0                                                | 0                                                             |
|                                                                                                                                                                                                                                                                              | 0                          |                                |                                                  |                                                               |
| any study treatment dose discontinuation                                                                                                                                                                                                                                     | 0 0                        |                                |                                                  |                                                               |
|                                                                                                                                                                                                                                                                              | 1 (0.28)                   |                                |                                                  |                                                               |
|                                                                                                                                                                                                                                                                              | 0                          |                                |                                                  |                                                               |
| polatuzumab vedotin/placebo ciscontinuation                                                                                                                                                                                                                                  |                            |                                |                                                  |                                                               |
| polatuzumabvedotin/placebodosereduction polatuzumabvedotin/placebocloseinterruption                                                                                                                                                                                          | 0                          |                                |                                                  |                                                               |
|                                                                                                                                                                                                                                                                              | 1 (0.28)                   |                                |                                                  |                                                               |
|                                                                                                                                                                                                                                                                              | 0                          |                                |                                                  |                                                               |
|                                                                                                                                                                                                                                                                              |                            | 0                              |                                                  |                                                               |

Investigator text for Abs encoded using MedDRA yersion 24.0. Percentages are based on N in the column heacings.Multiple occurrences same AE are\\_counted separately. Includes treatment-emergent AEs cduring AE reporting period only, which is defined as new\\_or worsening AEfrom thefirst doseof anystudy drug through9odays after the lastdose of anystudydrug or prior toNALT,whichever is earlier.

G029044Database 1ock date:28MAR2019.

GO39942CCOD:28JUN2021.Dataextractdate:02AUG2021.

- Cardiac Arrhythmia

## Study POLARIX

Overall, the proportion of patients who experienced a cardiac arrhythmia event in the pola+R-CHP arm (3.0%) was comparable with the R-CHOP arm (4.6%).

The proportion of patients who experienced a Grade 3-4 cardiac arrhythmia event (highest grade) was 0.5% (2 patients) in the pola+R-CHP arm and 0.7% (3 patients) in the R-CHOP arm. No patients in the pola+R-CHP arm experienced a Grade 5 cardiac arrhythmia event compared with 1 patient (0.2%) in the R-CHOP arm.

Median time to onset of first cardiac arrhythmia was 2.17 months (range: 0.0 - 4.8 months) in the pola+RCHP arm and 3.45 months (range: 0.0 - 7.4 months) in the R-CHOP arm. Cardiac arrhythmia was reported as resolved in 61.5% (8/13 patients with events) in the pola+R-CHP arm and 55.0% (11/20 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of cardiac arrhythmia was 0.07 months (range: 0.0 - 3.1 months) in the pola+R-CHP arm and 0.07 months (range: 0.0 - 9.9 months) in the R-CHOP arm.

## Study GO29044

Three of 66 patients (4.5%) experienced 5 cardiac arrhythmia events (Table 25) with a median time to onset of 2.60 months (range: 0.17.8 months). Two patients experienced a Grade ≥3 cardiac arrhythmia

<div style=\"page-break-after: always\"></div>

event; 1 patient experienced Grade 3 supraventricular tachycardia and 1 patient experienced Grade 5 atrial fibrillation. Neither event was considered related to study treatment by the investigator.

All but one of the cardiac arrhythmia events were reported as resolved at data cut-off. Median time to resolution of cardiac arrhythmia was 0.07 months (range 0-3.5 months).

## Pooled safety population

Table 41 Overview of AEPI Cardiac Arrhythmia in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile-AEPI Cardiac Arrhythmias，Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s:G039942,G029044

|                                                                   | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (GO29044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   |
|-------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 20(4.6%) 21                | 13 (3.0%) 16                   | 3(4.5%) 5                                        | 16 (3.2%) 21                                                    |
| Total number of patients with at least one                        |                            |                                |                                                  |                                                                 |
| Grade5AE                                                          | (0.28)                     | 0                              | 1 (1.58)                                         | 1 (0.2%)                                                        |
| Grade3-5AE                                                        | 4 (0.9%)                   | 2 (0.58)                       | 2 (3.0%)                                         | 4 (0.8%)                                                        |
| Serious AE                                                        | 4 (0.9%)                   | 2 (0.5%)                       | 3 (4.5%)                                         | 5 (1.0%)                                                        |
| Serious Related AE to any study drug                              | 1 (0.28)                   | 1 (0.28)                       | 1 (1.58)                                         | 2 (0.48)                                                        |
| AE leading to study discontinuation                               | 1 (0.2%)                   | 0 0                            | 1 (1.5%)                                         | 1 (0.2%)                                                        |
| AE leading to any study treatment dose discontinuation            | 0                          |                                | 0                                                | 0                                                               |
| AE leading 04 any study treatment dose reduction                  | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to any study treatment dose interruption               | 1 (0.2%)                   | 0                              | 0                                                | 0                                                               |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to polatuzumabveclotin/placebodosereduction            | 0 0                        | 0                              | 0                                                | 0                                                               |
| AE leading topolatuzumabvedotin/placebo_doseinterruption          |                            | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo discontinuation                 | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo dose reduction                  | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo dose interruption               | 0                          | 0                              | 0                                                | 0                                                               |

same AE are\\_counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new\\_or worseningAEfrom thefirstdoseofanystudydrug through9odaysafterthelastdoseofanystudydrug orprior toNALT,whichever is earlier.

GO39942CCOD:28JUN2021.Data extractdate:02AUG2021.

GO29044 Database 1ock date: 28MAR2019.

- Hyperglycemia

## Study POLARIX

Overall, the proportion of patients who experienced hyperglycemia in the pola+R-CHP arm (6.0%) was comparable with the R-CHOP arm (6.2%).

Grade 3 hyperglycemia (highest grade) was reported in 1.8% (8 patients) in the pola+RCHP arm and 1.4% (6 patients) in the R-CHOP arm. No patients in either arm experienced Grade 4 or Grade 5 hyperglycemia.

Median time to onset of first hyperglycemia event was 0.79 months (range: 0.0 - 3.0 months) in the pola+R-CHP arm and 0.72 months (range: 0.0 - 3.5 months) in the R-CHOP arm. Hyperglycemia was reported as resolved in 53.8% (14/26 patients with events) in the pola+R-CHP arm and 48.1% (13/27 patients with events) in the R-CHOP arm, as of the CCOD. Median time to resolution of hyperglycemia was 2.28 months (range: 0.0 - 5.8 months) in the pola+R-CHP arm and 0.66 months (range: 0.1 - 8.8 months) in the R-CHOP arm.

## Study GO29044

A total of 6/66 patients (9.1%) experienced 10 events of hyperglycemia with a median time to onset of 0.39 months (range: 0.3 - 2.9 months).

Four patients experienced Grade ≥3 hyperglycemia; all 4 patients experienced Grade 3 events. All other events were Grade ≤ 2.

One SAE was reported (Grade 3 hyperglycemia) which was considered related to prednisone. No patient experienced a hyperglycemia event leading to study treatment discontinuation or interruption. One patient had their study treatment dose reduced.

<div style=\"page-break-after: always\"></div>

All hyperglycemia events were reported as resolved at data cut-off with a median time to resolution of 0.10 months (range 0.0-3.1 months).

## Pooled safety population

Table 42 Overview of AEPI Hyperglycemia in Previously untreated DLBCL patients, Safety-evaluable Patients

Overall AE Profile AEPI Hyperglycemia，Patients with 1L DLBCL， Safety-Evaluable Patients Protoco1s:G039942，G029044

|                                                                 | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   |
|-----------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Total number ofpatients with at least one AE Totalnumber of AEs | 27 (6.28) 36               | 26 (6.0%) 34                   | 6 (9.18) 10                                      | 32 (6.48) 44                                                    |
| Totalnumber of patients with at least one                       |                            |                                |                                                  |                                                                 |
| Grade5AE                                                        | 0                          | 0                              | 0                                                | 0                                                               |
| Grade3-5 AE                                                     | 6 (1.48)                   | 8 (1.88)                       | (6.18)                                           | 12 (2.48)                                                       |
| Serious AE                                                      | 0                          | 0                              | 1 (1.58)                                         | 1 (0.2%)                                                        |
| SeriousRelatedAE toanystudy drug                                | 0                          | 0                              | 1 (1.58)                                         | 1 (0.28)                                                        |
| AE leading to study discontinuation                             | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to any study treatment dose discontinuation          | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to any study treatment dose reduction                | 0                          | 1 (0.2%)                       | 1 (1.58)                                         | 2 (0.4%)                                                        |
| AE leading to any study treatment dose interruption             | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to polatuzumab vedotin/placebo discontinuation       | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading topolatuzumabvedotin/placebodosereduction            | 0 0                        | 0                              | 0                                                | 0                                                               |
| AE leading topolatuzumabvedotin/placebodoseinterruption         |                            | 0                              | 0                                                | 0                                                               |
| AE leading tovincristine/placebodiscontinuation                 | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo dose reduction                | 0                          | 0                              | 0                                                | 0                                                               |
| AE leading to vincristine/placebo doseinterruption              | 0                          | 0                              | 0                                                | 0                                                               |

Investigator text for AEs encoded using MedDRA yersion 24.0.Percentages are based on N in the column headings. Multiple occurrences of the\\_same AE in one individual\\_are counted only once except\\_for \"Total\\_number of AEs\" row in which multiple occurrences of the same AE are\\_counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new\\_or worseningAEfrom thefirst dose of anystudydrugthrough9odaysafter thelastdose of anystudydrug or prior toNALT,whichever is earlier.

GO39942CCOD:28JUN2021.Dataextractdate:02AUG2021.

G029044 Database 1ock date:28MAR2019.

## Serious adverse event/deaths/other significant events

- Deaths

## Study POLARIX

At the time of the clinical cut-off date (CCOD), a total of 111 patients (12.7%) had died due to any cause. The proportion of patients who died in the pola+R-CHP arm (12.0%) was comparable with the R-CHOP arm (13.5%). The most common cause of death during the entire study period in both treatment arms was disease progression (6.4% in the pola+R-CHP arm and 7.1% in the R-CHOP arm). Almost all deaths due to disease progression occurred during the follow-up period. Two patients (0.5%) in the R-CHOP arm died due to disease progression during the AE reporting period.

Fatal AEs were reported in 3.0% of patients in the pola+R-CHP arm and 2.5% of patients in the R-CHOP arm. Almost all deaths due to AEs occurred during the AE reporting period. One patient in the R-CHOP arm experienced a Grade 5 AE (acute myeloid leukemia) during the follow up period. Most of the fatal AEs in both arms were due to infections or complications of infection.

The most frequent Grade 5 AEs (by PT) were pneumonia (4 patients [0.9%] in the pola+R-CHP arm and 3 patients [0.7%] in the R-CHOP arm), death (4 patients [0.9%] in the pola+R-CHP arm and 1 patient [0.2%] in the R-CHOP arm) and septic shock (0 patients in the pola+R-CHP arm and 2 patients [0.5%] in the RCHOP arm). The proportion of patients who died due to AEs that were considered related to the treatment by the investigator was 1.4% (6 patients) in the pola+R-CHP arm and 1.1% (5 patients) in the R-CHOP arm.

The treatment-related AEs that led to death in the pola+R-CHP arm were pneumonia (3 patients), cardiac death, acute kidney injury and death.

<div style=\"page-break-after: always\"></div>

Treatment-related AEs that led to death in the R-CHOP arm were pneumonia (2 patients), multiple organ dysfunction syndrome, and sepsis. One additional patient had a Grade 5 AE (acute myeloid leukemia) during the follow-up period which the investigator assessed as related to study treatment.

## Supportive study GO29044

A total of 6 deaths were reported in the pola+R-CHP/G-CHP population; 2 patients died due to an AE (atrial fibrillation, septic shock) during the AE reporting interval and 4 patients died due to disease progression in the follow-up period .

One  patient  with  a  history  of  mitral  valve  repair  and  concurrent  conditions  including  mitral  valve regurgitation and coronary artery disease, died due to atrial fibrillation. The investigator assessed this event as unrelated to any study drug and related to concurrent illness. The second patient died due to septic shock considered related to doxorubicin and cyclophosphamide treatment.

## Pooled safety population

The  proportion  of  patients  who  died  in  the  pooled  safety  population  (11.6%  [58/501  patients])  was comparable with the R-CHOP arm from POLARIX (13.5% [59/438 patients]). The most common cause of death in both treatment arms was disease progression (6.4% in the pooled safety population and 7.1% in the R-CHOP arm from POLARIX).

Table 43 Summary of Deaths in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

Sunmary of Deaths, Patients with lL DLBCL，Safety-Evaluable Patients Protoco1s:G039942, G029044

|                                             | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+G029044) (N=501)   |
|---------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Totalnumber of deaths                       | 59(13.5)                   | 52 (12.0)                      | 6 (9.15)                                         | 58 (11.6)                                                     |
| Primary Cause of Death                      |                            |                                |                                                  |                                                               |
| Disease progression                         | 31 7.1$)                   | 28 ( 6.4)                      | 4 (6.1)                                          | 32 (6.4)                                                      |
| Adverse event                               | 11 2.5)                    | 13 ( 3.05)                     | 2 (3.0$)                                         | 15 ( 3.0)                                                     |
| Other                                       | 17 3.93)                   | 11 2.5)                        |                                                  | 11 (2.23)                                                     |
| DLBCL was a contributing factor             | 2 0.54)                    | ( 0.75)                        | 0                                                | 3 (0.6)                                                       |
| DLBCL not known to be a contributing factor | 15 3.4)                    | 8 (1.8)                        | 0                                                | 8 (1.6)                                                       |
|                                             | 12 (2.7)                   | 13 (3.0)                       | 2(3.0)                                           | 15 (3.0)                                                      |
| Primary Cause of Death                      |                            |                                |                                                  |                                                               |
| Disease progression                         | 2 (0.5)                    | 0                              |                                                  | 0                                                             |
| Adverse event                               | 10 2.3)                    | 13 (3.0)                       | (3.0号)                                           | 15 (3.0)                                                      |
| Deaths during follow-up                     | 46 (10.5)                  | 39 (9.0)                       | 4 (6.16)                                         | 43(8.6)                                                       |
| Primary Cause of Death                      |                            |                                |                                                  |                                                               |
| Disease progression                         | 29 6.6)                    | 28 (6.4)                       | 4 (6.1§)                                         | 32 (6.45)                                                     |
| Adverse event                               | 1 0.24)                    | 0                              | 0                                                | 0                                                             |
| Other                                       | 16 3.7)                    | 11 2.5)                        | 0                                                | 11 2.2)                                                       |
| DLBcL was a contributing factor             | 2 0.55)                    | 3 0.7)                         | 0                                                | 3 0.6)                                                        |
| DLBcL not known to be acontributing factor  | 14 3.2)                    | 8                              |                                                  | 8 1.6)                                                        |

or prior to NALT, whichever is earlier. Follow up period defined as time outside of the AE reporting period. Contributing factor includes treatmentrelated death，or if the investigator considers DLBcL tobe a contributing factor to the death. GO39942 CCOD:28JUN2021.Data extract date: 02AUG2021. G029044 Database 1ock date:28MAR2019.

Program:root/clinical\\_studies/R05541077/share/pool\\_1LDLBCL\\_SCS/prod/program/t\\_dd.sas anogsditppa/andano/poxd/sosToeiat1tood/axeus/LLotssod/satpnasteotutto/aoox:andano 10AUG2021 23:29

Page l of 1

Note:OnepatientintheR-CHoParmwithapartiallymissingdeathdate(unknownmonth,day)obtainedfromthepublicrecordwasincludedinthe 'Total number of deaths'row but excluded from the subtotal row of'Deaths during AE reporting period'or'Deaths during follow up' as thereporting period during which the death occurred could not be determined.

Table 44 Grade 5 AEs by SOC and Preferred Term in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MedDRA System Organ Class MedDRA Preferred Term                            | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (l.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | All Pola (l.8 mg/kg) +R-CHP/G-CHD (POLARIX + G029044] (N=501)   |
|----------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Total mumber of patients with at least one adverse event                   | 10(2.3)                    | 13 (3.0%)                      | 2(3.0%)                                          | 15 (3.0)                                                        |
| Overall total number of events                                             | 10                         | 13                             | 2                                                | 15                                                              |
| Infections and infestations                                                |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                   | 6(1.4)                     | 5 (1.1)                        | 1 (1.5)                                          | 6 (1.26)                                                        |
| Total number of events                                                     | 6                          | 5                              | 1                                                | 6                                                               |
| Pneumonia                                                                  | 3(0.74)                    | 4(0.96)                        | 0                                                | 4(0.86)                                                         |
| Septic shock                                                               | 2(0.54)                    | 0                              | 1 (1.5%)                                         | 1(0.2)                                                          |
| Sepsis                                                                     | 1(0.24)                    | 1 (0.26)                       | 0                                                | 1 (0.2%)                                                        |
| General disorders and administration site conditions                       |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                   | 2(0.56)                    | 5 (1.16)                       |                                                  | 5 (1.0%)                                                        |
| Total number of events                                                     | 2                          | 5                              | 0                                                | 5                                                               |
| Death                                                                      | [0.24]                     | 4 (0.96)                       |                                                  | 4(0.8%)                                                         |
| Cardiac death                                                              | 0                          | 1 (0.25)                       | 口                                                | 1(0.2%)                                                         |
| Multiple organ dysfunction symdrome                                        | 1 (0.24)                   | 0                              | 0                                                | 0                                                               |
| Cardiac disorders Total number of patients with at least one adverse event | 1(0.24)                    | 0                              | 1 (1.5)                                          | 1 (0.2)                                                         |
| Total number of events                                                     | 1                          |                                | 1                                                | 1                                                               |
| Atrial fibrillation                                                        | 0                          |                                | (1.5)                                            | 1 (0.24)                                                        |
| Atrioventricular block complete                                            | 1 (0.24)                   | 口 0                            | 0                                                | 0                                                               |
| Gastrointestinal disorders                                                 |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                   | 0                          | 1 (0.26)                       | 口                                                | 1 (0.26)                                                        |
| Total number of events                                                     |                            | 1                              |                                                  | 1                                                               |
| Intestinal perforation                                                     | 0                          | 1 (0.25)                       | 0                                                | 1 (0.25)                                                        |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class HedDRA Preferred Term           | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (l.8 mg/kg) +R-CHP/G-CHD (G029044) (N=66)   | All Pola (l.8 mg/kg) +R-CHP/G-CHD (POLARIX + G029044) (N=501)   |
|-----------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Renal and urinary disorders                               |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event. | 0                          | 1(0.2)                         | 0                                                | 1(0.24)                                                         |
| Total number of events Acute kidney injury                | D                          | 1(0.25)                        | 0                                                | 1(0.2%)                                                         |
| Respiratory, thoracic and mediastinal disorders           |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event  | 0                          | 1(0.24)                        | 0                                                | 1(0.24)                                                         |
| Total number of events                                    | D                          | 1                              |                                                  |                                                                 |
| Respiratory failure                                       | 0                          | 1(0.25)                        | 0                                                | 1(0.24)                                                         |
| Injury, poisoning and procedural complications            |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event  | 1(0.24)                    | 0                              |                                                  | 0                                                               |
| Total number of events                                    | 1                          | 0                              | 0                                                |                                                                 |
| Injury                                                    | 1(0.24)                    | 0                              | 0                                                | 0                                                               |

<!-- image -->

- Other serious adverse event

## Study POLARIX

The proportion of patients with at least one SAE in the pola+R-CHP arm (34.0%) was comparable with the R-CHOP arm (30.6%).

SA Es were most commonly reported (≥5% of patients in either arm) in the following SOCs (pola+R -CHP arm and R-CHOP arm, respectively):

- Infections and infestations (14.0% and 10.3%)
- Blood and lymphatic system disorders (11.5% and 9.1%)
- Gastrointestinal disorders (7.1% and 5.9%)
- General disorders and administration site conditions (6.0% and 4.6%)

The proportion of patients with at least one SAE considered related to treatment in the Pola+R-CHP arm (25.7%) was higher than in the R-CHOP arm (19.6%).

The most common related SAEs by PT (≥1% of patients in either arm) were (pola+RCHP arm and R -CHOP arm, respectively):

- Febrile neutropenia (9.7% and 5.7%)
- Pneumonia (3.7% and 3.0%)
- Diarrhea (2.3% and 0.2%)
- Neutropenia (0.9% and 1.4%)

<div style=\"page-break-after: always\"></div>

- Sepsis (0.9% and 1.1%)
- Pyrexia (1.1% and 0.7%)
- Urinary tract infection (1.1% and 0.2%)
- Vomiting (1.1% and 0.5%).

No patients in either treatment arm discontinued study treatment due to the SAEs of febrile neutropenia, diarrhea or urinary tract infection.

## Supportive study GO29044

The majority of SAEs in Study GO29044 were due to cytopenia and infections.

A total of 27/66 patients (40.9%) had SAEs. By SOC, SAEs reported in ≥5% of patients comprised of blood and lymphatic  system  disorders  (16.7%),  and  infections  and  infestations  (13.6%).  By  preferred  term, febrile neutropenia, neutropenia, atrial fibrillation, influenza A virus test positive, syncope, pneumonia, and pulmonary embolism were the only SAEs reported in ≥1 patient.

SAEs  considered  related  to  treatment  were  reported  in  17  patients  (25.8%).  The  SAEs  were  febrile neutropenia (6 patients), neutropenia (4 patients), pneumonia (3 patients), atrial fibrillation, clostridium difficile  infection,  oral  fungal  infection,  septic  shock,  diarrhea,  vomiting,  malnutrition,  hyperglycemia, asthenia, arthritis, and pulmonary embolism. With the exception of vomiting and a fatal SAE of septic shock in  one  patient  and  a  fatal  SAE  of  atrial  fibrillation  in  a  second  patient,  all  other  related  SAEs  were resolved/resolved with sequelae.

## Pooled safety population

The proportion of patients with at least one SAE in the pooled safety population (34.9% [175/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable with the R-CHOP arm (30.6% [134/438 patients]).

Table 45 Serious Adverse Events by SOC and Preferred Term Occurring in ≥ 1% of Patients in either POLARIX Treatment Arm in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

<div style=\"page-break-after: always\"></div>

and Preferred Term, Patients with lL DLBCL, Safety-Evaluable Patients Prot0001s: G039942, G029044

| MedDRA System Organ Class MedDRA Preferred Term           | R-CHOP (POLARIX) (N=438)                                  | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A1l Pola (l.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Infections and infestations                               |                                                           |                                |                                                  |                                                                 |
| Pneumonia                                                 | 17(3.98)                                                  | 18 (4.1%)                      | 5(7.69)                                          | 23 (4.6%)                                                       |
| Sepsis                                                    | 7 (1.6%)                                                  | 5 (1.1%)                       | 1 1.5%)                                          | 1.2%)                                                           |
| Urinary tract infection                                   | 3(0.7%)                                                   | 8(1.8%)                        | 口                                                | 8 (1.6%)                                                        |
| Blood and lymphatic system disorders                      |                                                           |                                |                                                  |                                                                 |
| Febrile neutropenia                                       | 28 (6.4)                                                  | 43 186'6)                      | (13.6)                                           | 52 (10.4)                                                       |
| Neutropenia                                               | 6 (1.4)                                                   | 4 (0.9%)                       | 40 (6.1%)                                        | 1.6%)                                                           |
| Anaemia                                                   | 6 (1.4%)                                                  | 4 (0.98)                       |                                                  | 0.8%)                                                           |
| Gastrointestinal disorders                                |                                                           |                                |                                                  |                                                                 |
| Diarrhoea                                                 | (0.5)                                                     | 11 (2.58)                      | 1 ( 1.5)                                         | 12(2.4)                                                         |
| Vomiting                                                  | (0.58)                                                    | (1.18)                         | 10 (1.58)                                        | (1.28)                                                          |
| Small intestinal obstruction                              | (1.1:)                                                    |                                |                                                  | 60                                                              |
| General disorders and acministration site Pyrexia 8(1.8%) | General disorders and acministration site Pyrexia 8(1.8%) | Conditions 8 (1.8%)            | 0                                                | 8( 1.68)                                                        |

G039942 CC0D: 28JUN2021. Data eXtract date: 02AUG2021.

G029044 Database lock date: 28MAR2019.

<!-- image -->

## Laboratory findings

## 3-4 (Worst-Grade) Laboratory Test Parameters, Safety-Evaluable Patients

|                                  | R-CHOP (POLARIX) N=438   | Pola-R-CHP (POLARIX) N=435   | Pola (1.8 mg/kg) +R-CHP/G-CHP (GO29044) N=66   | AllPola (1.8mg/kg) +R-CHP/G-CHP (POLARIX + G029044) N=501   |
|----------------------------------|--------------------------|------------------------------|------------------------------------------------|-------------------------------------------------------------|
| HematologyLaboratoryParameters   |                          |                              |                                                |                                                             |
| ↓ Lymphocytes (abs)              | 204/436 (46.8%)          | 205/431 (47.6%)              | 37/66 (56.1%)                                  | 242/497 (48.7%)                                             |
| ↓Neutrophils (total, abs)        | 161/430 (37.4%)          | 152/427 (35.6%)              | 21/66 (31.8%)                                  | 173/493 (35.1%)                                             |
| ↓ Leukocytes (total)             | 132/436 (30.3%)          | 127/432 (29.4%)              | 23/66 (34.8%)                                  | 150/498 (30.1%)                                             |
| ↓Hemoglobin                      | 39/436 (8.9%)            | 45/432 (10.4%)               | 3/66 (4.5%)                                    | 48/498 (9.6%)                                               |
| ↓Platelets                       | 24/436 (5.5%)            | 30/432 (6.9%)                | 4/66 (6.1%)                                    | 34/498 (6.8%)                                               |
| BiochemistryLaboratoryParameters |                          |                              |                                                |                                                             |
| ↑ Uric acid                      | 86/435 (19.8%)           | 95/430 (22.1%)               | 7/66 (10.6%)                                   | 102/496 (20.6%)                                             |
| ↑Glucose                         | 26/435 (6.0%)            | 28/431 (6.5%)                | 7/66 (10.6%)                                   | 35/497 (7.0%)                                               |

Source:tIb\\_abn\\_1LP\\_SE

## · Immunogenicity

<div style=\"page-break-after: always\"></div>

In pivotal Study POLARIX, for all patients, the baseline prevalence of anti-drug antibodies (ADAs) was 2.4% (20/849 ADA evaluable patients). The 8 patients from the pola+R-CHP treatment arm who tested positive for  ADA  at  baseline  were  treatment  unaffected  (ADA  response  was  similar  to,  or  lower  than,  that  at baseline). Post-baseline, ADAs were detected in 6 of 427 (1.4%) ADA-evaluable patients treated with pola. All  6  ADA-positive  patients  had  treatment-induced  responses  (ADA  negative  at  baseline  or  missing  a baseline sample for ADA analysis and at least one positive post-basel ine ADA result). All 6 patients with treatment-induced ADA were negative for neutralizing antibody.

Table 46 Incidence of Anti-Drug Antibodies to Pola in POLARIX

|                                               | Arm A Pola+R-CHP (N=433)   | ArmB R-CHOP (N=425)   | All Patients (N=858)   |
|-----------------------------------------------|----------------------------|-----------------------|------------------------|
| BaselinePrevalenceofADAs                      |                            |                       |                        |
| Baseline evaluablepatients                    | 424                        | 425                   | 849                    |
| Patients with a positive sample at baseline   | 8 (1.9%)                   | 12 (2.8%)             | 20 (2.4%)              |
| Patients with no positive samples at baseline | 416                        | 413                   | 829                    |
| Post-BaselineIncidenceofADAs                  |                            |                       |                        |
| Post-baseline evaluable patients              | 427                        |                       |                        |
| Patients Positive for ADA                     | 6 (1.4%)                   |                       |                        |
| Treatment-Induced                             | 6                          |                       |                        |
| Treatment-Enhanced                            | 0                          |                       |                        |
| Patients negative for ADA                     | 421                        |                       |                        |
| Treatmentunaffected                           | 8                          |                       |                        |

ADA=anti-drug antibodies;Pola=polatuzumab vedotin;R-CHP=rituximab plus

cyclophosphamide, doxorubicin, and prednisone; R-CHOP=rituximab plus cyclophosphamide, doxorubicin,vincristine,andprednisone.

Baselineevaluablepatient=apatientwithanADAassayresult fromabaselinesample

Post-baseline evaluable patient = a patient with an ADA assay result from at least one post-baseline sample.

NumberofpatientspositiveforADA=thenumber(andpercentage)ofpost-baselineevaluable patientsdeterminedtohavetreatment-inducedADAortreatment-enhancedADAduringthe study period.

Treatment-induced ADA = a patient with negative or missing baseline ADA result(s) and at least onepositivepost-baselineADAresult.

Treatment-enhancedADA=apatientwithpositiveADAresult atbaselinewhohasoneormore post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.

NumberofpatientsnegativeforADA=numberofpost-baselineevaluablepatientswithnegative or missing baseline ADA result(s) and all negative post-baseline results, or a patient who is treatment unaffected.

Treatmentunaffected=Apost-baselineevaluablepatientwithapositiveADAresult atbaseline and (a) where all post-baseline titer results areless than 0.60 t.u. greater than the baseline titer result, OR (b) where all post-baseline results are negative or missing.

Source: t\\_ada1

For any positive samplewith titer result less than the minimum reportable titer or any positive sample where a titer cannot be obtained, titer value is imputed as equal to the minimum reportable titer.

For supportive Study GO29044, there were no observed ADA responses at either baseline or post-baseline timepoints.

Table 47 Characterization of ADA Positive Samples in Study GO39942

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Patient Number   | Visit                 | Titer Units   | PolatuzumabVedotin Total Antibody μg/mL   | Polatuzumab Antibody Immunodepletion   | Patient Treatment- EmergentStatus   | Duration of ADA Response   | Neutralizing Antibody   |
|------------------|-----------------------|---------------|-------------------------------------------|----------------------------------------|-------------------------------------|----------------------------|-------------------------|
| 10000            | Pre-dose Cycle 4 Day1 | <1.7          | 7.97                                      |                                        | Induced                             | persistent                 | negative                |
|                  | TC/ED                 | <1.7          | 0.165                                     |                                        |                                     |                            | negative                |
| 10058            | 3MFU                  | <1.7          | 0.0568                                    |                                        | Induced                             | persistent                 | negative                |
| 10082            | TC/ED                 | <1.7          | 5.07                                      | 一                                      | Induced                             | persistent                 | negative                |
| 10225            | Pre-dose Cycle 4 Day1 | <1.7          | 4.85                                      |                                        | Induced                             | persistent                 | negative                |
|                  | TC/ED                 | <1.7          | 0.617                                     |                                        |                                     |                            | negative                |
| 10267            | Pre-dose Cycle 4 Day1 | <1.7          | 5.98                                      |                                        | Induced                             | persistent                 | negative                |
|                  | 3MFU                  | <1.7          | <0.05                                     |                                        |                                     |                            | negative                |
|                  | TC/ED                 | <1.7          | 0.934                                     |                                        |                                     |                            | negative                |
| 10728            | Pre-dose Cycle 4Day1  | <1.7          | 9.37                                      |                                        | Induced                             | persistent                 | negative                |
|                  | TC/ED                 | <1.7          | 3.06                                      |                                        |                                     |                            | negative                |

Minimum reportable titer =1.70

ADA= anti-drug antibodies;Polatuzumab antibody=unconjugated humanized anti-CD79b antibody.

Treatment-Emergent ADA = the number of post-baseline evaluablepatients determined tohave treatment-induced ADA or treatment-enhanced ADA during the study period.

Treatment-induced ADA = a patient with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

Treatment-enhancedADA=apatient withpositiveADAresult at baselinewhohas oneormorepost-baseline titerresults that are atleast 0.60 t.u.greater thanthebaselinetiterresult.

3MFU=3-month follow-up visit; ADA=anti-drug antibody; TC/ED=treatment completion/early discontinuation

+=positive forimmunodepletion; immune response directed mainly at antibody portion.

-=negative forimmunodepletion; immune response directed mainly to linker, drug, or neo-epitopes.

first and last ADApositivesamples are separated by aperiod &gt;=16 weeks,irrespectiveof anynegative samples inbetween.

Transient ADA= ADA positive result detected (a) at only one post-baseline sampling time point (excluding last time point) OR (b) at 2 or more time points during treatment where the first and last ADApositive samples are separated by a period of &lt;16weeks, irrespective of any negative samples in between.

Source:|\\_ada1,I\\_ada2

Table 48 Incidence of ADA to Pola in Study GO29044

|                                               | R-CHP+Pola 1.8 mg/kg (N=1)   | G-CHP+Pola 1.4 mg/kg (N=6)   | G-CHP+Pola 1.8 mg/kg (N=6)   | EXP R- CHP+Pola 1.8 mg/kg (N=33)   | EXP G-CHP+Pola 1.8 mg/kg (N=17)   | All Pola Treated Patients (N=63)   |
|-----------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------------|-----------------------------------|------------------------------------|
| BaselinePrevalenceofADAs                      |                              |                              |                              |                                    |                                   |                                    |
| Baselineevaluablepatients                     |                              | 6                            | 6                            | 30                                 | 17                                | 60                                 |
| Patients with a positive sample at baseline   | 0                            | 0                            | 0                            | 0                                  | 0                                 | 0                                  |
| Patients with no positive samples at baseline |                              | 6                            | 6                            | 30                                 | 17                                | 60                                 |
| Post-BaselineIncidenceofADAs                  |                              |                              |                              |                                    |                                   |                                    |
| Post-baseline evaluable patients              |                              | 6                            | 6                            | 33                                 | 17                                | 63                                 |
| Patients Positivefor ADA                      | 0                            | 0                            | 0                            | 0                                  | 0                                 | 0                                  |
| Patients negative for ADA                     | 1                            | 6                            | 6                            | 33                                 | 17                                | 63                                 |
| Treatment unaffected                          | 0                            | 0                            | 0                            | 0                                  | 0                                 | 0                                  |

ADA=anti-drug antibodies;EXP=expansion; G-CHP=obinutuzumabplus cyclophosphamide, doxorubicin, and prednisone;Pola=polatuzumab vedotin; R-CHP=rituximab plus cyclophosphamide, doxorubicin, and prednisone.

Baseline evaluablepatient=apatient with anADA assayresult fromabaselinesample.

Post-baseline evaluable patient = a patient with an ADA assay result from at least one post-baseline sample

Number of patients positive for ADA = the number (and percentage) of post-baseline evaluable patients detemined to have treatment-induced ADA or treatment-enhanced ADA during the study period.

Treatment-induced ADA = a patient with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.

Treatment-enhanced ADA = a patient with positive ADA result at baseline whohas one or morepost-baseline titer results that are at least 0.60 t.u. qreaterthanthebaselinetiterresult.

Number of patients negative for ADA = number of post-baseline evaluable patients with negative or missing baseline ADA result(s) and all negative post-baseline results, or a patient who is treatment unaffected.

Treatment unaffected =A post-baseline evaluable patient with a positive ADA result at baseline and (a) where all post-baseline titer results are less than 0.60 t.u. greater than the baseline titer result, OR (b) where all post-baseline results are negative or missing.

For any positive sample with titer result less than the minimum reportable titer or any positive sample where a titer cannot be obtained, titer value is imputedasequaltotheminimumreportabletiter.

Source GO29044 Final CSR,Report 1109685, Section 8.2.

- Vital sign, physical findings and other observations related to safety
- o Study POLARIX

Vital  signs  parameters  in  both  treatment  arms  were  consistent  throughout  treatment  and  no  clinically meaningful difference from baseline to any time post-baseline was observed between the pola+R-CHP and R-CHOP treatment arms in mean body surface area, mean diastolic blood pressure, mean systolic blood

<div style=\"page-break-after: always\"></div>

pressure, mean pulse rate, mean respiratory rate, mean oxygen saturation (%), mean temperature, mean height or mean weight.

At screening, 5 patients (1.2%) in the pola+R-CHP arm and 3 patients (0.7%) in the R-CHOP arm had a clinically significant ECG abnormality.

Post-baseline, the proportion of patients with clinically significant ECG abnormalities was 1.3% (5 patients) in the pola+R-CHP arm and 1.0% (4 patients) in the R-CHOP arm.

## Safety in special populations

- Age

Table 49 Overview of safety profile in patients &lt;65 (N=428), safety-evaluable patients

Table 50 Overview of safety profile in patients ≥65 (N=511), safety -evaluable patients

<!-- image -->

<div style=\"page-break-after: always\"></div>

```
Overall AE Profile by Age (< 65 vs.>=65 years)，Patients with 1L DLBCL, Safety-Evaluable Patients
```

Protoco1s:G039942,G029044 Age Group: &gt;= 65 (N=511) Pola (1.8 mg/kg) A11 Pola (1.8 mg/kg) R-CHOP Pola-R-CHP +R-CHP/G-CHP +R-CHP/G-CHP (POLARIX) (POLARIX) (GO29044) (POLARIX+GO29044) (N=235) (N=227) (N=49) (N=276) Total number of patients with at least one AE 232 (98.78) 223(98.28) 49(1008) 272 (98.68) Total number of AEs 2776 2933 747 3680 Totalnumber of patients with at least one Grade 5 AE 9 (3.88) 9 (4.0%) 2 (4.18) 11 (4.0%) Grade 3-5 AE 154 (65.58) 150 (66.18) 34 (69.48) 184 (66.7%) Serious AE 81 (34.5%) 89 (39.2%) 22 (44.98) 111 (40.28) Serious Related AE to any study drug 53 (22.68) 66 (29.1%) 15 (30.6%) 81 (29.38) AE leading to study discontinuation 9 3.8%) 9 4.0%) 3 (6.18) 12 (4.38) AE leading to any study treatment dose discontinuation 18 7.7%) 22 (9.78) 8 (16.38) 30 (10.9%) AE leading to any study treatment dose reduction 28 (11.98) 24 (10.6%) 8 (16.38) 32 (11.6%) AE leading to any study treatment dose interruption 63 (26.88) 54 (23.8%) 12 (24.58) 66 (23.98) AE leading to polatuzumab vedotin/placebo discontinuation 15 6.48) 15 6.68) 8 (16.38) 23 (8.38) AE leading to polatuzumab vedotin/placebo dose reduction 20 (8.58) 11 (4.88) 5 (10.28) 16 (5.88) AE leading to polatuzumab vedotin/placebodoseinterruption 41 (17.4%) 35 (15.4%) 5 (10.28) 40 (14.58) AE leading to vincristine/placebo discontinuation 15 6.4%) 15 (6.68) 0 15 (5.48) AE leading to vincristine/placebo dose reduction 21 (8.98) 11 （ 4.88) 0 11 (4.08) AE leading to vincristine/placebo dose interruption 39 (16.6%) 35 (15.4%) 0 35 (12.7%) of the same AE in one individual are counted only once except for \"Total number of AEs\"row in which multiple occurrences of the same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 9o days after the last dose of any study drug or prior to NALT,whichever is earlier. G039942 CCOD: 28JUN2021.Data \\_extract date:02AUG2021. G029044 Database 1ock date:28MAR2019.

## · Gender

## Table 51 Overview of safety profile in male (N=504), safety-evaluable patients

Table 52 Overview of safety profile in female (N=435), safety-devaluable patients

<!-- image -->

<div style=\"page-break-after: always\"></div>

```
OverallAE Profile by Sex (Male vs.Female),Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s: G039942, G029044 Sex: Female (N=435)
```

|                                                                   | R-CHOP (POLARIX) (N=204)   | Pola-R-CHP (POLARIX) (N-199)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N-32)   | Al1 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+ GO29044) (N=231)   |
|-------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 201 (98.5*) 2629           | 196 (98.5) 2849                | 32(100%) 549                                     | 228 (98.7%) 3398                                               |
| Totalnumber ofpatients with at least one                          |                            |                                |                                                  |                                                                |
| Grade 5AE                                                         | 1 0.5%)                    | (3.5)                          | 2 (6.3%)                                         | 6 (3.9%)                                                       |
| Grade 3-5 AE                                                      | 127 (62.3%)                | 124 (62.3$)                    | 22 (68.8%)                                       | 146 (63.2%)                                                    |
| Serious AE                                                        | 56 (27.5%)                 | 67 (33.7%)                     | 16 (50.0%)                                       | 83 (35.9%)                                                     |
| Serious Related AE to any study drug                              | 34 (16.7%)                 | 53 (26.68)                     | 10 (31.3)                                        | 63 (27.3*)                                                     |
| AE leading to study discontinuation                               | 1 0.5%)                    | 7 3.5%)                        | 1 (3.1)                                          | 8 3.5)                                                         |
| AE leading to any study treatment dose discontinuation            | 16 7.8$)                   | 12 6.0%)                       | 5 (15.6)                                         | 17 7.4%)                                                       |
| AE leading to any study treatment dose reduction                  | 34 (16.7%)                 | 25 (12.6)                      | 3 (9.4%)                                         | 28 (12.1*)                                                     |
| AE leading to any study treatment dose interruption               | 59 (28.9%)                 | 52 (26.1)                      | 9 (28.1)                                         | 61 (26.4%)                                                     |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 14 (6.9%) 27               | 8 4.0%)                        | 5 (15.6)                                         | 13 (5.6)                                                       |
| AE leading to polatuzumab vedotin/placebo dose reduction          | (13.2%)                    | 13 6.5%)                       | 2 (6.3%)                                         | 15 (6.5%)                                                      |
| AE leading to polatuzumab vedotin/placebo dose interruption       | 33 (16.2%)                 | 29 (14.6)                      | 2 (6.3%)                                         | 31 (13.4&)                                                     |
| AE leading to vincristine/placebo discontinuation                 | 14 (6.9%) 28               | 8 (4.0%)                       | 0                                                | 8 (3.5%)                                                       |
| AE leading tovincristine/placebodosereduction                     | (13.7%)                    | 14 (7.0%)                      | 0                                                | 14 (6.1$)                                                      |
| AE leading to vincristine/placebo dose interruption               | 31 (15.2$)                 | 29 (14.6%)                     | 0                                                | 29 (12.6)                                                      |

<!-- image -->

- Race

## Study POLARIX

The majority of enrolled patients were of White (N=523) or Asian (N=168) ethnicity and assessment of differences between other race subgroups could not be performed due to the small sample sizes in these race  subgroups  (American  Indian  or  Alaska  Native  [N=3],  Black  or  African  American  [N=17],  Native Hawaiian or Other Pacific Islander [N=3], Other [N=17]).

Overall,  the  safety  profile  was  generally  comparable  between  White  and  Asian  subgroups  with  some numerical differences.

Grade ≥ 3 AEs were reported in a higher proportion of Asian patients (pola+R -CHP: 73.8% and R-CHOP: 67.9%) compared with White patients (pola+R-CHP: 58.9% and R-CHOP: 59.6%) in both treatment arms. The proportion of deaths due to AEs was numerically higher in the White race subgroup (pola+R-CHP: 10 deaths [4.3%] vs. R-CHOP: 8 deaths [3.4%]) compared with Asian race subgroup (pola+R-CHP: 1 death [1.2%] vs. RCHOP: 1 death [1.2%]).

## Supportive study GO29044

The majority of patients enrolled in GO29044 were White (57/66 patients). Overall, no assessment of differences between race subgroups could be performed due to the small sample size in other race groups.

- Body weight

To  investigate  the  incidence  of  AEs  by  weight,  patients  were  categorized  into  two  baseline  weight categories; ≤100 kg (N=847) and &gt;100 kg (N=86).

Table 53 Overview of safety profile in body weight ≤100 kg (N=847), safety -evaluable patients

<div style=\"page-break-after: always\"></div>

OverallAE Profile by Baseline Weight(&gt;100 kg vs.&lt;-100 kg),Patients with 1L DLBCL，Safety-Evaluable Patients

<!-- image -->

Table 54 Overview of safety profile in body weight &gt;100 kg (N=86), safety-evaluable patients

|                                                                   | R-CHOP (POLARIX) (N=36)   | Pola-R-CHP (POLARIX) (N=43)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=7)   | Al1 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+ GO29044) (N=50)   |
|-------------------------------------------------------------------|---------------------------|-------------------------------|-------------------------------------------------|---------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 36(100%) 454              | 43(100%) 694                  | 7（100%） 120                                     | 50(100%) 814                                                  |
| Total number of patients with at least one                        |                           |                               |                                                 |                                                               |
| Grade 5 AE                                                        | 2 (5.6%)                  | 2 (4.7%)                      | 0                                               | (4.0%)                                                        |
| Grade 3-5 AE                                                      | 20 (55.6%)                | 22 (51.2%)                    | 6 (85.7%]                                       | 28 (56.0%)                                                    |
| Serious AE                                                        | 13 (36.1%)                | 14 (32.6%)                    | 4 (57.1%)                                       | 18 (36.0%)                                                    |
| Serious Related AE to any study drug                              | 6 (16.7%)                 | 9 (20.9%)                     | 2 (28.6%)                                       | 11 (22.0%)                                                    |
| AE leading to study discontinuation                               | 2 5.6)                    | 2 (4.7&)                      | 1 (14.3)                                        | 3 (6.0%)                                                      |
| AE leading to any study treatment dose discontinuation            | 2 5.6%)                   | 1 (2.3)                       | 1 (14.3)                                        | 2 (4.0%)                                                      |
| AE leading toany study treatment dose reduction                   | 3 (8.3)                   | 6 (14.0%)                     | 0                                               | (12.0%)                                                       |
| AE leading to any study treatment dose interruption               | 11 (30.6%)                | 10 (23.3%)                    | 3 (42.9%)                                       | 13 (26.0%)                                                    |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 2 (5.6)                   | 1 (2.3)                       | 1 (14.3$)                                       | 2 (4.0%)                                                      |
| AE leading to polatuzumab vedotin/placebo dose reduction          | 3 (8.3%)                  | 5 (11.6%)                     | 0                                               | 5 (10.0%)                                                     |
| AE leading to polatuzumab vedotin/placebo dose interruption       | 5 (13.9%)                 | 5 (11.6%)                     | 2 (28.6%)                                       | (14.0%)                                                       |
| AE leading to vincristine/placebo discontinuation                 | 2 （5.6)                   | 1 (2.3%)                      | 0                                               | (2.0%)                                                        |
| AE leading to vincristine/placebo dose reduction                  | 2 (5.6%)                  | (9.3)                         | 0                                               | (8.0%)                                                        |
| AE leading to vincristine/placebo dose interruption               | (13.9*)                   | (11.6%)                       | 0                                               | (10.0%)                                                       |

G039942 CC0D:28JUN2021.Data eXtract date: 02AUG2021.

G029044 Database 1ock date: 28MAR2019.

<!-- image -->

## · Hepatic impairment

To investigate the incidence of AEs by hepatic impairment, patients were categorized into four groups based on hepatic function at baseline:

- -normal hepatic function (baseline bilirubin ≤ ULN and aspartate aminotransferase [AST] ≤ ULN); N=751
- -mild hepatic impairment (baseline bilirubin ≤  ULN and AST &gt; ULN); N=131 and/or (ULN &lt; baseline bilirubin ≤ 1.5 x ULN); N=34
- -moderate hepatic impairment (1.5 x ULN &lt; baseline bilirubin  ≤  3 x ULN); N=14

<div style=\"page-break-after: always\"></div>

- -severe hepatic impairment (baseline bilirubin &gt; 3 x ULN); N=2

## Table 55 Overview of safety profile in normal hepatic function (N=751), safety-evaluable patients

```
Overall AE Profile by Hepatic Status,Patients with 1L DLBcL，Safety-Evaluable Patients Prot0co1s:G039942,G029044 Baseline Hepatic Function Group: Normal (N-751)
```

R-CHOP

(N=349)

(POLARIX)

344(98.6)

4101

5

201

(1.48)

102

(57.6*)

67

5

19

88

43

14

49

33

14

47

Total number of AEs

Totalnumber of patients with at least one AE

Totalnumber ofpatients with atleast one

Grade 3-5 AE

Grade 5 AE

Serious AE

AE leading to study discontinuation

Serious Related AE to any study drug

AE leading to any study treatment dose discontinuation

AE

study treatment dose reduction

AE leading to any

AE

polatuzumab vedotin/placebo discontinuation study treatment dose interruption

leading

AE

leading leading

AE

leading to

to any

to polatuzumab vedotin/placebo dose reduction tovincristine/placebo discontinuation

to polatuzumab vedotin/placebo dose interruption to vincristine/placebo dose reduction

AE leading

Pola-R-CHP

(N-343)

(POLARIX)

335(97.7%)

4174

7

(2.0)

113

201

85

7

19

79

34

12

46

19

12

45

(32.9)

(58.6*)

(24.8%)

5.5$)

2.0)

9.9$)

3.5)

(23.0%)

5.5)

(13.4)

3.5$)

(13.1)

5.5$)

A11 Pola (1.8 mg/kg)

(POLARIX+ G029044)

+R-CHP/G-CHP

(N=402)

394(98.0)

5056

6

239

（2.2%）

135

10

99

26

41

19

96

24

51

12

19

45

(59.5$)

(24.68)

(33.6)

2.5%)

(10.2)

6.5%)

(23.9*)

(6.0%)

4.7%)

(12.7%)

4.7%)

AE leading

AE leading to vincristine/placebo dose interruption

(19.2)

(29.2)

1.4)

(12.3)

5.4%)

(25.2$)

9.5)

4.0%)

(14.0*)

(10.0%)

(4.0%)

(13.5)

Pola (1.8 mg/kg)

(G029044)

+R-CHP/G-CHP

(N-59)

59(100)

882

2

38

（3.4)

22

(64.4%)

14

3

7

7

17

7

5

5

0

0

0

（3.0%)

(11.2)

Investigator text for AEs encoded using MedDRA version 24.o. Percentages are based on N In the column headings. Muitiple occurrences of the same AE in one individualare counted only once except for \"Total number of AEs\" row in which multiple occurrences of the same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any studydrug through 9o days after the last dose of anystudydrug or prior toNALr,whichever is earlier. G039942 CC0D:28JUN2021.Data extract date:02AUG2021.

G029044 Database 1ock date: 28MAR2019.

## Table 56 Overview of safety profile in mild hepatic impairment (N=131), safety-evaluable patients

Table 57 Overview of safety profile in mild hepatic impairment (N=34), safety-evaluable patients

<!-- image -->

(23.7%)

(37.3*)

(5.1%)

(11.9%)

(11.9$)

(28.8)

8.5%)

(11.9$)

（8.5)

19

35

<div style=\"page-break-after: always\"></div>

```
Prot0co1s:G039942,G029044
```

Baseline Hepatic Function Group:Mild 2 (N-34)

|                                                                   | R-CHOP (POLARIX) (N=12)   | Pola-R-CHP (POLARIX) (N=20)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=2)   | Al1 Pola (1.8 mg/kg) +R-CHP/G=CHP (POLARIX + GO29044) (N=22)   |
|-------------------------------------------------------------------|---------------------------|-------------------------------|-------------------------------------------------|----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 12 （100%) 128             | 20 (100%) 308                 | 2（100) 19                                       | 22(100%) 327                                                   |
| Totalnumber ofpatients withat lea 北 one                           |                           |                               |                                                 |                                                                |
| Grade 5 AE                                                        | 2 (16.7)                  | 3 (15.0%)                     | 0                                               | (13.6%)                                                        |
| Grade 3-5 AE                                                      | 9 (75.0%)                 | (65.0%)                       | 1 (50.0%)                                       | 14 (63.6%)                                                     |
| Serious AE                                                        | 7 (58.3)                  | 9 (45.0%)                     | 1 (50.0%)                                       | 10 (45.5%)                                                     |
| Serious Related AE to any study drug                              | 4 (33.3*)                 | 8 (40.0%)                     | 1 (50.0%)                                       | (40.9%)                                                        |
| AE leading to study discontinuation                               | 2 (16.7%)                 | 3 (15.0%)                     | 0                                               | 3 (13.6)                                                       |
| AE leading to any study treatment dose discontinuation            | 3 (25.0*)                 | 5 (25.0%)                     | 0                                               | 5 (22.7%)                                                      |
| AE leading to any study treatment dose reduction                  | 0                         | 2 (10.0*)                     | 1 (50.0)                                        | 3 (13.6)                                                       |
| AE leading to any study treatment dose interruption               | 3 (25.0%)                 | 6 (30.0%)                     | 0                                               | 6 (27.3)                                                       |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 3 (25.0%)                 | 4 (20.0%)                     | 0                                               | (18.2)                                                         |
| AE leading to polatuzumab vedotin/placebo dose reduction          | 0                         | 2 (10.0%)                     | 0                                               | 2 (9.1$)                                                       |
| AE leading to polatuzumab vedotin/placebo dose interruption       | 2 (16.7%)                 | (20.0%)                       | 0                                               | (18.2%)                                                        |
| AE leading to vincristine/placebo discontinuation                 | 3 (25.0%)                 | (20.0%)                       | 0                                               | (18.2)                                                         |
| AE leading to vincristine/placebo dose reduction                  | 0                         | 2 (10.0%)                     | 0                                               | 2 (9.1%)                                                       |
| AE leading tovincristine/placebo dose interruption                | 2 (16.7%)                 | (20.0%)                       | 0                                               | (18.2%)                                                        |

based on N in the column headings. Muitiple occurrences of the\\_same AE in one individual\\_are counted only once except\\_for same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 9o days after the last dose of any study drug or prior toNALT,whichever is earlier.

GO39942 CC0D:28JUN2021.Data extract date: 02AUG2021.

G029044 Database 1ock date:28MAR2019.

## Table 58 Overview of safety profile in moderate hepatic impairment (N=14), safety-evaluable patients

Overall AE Profile by Hepatic Status,Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s:G039942,G029044

Baseline Hepatic Function Group:Moderate (N-14)

|                                                                   | R-CHOP (POLARIX) (N=5)   | Pola-R-CHP (POLARIX) (N=9)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N-0)   | Al1 Pola (1.8 mg/kg) +R-CHP/G=CHP (POLARIX +GO29044) (N=9)   |
|-------------------------------------------------------------------|--------------------------|------------------------------|-------------------------------------------------|--------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | （100%) 70                | 9(100%) 161                  | 0 0                                             | 9(100%) 161                                                  |
| Totalnumber of patients with at least one Grade 3-5AE             | (80.0%)                  | (77.8%)                      | 0                                               | (77.8$)                                                      |
| Serious AE                                                        | (20.0%)                  | 5 (55.6%)                    | 0                                               | (55.6)                                                       |
| Serious Related AE to anystudydrug                                | (20.0%)                  | 5 (55.6%)                    | 0                                               | 5 (55.6%)                                                    |
| AE leading to any study treatment dose interruption               | (20.0%)                  | 3 (33.3)                     | 0                                               | 3 (33.3$)                                                    |
| AE leading to poiatuzumabvedotin/placebo dose interruption        | (20.0%)                  | 2 (22.2%)                    | 0                                               | 2 (22.2%)                                                    |
| AE leading to vincristine/placebo dose interruption               | (20.0%)                  | 2 (22.2%)                    | 0                                               | 2 (22.2)                                                     |

Investigator text for AEs encoded using MedDRA version 24.o.Percentages are based on N in the column headings. Muitiple occurrences ofthe sameAE in one individualare counted only once except for \"Total number ofAEs\"row inwhich muitiple occurrences of the same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NAlT,whichever is earlier.

GO39942 CC0D:28JUN2021.Data extract date:02AUG2021.

G029044 Database 1ock date:28MAR2019.

## Table 59 Overview of safety profile in severe hepatic impairment (N=2), safety-evaluable patients

OverallAE Profile by Hepatic Status,Patients with 1L DLBcL,Safety-Evaluable Patients Protoco1s: G039942，G029044

Baseline Hepatic Function Group:Severe (N-2)

|                                                                                                                                                                                                                                                                                                                                                                                                                                        | R-CHOP (POLARIX) (N-1)                               | Pola-R-CHP (POLARIX) (N=1)                                 | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N-0)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+ G029044) (N=1)     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs                                                                                                                                                                                                                                                                                                                                                                      | (100%) 4                                             | 1 (100%) 10                                                | 0 0                                             | 1 (100%) 10                                                    |
| Totalnumber ofpatientswith at least one Grade 5AE Grade3-5AE AE leading Serious AE AE leading tostudydiscontinuation to any study treatment dose discontinuation AE leading to any study treatment dose reduction AE leading to polatuzumabvedotin/placebo discontinuation AE leading to polatuzumab vedotin/placebo dose reduction AE leading to vincristine/placebo discontinuation AE leading to vincristine/placebo dose reduction | 0 1 (100%) 0 1 0 (100%) 1 (100%) 0 1 (100%) 0 (100%) | (100%) (100%) (100号) (100%) (100%) 0 1 (100%) 0 1 (100%) 0 | 0 0 0 0 0 0 0 0 0 0                             | (100%) (100%) 1 1 (100%) (100%) (100%) 0 1 (100%) 0 1 (100%) 0 |

Investigator text for AEs encoded using MedDRA version 24.0. Percentages are based on N In the column headings. Muitiple occurrences of the same AE in one individual\\_are counted only once except\\_for same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only,which is defined as new or worsening AE fromthe first dose of any study drug through 90 days after the last dose of any study drug or prior to NAlT,whichever is earlier.

GO39942 CC0D:28JUN2021.Data extract date: 02AUG2021.

G029044 Database 1ock date:28MAR2019.

<div style=\"page-break-after: always\"></div>

## · Renal impairment

To investigate the incidence of AEs by renal impairment, patients were categorized into four groups based on GFR at baseline:

- -normal renal function (creatinine clearance [CrCL] ≥90 mL/min); N=386
- -mild renal impairment (CrCL ≥60 mL/min to &lt;90 mL/min); N=428
- -moderate renal impairment (CrCL ≥30 mL/min to &lt;60 mL/min); N=116
- -severe renal impairment (C rCL ≥15 mL/min to &lt;30 mL/min); N=2

## Table 60 Overview of safety profile in normal renalfunction (N=386), safety-evaluable patients

```
Overall AE Profile by Renal Impairment, Patients with 1L DLBCL，Safety-Evaluable Patients Protoco1s: G039942,G029044
```

Baseline Renal Impairment: Norma1 (N-386)

|                                                                   | R-CHOP (POLARIX) (N-184)   | Pola-R-CHP (POLARIX) (N=172)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=30)   | Al1 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+ G029044) (N=202)   |
|-------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 179(97.3) 2170             | 168 (97.7%) 2025               | 30(100%) 395                                     | 198 (98.0) 2420                                                |
| Totalnumber ofpatients with at least one                          |                            |                                |                                                  |                                                                |
| Grade 5AE                                                         | 2 (1.1%)                   | 4 (2.3)                        | 0                                                | (2.0%)                                                         |
| Grade 3-5AE                                                       | 100 (54.3$)                | 93 (54.1%)                     | 17 (56.7%)                                       | 110 (54.5$)                                                    |
| Serious AE                                                        | 52 (28.3*)                 | 52 (30.2)                      | 11 (36.7%)                                       | 63 (31.2)                                                      |
| Serious Related AE to any study drug                              | 32 (17.4)                  | 40 (23.3)                      | 5 (16.7%)                                        | 45 (22.3)                                                      |
| AE leading to study discontinuation                               | 2 1.1*)                    | 4 2.3%)                        | 1 （ 3.3)                                         | 5 (2.5%)                                                       |
| AE leading to  any study treatment dose discontinuation           | 13 7.1$)                   | 4 2.3%)                        | (3.3)                                            | 5 2.5%)                                                        |
| AE leading to any study treatment dose reduction                  | 21 (11.4)                  | 14 (8.1)                       | 3 (10.0%)                                        | 17 (8.4)                                                       |
| AE leading to any study treatment dose interruption               | 47 (25.5)                  | 37 (21.5*)                     | 7 (23.3%)                                        | 44 (21.8%)                                                     |
| AE leading to polatuzumab vedotin/placebo discontinuation         | 9 4.9)                     | 3 1.7$)                        | 1 (3.3)                                          | 4 (2.0%)                                                       |
| AE leading to polatuzumab vedotin/placebo dose reduction          | 18 9.8$)                   | 8 4.7%)                        | 2 (6.7%)                                         | 10 (5.0)                                                       |
| AE leading to polatuzumabvedotin/placebo dose interruption        | 20 (10.9*)                 | 19 (11.0%)                     | 2 (6.7%)                                         | 21 (10.4%)                                                     |
| AE leading to vincristine/placebo discontinuation                 | 9 4.9%)                    | 3 1.7%)                        | 0                                                | 3 （ 1.5)                                                       |
| AE leading to vincristine/placebo dose reduction                  | 18 9.8+)                   | 8 4.7%)                        | 0                                                | 8 4.0%)                                                        |
| AE leading to vincristine/placebo dose interruption               | 19 (10.3%)                 | 19 (11.0%)                     | 0                                                | 19 (9.4)                                                       |

are \"Total number of AEs\" row in which muitiple occurrences of the same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 9o days after the last dose of any study drug or prior to NALr, whichever is earlier.

G039942 CC0D:28JUN2021.Data eXtract date: 02AUG2021.

G029044 Database 1ock date: 28MAR2019.

Table 61 Overview of safety profile in mild renal impairment (N=428), safety-evaluable patients

Overall AE Profile by Renal Impairment, Patients with 1L DLBCL，Safety-Evaluable Patients Prot0co1s: G039942,G029044

Baseline Renal Impairment:Mild (N=428)

|                                                                   | R-CHOP (POLARIX) (N=197)   | Pola-R-CHP (POLARIX) (N=204)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=27)   | Al1 Pola (1.8 mg/kg) +R-CHP/G=CHP (POLARIX +GO29044) (N-231)   |
|-------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Total number of patients with at least one AE Total number of AEs | 195 (99.0%) 2245           | 200(98.0%) 2614                | 27(100%) 401                                     | 227(98.3) 3015                                                 |
| Total number of patients with at least one                        |                            |                                |                                                  |                                                                |
| Grade 5 AE                                                        | 6 (3.0%)                   | 9 (4.4&)                       | (3.7%)                                           | 10 (4.3)                                                       |
| Grade 3-5 AE                                                      | 120 (60.9%)                | 129 (63.2%)                    | 20 (74.1*)                                       | 149 (64.5*)                                                    |
| Serious AE                                                        | 61 (31.0%)                 | 72 (35.3*)                     | 13 (48.1%)                                       | 85 (36.8%)                                                     |
| Serious Related AE to any study drug                              | 39 (19.8)                  | 52 (25.5%)                     | 10 (37.0%)                                       | 62 (26.8%)                                                     |
| AE leading to study discontinuation                               | 6 3.0%)                    | 6 4.4%)                        | 1 (3.7%)                                         | 10 (4.3%)                                                      |
| AE leading to any study treatment dose discontinuation            | 11 (5.6%)                  | 15 (7.48)                      | 6 (22.2%)                                        | 21 (9.1%)                                                      |
| AE leading to any study treatment dose reduction                  | 23 (11.7%)                 | 22 (10.8%)                     | 5 (18.5%)                                        | 27 (11.7%)                                                     |
| AE leading to anystudy treatmentdose interruption                 | 45 (22.8%)                 | 47 (23.0%)                     | 8 (29.6%)                                        | 55 (23.8%)                                                     |
| AE leading                                                        | 11 5.6%)                   | 11 (5.4%)                      | 6 (22.28)                                        | 17 7.4%)                                                       |
| AE leading to polatuzumab vedotin/placebo dose reduction          | 18 9.1)                    | 13 6.4%)                       | 3 (11.1%)                                        | 16 (6.9%)                                                      |
| AE leading to polatuzumab vedotin/placebo dose interruption       | 28 (14.2%)                 | 28 (13.7%)                     | 4 (14.8%)                                        | 32 (13.9%)                                                     |
| AE leading to vincristine/placebo discontinuation                 | 11 5.6%)                   | 11 5.4$)                       | 0                                                | 11 4.8%)                                                       |
| AE leading to vincristine/placebo dose reduction                  | 17 8.6%)                   | 14 6.9%)                       | 0                                                | 14 6.1%)                                                       |
| AE leading to vincristine/placebo dose interruption               | 27 (13.7%)                 | 28 (13.7%)                     | 0                                                | 28 (12.1)                                                      |

Investigator text for AEs encoded using MedDRA version 24.0. are of the same AE in oneindividual\\_are counted only once exceptfor same AE are counted separately. Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worseningAE from the first dose of any study drug through 9o days after the last dose ofany study drug or prior to NALr,whichever is earlier. G039942 CC0D:28JUN2021.Data extract date:02AUG2021.

G029044 Database 1ock date: 28MAR2019.

<div style=\"page-break-after: always\"></div>

Table 62 Overview of safety profile in moderate renal impairment (N=116), safety-evaluable patients

OverallAE Profile by Renal

Impairment,

Patients with 1L DLBCL，Safety-Evaluable Patients

<!-- image -->

Protoco1s: G039942, G029044

Table 63 Overview of safety profile in severe renal impairment (N=2), safety-evaluable patients

<!-- image -->

## Safety related to drug-drug interactions and other interactions

R-CHP did not appear to have a clinically relevant impact on the PK of pola when given in combination based on observed data and population PK analysis. The PK of pola in the pivotal POLARIX study and supportive Study GO29044 are in line with the other studies of pola. Population PK analysis of POLARIX further supports the pola PK similarity among different studies. A two-analyte (acMMAE-MMAE) integrated pop-PK analysis  (Report 1090510)  based  on  PK  data  from  460  NHL  patients  from  Studies  DCS4968g, GO27834, GO29044, and GO29365 (excluding Arm G and Arm H) was previously established to characterize the  PK  properties  of  acMMAE  and  unconjugated  MMAE.  The  previously  developed  population  PK  model

<div style=\"page-break-after: always\"></div>

provides  a  good  description  of  acMMAE  and  unconjugated  MMAE  concentrations  following  intravenous administration of pola+R-CHP in patients with previously untreated DLBCL.

In the supportive Study GO29044, pola did not appear to have a clinically relevant impact on the PK of cyclophosphamide  or  doxorubicin  when  given  in  combination  based  on  observed  data.  No  significant difference in cyclophosphamide or doxorubicin PK was observed for DLBCL patients receiving 1.8 mg/kg of pola+R/G-CHP based on similar cross-cycle exposure comparisons of each analyte both prior to and after administration of pola (Shemesh et al. 2020).

## Discontinuation due to adverse events

- AEs leading to study discontinuation

## Study POLARIX

The proportion of patients who experienced AEs leading to study discontinuation in the pola+R-CHP arm (3.0% [13 patients]) was comparable to the R-CHOP arm (2.3% [10 patients]). All AEs leading to study discontinuation were Grade 5 AEs.

## Supportive study GO29044

The  events  that  led  to  study  withdrawal  were  events  associated  with  underlying  disease,  with  no apparent/clinically meaningful/relevant pattern among the other events leading to withdrawal.

A total  of  3/66  patients  (4.5%)  had  5  AEs  leading  to  study  discontinuation.  The  AEs  leading  to  study discontinuation by PT were Escherichia urinary tract infection, syncope and atrial fibrillation (both reported in the same patient), and pneumonia and coronary artery disease (both reported in the same patient).

## Pooled safety population

The  proportion  of  patients  who  experienced  AEs  leading  to  study  discontinuation  in  the  pooled  safety population  (3.2%  [16/501  patients])  was  consistent  with  the  pola+R-CHP  arm  from  POLARIX  and comparable  to  the  R-CHOP  arm  (2.3%  [10/438  patients]).  The  majority  of  events  that  led  to  study withdrawal were events associated with underlying disease, with no apparent/clinically meaningful/relevant pattern among the other events leading to study withdrawal.

Table 64. Summary of Adverse Events Leading to Study Discontinuation

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class MedDRA Preferred Term   | Grade                                      | R-CHOP (POLARIX) (N=438)     | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)                      | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   |
|---------------------------------------------------|--------------------------------------------|------------------------------|--------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Anyadverse events                                 | -Any Grade Grade 1-2 2 Grade 3-4 3 Grade5  | 10 (2.38) 0 0 0 0 10 (2.38)  | 13 (3.0%) 0 0 0 0 13 (3.0%)    | 3 (4.5%) 1 (1.5%) 1 (1.58) (1.58) 1 (1.5%) (1.58) 2 (3.0%) 1 (1.5%) | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     | 16 (3.28) 1 (0.2%) 1 (0.2%)                                     |
| Infections and infestations -Overall              | -Any Grade Grade 1-2 2 Grade 3-4 3 Grade 5 | 6 (1.48) 0 0 0 0             | 5 (1.18) 0 0 0 0               | 1 (1.5%) 1 (1.58) 1 (1.58) 0                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        | (0.28) 1 (0.28) 5 (1.0%)                                        |
| Pneumonia Sepsis                                  | -Any( Grade Grade 3-4 3                    | 6 (1.48) 3 (0.7%) 0 0        | 5 (1.18) 4 (0.98) 0 0 4        | 1 (1.5%) 1 (1.58) 1 (1.58)                                          | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      | 5 (1.0%) 1 (0.28) 1 (0.28)                                      |
| Escherichia urinary tract                         | Grade 5 -Any Grade Grade 5 -Any Grade      | 3 (0.78) 1 (0.28) 1 (0.2%) 0 | (0.9%) 1 (0.28) 1 (0.2%) 0     | 0 0 0 1 (1.58)                                                      | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        | 4 (0.8%) 1 (0.28) (0.2%)                                        |
| infection                                         | Grade 1-2 2                                | 0 0                          | 0 0                            | 1 (1.58)                                                            | 1 (0.2%)                                                        | 1 (0.2%)                                                        | 1 (0.2%)                                                        | 1 (0.2%)                                                        | 1 (0.2%)                                                        | 1 (0.2%)                                                        | 1 (0.2%)                                                        |
| Septic shock                                      | -Any Grade                                 | 2 (0.5%)                     | 0                              | 1 (1.58)                                                            | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      | 1 (0.2%) 1                                                      |
|                                                   |                                            |                              |                                |                                                                     | (0.2%)                                                          | (0.2%)                                                          | (0.2%)                                                          | (0.2%)                                                          | (0.2%)                                                          | (0.2%)                                                          | (0.2%)                                                          |
|                                                   |                                            |                              |                                | 0                                                                   | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
|                                                   | Grade 5                                    | 2                            |                                |                                                                     |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
|                                                   |                                            |                              | 0                              | 0                                                                   | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               | 0                                                               |
|                                                   |                                            | (0.58)                       |                                |                                                                     |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |

| MedDRA System Organ Class MedDRA Preferred Term    | Grade              | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX +GO29044) (N=501)   |
|----------------------------------------------------|--------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Generaldisordersand administration site conditions |                    |                            |                                |                                                  |                                                                |
| -Overall                                           | - Any Grade        | 2 (0.58)                   | (1.1%)                         | 0                                                | 5 (1.0%)                                                       |
|                                                    | Grade 5            | 2 (0.58)                   | 5 (1.1%)                       | 0                                                | 5 (1.0%)                                                       |
| Death                                              | - Any Grade        | 1 (0.2%)                   | 4 (0.9%)                       | 0                                                | 4 (0.8%)                                                       |
|                                                    | Grade 5            | 1 (0.28)                   | 4 (0.9%)                       | 0                                                | 4 (0.8%)                                                       |
| Cardiac death                                      | -Any Grade Grade 5 | 0 0                        | 1 (0.2%)                       | 0                                                | 1 (0.2%)                                                       |
|                                                    | Any Grade          | 1 (0.28)                   | (0.28)                         | 0                                                | 1 (0.28)                                                       |
| Multiple organ dysfunction syndrome                |                    |                            | 0                              | 0                                                | 0                                                              |
|                                                    | Grade 5            | 1 (0.28)                   | 0                              | 0                                                | 0                                                              |
| Cardiac disorders                                  |                    |                            |                                |                                                  |                                                                |
| Overall                                            | - Any Grade        | 1 (0.28)                   | 0                              | 2 (3.0%)                                         | 2 (0.48)                                                       |
|                                                    | Grade 3-4          | 0                          | 0                              | 1 (1.58)                                         | 1 (0.2%)                                                       |
|                                                    | 3                  | 0                          | 0                              | 1 (1.5%)                                         | (0.28)                                                         |
|                                                    | Grade              | 1 (0.28)                   | 0                              | 1 (1.5%)                                         | 1 (0.2%)                                                       |
| Atrial fibrillation                                | - Any Grade        | 0                          | 0                              | (1.5%)                                           | (0.28)                                                         |
|                                                    | Grade              | 0                          | 0                              | 1 (1.5%)                                         | 1 (0.2%)                                                       |
| Coronaryarterydisease                              | -Any Grade         | 0                          | 0                              | 1 (1.5%)                                         | (0.2%)                                                         |
|                                                    | Grade 3-4          | 0                          | 0                              | 1 (1.5%)                                         | 1 (0.28)                                                       |
|                                                    | 3                  | 0                          | 0                              | 1 (1.5%)                                         | 1 (0.2%)                                                       |
| Atrioventricular block complete                    | -Any Grade         | 1 (0.2%)                   | 0                              | 0                                                | 0                                                              |
|                                                    | Grade 5            | 1 (0.2%)                   | 0                              | 0                                                | 0                                                              |

| MedDRA System Organ Class MedDRA Preferred Term   | Grade                       | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX+GO29044) (N=501)   |
|---------------------------------------------------|-----------------------------|----------------------------|--------------------------------|--------------------------------------------------|---------------------------------------------------------------|
| Gastrointestinal disorders -Overall-              | -Any Grade                  | 0 0                        | (0.2%) (0.28)                  | 0 0                                              | 1 (0.28) 1 (0.28)                                             |
| Intestinal perforation                            | Grade 5 - Any Grade Grade 5 | 0 0                        | (0.2%) (0.28)                  | 0 0                                              | (0.2%) 1 (0.2%)                                               |
| Nervous system disorders -Overall-                | -Any Grade Grade 3-4 3      | 0 0 0                      | 0 0 0 0                        | (1.58) (1.58)                                    | 1 (0.28) 1 (0.2%) (0.2%)                                      |
| Syncope                                           | - Any Grade Grade 3-4       | 0 0 0                      | 0 0                            | (1.5%) (1.58) (1.58)                             | (0.28)                                                        |
| Renal and urinary disorders -Overall-             | 3 - Any Grade               | 0 0                        | (0.2%) 1 (0.2%)                | (1.58)                                           | (0.2%) 1 (0.28) 1                                             |
| Acute kidney injury                               | Grade 5 -Any Grade Grade 5  | 0 0                        | (0.28) (0.2%)                  | 0 0:0 0                                          | (0.2%) 1 (0.2%) 1 (0.28) 1 (0.28)                             |
| Respiratory, thoracic and                         | AnyGrade                    |                            | (0.2%)                         | 00 0                                             |                                                               |
| mediastinal disorders -Overall                    |                             | 0                          | (0.2%)                         |                                                  | (0.2%)                                                        |
|                                                   | Grade 5                     | 0                          |                                |                                                  | 1 (0.28)                                                      |
| Respiratory failure                               | - Any Grade                 | 0                          | (0.2%)                         |                                                  |                                                               |
|                                                   |                             |                            |                                |                                                  | 1 (0.28)                                                      |
|                                                   | Grade 5                     |                            |                                | 0                                                | 1 (0.2%)                                                      |
|                                                   |                             | 0                          | (0.2%)                         |                                                  |                                                               |

<div style=\"page-break-after: always\"></div>

| MedDRASystemOrganClass MedDRA PreferredTerm                  | Grade                               |                                   | R-CHOP Pola-R-CHP (POLARIX) (POLARIX) (N=438) (N=435)   | Pola (1.8mg/kg) +R-CHP/G-CHP (GO29044) (N=66)   | All Pola (1.8 mg/kg) +R-CHP/G-CHP （POLARIX +GO29044) (N=501)   |
|--------------------------------------------------------------|-------------------------------------|-----------------------------------|---------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------|
| Injury,poisoningandprocedural complications -Overall- Injury | -Any Grade Grade5 -Any Grade Grade5 | 1 (0.28) 1 (0.28) (0.2%) 1 (0.28) | 0 0 0 0                                                 | 0 0 0 0                                         | 0 0 0 0                                                        |

Investigatortext for AEs encodedusingMedDRAversion24.0.Allcountsrepresent patients.Multipleoccurrencesof the same AE in one individualarecountedonceatthehighestgradefor thispatient.TotheSocOverallrowcounts，apatient contributesonly withtheAE occuring withthehighest grade withinthe Soc.Percentages are basedon N inthe columnheadings.Includes treatmentemergent AEs during AEreportingperiod only，which is defined as new or worsening AE from the first doseof any study drugthrough GO39942CC0D:28JUN2021.Dataextractdate:02AUG2021.

G029044Databaselockdate:28MAR2019.

- AEs leading to treatment discontinuation

## Study POLARIX

Overall, the proportion of patients who experienced at least one AE leading to discontinuation of any study treatment in the pola+R-CHP arm (6.2%) was comparable to the R-CHOP arm (6.6%).

In most SOCs, the proportion of patients discontinuing any study treatment due to an AE was comparable between the pola+R-CHP and R-CHOP arms. However, in the most common SOC with AEs leading to study treatment discontinuation for the R-CHOP arm (Nervous system disorders), a higher proportion of R-CHOP patients experienced an AE leading to discontinuation (2.5% [9 patients]) than the pola+R-CHP arm (0.7% [3 patients]). This difference was primarily driven by a higher incidence of AEs associated with peripheral neuropathy in the R-CHOP arm.

The proportion of patients who experienced AEs leading to discontinuation of pola study treatment in the pola+R-CHP arm (4.4%) was comparable to the proportion of patients who experienced AEs leading to discontinuation of vincristine study treatment in the R-CHOP arm (5.0%).

A numerically higher percentage of patients experienced an AE in the Nervous system disorders SOC which led to vincristine discontinuation (2.1% [9 patients]) than led to pola discontinuation (0.7% [3 patients]). This difference was primarily driven by a higher incidence of AEs related to peripheral neuropathy in the RCHOP arm. In other SOCs, the proportion of patients discontinuing pola/vincristine in the pola+R-CHP and R-CHOP arms, respectively, was comparable.

The most common AEs by PT (≥ 2 patients each in the pola+ R-CHP and R-CHOP arm, respectively), leading to pola/vincristine treatment discontinuation were pneumonia (4 patients [0.9%] in each arm), neuropathy peripheral  (1  patient  [0.2%]  and  4  patients  [0.9%]),  peripheral  motor  neuropathy  (0  patients  and  2 patients [0.5%]) and death (2 patients [0.5%] and 1 patient [0.2%]).

The proportion of patients who experienced AEs leading to discontinuation of rituximab study treatment in the pola+R-CHP arm (4.6%) was comparable to the R-CHOP arm (4.8%).

The proportion of patients who experienced AEs leading to discontinuation of any of the components of the CHP regimen (cyclophosphamide, doxorubicin, prednisone) in the pola+R-CHP arm (3.4%) was comparable to the R-CHOP arm (3.7%).

## Supportive study GO29044

The majority of events that led to withdrawal of study treatment were consistent with the known risks of each individual component.

A total of 8/66 patients (12.1%) in the pola+R-CHP/G-CHP population had AEs leading to discontinuation of  pola.  The  AEs  leading  to  pola  discontinuation  by  PT  were  neuropathy  peripheral,  syncope,  tremor, Escherichia urinary tract infection, septic shock, thrombocytopenia, febrile neutropenia, and coronary artery disease. In the majority of patients, these AEs led to discontinuation of all the study drugs.

<div style=\"page-break-after: always\"></div>

A total of 7 patients (10.6%) had an AE leading to discontinuation of rituximab/obinutuzumab. AEs that led to discontinuation of rituximab/obinutuzumab were Escherichia urinary tract infection, syncope, tremor, febrile neutropenia, thrombocytopenia, pneumonia and septic shock.

A total of 7 patients (10.6%) had an AE leading to discontinuation of doxorubicin, cyclophosphamide, or prednisone (CHP). AEs that led to discontinuation of any of the CHP study treatments were Escherichia urinary tract infection, septic shock, febrile neutropenia, thrombocytopenia, syncope, tremor and coronary artery disease.

## Pooled safety population

The incidence of AEs leading to withdrawal of any component of the study treatment was comparable between the pooled safety population (7.0% [35/501 patients]) and the R-CHOP arm from POLARIX (6.6% [29/438 patients]).

The proportion of patients who experienced AEs leading to discontinuation of pola study treatment in the pooled  safety  population  (5.4%  [27/501  patients])  was  comparable  to  the  proportion  of  patients  who experienced AEs leading to discontinuation of vincristine study treatment in the R-CHOP arm from POLARIX (5.0% [22/438 patients]).

The proportion of patients who experienced AEs leading to discontinuation of rituximab/obinutuzumab study treatment in the pooled safety population (5.4% [27/501 patients]) was comparable to the proportion of patients who discontinued rituximab treatment in the R-CHOP arm from POLARIX (4.8% [21/438 patients]).

The proportion of patients who experienced AEs leading to discontinuation of any of the components of the CHP regimen (cyclophosphamide, doxorubicin, prednisone) in the pooled safety population (4.4% [22/501 patients]) was comparable to the R-CHOP arm from POLARIX (3.7% [16/438 patients]).

Table 65 Adverse Events by Preferred Term Leading to Discontinuation of Any Study Treatment in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

<div style=\"page-break-after: always\"></div>

and Preferred Term, Patients with lL DLBCL, Safety-Evaluabie Patients P10t0c01s:G039942,G029044

| MedDRA System Organ Class MedDRA Preferred Term          | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (l.8 mg/kg) +R-CHP/G-CHP (G029044) (99=N)   | All Pola (l.8 mg/kg) +R-CHP/G-CHP (POLARIX + GO29044) (N=501)   |
|----------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Total number of patients with at least one adverse event | 29[6.61)                   | 27(6.29)                       | (12.19)                                          | 35(7.0%)                                                        |
| Overall total number of events                           | 30                         | 27                             | 9                                                | 36                                                              |
| Infections and infestations                              |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 10 (2.34)                  | 7 (1.65)                       | 3(4.5%)                                          | 10 (2.05)                                                       |
| Total number of events                                   | 10                         | 7                              | 3                                                | 10                                                              |
| Pneumonia                                                | 6 (1.44)                   | 5 (1.16)                       | 1 (1.5)                                          | 6 (1.26)                                                        |
| Sepsis                                                   | 1 (0.24)                   | 1 (0.24)                       | 0                                                | 1 (0.24)                                                        |
| Escherichia urinary tract infection                      | 0                          | 0                              | 1 (1.5%)                                         | 1 (0.25)                                                        |
| Septie shock                                             | 0                          | 0                              | 1 (1.5%)                                         | 1 (0.24)                                                        |
| Vulvovaginal mycotic                                     | 0                          | 1 (0.25)                       | 0                                                | 1 (0.2号)                                                        |
| infection Intervertebral discitis                        | 1 (0.24)                   | 0                              | 0                                                | 0                                                               |
| Peritonitis                                              | 1 [0.24]                   | 0                              | 0                                                | 0                                                               |
| Prostate infection                                       | 1(0.21)                    | 0                              | 0                                                | 0                                                               |
| Nervous system disorders                                 |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 11 [2.54)                  | 3(0.75)                        | 3(4.5%)                                          | 6(1.24)                                                         |
| Total number of events                                   | 11                         | 3                              | 3                                                | 6                                                               |
| Neuropathy peripheral                                    | 4 (0.94)                   | 1 (0.25)                       | (1.54)                                           | 2 (0.45)                                                        |
| Peripheral neuropathy                                    | 1 [0.24)                   | (0.29)                         | 0                                                | (0.2%)                                                          |
| Peripheral motor neuropathy                              | 2 (0.54)                   | 0                              | 0                                                | 0                                                               |
| Peripheral sensory neuropathy                            | 2 (0.54)                   | 0                              | 0                                                | 0                                                               |
| Polymeuropathy                                           |                            | 1 (0.26)                       | 0                                                | (0.25)                                                          |
| Symcope                                                  |                            | 0                              | 1 (1.55)                                         | 1 (0.25)                                                        |
| Tremor                                                   | 000                        | 口                              | 1 (1.5%)                                         | 1 (0.25)                                                        |
| Cerebral infaretion                                      | 1 (0.24)                   | 0                              | 0                                                | 0                                                               |
| Hypoaesthesia.                                           | 1 (0.24)                   | 0                              | 0                                                | 0                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MedDRA System Organ Class MedDRA Preferred Term                               | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|-------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Respiratory. thoracie and mediastinal disorders                               |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                      | 1(0.24)                    | 6 (1.46)                       |                                                  | 6 (1.2%)                                                        |
| Total number of events                                                        | 1                          | 6                              |                                                  | 6                                                               |
| Pneumonitis                                                                   | 0                          | 2 (0.56)                       | 0                                                | 2 (0.4%)                                                        |
| Dyspnoea                                                                      | 1 (0.24)                   | 1 (0.25)                       | 0                                                | 1 (0.26)                                                        |
| Interstitial lung disease                                                     | 0                          | 1 (0.25)                       | 0                                                | 1 (0.26)                                                        |
| Pulmonary oedema                                                              | 0                          | 1 (0.25)                       | 口                                                | 1 (0.26)                                                        |
| Respiratory failure                                                           | 0                          | 1(0.2%)                        | 0                                                | 1(0.24)                                                         |
| General disorders and acministration site conditions                          |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                      | 2(0.55)                    | 5 (1.1)                        | 0                                                | 5(1.0%)                                                         |
| Total number of events                                                        | 2                          | 5                              | 0                                                | 5                                                               |
| Death                                                                         | [0.24)                     | 3(0.76)                        | 0                                                | 3(0.6)                                                          |
| Cardiac death                                                                 | 0                          | 1 (0.2%)                       | 0                                                | 1 (0.2%)                                                        |
| Fatigue                                                                       | 0                          | 1(0.2%)                        |                                                  | 1 (0.2%)                                                        |
| Chest pain                                                                    | 1 [0.24]                   | 0                              | 00                                               | 0                                                               |
| Blood and lymphatic system disorders                                          |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                      | 0                          | 3(0.76)                        | 2(3.0号)                                          | 5 (1.0%)                                                        |
| Total number of events                                                        | 0                          | 3                              | 2                                                | 5                                                               |
| Neutropenia                                                                   | 0                          | 2(0.56)                        | 0                                                | 2(0.46)                                                         |
| Thrombocytopenia                                                              | 0                          | 1 (0.25)                       | 1 1.591                                          | 2(0.41)                                                         |
| Febrile neutropenia                                                           | 0                          | 0                              | 1.5)                                             | 1(0.2%)                                                         |
| Gastrointestinal disorders Total number of patients with at least one adverse | 3 8(0.74)                  | 2(0.55)                        | 0                                                | 2(0.4%)                                                         |
| event                                                                         |                            |                                |                                                  |                                                                 |
| Total number of events                                                        | 3                          | 2                              |                                                  | 2                                                               |
| Intestinal perforation                                                        | 0                          | 1(0.25)                        | 0                                                | 1(0.2%)                                                         |
| Necrotising colitis                                                           | 0                          | 1 (0.25)                       | 0                                                | 1 (0.2%)                                                        |
| Intestinal obstruction                                                        | 1 (0.24)                   |                                | 口                                                | 0                                                               |
| Intra-abdominal                                                               | 1 (0.24)                   | 00                             | 0                                                | 0                                                               |
| haemorrhage Nausea                                                            | 1 [0.24)                   |                                | 0                                                | 0                                                               |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class MedDRA Preferred Term                                            | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (2029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|--------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Cardiac disorders                                                                          |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event                                   | 1 (0.24)                   | 0                              | 1(1.5)                                           | 1 (0.2)                                                         |
| Total number of events                                                                     | 1                          |                                | 1                                                |                                                                 |
| Coronary artery disease Left ventricular                                                   | 0 1 (0.24]                 | 0 口                            | 1 (1.54) 0                                       | (0.25) 0                                                        |
| dysfunction Renal and urinary disorders Total number of patients with at least one adverse | 1(0.24)                    | 1 (0.2)                        | 0                                                | 1 (0.2号)                                                        |
| event Total number of events Acute kidney injury                                           | 1                          | 1(0.2%)                        | 0                                                | 1 1 (0.24)                                                      |
|                                                                                            | 1 (0.24)                   |                                |                                                  |                                                                 |
| Investigations Total number of patients with at least one adverse event                    | 1 (0.2%)                   | 口                              | 0                                                |                                                                 |
| Ejection fraction decreased                                                                | 1(0.2)                     | 0                              |                                                  |                                                                 |
| Total number of events                                                                     | 1                          | 0                              |                                                  |                                                                 |

G029044 Database 1ock date: 28MAR2019.

<!-- image -->

## · AEs leading to dose reduction

Table 66 Adverse Events by Preferred Term Leading to Any Study Treatment Dose Reduction in Previously Untreated DLBCL Patients, Safety-Evaluable Patients

Adverse Events Leading to Dose Reduction for Any Study Drug by System Organ Class and Preferred Term, Patients with lL DLBCL, Safety-Evaluable Patients Pr0t0co1s:G039942.G029044

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class HedDRA Preferred Ierm          | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | Al1 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|----------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Total number of patients with at least one adverse event | 57(13.0)                   | 40(9.2%)                       | 8 (12.16)                                        | 48(9.6%)                                                        |
| Overall total number of events                           | 78                         | 47                             | 11                                               | 58                                                              |
| Nervous system disorders                                 |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 36(8.24)                   | 20(4.66)                       | 3(4.5)                                           | 23(4.69)                                                        |
| Total number of events                                   | 38                         | 20                             | 3                                                | 23                                                              |
| Neuropathy peripheral                                    | 22 (5.0%)                  | 9 (2.1%)                       | 1(1.5)                                           | 10 (2.0%)                                                       |
| Peripheral sensory neuropathy                            | 10 (2.3)                   | 8 (1.86)                       | 2(3.0)                                           | 10 (2.04)                                                       |
| Polymeuropathy Paraesthesia                              | 2 (0.5)                    | 1 (0.25)                       | 0                                                | 1 (0.25)                                                        |
|                                                          | 1 ( 0.241                  | 1 (0.26)                       | 0                                                | 1 (0.24)                                                        |
| Dysaesthesia                                             | 0 2 (0.5t)                 | 1 (0.24) 0                     | 0 0                                              | 1 (0.24) 0                                                      |
| Peripheral motor neuropathy                              |                            |                                |                                                  |                                                                 |
| Blood and lymphatic system disorders                     |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 6(1.4)                     | 7 (1.66)                       | 2(3.0%)                                          | 9(1.86)                                                         |
| Total number of events                                   | 14                         | 7                              | 2                                                | 6                                                               |
| Febrile neutropenia                                      | 2 (0.55)                   | 5 (1.14)                       | （ 1.58)                                          | (1.24)                                                          |
| Neutropenia                                              | 3 0.741                    | 1 (0.25)                       | (1.5)                                            | 2 (0.4%)                                                        |
| Thrombocytopenia                                         | 2 0.54)                    | 1 (0.24)                       | 0                                                | 1 (0.24)                                                        |
| Leukopenia                                               | 2 ( 0.5)                   | 口                              | 0                                                | 0                                                               |
| Anaemia                                                  | ( 0.24)                    | 口                              | 0                                                | 口                                                               |
| Erythropenia                                             | (0.24)                     | 0                              | 0                                                | 口                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MedDRA System Organ Class HedDRA Preferred Term          | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (1.8 mg/kg) +R-CHP/G-CHP (POLARIX +G029044) (N=501)   |
|----------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|----------------------------------------------------------------|
| Investigations                                           |                            |                                |                                                  |                                                                |
| Total number of patients with at least one adverse event | 6( 1.4)                    | 4(0.9%)                        | 2( 3.0%)                                         | 6 (1.2%)                                                       |
| Total number of events                                   | 7                          | 7                              | 2                                                | 9                                                              |
| Weight decreased                                         | 2 0.55)                    | 1 (0.25)                       | 2( 3.06)                                         | 3(0.6)                                                         |
| Neutrophil count                                         | (0.24]                     | (0.24)                         | 0                                                | 1(0.24)                                                        |
| decreased Alanine aminotransferase increased             | 0                          | 1 (0.26)                       | 0                                                | (0.2号)                                                         |
| Aspartate aminotransferase increased                     | 0                          | 1 (0.25)                       | 0                                                | (0.2%)                                                         |
| Blood alkaline phosphatase increased                     | 0                          | 1 (0.25)                       | 0                                                | (0.25)                                                         |
| Blood creatinine increased                               | 0                          | 1 (0.25)                       | 0                                                | (0.25)                                                         |
| Platelet count decreased                                 | 0                          | 1 (0.24)                       | 0                                                | 1 (0.2%)                                                       |
| Blood bilirubin increased                                | 1 (0.24)                   | 0                              | 0                                                | 0                                                              |
| Haemoglobin decreased                                    | 1 0.24)                    | 0                              | 0                                                | 口                                                              |
| N-terminal prohormone brain natriuretic peptide          | 1 (0.24]                   | 0                              | 0                                                | 0                                                              |
| increased Troponin t increased                           | 1( 0.2%)                   | 0                              | 0                                                |                                                                |
| Gastrointestinal disorders                               |                            |                                |                                                  |                                                                |
| Total number of patients with at least one adverse event | 6( 1.4%)                   | 3(0.74)                        | 0                                                | 3(0.6%)                                                        |
| Total number of events                                   | 6                          | 3                              |                                                  | 3                                                              |
| Diarrhoea                                                | 2 0.54)                    | 2 (0.54)                       | 0                                                | 2(0.49)                                                        |
| Constipation                                             | 口                          | 1 (0.24)                       | 0                                                | 1 (0.24)                                                       |
| Vomiting                                                 | 0.541                      | 0                              | 0                                                | 口                                                              |
| Abdominal distension                                     | 1 0.24)                    | 0                              | 0                                                | 口                                                              |
| Subileus                                                 | 1 0.24)                    | 0                              | 0                                                | 口                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| MedDRA System Organ Class MedDRA Preferred Term          | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | A11 Pola (l.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|----------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| General disorders and administration site conditions     |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 3(0.7%)                    | 2(0.55)                        | 1 (1.5)                                          | 3(0.66)                                                         |
| Total number of events                                   | 4                          | 2                              | 1                                                | 3                                                               |
| Fatigue                                                  | 2 0.5%)                    | 1 (0.25)                       | 0                                                | 1 (0.25)                                                        |
| Oedema peripheral                                        | 0.24)                      | 0                              | 1 (1.5%)                                         | 1 (0.24)                                                        |
| Peripheral swelling                                      | 口                          | 1 (0.24)                       | 0                                                | 1 (0.2)                                                         |
| Malaise                                                  | 1 ( 0.24)                  | 0                              | 0                                                | 0                                                               |
| Infections and infestations                              |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 4(0.9%)                    | 1 (0.24)                       | 1 ( 1.5%)                                        | 2 (0.45)                                                        |
| Total number of events                                   | 4                          | 1                              | 1                                                | 2                                                               |
| Clostridium difficile infection                          | 0                          | 0                              | 1(1.5%)                                          | 1(0.2%)                                                         |
| Sepsis                                                   | 2 (0.54)                   | 0                              | 0                                                | 0                                                               |
| Staphylococcal infection                                 | 0                          | 1 (0.25)                       | 0                                                | 1 (0.2%)                                                        |
| Neutropenic sepsis                                       | 1 0.2%1                    | 00                             |                                                  | 00                                                              |
| Pneumonia.                                               | 0.24)                      |                                | 00                                               |                                                                 |
| Metabolism and nutrition disorders                       |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 0                          | 3(0.7%)                        | 1 (1.5%)                                         | 4(0.89)                                                         |
| Total number of events                                   |                            |                                |                                                  | 5                                                               |
| Decreased appetite                                       | 0                          | 2(0.5)                         | 1 0                                              | 2(0.45)                                                         |
| Hyperglycaemia                                           | 口                          | 1 (0.25)                       | 1 (1.5%)                                         | 2 (0.4%)                                                        |
| Hypocalcaemia                                            | 0                          | (0.25)                         | 0                                                | 1 (0.25)                                                        |
| Psychiatric disorders                                    |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event | 2 (0.5)                    | 0                              | 1(1.5)                                           | 1(0.25)                                                         |
| Total number of events                                   | 2                          | 0                              |                                                  | 1                                                               |
| Affect lability                                          | 0                          | 口                              | (1.5%)                                           | (0.24)                                                          |
| Adjustment disorder                                      | 1 (0.24)                   | 口                              | 0                                                | 0                                                               |
| Insomnia                                                 | (0.24)                     | 口                              | 0                                                | 0                                                               |

<div style=\"page-break-after: always\"></div>

| MedDRA System Organ Class MedDRA Preferred Term                                      | R-CHOP (POLARIX) (N=438)   | Pola-R-CHP (POLARIX) (N=435)   | Pola (1.8 mg/kg) +R-CHP/G-CHP (G029044) (N=66)   | All Pola (l.8 mg/kg) +R-CHP/G-CHP (POLARIX + G029044) (N=501)   |
|--------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|-----------------------------------------------------------------|
| Cardiac disorders                                                                    |                            |                                |                                                  |                                                                 |
| Total number of patients with at least ome adverse event                             | 1 ( 0.2)                   | 1 (0.24)                       | 0                                                | 1(0.24)                                                         |
| Total number of events Palpitations                                                  | 1 (0.24)                   | 1 1(0.24)                      | 0                                                | 1 1 (0.24)                                                      |
| Ear and labyrinth disorders Total number of patients with at least one adverse event | 1 ( 0.2)                   | 1(0.24)                        | 0                                                | 1(0.24)                                                         |
| Total number of events Tinnitus                                                      | 1 0                        | 1(0.24)                        | 0                                                | 1 (0.24)                                                        |
| Hypoacusis                                                                           | 1 [ 0.24)                  | 0                              | 0                                                | 0                                                               |
| Hepatobiliary disorders Total number of patients with at least one adverse event     | 0                          | 1(0.24)                        | 0                                                | 1(0.2号)                                                         |
| Total number of events Hyperbilirubinaemia                                           | 0                          | 1 1(0.24)                      | 0                                                | 1 (0.24)                                                        |
| Vascular disorders                                                                   |                            |                                |                                                  |                                                                 |
| Total number of patients with at least one adverse event.                            | 1 (0.24)                   | 0                              | 0                                                | 0                                                               |
| Total number of events                                                               | 1                          | 0                              |                                                  | 0                                                               |
| Hypotension                                                                          | 1(0.2)                     | 0                              | 0                                                |                                                                 |

<!-- image -->

- AEs leading to treatment interruption

## Study POLARIX

The proportion  of  patients  who  experienced  AEs  leading  to  interruption  of  any  study  treatment  in  the pola+R-CHP arm (23.7%) was comparable to the R-CHOP arm (25.3%) with the most commonly reported AEs leading to study treatment interruption in the pola+R-CHP arm being in the Infections and infestations SOC and the most commonly reported AEs leading to study treatment interruption in the R-CHOP arm being in the Blood and lymphatic system disorders SOC.

The proportion of patients who experienced AEs leading to pola treatment interruption in the pola+R-CHP arm (14.0%) was comparable to the proportion of patients who experienced AEs leading to vincristine treatment interruption in the R-CHOP arm (13.7%).

The proportion of patients who experienced AEs leading to rituximab dose interruptions in the pola+R-CHP arm (22.3%) was comparable with the R-CHOP arm (23.7%).

The proportion of patients who experienced AEs leading to CHP dose interruptions in the pola+R-CHP arm (14.0%) was comparable with the R-CHOP arm (13.7%).

## Supportive study GO29044

<div style=\"page-break-after: always\"></div>

A total of 6 patients (9.1%) had an AE leading to interruption of pola. AEs that led to interruption of pola were  pulmonary  embolism,  ophthalmic  herpes  zoster,  bronchitis,  pneumonia,  febrile  neutropenia  and neutropenia.

Seventeen patients (17/66; 25.6%) had AEs leading to interruption of rituximab or obinutuzumab. AEs that led to dose interruption in more than 1 patient each were neutropenia (8 patients), infusion related reaction (4 patients) and thrombocytopenia (2 patients).

Seven  patients  (7/66;  10.6%)  had  an  AE  leading  to  interruption  of  cyclophosphamide,  doxorubicin  or prednisone  (CHP).  AEs  that  led  to  interruption  of  any  CHP  study  treatments  were  neutropenia,  febrile neutropenia,  pneumonia,  bronchitis,  ophthalmic  herpes  zoster,  catheter  site  pain,  and  pulmonary embolism.

## Pooled safety population

The proportion of patients who experienced AEs leading to interruption of any study treatment in the pooled safety population 24.2% [121/501 patients]) was consistent with the pola+R-CHP arm from POLARIX and comparable to the R-CHOP arm (25.3% [111/438 patients]).

The proportion of patients who experienced AEs leading to pola treatment interruption in the pooled safety population (13.4% [67/501 patients]) was comparable to the proportion of patients who experienced AEs leading to vincristine treatment interruption in the R-CHOP arm from POLARIX (13.7% [60/438 patients]).

The proportion of patients who experienced AEs leading to rituximab/obinutuzumab dose interruptions in the pooled safety population (22.8% [114/501 patients]) was comparable with the proportion of patients who had a rituximab treatment interruption in the R-CHOP arm from POLARIX (23.7% [104/438 patients]).

The proportion of patients who experienced AEs leading to CHP dose interruptions in the pooled safety population  (13.6%  [68/501  patients])  was  comparable  with  the  R-CHOP  arm  from  POLARIX  (13.7% [60/438 patients]).

## Post marketing experience

POLIVY (polatuzumab vedotin) is approved in the EU, in combination with bendamustine and rituximab, for the  treatment  of  adult  patients  with  R/R  DLBCL  who  are  not  candidates  for  hematopoietic  stem  cell transplant, and in the US, in combination with bendamustine and rituximab, for the treatment of adult patients with R/R DLBCL, not otherwise specified, after at least two prior therapies.

Since the International Birth Date (10 June 2019) through 09 June 2021, an estimated cumulative total of 10,529 patients have received polatuzumab from marketing experience (United States n=3,693 patients; European Union n=5,613 patients; Rest of the World n=1,223 patients). No new or unexpected safety findings have been identified in the post-marketing setting. The regimen of polatuzumab in combination with R-CHP administered in the POLARIX study is not yet approved.

## 2.5.1. Discussion on clinical safety

Safety data for polatuzumab vedotin 1.8 mg/kg in combination with R-CHP in patients with previously untreated DLBCL is based on the pivotal study POLARIX, N=873 (N=435 in the pola+R-CHP arm and N=438 in the R-CHOP arm). Additional supportive data from the GO29044 study are presented from a cohort of patients with previously untreated DLBCL (n=66) who received pola 1.8 mg/kg in combination with R-CHP

<div style=\"page-break-after: always\"></div>

(n=45) or G-CHP (obinutuzumab, cyclophosphamide, doxorubicin and prednisone [n=21]). The pooled population comprised all patients from POLARIX and GO29044 with previously untreated DLBCL receiving pola 1.8 mg/kg in combination with R-CHP/G-CHP (N=501). Separate data for pola +R-CHP and pola+GCHP in Study GO29044 would have allowed a direct comparison with the pola + R-CHP arm from POLARIX and a pooled population receiving similar treatment, therefore the MAH provided safety data from study GO29044 presented separately for pola +R-CHP and pola+G-CHP at least for all treatment-related AEs (all grades, grades 3-5 and SAEs). The nature and frequency of treatment-related AEs observed in the pola+RCHP arm of GO29044 were generally consistent with that observed in the pola+R-CHP of POLARIX (within the  limitation  of  the  overall  small  number  of  patients  in  GO29044).  It  is  noted  that  the  schedule  of treatments slightly differed across the two studies, i.e. 6 cycles for Pola + R-CHP in POLARIX with Rituximab as monotherapy in cycles 7 and 8 and 6-8 cycles for Pola + R-CHP and Pola + G-CHP in GO29044 study.

## Extent of exposure

The period for AEs collection was similar across the two studies (90 days after the last dose of study drug). In POLARIX study, the extent of exposure to pola/vincristine, rituximab, cyclophosphamide, doxorubicin and prednisone were similar across the 2 treatment arms.

Overall the total duration of pola treatment and number of cycles of Pola were comparable across the 2 studies, i.e. median duration of 3.5 months and median number of cycles of 6 for both studies. The median total cumulative dose of pola was however higher in GO29044 study compared to POLARIX study, i.e. 864 mg in Pola+R-CHP arm in GO29044, 828 mg in Pola+G-CHP arm in GO29044 and 762.0 mg in Pola+R-CHP arm in POLARIX which is not considered unexpected based on the different schedule of treatments across the two studies.

The exposure to rituximab was lower in Study GO29044 compared to POLARIX. In POLARIX the median number of cycles was 8 and the median total cumulative dose was 5329 mg for the Pola+R-CHP arm and 5380  mg  for  R-CHOP  arm;  in  study  GO29044  the  median  number  of  cycles  was  6  and  median  total cumulative dose was 4625.00 mg. The cumulative dose of cyclophosphamide and doxorubicin were higher in Study GO29044 compared to POLARIX, and similar for prednisone across the 2 studies. It cannot be ruled  out  that  the  differences  observed  in  cumulative  dose  of  pola,  rituximab,  cyclophosphamide  and doxorubicin can have an impact on the safety profile in patients across the studies POLARIX and GO29044.

The median RDI was &gt;99.8% for all components of study treatment in both studies reflecting a high treatment compliance.

## Adverse events

Overall the AEs occurred at similar rates in the pooled pola-treated subjects and in the R-CHOP arm of POLARIX, 98.2% and 98.4% respectively. The majority of reported AEs in the safety population were Grade ≥3 AEs, i.e. 61.5% in all pola + R -CHP/G-CHP pooled population and 59.8% in R-CHOP. Serious AEs were slightly more reported with all pola + R-CHP/G-CHP pooled population than with R-CHOP, i.e. 34.9% and 30.6%. It is showed that grade 3-5 and serious AEs were more reported in the Pola+R-CHP/G-CHP group in GO29044 study than Pola+R-CHP arm in POLARIX.

The  most  frequently  reported  AEs  in  the  pooled  safety  population  were  nausea  (42.3%),  neutropenia (32.1%), diarrhoea (33.3%), constipation (28.3%), fatigue (28.7%), anemia (28.7%), alopecia (23.8%) and neuropathy peripheral (23.0%). This remains coherent with the known safety profile of polatuzumab, except for alopecia considered as an additional ADR.

AEs with an incidence rate ≥10% that were r eported in the pooled safety population (all pola + R-CHP/GCHP) with a greater difference compared to R-CHOP arm of POLARIX were diarrhoea (33.3% and 20.1%, +13.2%), febrile neutropenia (14.8% and 8.0%, +6.8%), nausea (42.3% and 36.8%, +5.5%), pyrexia (16.4% and 12.6%, +3.8%), anemia (28.7% and 26.0%, +2.7%), fatigue (28.7% and 26.5%, +2.2%),

<div style=\"page-break-after: always\"></div>

decreased appetite (16.2% and  14.2%, +2.0%), weight decrease (13.8% and 11.9%, +1.9%), asthenia (13.0% and 12.1%, +0.9%), vomiting (15.2% and 14.4%, +0.8%), cough (12.8% and 12.1%, +0.7%) and neuropathy peripheral (23.0% and 22.6%, +0.4%).

The most frequently (≥10%) reported Grade 3 -4 AEs in the pooled safety population were neutropenia (28.5%), febrile neutropenia (14.4%) and anemia (11.0%). Febrile neutropenia and anemia were more reported in the pooled safety population than the R-CHOP arm of POLARIX study, i.e. +6.4% and +2.6% respectively.

The MAH provided the treatment-related AEs for the safety population. Overall the submitted analysis of treatment-related  AE  is  consistent  with  the  known  safety  profile  of  pola  with  no  new  safety  concern identified.

The adverse drug reactions were based on the pooled data from POLARIX in previously untreated DLBCL patients treated with Pola+R-CHP and study GO29365 in R/R DLBCL patients treated with pola+BR. Since comparable  safety  profile  of  Polivy  was  observed  in  previously  untreated  DLBCL  patients  treated  with Pola+R-CHP and in R/R DLBCL patients treated with pola+BR, the approach of ADRs in the pooled safety population is considered acceptable. However variability in the ADR frequencies was reported across the previously  untreated  DLBCL  patients  treated  by  pola+R-CHP  and  the  R/R  DLBCL  patients  treated  by pola+BR such as peripheral neuropathy (52.9% in pola+R-CHP vs 30.5% in pola+BR), neutropenia (38.4% in  pola+R-CHP vs 45.7% in pola+BR), nausea (41.6% in pola+R-CHP vs 33.1% in pola+BR), diarrhea (30.8% in pola+R-CHP and 35.8% in pola+BR). Therefore this ADR frequency variability in the two safety populations should be reflected in the section 4.8 of the SmPC, please refer to SmPC comments.

## Adverse events of special interest

Peripheral neuropathy (PN): In POLARIX, the incidence of PN events was similar in both arms, i.e. 53.9% in R-CHOP and 52.9% in Pola+R-CHP. The majority of PN events reported with pola+R-CHP were Grade 12 and one serious PN occurred in each arm (0.2% each), related to the treatment in both cases. The majority of PN events occurring in POLARIX resolved with a higher rate of PN resolution in R-CHOP arm compared to pola+R-CHP arm (66.9% and 57.8% respectively) which may be partly explained by the difference  in  median  time  to  onset  (2.27  months  in  pola+R-CHP  vs  1.87  months  in  R-CHOP)  and  the comparable median time to resolution across the two treatment arms. A higher rate of PN leading to any study treatment discontinuation and dose reduction was observed in R-CHOP arm compared to pola+RCHP arm. Indeed there was a higher proportion of patients that had a vincristine dose reduction due to PN in the R-CHOP arm (8.0%) than PN leading to pola dose reduction in the pola+R-CHP arm (3.9%). There was a lower incidence of PN in Pola +R-CHP/G-CHP group of the supportive study GO29044 compared to the pola+R-CHP arm in POLARIX, i.e. 39.4% and 52.9% respectively.

Neutropenia  including  febrile  neutropenia :  In  POLARIX,  the  incidence  of  neutropenia  events  was comparable in both treatment arms, i.e. 42.7% in R-CHOP and 46.0% in pola+R-CHP. The large majority of neutropenia were Grade 3-4 and occurred at similar rates in the two arms (40.2% in R-CHOP, 41.8% in pola+R-CHP).  No  Grade  5  events were  reported. Neutropenia leading to any study treatment discontinuation, dose reduction or treatment interruption were also reported at similar rates across the two arms. Serious neutropenia were more reported in Pola+R-CHP arm compared to R-CHOP (11.5% vs 8.4%). Neutropenia events resolved in most of the cases (98.0% in the pola+R-CHP arm and 97.9% in the R-CHOP arm). A higher incidence of neutropenia was observed in study GO29044 compared to POLARIX (51.5%). Of note, G-CSF prophylaxis was required in POLARIX during Cycles 1-6 while it was strongly encouraged but not mandatory in study GO29044. An overview of AEPI Neutropenia allowing a direct comparison of the safety-evaluable  patients  receiving  or  not  G-CSF  prophylaxis  was  provided.  The  occurrence  of  AEPI neutropenia was comparable across subjects with and without G-CSF prophylaxis use but the imbalance between the 2 groups of subjects (n=800 in G-CSF prophylaxis use and n=73 in non-prophylaxis use) prevents a clear conclusion on the comparison of neutropenia events by G-CSF status.

<div style=\"page-break-after: always\"></div>

Anemia : in POLARIX, the incidence of anemia events was comparable across the 2 treatment arms (26.9% in R-CHOP arm and 28.7% in Pola+R-CHP arm). Serious neutropenia were reported at similar rate in both arms, i.e. 1.4% in R-CHOP and 0.9% in Pola+R-CHP. It is noted a higher proportion of patients having Grade 3-4 neutropenia in Pola-R-CHP compared to R-CHOP (12.0% vs 8.7%) and no Grade 5 anemia in POLARIX. The majority of anemia events resolved in both arms, i.e. 84.8% in pola+R-CHP and 86.4% in R-CHOP. In study GO29044, the incidence of anemia was comparable to POLARIX (28.8%). The majority of anemia events were low grade with 4.5% of Grade 3-4 AEs and no Grade 5 anemia. No serious anemia event or anemia leading to treatment modification were observed in the supportive study

Thrombocytopenia : In POLARIX, the occurrence of thrombocytopenia was similar across pola+R-CHP arm and R-CHOP arms, i.e. 13.3% and 13.2% respectively. Grade 3-4 events were reported at comparable rate, i.e. 0.5% in pola+R-CHP and 0.2% in R-CHOP respectively, and serious thrombocytopenia occurred in two (0.5%) subjects in pola+R-CHP and one (0.2%) subject in R-CHOP. No Grade 5 thrombocytopenia was reported in POLARIX. One thrombocytopenia event led to study treatment discontinuation in pola+R-CHP arm and none in R-CHOP arm. Median time to onset was however longer in the pola+R-CHP arm compared to R-CHOP arm (1.68 months vs 0.41 months) but median time to resolution was similar across the two arms (0.36 months in both). More thrombocytopenia resolutions were observed in pola+R-CHP arm than R-CHOP arm, i.e. 94.8% and 86.2% respectively. Slightly more thrombocytopenia were reported in study GO29044 compared to POLARIX, i.e. 21.2% of patients experienced one thrombocytopenia event. Also more Grade 3-4 events were reported in GO29044 than in POLARIX (9.1%), but no SAE was observed. Most of the thrombocytopenia events resolved (92.9%).

Infection : In POLARIX the incidence of infection events, Grade 3-4 infections and serious infections was higher in pola+R-CHP arm compared to R-CHOP arm (49.7% vs 42.7%, 14.0% vs 11.2% and 14.0% vs 10.3%, respectively).  The proportion of Grade 5 infections was comparable in both treatment arms (1.1% in pola+R-CHP and 1.4% in R-CHOP); pneumonia was the most reported AE among the Grade 5 Infections (4 patients in pola+R-CHP arm, 3 patients in R-CHOP arm) and the other Grade 5 Infection AEs were septic choc and sepsis. The incidence of opportunistic infections was higher in pola+R-CHP than R-CHOP. The majority of infections events resolved (87% in pola+R-CHP and 84.5% in R-CHOP) with a similar median time to resolution. Slightly more patients with an infection event were reported in study GO29044 compared to POLARIX (53.0%) but Grade 3-5 and serious infections occurred at comparable rates in Pola+R-CHP/GCHP in study GO29044 and Pola+R-CHP in POLARIX.

Hepatic toxicity : hepatotoxicity events were more reported in the pooled safety population (all pola) than the R-CHOP arm in POLARIX, i.e. 10.2% and 7.3% respectively, and the majority of reported events were low grade. In POLARIX, the incidence of hepatotoxicity, Grade 3 events and serious events was higher in Pola+R-CHP arm than R-CHOP arm. The majority of hepatic toxicity reported in the study were ALAT and ASAT elevations. There was no Grade 4 or 5 hepatic toxicity event reported nor hepatotoxicity event leading to study treatment discontinuation in POLARIX. One SAE was observed in pola+R-CHP. Hepatic toxicity resolved in most of the cases in both arms, i.e. 87.0% in the pola+R-CHP arm and 84.4% in the R-CHOP arm. A total of 3 cases of potential DILI were reported in POLARIX: 1 in pola+R-CHP arm and 2 in R-CHOP arm. Two cases were confounded by events of sepsis and one was confounded by multiple organ dysfunction in  the  setting  of  febrile  neutropenia.  The  incidence  of  hepatotoxicity  in  Pola+R-CHP/G-CHP  in  study GO29044 was comparable to R-CHOP arm in POLARIX. All events were low grade except one Grade 3 hepatic toxicity.

Carcinogenicity  /  secondary  malignancies :  Carcinogenicity  has  been  identified  as  an  important potential risk with Polivy. Overall, carcinogenicity events were reported at comparable rates across the two treatment arms in POLARIX, i.e. 0.9% in pola+R-CHP arm and 1.1% in R-CHOP arm, and no Grade 5 event

<div style=\"page-break-after: always\"></div>

was reported. There were more serious events observed in pola+R-CHP arm than R-CHOP arm (3 [0.7%] vs 1 [0.2%] cases) but comparable median time to onset (5.86 and 5.06 months respectively). A higher proportion of carcinogenicity events resolved in R-CHOP arm compared to pola+R-CHP at the DCO (60% vs 25%).

Pulmonary toxicity : Overall similar incidence of pulmonary toxicity (1.6%) was observed across the two treatment arms in POLARIX. The majority of the events were low grade. There was one Grade 3 event in pola+R-CHP arm and one Grade 4 event in R-CHOP, and no Grade 5 pulmonary event was reported in POLARIX. Serious pulmonary toxicity events were reported in 2 subjects in R-CHOP arm and one subject in pola+R-CHP. One case (1.5%) of pulmonary toxicity was reported in study GO29044 (pola 1.8 mg/kg +RCHP/G-CHP) and this event was Grade 2.

Infusion-related reactions (IRR): Overall the incidence of IRR in POLARIX was comparable across the treatment arms (16.0% in R-CHOP arm and 13.3% in pola+R-CHP arm). However the proportion of patients experiencing IRR observed in study GO29044 was inconsistent with POLARIX with a very higher IRR rate, i.e. 45.5%: this inconsistency in the incidence of IRR between POLARIX and GO29044 studieswas justified by the MAH by the IRR AEPI search strategy not aligned across the two studies. Proportion of patients who experienced IRRs from pola+R-CHP/G-CHP arms in study GO29044 was comparable with the pola+R-CHP arm in POLARIX (13.3% [58/435]) when the search strategy for IRR in GO29044 was aligned with that of POLARIX.

. The majority of IRR reported in the pooled safety population were low grade and no Grade 5 event was reported. The large majority of IRR cases resolved.

Tumor lysis syndrome : In POLARIX, slightly more TLS events were reported in R-CHOP arm compared to Pola+R-CHP (4 [0.9%] and 2 [0.5%] patients reported TLS, respectively). Grade 3-4 and serious TLS occurred at comparable rate, and no Grade 5 was reported in the study. All cases of TLS reported in POLARIX resolved. There was no case of TLS in study GO29044.

Cardiac arrhythmia : This AEPI is considered as adverse reaction with clinical consequences, even serious but  occurring  with  a  low  frequency  in  the  RMP  but  not  mentioned  in  the  SmPC.  In  POLARIX  cardiac arrhythmia events were slightly more reported in R-CHOP compared to Pola+R-CHP arm, i.e. 4.6% vs 3.0%. The majority of the reported events were low grade. The proportion of patients who experienced a Grade  3-4  cardiac  arrhythmia  event  was  comparable  across  the  two  arms  and  one  Grade  5  cardiac arrhythmia was reported in R-CHOP while none in pola+R-CHP. Serious AEs were reported at comparable rate in both arms.

Hyperglycemia : In POLARIX the proportion of patients reporting hyperglycemia was comparable across the treatment arms (6.2% in R-CHOP arm and 6.0% in pola+R-CHP arm). The majority of hyperglycemia events  were  low  grade.  No  Grade  4,  grade  5,  serious  events  nor  hyperglycemia  leading  to  dose discontinuation or reduction were reported in POLARIX. One case of hyperglycemia led to treatment dose reduction in pola+R-CHP arm. The hyperglycemia events in POLARIX resolved in 53.8% of the cases in pola+R-CHP arm and 48.1% in R-CHOP arm.

## Serious adverse event / deaths

The most common cause of death across the safety population was disease progression. Fatal AEs were more reported in the pola+R-CHP arm compared to R-CHOP arm in POLARIX (3.0% vs 2.5%). The most frequent Grade 5 AEs in the pooled safety group (all pola) were pneumonia (4 patients [0.8%]) and death (4 patients [0.8%]). The treatment-related AEs that led to death in the pola+R-CHP arm were pneumonia (3 patients), cardiac death, acute kidney injury and death. In the supportive study GO29044, 2 patients had a fatal AE: one case of fatal atrial fibrillation assessed by the investigator as unrelated to any study

<div style=\"page-break-after: always\"></div>

drug and related to concurrent illness and one case of fatal septic shock considered related to doxorubicin and cyclophosphamide treatment. Pneumonitis and infections are known risks with polatuzumab. Infections and  AV  block  were  also  reported  as  Grade  5  AEs  in  R-CHOP  arm  in  POLARIX,  i.e.  1.4%  and  0.2% respectively.

Overall SAEs were more frequent in the pooled safety population (all pola) than the R-CHOP arm in POLARIX study, i.e. 34.9% and 30.6% respectively, driven by the incidence rate of SAEs in Pola + R-CHP/G-CHP group in study GO29044 (40.9%). In POLARIX, the proportion of patients with at least one SAE in the pola+R-CHP arm was comparable with the R-CHOP arm but more SAEs were treatment-related in pola+RCHP than R-CHOP (25.7% and 19.6% respectively). The most common treatment-related SAEs reported with  pola+R-CHP/G-CHP  in  both  studies  were  febrile  neutropenia  (10.4%),  neutropenia  (1.6%)  and infections (pneumonia [4.6%], sepsis [1.2%], urinary tract infection [1.6%], clostridium difficile infection, oral fungal infection, septic shock) and diarrhea (2.4%).The most frequent SAEs with R-CHOP were febrile neutropenia (6.4%) and pneumonia (3.9%).

## Laboratory findings

Overall the Grade 3-4 laboratory findings were comparable across the treatment groups.

## Immunogenicity

The post-baseline ADAs were reported at a low rate in ADA-evaluable patients treated with pola in POLARIX (1.4%, all treatment-induced) and none of them was neutralizing. There were no patients ADA positive at post-baseline in the supportive study GO29044. There was no data supporting a potential impact of ADAs to pola on safety and efficacy.

## Vital sign, physical findings and other observations related to safety

In POLARIX, no new signal was detected regarding vital signs and the number of patients with a clinically significant ECG abnormality was low and comparable between the treatment arms at screening and post baseline.

## Safety in special population

It is observed that the ≥65 group experienced more events than the &lt;65 group with regard to the Grade 5 AEs (4.0% vs 1.8%), the Grade 3-5 AEs (66.7% vs 55.1%), the serious AEs (40.2% vs 28.4%), AEs leading  to  any  study  discontinuation  (4.3%  vs  1.8%),    AEs  leading  to  any  study  treatment  dose discontinuation (10.9% vs 2.2%), AEs leading to any study treatment dose reduction (11.6% vs 7.1%) and AEs leading to pola/placebo discontinuation (8.3% vs 1.8%). The differences in safety profile between the &lt;65 and the ≥65 years patients  are reflected in section 4.4 of the SmPC.

There was an increase of the incidence of Grade 3-5 AEs, SAEs and AE leading to dose discontinuation/interruption in moderate and severe HI that should be interpreted with caution due to the small number of patients; furthermore the SmPC mentioned that the administration of Polivy in patients with moderate or severe hepatic impairment should be avoided.

With regard to the renal function, the proportion of patients who experienced allgrade AEs, Grade ≥ 3 AEs, SAEs and AEs leading to any study treatment discontinuation in both treatment arms increased with the severity of renal impairment, with very limited data on severe renal impairment (N=2).

## Discontinuation due to adverse events

AEs leading to study discontinuation were more reported in the pola+R-CHP arm than the R-CHOP arm from POLARIX (3.0% vs 2.3%). In POLARIX all AEs leading to study discontinuation were the reported Grade 5 AEs. In study GO29044 only one of the two reported Grade 5 AEs led to study discontinuation (atrial fibrillation). The most reported AEs in the pooled safety population were pneumonia and death.

<div style=\"page-break-after: always\"></div>

Overall the rate of AE leading to treatment discontinuation was comparable across the treatment arms in POLARIX  (6.2%  in  pola+R-CHP  arm  and  6.6%  in  R-CHOP  arm).  However  the  incidence  rate  in  study GO29044 was higher, i.e. 12.1%, with more reported AE leading to treatment discontinuation is SOCs Infections  and  infestations  and  Nervous  system  disorders.  Pneumonia,  pneumonitis,  neutropenia  and peripheral neuropathy were the most reported AEs leading to any treatment discontinuation in the pooled safety population.

AEs leading to dose reduction occurred more frequently in R-CHOP arm from POLARIX than all pola pooled safety  population,  i.e.  13.0%  and  9.6%,  mostly  driven  by  the  rate  of  AEs  leading  to  vincristine  dose reduction (10.3%) in R-CHOP arm which is higher than that leading to a pola dose reduction (5.8%) in the pooled  population.  The  majority  of  AE  leading  to  dose  reduction  in  the  pooled  safety  population  were Nervous system disorders SOC.

In POLARIX, the incidence of AEs leading to interruption of any study treatment in the pola+R-CHP arm (23.7%) was comparable to the R-CHOP arm (25.3%). Infections and infestations were the most reported AEs leading to interruption of any study treatment in pola+R-CHP arm while it was Blood and lymphatic system disorders in R-CHOP arm.

## Post-marketing experience

No new or unexpected safety findings have been identified in the post-marketing setting. The regimen of pola in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) administered in the POLARIX study is not yet approved.

## 2.5.2. Conclusions on clinical safety

Overall,  no  new  safety  concern  arises  from  the  safety  data  from  polatuzumab  vedotin  1.8  mg/kg  in combination  with  R-CHP  in  patients  with  previously  untreated  DLBCL.  The  safety  profile  remained  not negligible with a high incidence o f Grade ≥3 AEs and SAEs (mainly myelosuppression and infections) to consider in the context of a life-threatening condition.

The following measures are considered necessary to address issues related to safety:

The updated CSR from study Polarix; A Phase III, multicenter, randomized, double-blind, placebocontrolled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus  in previously untreated patients with DLBCL aimed to study long term safety, will be submitted as category 3 measure (see RMP).

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 2.1 with the following content:

## Safety concerns

Table 1. Summary of safety concerns

| Important identified risks   | Not applicable                   |
|------------------------------|----------------------------------|
| Important potential risks    | Carcinogenicity                  |
| Missing information          | Long term safety                 |
|                              | Use in Severe Hepatic Impairment |
|                              | Use in Severe Renal Impairment   |
|                              | Use in Pregnancy and Lactation   |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Table 2. Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                                                                                                            | Summary of Objectives                                                                                                                                                                                                            | Safety Concerns Addressed                                                                                                                                                                                                        | Milestones                                                                                                                                                                                                                       | Due Date(s)                                                                                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1  Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorization                                                                                                                                                                               | Category 1  Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorization                                                                                                        | Category 1  Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorization                                                                                                        | Category 1  Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorization                                                                                                        | Category 1  Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorization                                                                                                        |
| There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                              | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                       | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                       | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                       | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                       |
| Category 2  Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances.                                                                              | Category 2  Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances.       | Category 2  Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances.       | Category 2  Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances.       | Category 2  Imposed mandatory additional pharmacovigilance activities that are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances.       |
| There are no imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing                                                                                                                            | There are no imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing                                                     | There are no imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing                                                     | There are no imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing                                                     | There are no imposed mandatory additional pharmacovigilance activities which are specific obligations in the context of a conditional marketing authorization or a marketing                                                     |
| Category 3  Required additional pharmacovigilance activities (by a competent authority such as CHMP/PRAC or NCA)  i.e. studies that investigate a safety concern or evaluate the effectiveness of risk-minimization activities                                                                        | Category 3  Required additional pharmacovigilance activities (by a competent authority such as CHMP/PRAC or NCA)  i.e. studies that investigate a safety concern or evaluate the effectiveness of risk-minimization activities | Category 3  Required additional pharmacovigilance activities (by a competent authority such as CHMP/PRAC or NCA)  i.e. studies that investigate a safety concern or evaluate the effectiveness of risk-minimization activities | Category 3  Required additional pharmacovigilance activities (by a competent authority such as CHMP/PRAC or NCA)  i.e. studies that investigate a safety concern or evaluate the effectiveness of risk-minimization activities | Category 3  Required additional pharmacovigilance activities (by a competent authority such as CHMP/PRAC or NCA)  i.e. studies that investigate a safety concern or evaluate the effectiveness of risk-minimization activities |
| Study GO29365 A Phase Ib/II, multicenter, open-label study evaluating the safety, tolerability, and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in patients with R/R follicular lymphoma or R/R diffuse large B-cell lymphoma. (Ongoing) | To evaluate the risk of carcinogenicity in polatuzumab vedotin treated patients and provide all updated time-related endpoints for pooled Arm G+H.                                                                               | Carcinogenicity                                                                                                                                                                                                                  | Final CSR                                                                                                                                                                                                                        | Q3 2022                                                                                                                                                                                                                          |
| A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with R-CHP versus in previously untreated patients with DLBCL. (Ongoing)                                                                           | To evaluate the safety and efficacy of polatuzumab vedotin plus R-CHP compared with R- CHOP.                                                                                                                                     | Long-term safety                                                                                                                                                                                                                 | Update CSR at the time of final overall survival analysis                                                                                                                                                                        | Q4 2022                                                                                                                                                                                                                          |

## Risk minimisation measures

Table 3. Summary Table of Risk-Minimization Activities by Safety Concern

| Safety Concern           | Routine Risk-Minimization Activities        |
|--------------------------|---------------------------------------------|
| Important Potential Risk | Important Potential Risk                    |
| Carcinogenicity          | Proposed risk communication is described in |

<div style=\"page-break-after: always\"></div>

|                                                | SmPC: • Section 5.3 Preclinical safety data Routine risk-minimization activities recommending specific clinical measures to address the risk: Information on carcinogenicity is provided in SmPC Section 5.3 Other risk-minimization measures beyond the Product Information: N/A                                                                                                                                                                                                       |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information                            | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Long-Term Safety                               | Proposed risk communication is described in SmPC: • None Package Leaflet: • None Routine risk minimization activities recommending specific clinical measures to address the risk: None Other risk minimization measures beyond the Product Information: N/A                                                                                                                                                                                                                            |
| Use in Patients with Severe Hepatic Impairment | Proposed risk communication is described in SmPC: • Section 4.2 Posology and method of administration: Special populations  Hepatic impairment • Section 5.2 Pharmacokinetic properties: Hepatic impairment Routine risk-minimization activities recommending specific clinical measures to address the risk: Information on posology for patients with severe hepatic impairment is provided in SmPC Section 4.2 Other risk-minimization measures beyond the Product Information: N/A |

<div style=\"page-break-after: always\"></div>

| Use in Patients with Severe Renal Impairment                     | Proposed risk communication is described in SmPC: • Section 4.2 Posology and method of administration: Special populations  Renal impairment • Section 5.2 Pharmacokinetic properties: Renal impairment Routine risk-minimization activities recommending specific clinical measures to address the risk: Information on posology for patients with severe renal impairment is provided in SmPC Section 4.2 Other risk-minimization measures beyond the Product Information: N/A   |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in Pregnancy and Lactation                                   | Proposed risk communication is described in SmPC: • Section 4.6 Fertility, pregnancy and lactation Package Leaflet: • Section 2 What you need to know before you use Polivy Routine risk-minimization activities recommending specific clinical measures to address the risk: Information on use of polatuzumab vedotin in pregnancy is provided in SmPC Section 4.6 Other risk-minimization measures beyond the Product Information: N/A                                           |
| N/A = not applicable; SmPC = summary of product characteristics. | N/A = not applicable; SmPC = summary of product characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                    |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC have been updated.  The Package Leaflet has been updated accordingly.

The Annex II has been updated with the deletion of section E as all Specific Obligations have been fulfilled. Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) which were reviewed and accepted by the CHMP.

## 2.7.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

DLBCL is the most common histologic subtype of NHL, accounting for 30% of NHL cases (Armitage and Weisenburger 1998) and 80% of aggressive lymphomas. In 2020, 544,352 new NHL cases worldwide were estimated with over 163,000 patients estimated to be diagnosed with DLBCL (Global Cancer Observatory 2020). While DLBCL is mostly frequently diagnosed between ages of 65 and 74 years (with median age of 65 years at diagnosis [SEER]), it can also occur in the younger population, including children and young adults. Initially, DLBCL may be asymptomatic, but it may also be associated with constitutional symptoms such as fever, recurrent night sweats, weight loss, and/or local effects of lymph node enlargement, as well as those of bone marrow failure. Without treatment, DLBCL is fatal with a median survival of approximately 6 months (Armitage and Weisenburger 1998).

## 3.1.2. Available therapies and unmet medical need

The standard of care therapy for DLBCL involves frontline multi-agent chemotherapy with complementary mechanisms of action combined with immunotherapy. Up to 8 cycles of R-CHOP given in 21-day intervals (R-CHOP-21), or R-CHOP-like chemotherapy is considered to be the standard of care therapy for patients with previously untreated DLBCL. Although the biologic features of DLBCL are evaluated in clinical practice and clinical research, they do not clearly guide the choice of therapy, as no definitive studies have demonstrated superiority to R-CHOP in biomarker-selected populations. The fact that most patients who are not cured by R-CHOP or comparable immunochemotherapy will eventually die of lymphoma underscores the need for novel approaches in upfront and subsequent lines of therapy for this aggressive disease.

There is therefore a high unmet medical need in the 1L setting and a strong rationale for introducing novel therapeutic agents that can build upon R-CHOP and improve outcomes in patients with previously untreated DLBCL by preventing or delaying relapse.

## 3.1.3. Main clinical studies

The main clinical study provided by the MAH in this application is a phase III pivotal study (Study GO39942: POLARIX) which is a multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety  of  polatuzumab  vedotin  in  combination  with  R-CHP  versus  R-CHOP  in  previously  untreated patients with diffuse large B-cell lymphoma.

A total of 879 patients were included (ITT population) in the pivotal phase III, comparative randomized POLARIX study, 440 in pola+R-CHP arm and 439 in R-CHOP arm. Patients received six cycles of either pola+R-CHP  (and  vincristine  placebo)  or  standard  R-CHOP  chemotherapy  (and  polatuzumab  vedotin placebo) at 21-day intervals. Both arms then received two additional cycles of single agent rituximab. This design is acceptable as R-CHOP remains the standard of care therapy in previously untreated DLBCL. The

<div style=\"page-break-after: always\"></div>

polatuzumab vedotin dose of 1.8 mg/kg given every 21 days in combination with R/G-CHP for 6 or 8 cycles was determined in the dose-finding study (Study GO29044). Inclusion and exclusion criteria are acceptable and are  in  accordance  with  the  claimed  indication.  Treatment  arms  were  generally  well-balanced  with respect to demographic and baseline characteristics. For both regimens, treatment exposure remained high. Approximately 90% of patients in each treatment arm received 6 cycles of CHP treatment.

## 3.2. Favourable effects

A statistically significant improvement in the primary endpoint of Investigator-assessed PFS is observed following treatment with pola+R-CHP compared to R-CHOP. A reduction in the risk of progression/relapse or death by 27% is observed in patients treated in pola+R-CHP arm (stratified HR: 0.73 [95% CI: 0.57, 0.95]; two-sided log-rank p-value=0.0177, twosided α=0.05) with a minimum of 24 months from study enrollment in both arms. Results of all sensitivity analyses were consistent with results of the primary analysis of Investigator-assessed PFS in the ITT population.

Results of the primary endpoint are also supported by the EFSeff secondary endpoint. A significant reduction in the risk of occurrence of disease by 25% was observed in patients treated in pola+R-CHP arm compared in patients treated in R-CHOP arm (stratified HR: 0.75 [95% CI: 0.58, 0.96]). Also, the BICR-assessed CR rate was high (78.0% [95%CI: 73.79, 81.74] vs. 74.0% [95% CI: 69.66, 78.07]). In addition, concordance between BICR and Investigator assessments of CR was high (88.7%).

## 3.3. Uncertainties and limitations about favourable effects

A total of 53 deaths (12.0% patients) were reported in the pola+R-CHP arm, and 57 deaths (13.0% patients) were reported in the R-CHOP arm. With very few events in both arms, OS results were still immature at the time of the interim analysis of OS and did not meet the pre-specified threshold for statistical significance (stratified HR: 0.94 [95% CI: 0.65, 1.37])'. Final OS data are expected in order to further document long term efficacy and safety provided by a pola+R-CHP regimen compared to a RCHOP regimen in this population. Indeed, the OS results provided in this report come from the interim OS analysis performed at the time of the PFS analysis. Therefore, the MAH will provide an update of the CSR of study Polarix containing the final OS results by Q4 2022 as a post approval measure (see RMP) which is acceptable.

The CHMP requested data from an additional China extension cohort of Study GO39942 (POLARIX) that are analyzed within an Asia subpopulation analysis and are reported in an Asia subpopulation CSR that includes all Chinese patients enrolled in the China extension and in the main global study. For this purpose, the MAH has requested approval for providing and opening access to Chinese Human Genetic Resources abroad from the Human Genetics Resources Administration of China (HGRAC) and would be able to provide the data from China extension cohort, in the form of Asia subpopulation CSR, if granted by HGRAC. For the time being access is not granted and the data may be submitted later - as recommended by the CHMP - when available.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Myelosupression was reported across all studies. Neutropenia, including febrile neutropenia, anemia and thrombocytopenia were all included in the AEs of particular interest. In the pivotal study, the incidence of neutropenia events was comparable in both treatment arms, i.e. 42.7% in R-CHOP and 46.0% in pola+RCHP but higher serious neutropenia events were reported in the pola+R-CHP arm compared to the RCHOP arm (11.5% vs 8.4%), mainly due to a higher incidence of serious febrile neutropenia in the pola+R-CHP arm (9.9%). The incidence of anemia events was comparable across the 2 treatment arms in POLARIX (26.9% in R-CHOP arm and 28.7% in Pola+R-CHP arm) but Grade 3-4 events were more reported with pola+R-CHP than R-CHOP (12.0% vs 8.7%). Incidence of thrombocytopenia was similar across pola+R-CHP arm and R-CHOP arms, i.e. 13.3% and 13.2% respectively. The majority of myelosuppression events resolved.

Infections are expected with polatuzumab vedotin. In the pivotal study, the incidence of infectious events, Grade 3-4 infections and serious infections was higher in pola+R-CHP arm compared to R-CHOP arm (49.7% vs 42.7%, 14.0% vs 11.2% and 14.0% vs 10.3%, respectively). Most of the fatal AEs in both arms were due to infections or complications of infection. The proportion of Grade 5 infections was comparable in both treatment arms (1.1% in pola+R-CHP and 1.4% in R-CHOP). Pneumonia was the most reported AE among the Grade 5 Infections (4 patients in pola+R-CHP arm, 3 patients in R-CHOP arm) and the other Grade 5 Infection AEs were septic shock and sepsis. The incidence of opportunistic infections was higher in pola+R-CHP than R-CHOP.

Peripheral neuropathy was reported across all studies. In the pivotal study, PN events occurred at comparable incidence in both treatment arms (53.9% in R-CHOP and 52.9% in Pola+R-CHP) and the majority of PN was low grade. None was fatal and 2 cases of PN were serious (one in each arm). The majority of PN events occurring in POLARIX resolved with a higher rate in R-CHOP arm compared to pola+R-CHP arm (66.9% and 57.8% respectively) which may be partly explained by the difference in median time to onset (2.27 months in pola+R-CHP vs 1.87 months in R-CHOP) and the comparable median time to resolution across the two treatment arms. The most commonly reported PN events were neuropathy peripheral (24.1% and 22.6%), peripheral sensory neuropathy (19.5% and 21.5%), paraesthesia (6.7% and 4.6%), hypoaesthesia (3.7% and 3.2%), polyneuropathy (1.4% and 2.5%), and peripheral motor neuropathy (0.7% and 2.3%) in the pola+R-CHP and R-CHOP arms, respectively.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no new uncertainties about the unfavourable effects of Polivy.

## 3.6. Effects Table

Table 67: Effects Table for [polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated DLBCL] (data cut-off: 28 June 2021)

| Effect             | Short description   | Unit               | Treatme nt         | Control            | Uncertainties / Strength of evidence   | References         |
|--------------------|---------------------|--------------------|--------------------|--------------------|----------------------------------------|--------------------|
| Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                     | Favourable Effects |
| PFS                | Primary endpoint    | Nb patients        | 107 (24.3%)        | 134 (30.5%)        | Stratified HR=0.73;                    | Study GO39942)     |

<div style=\"page-break-after: always\"></div>

| Effect                | Short description    | Unit                        | Treatme nt           | Control              | Uncertainties / Strength of evidence                                                                                                                                                              | References                    |
|-----------------------|----------------------|-----------------------------|----------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
|                       |                      | with events (%)             |                      |                      | 95%CI: 0.57, 0.95, p=0.0177                                                                                                                                                                       | POLARIX study                 |
| EFSeff                | Secondary endpoint   | Nb patients with events (%) | 112 (25.5%)          | 138 (31.4%)          | Stratified HR=0.75; 95%CI: 0.58, 0.96, p=0.0244                                                                                                                                                   | Study GO39942) POLARIX study  |
| CR rate               | Secondary endpoint   | %(95% CI)                   | 78% (73.79, 81.74)   | 74% (69.66, 78.07)   | P= 0.1557                                                                                                                                                                                         | Study GO39942) POLARIX study  |
| OS                    | Secondary endpoint   | Nb of deaths                | 53                   | 57                   | interim results performed at the time of the PFS analysis                                                                                                                                         | Study GO39942) POLARIX study  |
| Unfavourable Effects  | Unfavourable Effects | Unfavourable Effects        | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                              | Unfavourable Effects          |
| Fatal AEs             |                      | %                           | 3.0                  | 2.3                  | In pola+R-CHP: pneumonia, sepsis, death, intestinal perforation, kidney injury, respiratory failure                                                                                               | Study GO39942 (POLARIX study) |
| Other SAEs            |                      | %                           | 34.0                 | 30.6                 | In pola+R-CHP (by SOC): Infections and infestations (14.0%), Blood and lymphatc system disorders (11.5%), GI disorders (7.1%)                                                                     | Study GO39942 (POLARIX study) |
| Peripheral neuropathy | All grades           | %                           | 52.9                 | 53.9                 | In pola+R-CHP (by PT): neuropathy peripheral (24.1%), peripheral sensory neuropathy (19.5%), paraesthesia (6.7%), hypoaesthesia (3.7%), polyneuropathy (1.4%), peripheral motor neuropathy (0.7%) | Study GO39942 (POLARIX study) |
| Serious infections    | All grades           | %                           | 14.0                 | 10.3                 | In pola+R-CHP: Serious pneumonia (4.1%), serious sepsis (1.1%), and serious urinary tract infection (1.8%)                                                                                        | Study GO39942 (POLARIX study) |
| Serious neutropenia   | All grades           | %                           | 11.5                 | 8.4                  | In pola+R-CHP: serious febrile neutropenia (9.9%)                                                                                                                                                 | Study GO39942 (POLARIX study) |

Abbreviations: PFS: progression free survival, defined as the time from randomization to the first occurrence of disease progression or relapse as assessed by the investigator, using the Lugano Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurs earlier, EFSeff: investigatorAssessed Event-Free Survival for Efficacy Reasons, defined as the time from the date of randomization to the earliest occurrence of disease progression/relapse, death, biopsy that is positive for residual disease after treatment completion, or start of a NALT due to efficacy reasons, CR rate: BICR-Assessed Complete Response Rate at End of Treatment by PET-CT, OS: overall survival, AE: adverse event, GI: gastrointestinal, PT: preferred term, SAE: serious adverse event, SOC: system organ class

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The primary efficacy endpoint of the pivotal phase III, comparative, POLARIX study defined as PFS was achieved. A statistically significant improvement in the primary endpoint of Investigator-assessed PFS is observed following treatment with pola+R-CHP compared to R-CHOP, the 1L DLCBL standard of treatment. One could question the clinical relevance of these results as only a difference of 27 events is observed between both arms of treatment. This slight improvement of PFS is supported by sensitivity analyses and secondary endpoints. The use of polatuzumab vedotin instead of vincristine did not lead to improvement in treatment-related symptoms and peripheral neuropathy in POLARIX study. The CHMP considers interim OS results are still immature and could be considered as not sufficiently robust.  However, OS interim results do not indicate detrimental effect of polatuzumab vedotin.

The pivotal POLARIX study met its primary endpoint PFS and no large differences in safety risks, have been found. In this clinical situation, the presented median follow-up time is considered sufficient, and maturity of data is not relevant as a cure rate of 60% is anticipated in the control arm. No detriment in OS of polatuzumab vedotin is to be anticipated considering the results in combination with follow-up exceeding the time period in which most of the relapses would have occurred (i.e. 24 months).

The safety profile of pola+R-CHP does not raise new safety concern compared to pola+BR.  Therefore, efficacy and safety data provided from untreated patient could be considered as confirmatory safety and efficacy data for treatment of patients with relapsed/refractory DLCBL.

The PFS gain, as primary endpoint in the pivotal study, and no detriment in OS is sufficient to establish clinical benefit of polatuzumab vedotin as a substitute for vincristine in the combination regimen.

## 3.7.2. Balance of benefits and risks

The balance of benefits and risks of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated DLBCL is positive provided changes in SmPC and additional post-approval measures.

## 3.7.3. Additional considerations on the benefit-risk balance

Per current Polivy SmPC Annex II.E, provision of efficacy and safety data by Q4 2021 is the last remaining specific obligation (SOB-CLIN-003) to the CMA  of Polivy for the treatment of patients with relapsed/refractory DLBCL who are not candidates for haematopoietic stem cell transplant. The pivotal POLARIX study met its primary endpoint PFS and no large differences in safety risks, have been found. Therefore, efficacy and safety data provided from untreated patient could be considered as confirmatory safety and efficacy data for treatment of patients with relapsed/refractory DLCBL. With the submission of this Type II variation, all specific obligations related to the CMA are fulfilled. As a result, the CHMP agreed on  a  full  marketing  authorisation  in  accordance  with  Article  14(1)  of  Regulation  (EC)  No  726/2004 (marketing authorisation not subject to specific obligations).

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of the indication to include: Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) based on the efficacy and safety data from the Pivotal Phase III Study GO39942 (POLARIX). Annexes I, II, IIIB are revised. The RMP is also updated.  This submission fulfills SOB003 thus supporting the switch from CMA to full MA.

In addition, the CHMP, having considered the application as set out in the appended assessment report and having reviewed the data submitted by the marketing authorisation holder including the evidence concerning compliance with specific obligations, is of the opinion that the risk-benefit balance of the above mentioned medicinal product remains favourable, that all specific obligations laid down in Annex II have been fulfilled and that comprehensive data supports a favourable benefit-risk balance of the above mentioned medicinal product. Therefore, pursuant to Article 14-a(8) of Regulation (EC) No 726/2004, the CHMP recommends by consensus the granting of a marketing authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 for the above mentioned medicinal product for which the draft Summary of Product Characteristics is set out in Annex I.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP is of the opinion that Polivy is not similar to Minjuvi, Yescarta or Kymriah within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix X&gt;

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Polivy-H-C-4870-II-0012'

## Attachments

1. SmPC, Annex II, Package Leaflet (changes highlighted) of Polivy, 30 mg powder for concentrate for solution for infusion with changes highlighted as adopted by the CHMP on 24 March 2022.

## Appendix

1. CHMP AR on similarity dated 24 March 2022

<div style=\"page-break-after: always\"></div>

## Reminders to the MAH

1. In accordance with Article 13(3) of Regulation (EC) No 726/2004 the Agency makes available a European Public Assessment Report (EPAR) on the medicinal product assessed by the Committee for Medicinal Products for Human Use. The EPAR is first published after the granting of the initial marketing authorisation (MA) and is continuously updated during the lifecycle of the medicinal product. In particular, following a major change to the MA, the Agency further publishes the assessment report of the CHMP and the reasons for its opinion in favour of granting the change to the authorisation, after deletion of any information of a commercially confidential nature.

Should you consider that the CHMP assessment report contains commercially confidential information, please provide the EMA Procedure Assistant your proposal for deletion of commercially confidential information (CCI) in 'track changes' and with detailed justification by 08 April 2022. The principles to be applied for the deletion of CCI are published on the EMA website at https://www.ema.europa.eu/en/documents/other/heads-medicines-agencies/europeanmedicines-agency-guidance-document-identification-commercially-confidential-information\\_en.pdf

In addition, should you consider that the CHMP assessment report contains personal data, please provide the EMA Procedure Assistant your proposal for deletion of these data in 'track changes' and with detailed justification by 08 April 2022. We would like to remind you that, according to Article 4(1) of Regulation (EU) 2016/679 (General Data Protection Regulation, 'GDPR') 'personal data' means any information, relating to an identified or identifiable natural person (the 'data subject'). An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.

It is important to clarify that pseudonymised data are also considered personal data. According to Article 4(5) of GDPR pseudonymisation means that personal data is processed in a manner that the personal data can no longer be attributed to a specific data subject without the use of additional information (e.g. key-coded data).

Accordingly, the name and the patient identification number are two examples of personal data which may relate to an identified or identifiable natural person. The definitions also encompass for instance: office e-mail address or phone number of a company, data concerning health, e.g. information in medical records, clinical reports or case narratives which relates to an identifiable individual.'

2. The MAH is reminded to submit an eCTD closing sequence with the final documents provided by Eudralink during the procedure (including final PI translations, if applicable) within 15 days after the Commission Decision, if there will be one within 2 months from adoption of the CHMP Opinion, or prior to the next regulatory activity, whichever is first. If the Commission Decision will be adopted within 12 months from CHMP Opinion, the closing sequence should be submitted within 30 days after the Opinion. For additional guidance see chapter 4.1 of the Harmonised Technical Guidance for eCTD Submissions in the EU.
3. If the approved RMP is using Rev. 2 of the 'Guidance on the format of the RMP in the EU' and the RMP 'Part VI: Summary of the risk management plan' has been updated in the procedure, the MAH is reminded to provide to the EMA Procedure Assistant by Eudralink a PDF version of the 'Part VI: Summary of the risk management plan' as a standalone document, within 14 calendar days of the receipt of the CHMP Opinion. The PDF should contain only text and tables and be free of metadata, headers and footers.